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Abstract 
 
Background: The UK National Health Service (NHS) currently spends in 
excess of £17 billion per annum on medicines. To ensure sustainability, 
medicines with limited clinical value should not be routinely prescribed. The 
randomised controlled trial (RCT) aims to meet regulatory standards, therefore 
it has limited value to guide practice when multiple agents from the same 
therapeutic class are available. The quantitative trade-off analysis, with 
consideration to efficacy, safety, tolerability and / or cost, may enable the 
translation of regulatory data to clinically-relevant data for new and existing 
medicines.  
Methods: This concept aims to provide clarity to clinicians and guideline 
developers on the efficient use of new medicines where multiple options exist 
for the same licensed indication. Research projects of clinical relevance were 
identified from an academically led London Area Prescribing Committee 
(APC). Therapeutic areas included refractory epilepsy, hypertension and heart 
failure, overactive bladder syndrome, and atrial fibrillation. Frequentist and / or 
Bayesian meta-analysis were performed and supplemented with a trade-off 
analysis with parameters determined in consultation with field experts.  
Results: The trade-off analysis was able to establish a rank order of 
treatments considered thereby providing clarification to decision-makers on 
the DTC / APC panel where regulatory data could not. The results, presented 
as a hierarchy of treatments, enabled modifications to prescribing trends 
within North Central London as the pilot site, resulting in significant cost 
avoidance and cost savings for the NHS. 
Conclusions: The quantitative trade-off analysis was able to resolve 
concerns raised by the DTC / APC panel via translation of regulatory data to 
clinically-relevant data with consideration to defined benefits and harms. 
Results were implemented successfully within a local pilot health economy. 
This approach is recommended as an extension of existing methods required 
by regulatory agencies in the assessment and licensing of new medicines.  
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Impact Statement 
 
The UK National Health Service (NHS) currently spends 15% of its £116 
billion budget per annum on medicines; this is in excess of £17 billion, having 
grown from £13 billion in 2011-12. To ensure that the most effective medicines 
are available to patients, provider Acute Trusts have established local and / or 
regional Drugs and Therapeutics Committees (DTCs) to maintain a local 
formulary. Despite being the gold standard in evidence based medicine, 
randomised controlled trials (RCT) are designed to meet regulatory standards; 
therefore it has limited applicability in guiding clinical practice, particularly 
when multiple agents from the same therapeutic class are available. Guidance 
published by the National Institute for Health and Clinical Excellence (NICE) 
determines the clinical and cost-effectiveness of each individual new 
medicine, where the output is either the recommendation or non-
recommendation of said medicine; where it is recommended it has to be made 
available for prescribing among other recommendations. Establishing the 
place in therapy for new and / or existing treatment as part of the DTC review 
is therefore often unclear.  
The UCL Research Department of Epidemiology & Public Health aim to 
provide leading and multi-disciplinary research with impact on real-world policy 
and practice. The quantitative trade-off analysis is a concept that gives 
consideration to key efficacy versus acceptability versus cost parameters for a 
range of similar medicines licensed for a given therapeutic indication, and 
aims to provide clarity to clinicians and guideline developers where multiple 
options exist. The methodology employed in order to undertake this analysis is 
based on Bayesian statistics, using network meta-analysis (NMA) techniques, 
via the WinBUGS software. Specific therapeutics areas explored include: 
refractory epilepsy; cardiovascular disease (hypertension and heart failure); 
overactive bladder syndrome; and atrial fibrillation.  
The research themes and projects were conceived in conjunction with a multi-
disciplinary Area Prescribing Committee (regional DTC) within London and 
made possible via effective collaboration across a number of academic 
organisations including University College London, UCL Hospitals, University 
of Bristol, and the London School of Hygiene and Tropical Medicine. Specific 
areas of collaboration included individuals with a background in statistics 
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modelling and methodology, clinical / medical, health economics, and patient 
partnerships.  
The application of the quantitative trade-off analysis has successfully aided in 
the establishment of a hierarchy of treatments where regulatory data could 
not, and has been used to change practice across a pilot area of the UK NHS 
resulting in cost savings or cost-avoidance without compromising on patient 
care. Indirect comparisons, generated through NMA as conducted across a 
number of clinical specialities, not only helped develop rational treatment 
hierarchies, but also provide guidance on the choice of high priority 
comparator agents for direct head-to-head analysis in the form of an RCT. 
This approach is recommended as an extension of existing methods required 
by regulatory agencies in the assessment and licensing of new medicines. 
The outputs of the analyses conducted have been published in leading 
medical journals to inform wider practices.   
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1.0 Chapter 1: Introduction 
 
1.1 Introductory Statement 
Rational prescribing of medicines has been the cornerstone of modern 
medicine and is increasingly an important area for research for many 
reasons. The UK NHS currently spends 15% of its £116 billion budget 
on medicines. This has increased from £13 billion in 2011/12 to £16.8 
billion in 2015/16.(1) Spend in London (£2,852.8m) is the highest for all 
NHS England regions owing to its higher population.(2) The regulatory 
process, undertaken by the European Medicines Agency (EMA) is well 
established in the assessment of the clinical effectiveness of new 
medicines. The Technology Appraisal process undertaken by the 
National Institute for Health and Clinical Excellence (NICE) goes one 
step further to determine the clinical and cost-effectiveness of each 
individual new medicine. However, guidance offered from such 
appraisals is either the recommendation or non-recommendation of the 
new medicine; where if recommended it has to be made available for 
prescribing among other recommendations.  
The current standards for approval or recommendation therefore fail to 
assess whether new treatments are better or less efficacious or 
tolerated than existing alternatives. The place in therapy for the new 
and / or existing treatment therefore is often unclear and becomes 
compounded with every additional new medicine introduced into the 
market. With effective marketing techniques this introduces the 
possibility that patients may be harmed or less effectively managed 
through receiving newly approved treatments instead of alternative 
established treatments. In addition, the UK health economy also 
suffers as new treatments prescribed on the NHS are considerably 
more expensive, therefore providing these requires a disinvestment 
from other areas. A clear understanding of the potential benefits 
(efficacy) and harms (safety / tolerability) is needed to determine 
this.(3) 
Comparative Effectiveness Research (CER) has gained interest by the 
US FDA [Food and Drug Administration] as part of their process for 
approval of a new medicine. Although the European Medicines Agency 
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(EMA) has supported the requirement of active-comparator studies 
since 2004, the full spectrum of CER remains a new concept.  
The quantitative trade-off analysis is used in many areas of marketing 
new products to consumers, but remains a new concept to healthcare, 
in particular for stratification of place in therapy for new medicines. The 
submission of trade-off analysis as part of the dataset required by 
regulatory authorities prior to the approval and widespread adoption of 
a new medicine has the potential to reduce unnecessary spend on 
inferior or more costly equivalent treatments.  
This thesis explores the quantitative trade-off analysis across four 
therapeutic areas, namely refractory epilepsy, cardiovascular disease 
(hypertension and heart failure), overactive bladder syndrome, and 
atrial fibrillation. A brief introduction into their aetiology, epidemiology, 
clinical manifestations and treatment is provided within each section. 
Pertinent clinical information concerning key efficacy and adverse 
events are also described as part of the appraisals which are used to 
develop the trade-off analyses.  
 
1.2 Drug Appraisal Process in Clinical Trials 
Clinical Trials are research studies involving human subjects, often 
patients, which aim to evaluate the safety and effectiveness of a new 
treatment. Clinical trials are the most reliable method of evaluating new 
treatments provided their design objectives have been appropriately 
met.  
 
1.2.1 Phase I clinical trials 
In phase I clinical trials the investigational drug is given to humans for 
the first-time. These studies are usually conducted in healthy 
volunteers. However, there are some circumstances when patients 
are used, often in situations where patients may have a severe or 
rare disease where there are a lack of adequate treatment options 
currently available thereby constituting an unmet clinical need. The 
emphasis of the design of phase I studies is to determine the 
metabolic and pharmacological actions of the investigational drug in 
humans, including any adverse events associated with incremental 
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dose increases, and, if possible, to gain any early evidence on clinical 
effectiveness. The total number of subjects included in Phase I 
studies is often small, usually in the range of 20-80.  
 
1.2.2 Phase II clinical trials 
Phase II clinical trials are the early controlled clinical studies 
conducted to obtain some preliminary data on the effectiveness of the 
drug for a particular indication [or indications] in patients with the 
actual disease or condition. This phase of testing also helps 
determine the common short-term adverse effects and risks 
associated with using the drug in the proposed patient population. 
Phase II studies usually involve a few hundred patients and such data 
will be used to inform on the dosage and design of the larger, usually 
multi-centre, phase III studies. Many adverse effects are still unlikely 
to be detected due to the small patient numbers. The observed 
efficacy may still be a chance finding as the power of the study will be 
low. 
 
1.2.3 Phase III clinical trials 
Phase III clinical trials are intended to gather pivotal clinical 
information about the effectiveness and safety of a new treatment that 
will be used to evaluate its overall risk:benefit relationship. Phase III 
trials involve larger numbers of patients (hundreds or thousands) who 
are usually randomised to receive the new treatment or the current 
best available (including placebo). The aim is to assess how well the 
new treatment works in a meaningful number of patients which meet 
a statistical power in order to extrapolate or generalise the findings 
from the sample population to the general population. The larger 
numbers also supports identification of serious adverse effects, 
however, the rigid design often precludes the recruitment of ‘at-risk’ 
patient groups. The aim of the phase III clinical trial is to satisfy 
regulatory criteria in order to obtain a Marketing Authorisation.  
 
1.2.4 Phase IV clinical trials 
Phase IV clinical trials are conducted to identify and evaluate the 
long-term effects of new medicines and treatments over a lengthy 
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period for a greater number of patients. Phase IV research occurs 
following regulatory approval and marketing of a new medicine, with 
data capture primarily from the primary care (general practice) setting 
or routine specialist care. Although the protocol for such 
pharmacovigilence plans may include assessment for efficacy, safety 
and side-effects in the post-marketing period, data collection is largely 
centred around safety and tolerability.  
 
1.3 Pharmaceutical Industry 
Clinical research sponsored by the pharmaceutical industry 
influences medical practice because the vast majority of clinical 
trials at all stages in a product's life cycle are funded by the 
pharmaceutical industry. Results that are unfavourable to the 
sponsor - that is, trials that find a new medicine is less clinically-
effective or cost-effective or even more harmful than other 
medicines used to treat the same condition, will thus pose 
considerable financial risks to companies. Pressure to show that the 
medicine causes a favourable outcome may result in biases in 
design, outcome, and reporting of industry-sponsored research.(4) 
Examples of such potential biases are outlined below and in section 
3.4.6. 
 
1.3.1 Design Bias 
Funding may promote study designs that are more likely to produce 
favourable results, such as designs involving only placebo or other 
poor comparators, inappropriate doses, carefully constructed 
experimental populations, poor surrogate endpoints, trial durations 
unlikely to show adverse effects, and protocols likely to show activity 
or unlikely to show adverse effects. An example of such biased 
design was seen in the trial of a new proton-pump inhibitor where the 
Sponsor compared the new medicinal product, esomeprazole (an 
active isomer of the racemic comparator, omeprazole), to a clinically 
inappropriately low dose of omeprazole.(5)  
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1.3.2 Data Interpretation 
Industry-supported trials and reviews of drugs should always be read 
with caution as they have been shown to be less transparent, have 
fewer reservations about methodological limitations of the included 
trials, and have more favourable conclusions compared to 
independent reviews.(6) A recent study published in the British 
Medical Journal reviewed 24 meta-analyses; eight were industry 
supported, nine had undeclared support, and seven had no support 
or were supported by non-industry sources. Compared with industry-
supported reviews and reviews with undeclared support, independent 
reviews had more often considered the potential for bias in the 
review; for example, they described the method of concealment of 
allocation, excluded patients or excluded studies. The seven industry-
supported reviews that had conclusions recommended the 
experimental drug without reservations, compared with none of the 
independent reviews. ‘Ghost-writing’ is also an issue as reports can 
be researched and written by, or on behalf of, pharmaceutical 
companies, and then published under the name of academics who 
had played little role in the research and writing process. The 
resulting articles affect the conclusions found in the medical literature, 
and are used in promoting drugs to healthcare providers.(7)  
For industry-funded trials, positive data are over-reported relative to 
negative data.(8) There may be other kinds of publication bias as 
well. Almost all journals earn considerable revenue from sales of 
reprints of articles sometimes selling hundreds of thousands of 
articles with high commercial value. This creates potential conflicts of 
interest that could affect publication patterns. Many journals earn 
money from the publication of supplements, often based on symposia 
sponsored by pharmaceutical companies. Peer-review of these 
supplements typically differs from those of normal issues of these 
journals. A recent analysis of new drugs approved by the FDA 
between 1998 and 2000 demonstrated that selective reporting of trial 
results occurred for commonly marketed drugs.(8) Moreover, over 
one half of all supporting trials for FDA-approved drugs remain 
unpublished at five years [or greater] post-approval.(9)  
Chapter 1: Introduction 
     - 30 - 
The marketing budgets of the drug industry are enormous although 
exact figures are difficult to come by. This is in part because 
marketing and administrative expenses are often grouped together 
and in part because some of the research and development budget is 
for marketing research.(10) Many healthcare professionals rely on 
drug company representatives and promotional materials to learn 
about new drugs. In the US, the pharmaceutical industry also has 
direct access to the general public where direct-to-consumer 
advertising is permitted [such advertising is not allowed for 
prescription-only medication in the UK]. In summary, one should 
remain vigilant that the commercial imperative is likely to result in an 
inappropriate influence on presentation of drug data. 
 
1.4 Regulatory Agencies 
Following the analysis of pre-clinical and clinical data, the relevant 
pharmaceutical company is required to apply for a Marketing 
Authorisation [product licence] and receive approval before the new 
medicine can be marketed and prescribed. This is done through the 
European Medicines Agency (EMA) for all European countries 
including Norway and Iceland [centralised route] or via the Medicines 
and Healthcare products Regulatory Agency (MHRA) in the UK 
[national decentralised route].(11)  
Where the regulatory agency concludes that the new drug’s benefit 
profile exceeds its risk profile, and presents an improvement in therapy 
in relation to its trial comparator, a Marketing Authorisation will be 
granted. However, as regulatory agencies typically only require 
evidence of effectiveness over placebo, this presents an issue for 
clinicians and commissioners of medicines in determining which new 
treatment should be made available from the range of options currently 
in the market. Since 2004 the EMA have mandated the requirement of 
an active comparator where a licensed medicine exists, however, this 
only provides data on one alternative where in practice a number are 
available. Furthermore, this process is not able to account for 
treatments that may be developed in tandem and therefore the use of 
a placebo or a historic control will be used. As such, the benefit and 
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harm profile of new medicines as compared with interventions already 
established in clinical practice are unknown.  
 
1.5 Commissioning Agencies 
Expenditure on pharmaceuticals is the fastest growing sector within 
healthcare in developed countries, including Canada,(12, 13) the 
United Kingdom,(14) Australia,(15) and the United States.(16, 17)  
Cost [and cost-effectiveness] is therefore an important consideration 
which has driven the recent proliferation of ‘fourth hurdle’ systems. In 
the UK, NICE was established in April 1999 which considers select 
new drugs for an evidence-based clinical and cost-effectiveness 
assessment to determine whether such therapies should be listed in 
public formularies. In Scotland, a similar body known as the Scottish 
Medicines Consortium [SMC] evaluates all new drugs before they can 
be prescribed within NHS Scotland. In London, a body akin to the SMC 
is currently under development. Although valuable, the outputs of 
these systems remain restricted to independent recommendations 
rather than a holistic assessment of all treatments available and 
therefore the corresponding place for each of these.   
 
1.6 Drug Evaluation in Clinical Practice  
In addition to regulatory authorities, such as the EMA, and national 
commissioning organisations, such as NICE, most local health 
economies exert local control over what drugs should be made 
available to prescribers [and subsequently to patients]. This is 
achieved through the management of local formularies where 
decisions on formulary entry and restrictions are made by a local drugs 
and therapeutics committee [or equivalent]. These committees 
evaluate the comparable efficacy and safety profiles of new medicines 
versus other available treatment options when deciding on the 
potential advantages and disadvantages of formulary inclusion; 
however this is done to varying degrees dependent upon local 
expertise. Additional considerations are given to convenience and cost.  
For example, a newly launched, EMA licensed, beta-adrenoceptor 
blocking drug is unlikely to gain approval for inclusion to a hospital 
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formulary if there are no robust data indicating that it is more effective 
than existing [often cheaper] options. Many new drugs do have some 
potential advantages, for example, once daily dosing in comparison to 
a twice daily regime, however such advantages may be considered 
insufficient to offset increased drug costs or lack of longer term safety 
assurances. Further, trials reporting statistical significance may not be 
indicative of clinical significance i.e. a difference that will make a 
meaningful difference to a patient and the treatment or management of 
their condition. Decisions from such committees across the UK are 
variable and are often associated with a high rate of approval. Per 
capita wastage of this type tends to be greatest in hospitals; this could 
be reduced if some simple principle of drug management and use were 
followed.  
Medicines evaluation of this type is highly developed at University 
College London Hospitals, which is coordinated by the Use of 
Medicines Committee (UMC), as identified by the House of Commons 
Select Committee on Health as part of their review on control of access 
to medicines.(18) This team of Pharmacists and Clinical 
Pharmacologists are closely involved in the business of the NCL Area 
Prescribing Committee.   
 
1.6.1 Spend on Medicines within the NHS 
Over the period 2016/17, the cost of NHS medicines prescribed in 
hospitals and the community totalled £17.4bn.(1) As expected, the 
highest area of spend is in London at £2,852.8m. This represents a 
34% rise since 2011/12 where the annual spend was £13.0bn. Spend 
in the community setting (primary care) accounted for 56.1%. With an 
ageing population, newer medicines coming to market with a larger 
price tag, and a finite NHS budget, it is important that medicines are 
prescribed wisely to offer as much as possible to the population as a 
whole.  
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1.6.2 Clinicians and Allied Healthcare Professionals are close to the 
research ideas 
The best health research ideas, and certainly those that are most 
applicable, come from clinical practice, especially through working 
with patients and the public. This is precisely the setting where 
Pharmacy Practice Research excels and underpins this thesis. 
Medicines Management teams based within an NHS hospital setting 
undertake clinical care for patients, both as individuals and at service 
level. Through discussions with colleagues, a number of topics of 
research were developed to form the chapters of this thesis as part of 
enhanced comparative effectiveness research. 
 
1.7 Comparative-Effectiveness Research 
Comparative effectiveness research (CER) is a relatively new concept 
which is designed to inform health-care decisions by providing 
evidence on the effectiveness, benefits and harm of different treatment 
options.(19) The evidence is generated from research studies that 
compare drugs, medical devices, tests, surgeries, or ways to deliver 
health care. 
 
There are two ways that this evidence may be found: 
 Researchers look at all of the available evidence regarding the 
benefits and harms of each drug available for the treatment or 
management of a specific condition from existing clinical trials, 
clinical studies, and other research. This is more commonly 
referred to as a systematic review of the existing literature. 
 Researchers conduct studies that generate new evidence of 
effectiveness or comparative effectiveness. 
 
CER requires the development, expansion, and use of a variety of data 
sources and methods to conduct timely and relevant research and 
disseminate the results in a form that is quickly usable by clinicians, 
patients, policymakers, and other payers.  
 
In general there are six steps involved in the conducting this type of 
research and ensuring continued development of the infrastructure to 
sustain and advance these efforts: 
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1. Identify clinical interventions available 
2. Review and synthesise current research 
3. Identify gaps between existing medical research and the needs of 
clinical practice 
4. Generate new scientific evidence and analytical tools.*  
5. Promote this new evidence by disseminating to medical 
practitioners and relevant stakeholders 
6. Translate the findings into clinical practice 
 
*New evidence may include performing one or more of the following analyses: cost-minimisation, 
cost-effectiveness, cost-benefit or cost-utility. 
 
The aim of CER is to provide an informed decision, based on the best 
possible evidence, on what the best treatment(s) is. In the absence of 
changes regarding the pathway of medicines obtaining a marketing 
authorisation as enforced by regulatory agencies, CER provides the 
most comprehensive overview for both the provider and commissioner.  
  
 
 
 
Figure 1: Process of Comparative Effectiveness Research (CER) from concept to 
practice   
(1) Identify clinical 
interventions 
available 
(2) Review and 
synthesise current 
research 
(3) Identify gaps 
between existing 
research and needs 
of clinical practice 
(4) Generate new 
scientific evidence 
[and analytical tools] 
(5) Promote new 
evidence 
[disseminate to 
stakeholders] 
(6) Translate findings 
into clinical practice 
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1.8 Pharmacy Practice Research 
The scope of pharmacy practice research is an umbrella term for 
research into pharmacy services, medicines use, professional practice 
and education.(20) New directions in healthcare policy, as well as 
changing structural, economic, social and cultural contexts of 
healthcare, and the aspirations of pharmacists for a greater role in the 
delivery of medicines provide the framework and background for the 
conception and execution of pharmacy practice research. The ultimate 
goal is to lead the way in adaptation of services with participation in 
original research seen as a fundamental component.  
Topics commonly addressed under this area of research include: 
 Pharmaceutical service provision, delivery and development 
 Quality and safety of services 
 Therapeutic outcomes consequent on service provision and 
medicines use 
 Pharmacoeconomics, costs and cost-effectiveness 
 Assessment of medicines-related needs from the perspectives 
of patients and carers 
 Health and pharmaceutical policy 
 
1.9 Trade-off Analysis 
Every pharmaceutical manufacturer of a new medicine approaches 
launch and marketing of their new product from the business 
perspective, whilst clinicians and healthcare professionals will view its 
clinical opportunities. A tool used by the Marketing Research 
community is the ‘trade-off analysis’ to support marketing decisions 
that require complex decision making incorporating several data 
points. Fundamentally, this approach assigns attributes to a particular 
product that is considered most important to its target consumers. 
Qualities of the trade-off analysis include: 
 An ability to differentiate between products so that recipients in 
the marketplace  gain clear direction for allocating their 
resources towards consumer benefits 
 A flexible model to adapt to the relative importance of a number 
of factors and variables 
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 Simplicity in the research process that is transparent, easy to 
understand and may be replicated 
 User-friendly results so that marketing applications are clear 
and actionable 
 
Within the context of this thesis, the trade-off analysis refers to a 
balance of defined efficacy and safety / tolerability parameters, as 
determined in conjunction with experts within the field that the research 
project relates to. The trade-off methodology would fall under the 
umbrella of Comparative Effectiveness Research as indicated by step 
4 of the process depicted in Figure 1. The results would be presented 
in table or graphical format to enable ease of transfer into a guideline, 
where required, for dissemination to relevant stakeholders.  
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2.0 Chapter 2: Aims & Objectives 
 
2.1 Rationale for the Research Project 
The NHS governance structure for the management of medicines 
provides delegated authority to local and / or regional Drugs and 
Therapeutics Committees (DTC) as well as local health economy 
commissioners. Individuals performing these tasks are required to 
make inferences from trial data when considering the merits of new 
medicines within the treatment pathway alongside existing therapy.  
 
Although NICE provide recommendations via its Technology Appraisal 
Guideline (TAG) publications on which therapies confer cost-
effectiveness within the UK NHS setting, they do not provide firm 
recommendations of which medicine(s) should be preferentially 
prescribed from a series of options within the same class. As such, 
variability in prescribing and therefore expenditure continues to occur 
across the UK.     
 
This fundamental approach will be applied to four areas of NHS 
business, as highlighted by the North Central London Joint Formulary 
Committee (NCL JFC) with adaptations to methodological techniques 
as necessary. The topics chosen impact primary care prescribing on a 
national basis.  
 
2.2 Research Question 
"Can the use of quantitative trade-off analysis guide efficient use of 
medicines within the UK NHS.” 
 
2.3 Aims and Objectives 
The aim of this research is to establish the use of post-trial quantitative 
trade-off methodology, applied to data obtained from randomised 
controlled trials to aid clinicians, medicines management committees, 
and commissioners in their decision making process to promote 
appropriate and cost-effective prescribing of medicines within the NHS. 
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The objective of this research is to demonstrate the value of a 
quantitative trade-off methodology and the benefits it may realise 
within the UK NHS. 
 
 
The impact of this is to allow consideration of improved post-marketing 
prescribing that could be enforced by policymakers such as medicines 
management or area prescribing committees. Study specific objectives 
were as follows: 
1. Assessment of the efficacy and tolerability profile of old versus 
new anti-epileptic drugs for the management of refractory focal 
epilepsy 
2. Assessment of the efficacy, tolerability and cost-effectiveness 
profile of angiotensin receptor blockers (candesartan and 
losartan) for the management of hypertension and heart failure 
3. Assessment of the efficacy and tolerability profile of old versus 
new antimuscarinic drugs for the management of overactive 
bladder syndrome 
4. Assessment of the efficacy, tolerability and cost-effectiveness 
profile of all novel anticoagulation therapies compared with 
warfarin for the prevention of stroke in AF 
The rationale for the choices of the exposures and outcomes selected 
for the investigations were as follows: 
 The medicines investigated are used for important chronic 
medical conditions where therapy is currently non-curative. 
Patients will therefore continue to receive these medicines, with 
new medicines within class continuing to emerge resulting in 
high spend for the NHS. Moreover, the conditions are relatively 
common meaning that the potential for exposure is high and 
hence safety / tolerability concerns as well as avoidable cost 
could have a substantial impact on a population scale.  
 The potential adverse event outcomes under investigation are 
associated with considerable morbidity and mortality, such as 
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head injury following uncontrolled seizures and stroke following 
poorly managed atrial fibrillation.   
 
2.3.1 Peer review assessments 
The projects undertaken as part of this thesis have undergone peer 
review assessment as indicated within their respective chapter. Where 
published, abstracts have been re-produced in the appendices 
(Appendix VII to Appendix X). 
 
2.4 Disclosure 
2.4.1 Ethics and Scientific Approval 
As data required for systematic reviews, meta-analysis, and or cost-
utility analysis are derived from publically accessible content, neither 
ethics nor scientific approval were required.  
 
2.4.2 Funding 
All data contained within this thesis was available free of charge as 
publically accessible content from published articles or as source data 
directly from the author or institution. A research grant was received 
from the National Institute for Health Research (NIHR) to facilitate 
progression of the topic relating to novel anticoagulants. However, the 
NIHR had no role in the study design, data collection, data analysis, 
data interpretation, or writing of the report. No academic or commercial 
funding was obtained for any of the other topics within the thesis.  
 
2.4.3 Collaboration 
For areas of conjoint work, the specific areas delivered by me and that 
undertaken by other parties are described within chapter 4 to chapter 7 
under ‘sub-section x.4 collaboration.’  
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3.0 Chapter 3: Methods (Data Management & Statistical 
Analyses) 
 
3.1 Data acquisition 
Advances in information technology have enable ease of access to 
published articles via publically available websites. For this thesis, 
published articles were acquired via the UCL library services 
subscription. Extraction of data however remains a manual process 
following a review of the article into local software identified as being fit 
for purpose.  
 
3.2 Data management & analysis 
Clinical trial data are published in relatively standard format owing to 
the integrity of the editorial process in ensuring that the study has been 
conducted to a certain standard. Demographic data relating to 
characteristics of the population at baseline is generally presented as a 
summary in table 1 with any specific variations described in the text. 
Key outcome measures specified a priori within the trial protocol are 
generally presented as a summary in table 2 with appropriate statistical 
analysis. Important methodological data and additional analyses are 
frequently published separately as supplementary material which is 
available as an adjunct to the main article. To ensure integrity in data 
management, it is important that datasets are carefully reviewed, 
extracted and analysed. In order to do this, a second independent 
person is required.  
 
3.3 Evidence Based Medicine 
The Cochrane Collaboration is an international organisation whose 
primary aim is to help people make well-informed decisions about 
health care by preparing, maintaining and promoting the accessibility 
of systematic reviews of the evidence that underpins them. The 
Cochrane Handbook provides guidance to authors for the preparation 
of Cochrane Intervention reviews. The latest version 5.1.0 (last edited 
20 March 2011) is available online at http://handbook.cochrane.org/  
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The Decision Support Unit (DSU) is a collaboration of Universities with 
expertise in data synthesis, as commissioned by the National Institute 
for Health and Clinical Excellence (NICE) to provide research and 
training resource to support the Technology Appraisal Programme. A 
series of seven Technical Support Documents (TSD) are published 
and publically accessible.  TSD 7 relates to a reviewers checklist 
describing points that should be addressed as part of the research 
plan.(21)  
Recommendations from the above were considered as part of the 
scope, protocol, methodology, assessment of outcomes and 
translation to clinically relevant findings from the various projects 
covered within this thesis.  
 
3.4 Systematic Review 
Systematic reviews provide one of the highest levels of clinical 
evidence(22) and is an important part of the hierarchy of evidence (see 
Figure 2).   
Chalmers and Altman defined a systematic review as “a review that 
has been prepared using a systematic approach to minimising biases 
and random errors which is documented in a materials and methods 
section. A systematic review may, or may not, include a meta-analysis: 
a statistical analysis of the results from independent studies, which 
generally aims to produce a single estimate of a treatment effect.”(23)  
A systematic review is an evidence-based critical assessment and 
synthesis of the results of trials or studies. This information can be 
used to shape medical decision making, to inform policy makers, to 
keep health care practitioners up to date, and to highlight areas where 
more research is needed.(24, 25) 
It is important that any future research builds on existing theories or 
knowledge, and that it does not duplicate the work of others. A 
systematic review provides a comprehensive overview of the extent of 
research on a particular subject and the level of current knowledge. 
The findings of a systematic review assist in defining research 
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objectives to fill in any important gaps as well as determining the 
strengths and weaknesses of different methodologies available. 
 
3.4.1 Key points 
 Reviews are essential tools for health professionals, 
researchers, consumers and policy makers who want to keep 
up with the evidence that is accumulating in their field 
 Systematic reviews allow for a more objective appraisal of the 
evidence that traditional narrative reviews and may thus 
contribute to resolve uncertainty when original research, 
reviews and editorials disagree 
 Meta-analysis (see section 3.5.1) , if appropriate, will enhance 
the precision of estimates of treatment effects, leading to 
reduced probability of false negative results, and potentially to 
a more timely introduction of effective treatments 
 Systematic reviews may demonstrate the lack of adequate 
evidence and thus identify areas where further studies are 
needed 
 
 
 
 
 
 
 
Figure 2: Pyramid of evidence-based medicine (from Murad MH et al.)(26) 
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3.4.2 Validity 
The validity of a systematic review is partially based on a 
comprehensive literature search. The Cochrane Handbook for 
Systematic Reviews of Interventions, which details the process of 
preparing Cochrane systematic reviews, defines a comprehensive 
search strategy as being replicable and thorough and as including a 
search of various sources.(27)  
The key characteristics of a systematic review are: 
 A clearly stated set of objectives with pre-defined eligibility criteria 
for studies 
 An explicit, reproducible methodology 
 A systematic search that attempts to identify all studies that would 
meet the eligibility criteria 
 An assessment of the validity of the findings of the included 
studies, for example through the assessment of risk of bias 
 A systematic presentation, and synthesis, of the characteristics 
and findings of the included studies 
An important advantage of systematic reviews is that they render the 
review process transparent. In traditional narrative reviews it is often 
not clear how the conclusions follow from the data examined. In an 
adequately presented systematic review it should be possible for the 
readers to replicate the quantitative components of the argument.  
 
3.4.3 Software 
To support the robust preparation and execution of a systematic 
review, the Cochrane Community make available Review Manager 
(RevMan), a software that is mandatory for any author of a Cochrane 
Review. RevMan, currently on version 5.3.5, has been developed 
through a continuous process of consultation with users and 
methodologists to ensure that data collection and analytical methods 
included are of the highest standard. RevMan 5 is free to access with 
the intention that reviews are for academic purpose.(28)  
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3.4.4 Search Strategy 
A comprehensive search strategy involves the development and 
implementation of a strategy that will lead to the identification of 
relevant published and (where required) unpublished studies from 
indexed biomedical databases and grey literature sources. It is 
recommended that a comprehensive search strategy include the use 
of two or more databases (with consideration of the unique 
contributions of each database); the hand-searching of the 
bibliographies of selected articles, conference proceedings, and 
abstracts; and personal communications with researchers.(29, 30) 
These steps are advocated to minimise selection bias.  
 
3.4.5 Reporting Quality of Randomised Evaluations  
To address the suboptimal reporting of meta-analyses in the past, an 
international group developed a guidance called the QUOROM 
statement (QUality Of Reporting Of Meta-analyses), which focused 
on the reporting of meta-analyses of RCTs. Recently, a revision to 
this guideline has been published, renamed PRISMA (Preferred 
Reporting Items for Systematic reviews and Meta-Analyses), which 
has been updated to address several conceptual and practical 
advances in the science of systematic reviews.(31)  Key changes are 
the inclusion of a protocol from the outset, which has been a standard 
part of the Cochrane Collaboration review process, and the evolution 
of terminology to encompass both systematic reviews and meta-
analyses. The definitions used within this updated statement have 
largely been adopted from those used by the Cochrane Collaboration. 
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Steps in conducting a systematic review 
1. Formulate the research question 
2. Define inclusion and exclusion criteria 
2.1. Participants 
2.2. Interventions and comparisons 
2.3. Outcomes 
2.4. Study design and methodological quality 
3. Locate studies (develop search strategies considering the following sources) 
3.1. The Cochrane Controlled Trials Register (CCTR) 
3.2. Electronic databases and trials registers not covered by CCTR 
3.3. Checking the reference lists 
3.4. Hand-searching of key journals 
3.5. Personal communication with experts in the field 
4. Select studies 
4.1. Have eligibility checked by more than one observer 
4.2. Develop strategy to resolve disagreements 
4.3. Keep log of excluded studies, with reasons for exclusions 
5. Assess study quality 
5.1. Consider assessment by more than one observer 
5.2. Use simple checklists rather than quality scales 
5.3. Always assess concealment of treatment allocation, blinding, and handling 
of patient attrition 
5.4. Consider blinding of observers to authors, institutions and journals 
6. Extract data 
6.1. Design and pilot data extraction form 
6.2. Consider data extraction by more than one observer 
6.3. Consider blinding of observers to authors, institutions and journals 
7. Analyse and present results 
7.1. Tabulate results from individual studies 
7.2. Examine forest plots 
7.3. Explore possible sources of heterogeneity 
7.4. Consider meta-analysis of all trials or sub-groups of trials 
7.5. Perform sensitivity analyses, examine funnel plots 
7.6. Make a list of excluded studies available to interested readers 
8. Interpret data 
8.1. Consider limitations, including publication and related biases 
8.2. Consider strength of evidence 
8.3. Consider applicability 
8.4. Consider numbers-needed-to-treat to benefit / harm 
8.5. Consider economic implications 
8.6. Consider implications for future research 
 
 
Figure 3: Steps in conducting a systematic review  
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3.4.6 Bias 
A bias is a systematic error, or deviation from the truth, in results or 
inferences.(27) The introduction of bias can influence the results of 
systematic reviews and lead to inaccurate pooled estimates of the 
effect measures. Biases can operate in either direction or at different 
levels of magnitude; different biases can lead to underestimation or 
overestimation of the true intervention effect. The greater the rigor in 
conduct of the systematic reviews, the more likely it will yield results 
that are closer to the truth. A number of factors can alter the estimate 
of an intervention’s effectiveness following a systematic review, such 
as: 
 Language restriction 
 Publication status 
 Sources of funding 
 Outcome reporting 
 Databases searched 
 Quality of study 
 
It is important to acknowledge that bias is not synonymous with 
imprecision. Bias refers to a systematic error, meaning that replication 
of the same process would reach the same conclusion. Imprecision 
however relates to random error, where replication of the same 
process would result in different outcomes.    
 
3.4.6.1 Language Restrictions 
The English language is generally perceived to be the universal 
language of science.(32, 33) The top 10 international medical journals 
in 11 medical specialities (measured by impact factor) are English-
language publications. The exclusive reliance, however, on data that 
are published in English, and that are used as the basis of systematic 
reviews of health care interventions, may not result in an accurate 
representation of existing evidence. Therefore, excluding publications 
in a language other than English (LOE) may lead to erroneous 
conclusions due to the introduction of language bias. 
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A review by the Canadian Agency for Drug and Technologies in 
Health (CADTH) could find no evidence of a systematic bias from the 
use of language restrictions in systematic reviews or meta-analysis of 
conventional medicines.(34) However, it was suggested that more 
research is needed, particularly in specific medical specialities, to 
better understand the role of language restriction. It is possible that 
the inclusion of publication in LOE may increase the external validity 
of the report where publications that are written in LOE are known to 
be influential. As such, it was a recommendation that systematic 
reviewers should include the search of foreign language studies when 
resources and time are available.  
 
3.4.6.2 Quality of Study 
The quality of study reporting is dependent upon when and where it is 
published. Recently published studies are subject to greater rigour 
than those previously with greater requirements imposed on trial 
protocols as well as conditions and reporting of the study. Advances 
in the respective field of the study topic also improve the quality of 
subject inclusion and assessment criteria. Those that are published 
will have undergone a comprehensive peer review process and 
therefore brought to a high standard worthy of circulation to the 
scientific community.  
 
3.4.6.3 Publication Status  
Publication bias is a well-known phenomenon whereby positive 
results have a better chance of being published and in journals with a 
higher impact factor. Conclusions based on published studies alone 
therefore have the potential to be misleading, however this should be 
weighed against the quality of study reporting for those that are 
unpublished (i.e. the absence of a formal peer review assessment 
renders the study and its findings to be unvalidated and therefore 
itself has the potential to be misleading).(35)  
It is not uncommon to see industry-funded trials published more 
routinely than those which are not. Journals that are marketed as 
open-access charge authors a publication fee which also acts as a 
barrier for non-industry sponsored publications, particularly if the 
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outcomes are negative. Almost all journals earn considerable revenue 
from sales of reprints of articles; this may also be a potential conflict 
of interest that affects publication patterns.  
 
3.4.6.4 Risk of Bias Assessment 
Risk of bias should be assessed using the Cochrane Risk of Bias 
Tool.(36) The purpose of this is to assign a judgement of high, low or 
unclear risk of bias for each of the following domains: selection bias 
(randomisation sequence and allocation concealment), performance 
bias (blinding of participants and carers), detection bias (blinding of 
outcome assessment), attrition bias (due to dropouts and exclusions), 
and reporting bias (selective outcome reporting). The assessment 
should be completed by one individual and then independently 
verified by another to ensure robust reporting.  
 
3.4.6.5 Source of Funding 
The pharmaceutical industry plays a vital role in financing the 
research required to develop new medicines. However, corporate 
financing of clinical research, which may be perceived as providing 
incentives for investigators and / or control over the study itself, may 
create conflicts of interest that can bias study results, for example 
methodological or reporting bias in favour of the investigational 
treatment yielding positive results that otherwise would not be 
seen.(37) 
 
3.4.7 Generalisability (External Validity) 
The generalisability is concerned with the extent to which the findings 
of a study can be applied to individuals beyond the sample. Many 
studies involve samples rather than a whole population. Studies are 
also focussed on a single location or a small number of areas, but 
there may be a strong argument that the findings have wider 
relevance.  
The most important issues that determine the generalisability of study 
findings are that the sampling strategies, procedures and sizes, 
response rates, and completeness of data.   
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3.5 Meta-analysis 
3.5.1 Concept 
Several studies are often published, investigating the efficacy and 
safety of the same medicine. Although the optimal way in which to 
determine the effects of a treatment is via a randomised controlled 
trial, undertaking one including a sufficiently large number of subjects 
becomes both overly complicated and costly. A frequentist meta-
analysis [henceforth referred to as meta-analysis] can be conducted 
to pool data concerning an endpoint of interest to estimate the overall 
point estimate and variance [often displayed as a pooled odds ratio or 
weighted / standardised mean difference with associated confidence 
intervals]. A meta-analysis is the quantitative analysis of two or more 
independent studies for the purpose of determining an overall effect 
and for exploring reasons for variation between study results. Like 
systematic reviews, meta-analyses are the highest level of evidence 
based medicine (see Figure 2). It is important to ensure that studies 
that are pooled together must have sufficiently homogenous 
characteristics.  
 
The merits of supporting a systematic review with a meta-analysis of 
the data include: 
 To increase power: Power is the chance of detecting a real 
effect as statistically significant if it exists. Many individual 
studies are too small to detect small effects, but when several 
are combined there is a higher chance of detecting an effect. 
 To improve precision: The estimation of an intervention effect 
can be improved when it is based on more information. 
 To answer questions not posed by the individual studies: 
Primary studies often involve a specific type of patient and 
explicitly defined interventions. A selection of studies in which 
these characteristics differ can allow investigation into the 
consistency of effect and, if relevant, allow reasons for 
differences in effect estimates to be investigated. 
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 To settle controversies arising from apparently conflicting 
studies or to generate new hypotheses: Statistical analysis of 
findings allows the degree of conflict to be formally assessed, 
and reasons for different results to be explored and quantified.  
 
Meta-analyses are increasingly being used to inform on clinical 
practice in healthcare as they are able to increase the power of the 
results observed in small RCTs providing a robust and unbiased 
account of the literature with more statistical certainty. It is important 
that a meta-analysis is not performed if there is significant 
heterogeneity between studies as it has the potential to inflate small 
study bias and therefore mislead on outcome measures.  
 
3.5.2 Model type 
The most frequently used statistical model used for meta-analysis is 
the Frequentist method. This assumes that unknown parameters are 
fixed constants, with probability defined by use of limiting relative 
frequencies.  
A meta-analysis may be based on a fixed-effect or random-effects 
model. In a fixed-effect model, it is assumed that the true effect of a 
treatment is the same value in each study (i.e. homogenous or fixed) 
across the patient population enrolled, with the differences between 
each study result being due solely to chance. An example of a fixed-
effect statistical measure is the Mantel-Haenszel method. A fixed-
effect model takes the inverse variance of the estimates as weights, 
and interpretation relies on an assumption of a common effect 
underlying every study. For example, if the effect size index used is 
the d value, the fixed-effect model assumes that the population value 
of d is the same in all studies included in the meta-analysis.  
In a random-effects model, the above assumption is not made, i.e. 
the treatment effects for the individual studies are assumed to vary 
around some overall average treatment effect.(38) A random-effects 
model incorporates the underlying among-study variation of effects 
into weights, which allows for the possibility that the population 
parameter varies from study to study.(39)  
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The approach used affects the estimated overall effect and its 
corresponding 95% confidence interval, therefore it is important to 
understand this when reporting the results. There is currently no 
consensus on whether it is more appropriate to use the fixed- or 
random-effects models, hence both are usually performed by the 
author and an explanation provided as to the choice made when 
reported the findings. This choice should reflect knowledge of the 
constituent data included within the analysis.  
 
3.5.3 Challenges 
Although meta-analysis is an objective process of synthesising 
studies, there are subjective decisions to make in the process. The 
results may be biased if certain aspects are not handled 
appropriately, for example (1) robust inclusion / exclusion criteria; (2) 
suitable statistical model and methods; (3) complete reporting with 
acknowledgement of strengths and limitations. These points should 
be clearly described to enable the reader to understand the process 
and assumptions made.   
 
3.5.4 Heterogeneity 
An important aspect of both systematic review and meta-analysis is 
an assessment of the consistency of treatment effect across the 
primary studies identified against the criteria. Identified trials will have 
not been undertaken against the same protocol, and as such there 
may be variations between patients groups, clinical setting, 
concomitant care / medication, and the method of delivery of the 
intervention. The possibility of variability, or heterogeneity, between 
the results of different trials should therefore be examined. See 
section 3.5.7 for further detail.   
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3.5.5 Summary statistics 
3.5.5.1 Odds ratios 
An odds ratio (OR) is a measure of association between an 
exposure and an outcome.(40) The OR represents the odds that an 
outcome will occur given a particular exposure, compared with the 
odds of the outcome occurring in absence of the exposure. The OR 
is therefore used for a dichotomous endpoint where an event either 
will or will not occur.  
The OR is derived by dividing the number of subjects with an event 
by the number who did not have the event. The OR can be 
calculated using the simple principle [A x D / B x C] within Table 1 
below. The accuracy of the OR is based on the size of the sample, 
where in general, the larger the sample size the more robust the 
estimate is. For this reason, it is also conventional to calculate the 
95% confidence intervals for the OR.  
 
Table 1: Calculating an odds ratio 
 Response No Response 
Active Treatment A B 
Placebo C D 
 
Equation 1: Calculating the 95% confidence interval for an odds ratio 
95% CI of In(OR) = In(OR) ± 1.96    ⁄   
 
 ⁄   
 
 ⁄   
 
 ⁄  
0.5 
 
An OR > 1 proposes that the exposure is associated with higher 
odds of achieving the outcome, whilst an OR < 1 proposes that the 
exposure is associated with lower odds of achieving the outcome. 
For example, if a new medicine is being assessed compared to 
placebo for its effect on a positive endpoint (i.e. efficacy), the OR 
would need to be greater than one to demonstrate it being more 
effective than placebo.  
The 95% confidence interval (CI) is used to measure the precision 
of the OR. A large CI compared with the OR estimate indicates a 
low level of precision of the OR, whereas a small CI indicates a 
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higher level of precision. The 95% CI does not report statistical 
significance, however, the 95% CI is often used as a proxy for the 
presence of statistical significance if it does not overlap the null 
value, i.e. the OR and its 95% CI are all greater than 1.  
 
3.5.5.2 Hazard Ratio (HR) 
The hazard ratio (HR) is reported to describe an outcome where the 
parameter of interest is affected by time. Being a ratio however, the 
value only informs on the extent by which the exposure reduces (or 
increases) the risk of the outcome from occurring at a given time 
point, and does not inform on time-dependent effect; in these 
circumstances a time-to-event curve, such as Kaplain-Meier, would 
be required.  
 
The interpretation of HR is the same as for OR, keeping in mind that 
the outcome relates to a time-sensitive endpoint.  
 
3.5.5.3 Mean Difference (MD) 
The mean difference (MD), also known as difference in means, is a 
measure of the absolute difference between the mean values in two 
difference groups. The use of absolute difference also prevents 
issues with negative numbers, e.g. the difference between -1 and 1 
is 2. MD enables an assessment of continuous data. See Figure 4 
for detail.  
 
 
 
 
Figure 4: Pictorial representation of mean (absolute) difference 
 
In situations where clinical trials have reported a common endpoint 
but utilised different units of measurement it is still possible to 
compare the means between groups using standardised mean 
difference (SMD). The SMD is a way to measure effect size, it 
       -2        -1         0         1         2 
x - y 
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standardises test results to enable comparison. Depending on the 
software used the SMD may be calculated via a pooled standard 
deviation (Cohen’s d) or via a weighted and pooled standard 
deviation (Hedges’ g), the latter referred to as Weighted Mean 
Difference (WMD).  
For continuous variables, in order to calculate an MD it is required to 
have the mean, standard deviation and sample size of each group. 
For the WMD calculation, the weight given to each study (i.e. how 
much influence the study has on the overall results) is determined 
by the precision of its estimate of effect or the number of 
participants included.  
 
3.5.5.4 Number Needed to Treat (NNT) 
The number needed to treat (NNT) is a way of reporting the results 
for which the outcome measure is binary, i.e. success or failure. In 
such an analysis, the comparison of one treatment with another 
provides an NNT which is a value identifying the number of patients 
needed to be treated with the new intervention to achieve one more 
success that would have been obtained by treating with the 
standard intervention.(41) Cook and Sackett (1995) proposed that 
NNT is clinically easier to interpret than odds ratio, risk reduction, 
mean difference, etc.(42) The NNT is also more powerful as it 
provides a measure of the clinical significance of a treatment effect 
over and above statistical significance.(43)  
NNT is calculated as the reciprocal of the difference between the 
proportion of success on the new treatment and the proportion of 
success on the old treatment. For example, the proportion of 
patients with an infection successfully treated with a new 
antimicrobial is 0.533 and with the existing antimicrobial is 0.133; 
therefore the NNT is 1 / (0.533-0.133) = 1 / 0.4 = 2.5. This means, 
for every 2.5 patients treated with the new antimicrobial we will have 
one more successful outcome. The smaller the NNT, the better the 
new treatment is in comparison to the existing treatment. In general, 
the NNT would always be positive; however it is possible to 
calculate a negative result which would indicate that the new 
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treatment is more harmful / less successful than the existing 
treatment. As with OR, 95% CI are also calculated to indicate 
precision of the estimate.  
Where the endpoint under assessment is a negative one, e.g. a 
safety endpoint, the analysis would be termed number needed to 
harm (NNH) where the expectation would be for the new treatment 
to have a larger NNH i.e. treat more patients to result in one more 
negative outcome.    
 
3.5.6 Displaying the Data 
3.5.6.1 Forest Plot 
A forest plot is the graphical representation of a meta-analysis. Each 
study is represented by a black square and a horizontal line which 
corresponds to the point estimate (median) and the 95% confidence 
interval, plotted according to the same outcome measure, e.g. odds 
ratio or mean difference. The area of the black square reflects the 
weight (contribution to the overall result based on its population 
size) of the study within the meta-analysis. The 95% confidence 
intervals would contain the true underlying effect in 95% of 
occasions if the study were repeated again and again. Each line is 
accompanied by a reference (author, date, number of subjects in 
the experimental arm with mean treatment effect, number of 
subjects in the control arm with mean treatment effect, weight (%), 
and / or study outcome measure).  
 
Below the studies, an overall result will be estimated indicating the 
pooled (weighted average) outcome measure, represented as a 
diamond. The width of the diamond may be reflective of the 95% 
confidence interval if a horizontal line is not reported. The p-value 
indicates the level of statistical significance. If the estimate or its 
95% CI (or the diamond in the case of the pooled estimate) do not 
touch the line of unity, the difference found between the two groups 
will be regarded as statistically significant i.e. p<0.05. See Figure 5 
for detail. 
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A logarithmic scale is often used when plotting odds ratio data on a 
forest plot, primarily because it is easier to represent the graphics in 
this format. In this format, an effect of 0.5 and 2 represent ratios of 
the same magnitude but in opposite directions, being equidistant 
from 1, the null effect. This allows the presentation of data (e.g. 
confidence intervals) using this scale to be plotted in a more 
symmetrical format around the point estimate.  
 
 
 
Figure 5: Forest plot (example) of the treatment effect estimated from 
individual studies.  
The overall weighted pooled outcome estimated lies to the left of the line of unity (for an outcome 
where a reduction indicates a better treatment response) indicating that the interventional 
treatment (LRC) is more effective than the control treatment (ORC). As the entire diamond lies to 
the left of the line, the pooled treatment effect is considered statistically significant.   
Study 1 
Study 2 
Study 3 
Study 4 
Study 5 
Study 6 
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3.5.7 Examination of results 
3.5.7.1 Funnel Plot  
Funnel plots are used to examine bias in the results of meta-
analysis. The plot is a scatter of effect estimates from the individual 
studies against a measure of each study’s size or precision. The 
standard error of the effect estimate is often used as the measure of 
study size and plotted on the vertical axis with a reversed scale that 
places the larger, more powerful studies towards the top. The effect 
estimates from smaller studies should scatter more widely at the 
bottom. In the absence of bias and between study heterogeneity, 
the scatter will be due to sampling variation alone and the plot will 
resemble a symmetrical inverted funnel (see Figure 6). A triangle 
centred on a fixed effect estimate and extending 1.96 standard 
errors either side will include approximately 95% of studies if no bias 
is present and the assumption is valid. If smaller or non-significant 
studies are less likely to be published, trials in the bottom left hand 
corner (when a desirable outcome is being considered) of the plot 
are often omitted, creating a degree of asymmetry in the funnel 
(publication bias). Although a subjective tool, the funnel plot is 
generally considered a good explanatory tool for investigating 
publication bias.(44) 
 
Figure 6: A scatter plot (funnel plot)  
Treatment effect estimated from individual studies on the horizontal axis against the standard 
error (proxy for study size / precision) on the vertical axis. The outer dashed lines indicate the 
triangular region within which 95% of studies are expected to lie in the absence of bias or 
heterogeneity. The solid vertical line corresponds to the line of unity and therefore no intervention 
effect. Image (a) represents a symmetrical plot in the absence of bias whilst (b) depicts an 
asymmetrical plot in the presence of bias. Image reproduced from Sterne JAC et al. 2011.(44) 
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3.5.7.2 L’Abbé Plot 
L’Abbé plots are used to illustrate treatment effect for one 
intervention compared with another.(45) The l’Abbé plot visually 
expresses within group variations in observed results through a plot 
of the event rate in the treatment group on the vertical axis and the 
control group on the horizontal axis.(45) Trials in which the 
experimental treatment is better than the control will be in the upper 
left quadrant of the plot, between the y-axis and the line of equality. 
If the experimental treatment is no better than the control, then point 
estimate will fall on the line of equality, and if the control is better 
than experimental then the point will be in the lower right of the plot, 
between the x-axis and the line of equality. The dashed line 
indicates the estimated effect. The size of the points is drawn 
proportional to the study size. The l’Abbé plot helps visualize 
evidence for small study bias of which publication bias is a potential 
cause.(46, 47) See Figure 7 for detail.  
 
 
Figure 7: L’Abbé plot  
Plot indicates the event rate in the experimental (intervention) group against the event rate in the 
control group, as an aid to exploring heterogeneity of effect estimate within a meta-analysis.  
  
Treatment 
better 
than 
control 
Control 
better 
than 
treatment 
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3.5.7.3 Cochran Q statistic  
The Cochran Q is calculated as the weighted sum of squared 
differences between individual study effects and the pooled effect 
across studies, with the weights being those used in the pooling 
method which forms part of the DerSimonian-Laird random-effects 
model.(48)  
 
This statistic is based on the squared difference between the 
estimated treatment effect in one trial (Ti) and the overall estimated 
treatment effect (T) weighted by the inverse of the estimated 
variance of the treatment effect in Ti (Wi); where k is the number of 
studies being combined.  
 
Equation 2: Calculation of the overall estimated treatment effect 
 
 
Equation 3: Calculation of the Cochran Q statistic 
 
Under the null hypothesis of homogeneity, this statistic follows a 
chi-squared distribution with k-1 degrees of freedom. When the 
value of the Q-statistic is large (that is, overall the trial effects are 
far from the mean effect, taking into account sampling variance) 
this is indicative of substantial heterogeneity and the null 
hypothesis of homogeneity is rejected. If there is no evidence of 
heterogeneity, the value of Q should be approximately equal to k-
1. 
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3.5.7.4 Higgins I-squared statistic  
The I-squared statistic is a more intuitive, simpler expression 
compared with Cochran Q, which describes the proportion of 
variation across studies that is due to inconsistency rather than 
chance.(48) The Cochran Q statistic must be calculated first. As 
the statistic is expressed as a percentage, any negative values 
should be read as equal to zero. Values of I-squared equal to 25%, 
50%, 75% and 100% represent low, moderate, high, and very high 
degrees of heterogeneity, respectively.  
 
Equation 4: Calculation of the I-squared statistic 
 
I2 = 100% x 
       
 
 
 
The magnitude of heterogeneity in a random-effects model can be 
quantified by calculating a point estimate of the among-study 
variance of true effects; tau-squared. If there is no variance 
between studies, the tau-squared value would be expected to be 
low (or zero). Where a value greater than 1 is reported, this would 
suggest the presence of substantial statistical heterogeneity.   
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3.6 Network Meta-analysis (NMA) and Mixed Treatment Comparison 
(MTC) 
3.6.1 Concept 
Like the [frequentist] meta-analysis, a network meta-analysis (NMA) 
is where the results of several quantitative studies are pooled 
together if homogenous characteristics are selected. However, a 
NMA offers a set of methods to visualise and interpret the wider 
picture of the evidence and to understand the relative merits and / or 
disadvantages of multiple interventions that may not have been 
compared directly, provided a ‘loop’ of direct comparisons can be 
made somewhere in the generated ‘network’.(49) NMA is also 
commonly referred to as multiple or mixed treatment comparison. 
NMA is commonly based on Bayesian methods, considered an 
alternative approach to the Frequentist method. Under Bayesian 
methods, the parameters are treated as random variables with 
probability defined as ‘degrees of belief’ i.e. the probability of an event 
is the degree to which you believe that the event is true.  
The results an NMA estimates for each pairwise comparison is 
achieved by combining all of the ‘direct evidence’ (evidence based on 
head-to-head comparisons between interventions made within 
individual studies) with all of the ‘indirect evidence’ (comparisons 
between interventions inferred from the network via common 
comparator interventions).(49, 50) In effect, indirect evidence 
comparing the effect of interventions A and B can be inferred from the 
direct evidence provided by a trial comparing A with C and a trial 
comparing B with C. NMA thus enables estimation of relative 
intervention effect estimates for every pair of interventions, regardless 
of whether or not they have been compared directly in a RCT. It also 
enables the ranking of treatments according to the probability that 
each is the best, or worst, for a given outcome. 
 
3.6.2 Introduction  
 When multiple interventions have been used and compared for the 
same disease and outcomes, network meta-analysis (also commonly 
referred to as multiple treatment comparison meta-analysis or mixed 
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treatment meta-analysis) offers a set of methods to visualise and 
interpret the wider picture of the evidence available and to better 
understand the relative merits and / or harms of the multiple 
interventions available.(49) 
The use of network meta-analysis has advantages over the traditional 
frequentist meta-analysis, as the methodology utilises the strengths 
from indirect evidence to increase certainty about the effect of all 
treatment options and also allows for estimation of comparative 
effects that have not been investigated in a head-to-head manner in 
randomised controlled trials.(50) 
Network meta-analysis has quickly gained popularity amongst 
clinicians, guideline developers, and health technology assessment 
agencies as part of the review of new treatments in the context of 
previously available evidence and treatments.(51) For many 
comparisons, the network meta-analysis may yield more reliable and 
definitive results than would a pairwise meta-analysis. 
Despite the increasing popularity and widespread use of network 
meta-analysis, an element of resistance from clinical practitioners 
remains, likely attributed to poor understanding of the certain 
methodological and interpretational aspects of this technique. Specific 
areas that require further elucidation to ensure high quality synthesis 
of evidence in the setting of multiple treatment options include: the 
strength of evidence included; risk of bias for each trial and treatment 
comparison included within the treatment network; tools and 
assessments in detecting and / or exploring heterogeneity within and 
between treatment comparisons that have not been conducted in a 
head-to-head manner; interpretation of the statistical models used 
and the effect measures estimated by the model.(52) The authors of 
this US Hospital Evidence-based Practice Centre identified 42 
network meta-analyses used as part of evidence synthesis by 
government agencies including health technology assessment 
panels, of which the majority used Bayesian methods (80.9 percent). 
The Bayesian analyses used either non-informative priors or did not 
report detail about priors used. Surprisingly, data evaluation regarding 
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convergence, heterogeneity, and inconsistency were not consistently 
reported.  
 
3.6.3 Methodology: Bayesian Statistical Analysis 
Markov Chain Monte Carlo (MCMC) simulation (see section 3.6.6.2), 
using Gibbs sampling, is an algorithm used to generate a sequence 
of samples from a joint probability distribution of two or more random 
variables and is particularly well adapted to sampling the treatment 
effects (posterior distribution) of a Bayesian network. This approach 
was used to generate the posterior distribution for each OR of 
interest. The median of the posterior distribution was taken as the 
point estimate and the 2.5th and 97.5th centiles provided the 95% 
credible interval (CrI).  
 
In general, Bayesian CrI and frequentist CI are non-interchangeable 
as CrI incorporate problem-specific contextual information from the 
prior distribution whereas CI are based solely on the on the data.(53) 
The interpretation of Bayesian CrI is that the posterior probability that 
the parameter lies within the CrI is 95%. For analyses where there 
are no beliefs on the baseline data or the effect size in advance of the 
analysis a non-informative prior is entered (i.e. a mean of zero and 
variance of 10,000). This also permits a more direct comparison with 
a frequentist meta-analysis which does not have a capability to 
include a prior. Twenty thousand iterations are traditionally used for 
each chain in the Bayesian analysis following a burn-in of 20,000 in 
order to reduce the occurrence of heterogeneity, variation or spurious 
findings.  
 
3.6.4 Application of an MTC 
MTC is an extension of pairwise meta-analysis that allows a 
comparison of treatments that have been compared in a connected 
network of treatment comparisons, even if all the treatments have not 
been directly compared in a head-to-head manner in randomised 
clinical trials.(28, 196, 197) The strength of the MTC approach is that 
the estimation of the relative effect between two treatments uses all 
the information available from the network of evidence including direct 
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comparisons and indirect comparisons without breaking 
randomisation. 
MTC analyses are an important tool for health economists, 
statisticians, and decision modellers interested in the extension of 
pair-wise meta-analysis to network meta-analysis (i.e. indirect 
treatment comparisons and mixed treatment comparisons). It is also 
an essential tool to gain an in-depth understanding of statistical 
modelling as part of evidence synthesis in the context of clinical 
effectiveness or economic evaluation.  
Bayesian methods may be used to statistically combine evidence 
from networks of trials whilst integrating statistical estimation within a 
probabilistic modelling framework. Assumptions made in the 
underlying pair-wise comparisons used for meta-analysis are critically 
appraised and examined as well as identification and management of 
potential heterogeneity and inconsistency.  
 
3.6.5 Network Geometry 
 When conducting and interpreting a network meta-analysis it is 
important to understand the evaluation of its geometry. That is, which 
of the treatments (referred to as nodes within the network) have been 
compared to another in a head-to-head manner in randomised 
controlled trials, which of the treatments are connected via a 
statistically generated parameter (connected indirectly through one or 
more ‘common comparators’), and what is the level of evidence 
informing each comparison. By examining the connections between 
each of the interventions included in a graphical manner, the reader 
of the analysis can determine how strong the evidence is for the 
treatment as a whole and for the individual comparisons, whether 
specific comparisons are over-represented or under-represented, and 
whether the network is well connected. The better connected a 
network is, the more reliable the estimates it provides will be.  
The strength of a network and therefore the analysis it generates is 
dependent upon its geometry (degree of diversity, co-occurrence, 
homophily, and auto-looping) and appropriate assumptions to avoid 
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statistical and conceptual heterogeneity. Variations of network 
constructs are illustrated in Figure 8.  
 
 
 
 
Figure 8: Examples of network geometry that form a network meta-analysis 
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Another method of determining how strong the evidence is for the 
treatment network is to provide a comparison of the estimates 
generated for two treatments compared in a head-to-head manner 
from a frequentist meta-analysis to the estimate generated by the 
network meta-analysis. Figure 9 provides an illustration of the 
‘complex’ geometry of a treatment network, which includes 34 
randomised pairwise comparisons of which warfarin (n=20), aspirin 
(n=16) and placebo (n=12) have the most links. Overall, 45 possible 
pairwise comparisons can be made between the nine treatments. Of 
these, 16 comparisons are informed directly by head-to-head 
evidence, but six of the direct connections have only one trial 
supporting the evidence. Therefore, a number of the comparisons 
that have not been directly studied are informed by indirect evidence 
from only two trials. Data generated by the model for nodes within the 
network that are not connected should be interpreted with caution. 
The diversity and strength of a network are determined by the number 
of different interventions included, the number of comparison of these 
interventions that are available, how represented they are within the 
network, and how much evidence they carry. For networks where 
there is a severe imbalance in terms of the amount of evidence or 
published data available for each intervention, there is potential that 
this will adversely affect power and reliability of the overall 
analysis.(54, 55) This is due to statistical inferences being made 
largely from the data provided by one or a few treatments within the 
network. 
Although the key strategy of meta-analysis is to strengthen the 
estimation of results through the pooling of similar data, evidence 
procured from small trials may be susceptible to a higher degree of 
bias (for example, more prominent publication and selective reporting 
bias) as well as showing spuriously larger treatment effects.  
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Figure 9: Geometry of a well-connected network of randomised controlled trials  
Example illustrates an evaluation of stroke prevention among populations with atrial fibrillation (AF).(56) 
Circles represent the drug as a node in the network; lines represent direct comparisons using RCTs; the 
thickness of lines represents the number of RCTs included in each comparison, also represented by the 
numbers.  
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3.6.6 Bayesian Statistics 
The use of statistical analyses in the 20th century favoured the 
frequentist statistic; however, a number of flaws in its design and 
interpretation were being apparent. These largely centred around the 
estimates being based against a fixed statistic (i.e. the p-value and 
the 95% confidence intervals). The use of Bayesian statistics has 
recently seen resurgence as a solution to a number of important 
problems in medicine being a method to determine the likelihood of 
the occurrence of an event. 
Bayesian statistics is a mathematical procedure that applies 
probabilities to statistical problems. An important difference compared 
with Frequentist analysis being the inclusion of prior beliefs (see 
Figure 10) although this is not necessary. A Prior is acquired from 
knowledge of the area of study but is independent to the current 
study, such as knowing what effect a placebo has on an outcome 
influences the baseline from which an intervention becomes 
important. An example in lay terms is provided below: 
Scenario Frequentist reasoning Bayesian reasoning 
Situation 
I have misplaced my 
phone somewhere in the 
home. I use the phone 
locator button on the base 
of the phone holder to 
activate the ring on the 
phone. I am then able to 
locate the phone by 
responding to the ring. 
Problem 
Which area of the home 
should I search? 
Solution 
I hear the phone ringing. I 
use my ears to identify 
where the sound is 
coming from. Therefore, 
upon hearing the ring, I 
infer the area of the home 
I should search to locate 
the phone. 
Solution 
I hear the phone ringing. 
In addition to using my 
ears, which will identify 
where the sound is 
coming from, I use my 
prior knowledge of where 
I have previously left or 
misplaced my phone. I 
combine my prior 
knowledge with the 
ringing to infer the area of 
the home to search in 
order to locate the phone. 
  
Another key difference is that the estimates generated report results 
with a 95% credible interval (CrI) rather than a confidence interval. As 
this is based on probability, the CrI reports the 95% most credible 
values, and indirectly guarantees that 95% of the values will like 
within the range specified, unlike the 95% confidence interval.    
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There are three key areas where the use of Bayesian methods is 
most informative (see below). As such, the use of Bayesian methods 
has been slowly adopted by NICE within their HTA process since 
2000.(57) 
1. Estimation of clinical effectiveness 
2. Modelling of cost-effectiveness 
3. Dealing with difficult / complex situations 
 
 
 
 
 
 
 
Figure 10: Illustration of the Bayesian distribution (analytical model)   
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3.6.6.1 WinBUGS 
WinBUGS (a Microsoft operating system version of BUGS: 
Bayesian Analysis Using Gibbs Sampling) is a versatile package 
that has been designed to carry out MCMC computations for a wide 
variety of Bayesian models. The software is distributed electronically 
and available free-of-charge directly from the BUGS project 
website.(58) This form of logistic regression analysis combines both 
direct and indirect data without breaking randomisation within a 
MCMC framework. Within this approach, indirect estimates can be 
combined in large samples if there is no interaction between the 
treatment effects and the populations or major subgroups in a 
trial.(59) 
WinBUGS can be used in statistical problems as simple as 
estimating means and variances or as complicated as fitting 
multilevel models, measurement error models, and missing data 
models.  
WinBUGS fits fixed-effect and multi-level (random-effects) models 
using Bayesian statistics, whilst Stata fits fixed-effects and limited 
multi-level models using maximum likelihood or generalised least 
squares. If no prior or a minimally-informative prior is used then the 
inferences from the two software should be numerically similar and 
the 95% confidence interval would be very similar to the 95% 
credible interval.  
The use of WinBUGS software has numerous advantages but also 
requires care in its use. The ‘burn in’ should be conservatively large 
to reduce inconsistency in the model outputs; a suggested minimum 
is 10,000 although 20,000 is conventionally used. Burn in refers to 
the practice of discarding an initial portion of a Markov Chain so that 
the influence of the initial value on the posterior inference is 
minimised. This is done on the assumption that after t iterations the 
chain has reached its target distribution and the earlier portion is 
discarded, using only the good samples for posterior inference. The 
value of t is the burn in number. Particular care must be taken in 
checking convergence, with sampling from the posterior distribution, 
as detailed within the manual. The Monte Carlo error (MCe), which 
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reflects both the number of simulations and degree of 
autocorrelation, should be no more than 5% of the posterior 
standard deviation of the parameters of interest (see section 
3.6.8.1).  
A step-by-step user guide developed to ensure consistency in 
application of WinBUGs throughout the thesis is described in 
section 10.2 (Appendix II: WinBUGS user guide).  
 
3.6.6.2 Markov Chain Monte Carlo (MCMC) 
The MCMC method is a general simulation method for sampling 
from posterior distributions and computing posterior quantities of 
interest. The MCMC procedure is used to generate a value for each 
parameter, by sampling randomly from its conditional distribution. 
This then acts as the ‘known’ value for that parameter. This process 
is carried out iteratively. A new parameter value is sampled from the 
distribution of each parameter in turn, and is used to update the 
‘known’ values for the conditional distribution of the next parameter. 
The phrase ‘Markov Chain’ refers to the fact that the procedure is 
based only on the last sampled values of each parameter, while 
‘Monte Carlo’ refers to the random sampling of the parameter 
values.  
Where used correctly, i.e. the chain is run for a very long time (burn 
in period of 10,000 iterations), the Markov Chain is guaranteed to 
converge to the target distribution. The initial values are discarded 
and the next say 10,000 iterations are recorded corresponding to 
the posterior distribution. The MCMC method has been successful 
in Bayesian MTC analysis. 
 
3.6.6.3 Coding 
The NICE Decision Support Unit publishes a series of Technical 
Support Documents on Evidence Synthesis. These describe the 
analytical approach for meta-analyses in order for the estimates 
generated to be appropriate for cost-effectiveness analysis and 
comparative effectiveness research.(60) Within the summary 
document, guidance on ‘good practice’ is provided recommending 
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how the evidence should be presented, including use of network 
diagrams and content of the results tables. Document 2 specifically 
outlines the framework for the synthesis of data when taking a 
Bayesian approach, with WinBUGS program code for a Bayesian 
analysis using MCMC simulation templates provided.  
For each of the analyses performed within this thesis, the WinBUGS 
program code developed for National Institute for Health and 
Clinical Excellence (NICE) was adapted for the MTC analysis. (61-
63) This coding can synthesise data from pair-wise meta-analysis, 
multi-arm trials, indirect comparisons and network-meta-analysis. 
The WinBUGS package computes and presents the analyses in 
both numerical and graphical outputs.  
 
3.6.6.4 Trade-Off Analysis 
An analysis of the strengths and weaknesses of a medicine is 
traditionally done following a review of its efficacy, safety, 
convenience and cost relative to alternatives available. This process 
is conventionally undertaken in a qualitative manner by a visual 
assessment of a summary table of one agent with another.  
In a Bayesian framework, probabilities regarding the distribution of 
parameters are estimated. In each MCMC cycle, each treatment ‘j’ 
is ranked according to the estimated effect size. The proportion of 
the cycle in which a given treatment ranks first out of the total gives 
the probability ‘P(j=1)’ that treatment j ranks first i.e. that this 
treatment is the best among the available treatment options. Similar 
probabilities are estimated for being the second best, the third best, 
etc. These probabilities sum to one for each treatment and rank.(64)  
The ‘Rank Monitor Tool’ is a built in function in WinBUGS which is 
used to estimate the median probability and its 95% confidence 
interval. The output is presented in table format, therefore in order to 
simplify its interpretation the values can be presented in graphical 
format in the form of a rank-o-gram (see Section 3.7.2).  
Using the principle that clinicians and patients consider a range of 
different endpoints when considering if a treatment is the best, the 
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rank-o-gram is able to accommodate multiple endpoints (each of the 
efficacy and safety / tolerability analyses performed) that WinBUGs 
has estimated in order to visualise an overall effect. For the purpose 
of this thesis, each endpoint included within this analysis is weighted 
equally and subject to careful interpretation in its reporting.   
 
3.6.7 Displaying the Data 
3.6.7.1 Box Plot 
A useful diagram to demonstrate values in this manner is a box (and 
whiskers) plot, as shown in Figure 11. The box is drawn from the 
lower quartile to the upper quartile; its length therefore provides the 
interquartile range. The horizontal line in the middle of the box 
represents the median. The ‘whiskers’ in the plot mark the extent of 
the data with 95% confidence. They are drawn on either end of the 
box to the minimum and maximum values. 
 
Figure 11: Box and whiskers plot 
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3.6.8 Examination of NMA Results 
3.6.8.1 Convergence 
An assessment on convergence should be undertaken to determine 
if the inferences from the MCMC simulation approach are reliable. 
Inferences based on non-converged Markov chains can be both 
inaccurate and misleading. This may be done via visual assessment 
of trace plots of the posterior distribution. Convergence of Markov 
chains is deemed to be achieved if plots of the Gelman–Rubin 
statistics indicate that the widths of pooled runs and individual runs 
stabilise around the same value.(65) It is difficult to determine 
conclusively that a chain (simulation) has converged, therefore the 
visual assessment aims to establish where it has not occurred (see 
Figure 12). Successful convergence is displayed in the plots as 
minimal fluctuations (e.g. ± 10) around an alpha point. The visual 
assessment should be corroborated through assessment of the ratio 
of the Monte Carlo error (MCe) with its standard deviation (SD) 
which confirmation of convergence validated with the value being 
sufficiently small (i.e. MCe/SD <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Trace plot (WinBUGs) examples of (top) chain where the 
convergence looks reasonable, and (bottom) chain which has clearly not 
reached convergence 
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3.6.8.2 Inconsistency (Bucher’s Test) 
The comparison of treatments from different RCTs gives rise to 
incomplete block structures referred to as a network or mixed 
treatment comparisons (MTC). In the analysis of outputs from such 
data structures it is important to determine whether the disparate 
evidence sources provide consistent information or if the pairwise 
comparisons are incoherent. This analysis considers whether or not 
there is any inconsistency between the loops of evidence created of 
indirect comparisons in the estimation of pairwise comparisons 
rather than between the individual trials included.(59, 66) The test 
itself involves an assumption that indirect evidence is consistent 
with direct comparisons.  
 
The variance is determined, for example, by comparing the 
difference between treatment A and B in RCT-1 (dAB) with the 
difference between treatment A and C in RCT-2 (dAC), where 
treatment A is the common comparator to establish the indirect 
comparison of treatment B and C. Where there are multiple trials 
that compared treatment A and B or A and C, the results used will 
be the estimates generated by the meta-analysis. 
 
Equation 5: Calculation of indirect comparison  
   d ind BC = dAB – dAC 
 
 Equation 6: Calculation of variance of calculated indirect comparison 
  Var (d ind BC) = Var (dAB) + Var (dAC) 
 
The inconsistency test is then determined through an assessment of 
the calculated difference compared with the actual difference. 
Based on the assumption that there is no difference between 
indirect and direct values, the test results should equal zero. The Z-
statistic and a corresponding p-value are used to determine if the 
difference is statistically significant. A Z-statistic value greater than 
1.96 (and p-value less than 0.05) are indicative of a statistically 
significant difference and poor model fit.(67)  
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3.6.8.3 Goodness of Fit 
Like the Cochran Q statistic for Frequentist meta-analysis, the sum of 
squared deviance (SumDev) residuals depicts how ‘good’ the data 
estimated fits within the model through a summary of the discrepancy 
between observed values and the values expected under the model. 
An assessment of the ‘goodness of fit’ of the model should be 
conducted through analysis of the posterior mean of the sum of the 
residual deviance contributions of each data point.(62, 68) A good fit 
would give a result that approximates the number of data points 
included within the analysis (N); a result which could only occur when 
the posterior distribution is approximately multivariate normal or the 
total population included within the analysis (aggregate of all studies) 
follows a normal distribution. Using the chi-squared distribution, the 
right-tailed probability can be calculated by a comparison of the 
SumDev and N, where a p-value less than 0.05 indicates poor model 
fit.  
 
3.6.8.4 Deviance Information Criterion (DIC) 
DIC is equal to the sum of the posterior mean of the residual deviance 
and the effective number of parameters.(68) The DIC penalises the 
posterior mean residual deviance (a measure of model fit) by the 
effective number of parameters in the model (as measure of 
complexity) and can therefore be viewed as a trade-off between the 
‘goodness of fit’ and ‘complexity’ of the model. Models with smaller DIC 
are better supported by the data.  
 
3.6.8.5 Bland-Altman Plot 
A Bland-Altman plot (agreement plot) is a method of displaying data 
to analyse the level of agreement between paired data, or conversely 
identify systematic difference between measurements or possible 
outliers. Values plotted should sit around the mean difference and 
within the boundaries of 95% confidence. The Bland-Altman plot will 
only graphically demonstrate if a data fall within the intervals of 
agreement, it is unable to dictate if these limits are acceptable. The 
limits should be based on clinical relevance.(69, 70) 
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3.7 Reporting of Trade-off Analysis 
3.7.1 NNT / NNH Plot 
For analyses where a single efficacy and a single safety / tolerability 
endpoint are defined as the parameters of interest for a trade-off 
assessment it is possible to convert these into their corresponding 
NNT and NNH. Like with a forest plot of odds ratio, a plot of NNT 
(vertical axis) versus NNH (horizontal axis) would be presented on a 
logarithmic scale. Treatments that feature in the lower right of the plot 
(i.e. low NNT and high NNH) are considered highly efficacious and 
well tolerated, ranking highest from the range of treatments 
investigated. Treatments within this cluster would be identified as the 
priority for future head-to-head RCT comparative studies.   
 
3.7.2 Rank-o-gram 
For analyses where multiple endpoints are defined as the parameters 
of interest for a trade-off assessment, the best graphical tool to 
present the probability of each treatment for multiple endpoints in a 
rank format is a line-graph known as a rank-o-gram. The peak 
probability (vertical axis) will be associated with a corresponding rank 
number (horizontal axis).(71) A peak probability at a rank of 1 would 
usually indicate the best treatment for a positive endpoint (i.e. 
efficacy), whereas this is likely to indicate the worst treatment for a 
negative endpoint (i.e. safety). These ‘rank probabilities’ can be 
estimated directly from WinBUGS. A similar method is available in 
other software whereby the surface under the cumulative ranking 
curve (SUCRA) is presented.  
 
3.7.3 Cost-Effectiveness Acceptability Curve (CEAC)  
For analyses that have included cost within a formal cost-
effectiveness assessment, it is conventional to perform sensitivity 
analyses to model potential variables in the population characteristics 
(e.g. age) or model inputs (e.g. cost of treatment). A recognised 
output of this analysis is a cost-effectiveness plane or acceptability 
curve, where the probability of an intervention being cost-effective is 
plotted against a specified value. Treatments that feature on the top 
left of the plot (i.e. with the highest score of probability at the lowest 
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willingness to pay) are the most dominant. The critical section of the 
plot is treatment(s) that appear with the highest probability in the 
£20,000 to £30,000 range.  
 
3.8 Pharmacoeconomics  
Pharmacoeconomics identifies, measures and compares the costs and 
consequences of drug therapy to healthcare systems and society. A 
number of economic techniques and evaluations may be used to 
compare two or more treatments available with the outcome measured 
in terms of cost and quality. The primary purpose of such economic 
evaluations is to enable budget-holding decision makers to consider 
the relative and absolute values of the available resources. 
Collaboration and expert support were sought for these aspects of the 
research projects in order to enhance the frequentist and Bayesian 
analyses. The additional parameter of cost enabled progress of the 
findings to guideline development. Further description is provided 
within each chapter. 
 
3.8.1 Cost-Effectiveness Analysis (CEA) 
A cost-effectiveness analysis (CEA) is a form of economic analysis in 
which consequences of different interventions are measured using a 
single outcome, usually in ‘natural’ units (for example, life-years 
gained, deaths avoided, heart attacks avoided or cases detected). 
Alternative interventions are then compared in terms of cost per unit 
of effectiveness.(72) Costs included within the analysis may be direct 
(medicines, staff, equipment, transport), productivity (carers, loss of 
income), or intangible (pain, suffering, adverse effects).  
It is an important component of analysis as it directly relates the 
financial and scientific implications of providing different interventions 
to a defined population as identified within the model created. The 
CEA calculation involves dividing the cost of an intervention in 
monetary units by the expected health gain measured in natural units 
(such as lives saved), producing a cost-effectiveness ratio.  
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3.8.2 Cost-Utility Analysis (CUA) 
A cost-utility analysis (CUA) is a form of financial analysis used to 
guide commissioning decisions, largely utilised by policymakers, with 
the specific output described in utilities, most commonly quality of life. 
The most commonly seen and well-known applications of this type of 
analysis is within the field of pharmacoeconomics, particularly used 
by NICE within the program of Health Technology Assessments 
(HTA). 
The CUA was developed to address the problem of CEA, which did 
not allow decision makers to compare the value of interventions for 
different health problems. As healthcare costs continue to rise the 
CUA becomes more applicable as it captures the value of 
improvement in morbidity and mortality.  
 
3.8.3 Cost-Minimisation Analysis (CMA) 
A cost-minimisation analysis (CMA) is a method of calculating drug 
costs to project the least costly medicine or therapeutic modality. This 
method is used when evaluating the costs of a specific drug 
compared with another, rather than a variety of alternatives. This 
method can also only be used when two treatments have been shown 
to be equivalent in their therapeutic effect (i.e. there is no incremental 
benefit) and therefore the cost is the only variable.   
 
3.8.4 Quality Adjusted Life Year (QALY) 
A quality adjusted life year (QALY) is a measure of health as 
combination of the duration of life and the health-related quality that 
an individual experiences within that duration.  
 
3.8.5 Incremental Cost-Effectiveness ratio (ICER)  
The cost per QALY, otherwise referred to as incremental cost-
effectiveness ratio (ICER) is the ratio between the difference in costs 
and the difference in benefits of two interventions. The ICER may be 
stated as (C1 – C0) / (E1 – E0) in a simple example where C0 and E0 
represent the cost and gain, respectively, from taking no health 
intervention action. C1 and E1 would represent the cost and gain, 
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respectively of taking a specific action. So, an example in which the 
costs and gains, respectively, are £140,000 and 3.5 QALYs, would 
yield a value of £40,000 per QALY. These values are useful for policy 
makers to determine relative priorities when determining treatments 
for disease conditions. It is important to note that CUA measures 
relative patient or general population utility of a treatment.  
In the UK, NICE is believed to have a threshold of about £30,000 per 
QALY – roughly twice the mean income after tax. Thus, any health 
intervention which has an incremental cost of more than £30,000 per 
additional QALY gained is likely to be rejected and any intervention 
which has an incremental cost of less than or equal to £30,000 per 
extra QALY gained is likely to be accepted as cost-effective. This 
implies a value of a full life of about £2.4 million.  
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4.0 Chapter 4: Research Project One – Antiepileptic 
drugs for Refractory Epilepsy 
 
4.1 Introduction 
This first research project explores the use of the quantitative trade-off 
methodology in pilot form following Bayesian network meta-analysis. 
This form of analysis is under-utilised within the evidence-based 
healthcare setting when attempting to determine the relative benefits 
and weaknesses of similar interventions. The Bayesian methodology 
will be undertaken to conduct a network meta-analysis of all published 
studies comparing anti-epileptic drugs for refractory epilepsy that meet 
strict criteria from randomised-controlled trials, including of head-to-
head design where available, to obtain estimates on their relative 
efficacy and safety. The use of a Bayesian meta-analysis rather than 
the traditional frequentist analysis will be suitable for this project as 
only a limited number of published trials have investigated these 
agents in a direct head-to-head comparison. The trade-off parameters 
selected for this analysis include 50% responder rate (reduction in 
seizure frequency from baseline) vs. withdrawal rate for the efficacy 
and tolerability endpoints, respectively. Both parameters are weighted 
equally.  
 
The goal for this project is to understand the strengths and limitations 
that currently exist with trial design within this therapeutic area, the 
potential for using this novel analysis, and to influence prescribing at 
the local specialist centres.  
 
4.2 Literature Review 
4.2.1 Epilepsy 
Epilepsy is a chronic, complex, neurological condition characterised 
by recurrent, unprovoked seizures.(73) Epilepsy is a heterogenous 
group of disorders that have been classified by the International 
League Against Epilepsy (ILAE).(74) Approximately 60% of patients 
diagnosed with epilepsy have localisation related (focal, local, partial) 
epilepsy, where generalised epilepsy accounts for approximately 40% 
of cases.(75) Epilepsy is a common disorder worldwide, affecting 50 
per 100,000 people,(76) with an estimated 400,000 individuals in the 
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UK, and responsible for over 1,000 deaths per year as a result of 
poor management.(77)  
 
4.2.2 Current Management 
Although a common condition, there are relatively few epilepsy 
specialists within the NHS, with many people with epilepsy being 
diagnosed and treated by non-specialists in both primary and 
secondary care. Consequently, there is data to support the claim that 
the management of this condition can often be sub-optimal.(78) Areas 
of specific concern include initial diagnosis and drug management. 
 
4.2.3 Licensing Regulations 
In the era of evidence-based practice, which is increasingly governing 
the practice of physicians, the choice of which AED to prescribe 
should be based upon the results of comparative randomised 
controlled trials (RCTs), or systematic reviews, however, at present 
there is insufficient guidance to assist clinicians on which AED to 
preferentially prescribe for patients with refractory epilepsy.(79) This 
is the consequence of pharmaceutical companies creating trial 
designs in order to comply with regulatory criteria (rather than a more 
enhanced clinically relevant design) as this is the minimum required 
to attain a Marketing Authorisation.   
 
In the first instance, new AEDs are tested in patients with refractory 
partial epilepsy as add-on treatment in randomised, placebo-
controlled trials. Few trials are subsequently conducted to compare 
such agents with traditional AEDs or indeed another new AED. 
Consequently, the selection of an AED for a patient by their physician 
remains based on an empirical assessment of the probability of 
achieving seizure freedom and associated side-effect profiles, rather 
than on the rational application of a treatment that corrects a specific 
functional or biochemical abnormality.(80) Based on this, there are 
currently no reliable tools to predict which AED, among the many 
known to be active against a given seizure type, will control the 
seizures in an individual patient; AED therapy is thus based mainly on 
a trial-and-error approach.(81) 
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4.2.4 Current Evidence and Gaps in the Literature 
For patients with newly-diagnosed partial and generalised tonic-clonic 
seizures, a variety of comparative, randomised, double-blind trials 
suggest similar efficacy [time to treatment failure, 12 month 
remission, or time to first seizure] for the traditional AEDs; phenytoin, 
carbamazepine, and sodium valproate, as for the newer AEDs; 
lamotrigine, and oxcarbazepine.(82-88)  
 
With regards to refractory partial-onset epilepsy,(89) have previously 
conducted a meta-analysis, showing that all of the newer AEDs are 
clearly more effective than placebo; however, with overlapping 
confidence intervals, the authors were unable to conclude which one 
was the most effective. Tolerability was also considered within this 
analysis, where the same conclusion was reached. As this analysis 
was performed over a decade ago, with the inclusion of unpublished 
studies and without some of the AEDs licensed in the UK at the 
present day, its conclusions are now outdated. 
 
In 2000, the ILAE published an evidence-based guideline to assist 
clinicians with the treatment of epilepsy, however, a hierarchy was not 
presented within the final document. This was due in part to a lack of 
published head-to-head randomised-controlled trials. 
 
Following a systematic review of published and unpublished data by 
NICE, a clinical guidance document (CG20) was published, providing 
guidance to physicians on which AEDs to prescribe at what stage and 
for which epilepsy classifications.(90) This guidance, however, still 
requires the physician to make a choice between up to five 
recommended AEDs per classification. An updated version has been 
published (CG137) however the limitation in their conclusion 
remains.(91) 
 
4.2.5 Issues with Current Literature 
Organisations actively involved in the production of guidelines on 
various aspects of epilepsy therapy include the ad-hoc 
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subcommittees of the American Academy of Neurology (AAN), and 
the American Epilepsy Society (AES); as well as the Scottish 
Intercollegiate Guidelines Network (SIGN); the U.K. National Institute 
of Clinical Excellence (NICE); and the International League Against 
Epilepsy (ILAE). 
 
Of the reviews conducted to date, none of the above have 
conclusively stated which of the AEDs available should be prescribed 
preferentially. Subsequently, the anticipated guidelines produced 
were not able to fully inform clinical practice as they did not present 
their findings in the form of a treatment algorithm. The major 
usefulness of this work however is that it highlighted the paucity of 
well-designed trials in this area of medicine where inadequate 
statistical inferences are often made to power the data to deliver a 
clinically meaningful result.(92)  
 
4.3 Rationale for this Research Project 
A recent review conducted by the National Institute for Health 
Research (NIHR, 2008) concluded that although a number of new 
AEDs have been licensed over the past decade, for several reasons, 
the trial data upon which these licenses were based have failed to 
inform clinical practice or policy.(93) A recent Health Technology 
Appraisal published by NICE also indicated that there is a need for 
more direct comparative data of newer versus newer, and newer 
versus older AEDs within clinical trials, with consideration given to 
different treatment sequences within both monotherapy and adjunctive 
therapy.(94)  
 
Various guidelines have been published over the past decade; 
however, physicians still continue to make individual prescribing 
decisions.(95) Consequently, significant variability in prescribing 
continues to be common place in clinical practice. This situation is 
perpetuated by physicians being presented with an increasing choice 
of new AEDs to prescribe for patients with refractory epilepsy, as data 
suggests their superiority over the traditional AEDs.(96) 
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Although RCTs are the gold standard of research methodology, the 
conduct of a large trial is very time consuming and expensive, hence 
the reluctance in uptake from the epilepsy research community. 
Decisions about the utility of an intervention or the validity of a 
hypothesis should be taken with caution based on the results of small 
RCTs, as results typically vary from one study to the next. Systematic 
reviews are increasingly conducted to summarise the available 
published data. 
 
4.4 Collaboration 
All work undertaken within this chapter of the thesis was undertaken by 
me. Systematic review support was provided by Dr Grosso in the form 
of a second independent check against the proforma. Advice and 
tuition on the use of WinBUGS was provided by Mr Wonderling with all 
analyses performed by me.  
 
4.5 Protocol 
4.5.1 Systematic Review 
Relevant randomised trials were searched for within the Cochrane 
Central Register of Controlled Trials (Cochrane Library 2009, issue 
2), which contains the Epilepsy Group’s specialised register, Medline 
(1950–March 2009), Embase (1980–March 2009) and Current 
Contents Connect [part of the ISI Web of Knowledge] (1998–March 
2009). The search terms and limits are provided below (see section 
4.5.4).  
 
In addition to the database search strategy, the reference lists of 
identified manuscripts were manually hand-searched to identify 
additional relevant studies. To formulate and ensure optimal reporting 
of the systematic review and meta-analysis, the established PRISMA 
[preferred reporting items for systematic reviews and meta-analysis] 
statement was followed.(97) 
 
4.5.1.1 Inclusion Criteria 
Trials were included if they were of randomised, double-blind, 
placebo-controlled or active-controlled add-on design 
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(investigating acetazolamide, carbamazepine, clobazam, 
clonazepam, ethosuximide, gabapentin, lacosamide, lamotrigine, 
levetiracetam, oxcarbazepine, phenobarbital, phenytoin, 
pregabalin, primidone, sodium valproate, tiagabine, topiramate, 
valproic acid, vibabatrin or zonisamide), provided they recruited 
adult patients (> 18 years) with simple / complex partial seizure 
with or without secondary generalised tonic-clonic seizures, were 
of parallel or cross-over design, of at least 8 weeks duration and 
reported seizure frequency and / or adverse effects as an 
outcome. 
 
4.5.1.2 Exclusion Criteria 
Studies were excluded if they contained a pre-randomisation run-in 
response-conditional design where patients were allocated 
treatment only if they showed a pre-determined response or if 
randomisation was preceded by an open-label period in order to 
minimise the inclusion of data from an enriched population.  
 
Additional exclusion criteria were: trials which incorporated a 
surgical intervention; trials which used other therapies which may 
affect seizure frequency; trials of open-label design; observational 
studies; conference proceedings; and publications available only in 
abstract form. Non-English language publications were also 
excluded (see Figure 13). 
 
The purpose of imposing these specific exclusion criteria was to 
permit extraction of data from the most robustly conducted studies 
of a similar design. Eligible studies identified were cross-checked 
against previous systematic reviews. 
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Figure 13: The PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) flow diagram of studies identified from the systematic review for 
inclusion in the network meta-analysis for refractory epilepsy 
 
 
 
 
431 potentially relevant studies identified for retrieval 
from the following electronic databases: 
 139   MEDLINE (via PubMed) 
 184   Cochrane [CENTRAL] 
 17     Cochrane [Epilepsy Register] 
    74     EMBASE (via OVID) 
   17     Current Contents 
38 studies met the pre-specified inclusion criteria 
393 studies excluded for the following reasons: 
 26    not double-blind 
    5 treatment period <8 weeks 
    34    did not evaluate the pre-specified  
    endpoint 
 286  duplications between databases 
21   seizure type (not refractory partial or 
secondary generalised) 
6 data extraction not possible due to 
reporting methods 
6 investigational drug not licensed for 
partial epilepsy  
 9 reviews 
43 studies included within the review  
5 additional studies included following a hand 
search from the references of included 
studies.  
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4.5.2 Endpoints 
Two primary endpoints were included as part of this review: 
 
1) The efficacy endpoint, specified a priori, was responder rate 
defined as a 50% reduction in seizure rate from baseline, as 
recommended by the European Medicines Agency (EMA) for 
investigations of medicinal products for the management of 
epilepsy. For studies that did not report their results in this 
manner, we calculated the proportion of patients with a 50% 
reduction in seizure rate through analysis of seizure diary rate at 
end of study minus baseline seizure rate.  
 
2) The tolerability endpoint, specified a priori, was the incidence of 
premature withdrawal from treatment due to drug-related adverse 
events. Where trials included groups randomized to different 
doses of the same drug, we selected the group receiving the dose 
closest to that in established use based on the clinical experience 
of senior members of the research project. 
 
4.5.3 Quality Assessment and Data Collection 
Data from systematic reviews or previous meta-analyses were not 
used to enable the collection of data from original sources; however, 
any such publications identified served as a comparator to ensure 
that all relevant studies had been included within this review. 
Secondary searches were conducted from the reference lists of 
manuscripts identified. To minimise bias, a second investigator 
(AMG) was included at this stage to review the references and 
abstracts retrieved by the search and select potentially relevant 
publications against the pre-specified inclusion and exclusion criteria. 
Important clinical and methodological study characteristics were 
extracted onto a standard form, checked and recorded to ensure 
consistency.  This included:  
 
1) Characteristics of trial participants (including age, prior therapy, 
and seizure type) 
2) Type of intervention (including type, dose, and duration) 
3) Type of outcome measure.  
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Any discrepancies or lack of agreement between the two reviewers 
were referred to a third independent investigator (ADH) for arbitration. 
An assessment of risk of bias (using established criteria)(27) was also 
undertaken. All analyses were based on intention to treat data. For 
any trials that reported data using a per-protocol analysis, intention to 
treat values were calculated. 
 
4.5.4 Search Terms 
See Table 2 and Table 3 for a list of the search terms and limits 
applied when conducting the database search. 
 
Table 2: Search strategy used to determine eligible published trials 
 Search term 
01. Epilepsy/ 
02. Epilepsy.tw 
03. Seizures/ 
04. Seizure$.tw 
05. Convulsions/ 
06. Convulsion$.tw 
07. Or/1-6 
08. Acetazolamide/ 
09. Carbamazepine/ 
10. Clobazam/ 
11. Clonazepam/ 
12. Ethosuximide/ 
13. Gabapentin/ 
14. Lacosamide/ 
15. Lamotrigine/ 
16. Levetiracetam/ 
17. Oxcarbazepine/ 
18. Phenobarbital/ 
19. Phenytoin/ 
20. Pregabalin/ 
21. Primidone/ 
22. Sodium valproate/ 
23. Tiagabine/ 
24. Topiramate/ 
25. Valproic acid/  
26. Vigabatrin/ 
27. Zonisamide/ 
28. Or/8-27  
29. Monotherapy.tw 
30. Adjunctive.tw 
31. 29 or 30 
32. Randomized controlled trials/ 
33. Randomized-controlled-trial.pt 
34. Or/32-33 
35. Treatment outcome.tw 
36. Tolerability/ 
37. Safety/ 
38. Side effects/ 
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39. Adverse effects/ 
40. Adverse events/ 
41. Or/35-40 
42. 7 and 28 and 31 and 34 and 41 
 
 
Table 3: Limits applied to each database as part of the systematic review 
Database Limits applied 
PubMed Humans; Randomised controlled trial; English; all adult: 19+ years 
Cochrane Central Register of Controlled Trials 
Embase Full text; Human; English language ; Article OR Erratum; Adult <18 to 64 years> OR aged 
<65 years+  
Current 
Contents 
English language; Article [document type]; Randomised Controlled Trial 
 
4.5.5 Quantitative (Statistical) Analysis – Frequentist Meta-Analysis 
Statistical analyses were performed in two stages. For the first stage, 
a random-effects ‘frequentist’ meta-analysis(38) was conducted, for 
placebo-controlled trials of AEDs for refractory epilepsy. The endpoint 
of interest was the calculation of a pooled odds ratio (OR) with 
corresponding 95% confidence interval (CI) for both the efficacy and 
tolerability endpoints. To evaluate heterogeneity of the effect 
estimates the Cochran Q (Chi-squared), Higgins I-squared and tau-
squared statistics were generated.(48)  
 
To explore potential inconsistency and small study bias further l’Abbé 
and Funnel plots, respectively, were generated.  
 
To generate the Forest plots and Funnel plots, Review Manager 
(RevMan) version 5.0 (Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2008) was used. To generate the l’Abbé 
plots, StatsDirect® 2.7.7 (Altrincham, Cheshire, UK) was used.  
 
4.5.6 Statistical Analysis – Bayesian Network Meta-Analysis 
For the second stage, the relative effectiveness and tolerability profile 
of each AED was analysed using an extension of the multivariate 
Bayesian hierarchical random-effects model for mixed multiple 
treatment comparisons using minimally informative prior 
distributions.(31, 98-100) The model included random-effects at the 
level of trials (see Figure 14 and Figure 15) which allowed the 
estimation of the variance of treatment effects between trials. Due to 
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the non-discrete methodology used within trials investigating 
antiepileptic drugs (i.e. dose escalation over the active period) the 
network meta-analysis was performed using only one evidence 
network i.e. the different agents (at the most appropriate dose) were 
treated as separate nodes.    
 
The control event rate used within the model was 0.16 for efficacy 
and 0.05 for tolerability. These were calculated as the mean across 
the studies which met the inclusion criteria as a means of determining 
the placebo-corrected response across the treatment network. The 
control event rate is synonymous with the minimally-informative prior.  
 
As number needed to treat (NNT) and number needed to harm (NNH) 
have increasingly been noted as being more clinically useful 
parameters in highlighting treatment effects, these summary 
estimates were calculated from the relative risk (RR) estimates 
generated by WinBUGS using one of the following equations: 1/(1 - 
RR) x CER if the RR was <1 or 1/(RR - 1) x CER if the RR was 
>1.(22) The 95% CrI values for NNT and NNH were estimated using 
the 95% CrI estimated for the RR using the same formulae above. A 
treatment hierarchy was also developed on the basis that the 
(posterior) probability that each treatment is the best (using the 95% 
CrI for the relative rank of each AED).  
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Figure 14: WinBUGS model for the AED network meta-analysis (efficacy endpoint) 
 
  
Random effect model: Includes correlation structure for 3-arm trials 
 
model{ 
sw[1] <- 0 
for(i in 1:84)  {  
       logit(p[i])<-mu[s[i]]+ delta[i]  * (1-equals(t[i],b[i]))                                                       #  model  
       r[i]~dbin(p[i],n[i])                                                                                      #  binomial likelihood 
        delta[i] ~ dnorm(md[i],taud[i])I(-5,5)                                              # trial-specific LOR distributions 
        taud[i] <- tau * (1 + equals(m[i],3) /3)                                # precisions of LOR distributions 
       md[i] <- d[t[i]] - d[b[i]]  +  equals(m[i],3) * sw[i]                         # means of LOR distributions 
 
#Deviance residuals for data i                                                                                        
       rhat[i] <- p[i] * n[i]                                                                                                           
       dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i]))  +  (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-rhat[i])))   
 
      }       
 
sumdev <- sum(dev[])                                                               # Calculate residual deviance 
 
 
for (i in 2:84)  {   sw[i] <- (delta[i-1] -  d[t[i-1]] + d[b[i-1]])/2}13               # adjustment for 3-arm trials 
 
for(j in 1:42){ mu[j]~dnorm(0,.0001) }                                   # vague priors for NS trial baselines 
    
d[1]<-0 
for (k in 2:12)  {d[k] ~ dnorm(0,.0001) }                                 # vague priors for basic parameters 
    
sd~dunif(0,2)                                            #  vague prior for random effects standard deviation   
tau<-1/pow(sd,2) 
 
rr[1]<-1 
for (k in 2:12)  {logit(v[k])<-logit(0.16 )+d[k] 
rr[k]<-v[k]/0.16  }                                 # calculate relative risk 
 
for (k in 1:12)   
{ ar[k]<-0.16*rr[k] 
arr[k]<-0.16-ar[k] 
nnt[k]<--1/arr[k]  }    # calculate NNT 
 
# Ranking and prob{treatment k is best} 
 for (k in 1:12) {  
               rk[k]<-rank(rr[],k) 
best[k]<-equals(rank(rr[],k),1)} 
 
# Pairwise ORs 
for (c in 1:(12-1)) 
          {  for (k in (c+1):12)   
                 {  lor[c,k] <- d[k] - d[c] 
                    log(or[c,k]) <- lor[c,k]  
                 } 
           } 
} 
 
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Figure 15: WinBUGS model for the AED network meta-analysis (tolerability endpoint) 
  
Random effect model: Includes correlation structure for 3-arm trials 
 
 
model{ 
sw[1] <- 0 
for(i in 1:80)  {  
       logit(p[i])<-mu[s[i]]+ delta[i]  * (1-equals(t[i],b[i]))                                                       #  model  
       r[i]~dbin(p[i],n[i])                                                                                      #  binomial likelihood 
        delta[i] ~ dnorm(md[i],taud[i])I(-5,5)                                              # trial-specific LOR distributions 
        taud[i] <- tau * (1 + equals(m[i],3) /3)                                # precisions of LOR distributions 
       md[i] <- d[t[i]] - d[b[i]]  +  equals(m[i],3) * sw[i]                         # means of LOR distributions 
 
#Deviance residuals for data i                                                                                        
       rhat[i] <- p[i] * n[i]                                                                                                           
       dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i]))  +  (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-rhat[i])))   
 
      }       
 
sumdev <- sum(dev[])                                                               # Calculate residual deviance 
 
for (i in 2:80)  {   sw[i] <- (delta[i-1] -  d[t[i-1]] + d[b[i-1]])/2}               # adjustment for 3-arm trials 
 
for(j in 1:40){ mu[j]~dnorm(0,.0001) }                                   # vague priors for NS trial baselines 
    
d[1]<-0 
for (k in 2:12)  {d[k] ~ dnorm(0,.0001) }                                 # vague priors for basic parameters 
    
sd~dunif(0,2)                                            #  vague prior for random effects standard deviation   
tau<-1/pow(sd,2) 
 
rr[1]<-1 
for (k in 2:12)  {logit(v[k])<-logit(0.049898392 )+d[k] 
rr[k]<-v[k]/0.049898392  }                                 # calculate relative risk 
 
for (k in 1:12)   
{ ar[k]<-0.049898392*rr[k] 
arr[k]<-0.049898392-ar[k] 
nnh[k]<--1/arr[k]  }    # calculate NNH 
 
# Ranking and prob{treatment k is best} 
 for (k in 1:12) {  
               rk[k]<-12+1-rank(rr[],k) 
best[k]<-equals(12+1-rank(rr[],k),1)} 
 
# Pairwise ORs 
for (c in 1:(12-1)) 
          {  for (k in (c+1):12)   
                 {  lor[c,k] <- d[k] - d[c] 
                    log(or[c,k]) <- lor[c,k]  
                 } 
           } 
} 
 
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4.6 Findings 
Out of 431 potentially eligible reports, a total of 43 studies, describing 
11 AEDs and including 8,546 patients with refractory epilepsy, met the 
inclusion criteria and were included within the network meta-
analysis.(101-112) All studies were published as full journal articles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: AEDs included within the network meta-analysis.  
Each AED represents a node within the star-shaped network. The lines between the nodes represent direct 
comparative data, where the number along the line indicates the number of studies for that particular link 
within the network. The purple (dotted) line represents a loop of direct comparative data which allows mixed 
treatment comparison (*includes the 3-arm study) 
  
Chapter 4: Research Project One – Antiepileptic drugs for Refractory Epilepsy 
     - 97 - 
 
4.6.1 Study Characteristics 
The main characteristics of the studies which met the pre-specified 
inclusion criteria and subsequently included within the analysis are 
summaries in Table 4 and Table 5. 
 
Of the 43 studies, 40 were placebo-controlled, two were active-
controlled (sodium valproate vs. vigabatrin, and gabapentin vs. 
vigabatrin), and one was a three-arm study (pregabalin vs. 
lamotrigine vs. placebo).(112) Figure 16 displays the treatment 
network graphically.  
 
The mean number of adjunctive baseline medications was between 1 
and 3. The duration of maintenance therapy ranged from 8 to 24 
weeks. None of the studies investigating acetazolamide, 
carbamazepine, clobazam, clonazepam, ethosuximide, 
phenobarbital, phenytoin or primidone fulfilled the inclusion criteria. 
Reasons for exclusion were a lack of double-blinding or trial duration 
of less than 8 weeks. Twenty of the 43 studies (6,212 patients) 
investigated the AED against placebo at more than one dose. Of 65 
possible pair-wise comparisons between the available interventions, 
including placebo, only 13 were actually reported and in all but three 
the comparator was placebo. 
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Table 4: Characteristics of studies included within the AED meta-analysis and network meta-
analysis 
Study Study 
design 
(weeks of 
treatment*) 
Daily treatment (number 
of subjects allocated) 
Male:Female Age range 
(years**) 
Type of 
epilepsy 
Number of 
concomitant 
AEDs 
(specified 
where stated) 
Placebo-controlled studies 
Gabapentin       
UK Gabapentin 
Study Group 
(1990)(101)  
Parallel 
(14) 
GBP 1200mg (61), 
placebo (66) 
53:74 14-73 SPS/CPS  
GTCS 
 2 
Sivenius et al 
(1991)(102)  
 
Parallel 
(12) 
GBP 900mg (18), GBP 
1200mg (9), placebo (18) 
20:23 16-59 SPS/CPS  
GTCS 
 2 
(CBZ, CLZ, 
VPA, PHT) 
Anhut et al 
(1994)(103)  
Parallel 
(12) 
GBP 900mg (111), GBP 
1200mg (52), placebo 
(109) 
154:120 12-67 SPS/CPS  
GTCS 
 2 
Yamauchi et al 
(2006)(104)  
Parallel 
(12) 
GBP 1200mg (86), GBP 
1800mg (41), placebo (82) 
101:108  16 SPS/CPS  2 
 
Lacosamide       
Ben-Menachem et 
al (2007)(105)  
Parallel 
(12) 
LCS 600mg (106), LCS 
400mg (108), LCS 200mg 
(107), placebo (97) 
192:226 18-68 SPS/CPS  
GTCS 
 2 
 
Halasz et al 
(2009)(106)  
Parallel 
(12) 
LCS 400mg (159), LCS 
200mg (163), placebo 
(163) 
250:235 16-70 SPS/CPS  
GTCS 
≥ 2 
Lamotrigine       
Loiseau et al 
(1990)(107)  
Crossover 
(2x8) 
LTG (23), placebo (23) 
[different doses] 
12:11 21-54 SPS/CPS  
GTCS 
 2 
 
Matsuo et al 
(1993)(109)  
Crossover 
(2x12) 
LTG (126), placebo (67) 
[different doses] 
60:133 18-63 SPS/CPS  
GTCS 
 3 
 
Messenheimer et 
al (1994)(108)  
Crossover 
(2x12) 
LTG (88), placebo (98) 
[different doses] 
46:52 18-64 SPS/CPS  
GTCS 
 3 
 
Biton et al 
(2005)(110)  
Parallel 
(12) 
LTG (58), placebo (59) 
[different doses] 
62:55 2-55 GTCS  2 
(PHT, PHB, 
CBZ, PRM, 
VPA) 
Naritoku et al 
(2007)(111)  
Parallel 
(12) 
LTG (118), placebo (121) 
[different doses] 
117:119  12 SPS/CPS  
GTCS 
 2 
 
Baulac et al 
(2010)(112) 
Parallel 
(17) 
LTG (141), placebo (141) 
[different doses] 
132:149 16-67 SPS/CPS  3 
 
Levetiracetam       
Cereghino et al 
(2000)(113)  
Parallel 
(14) 
LEV 1000mg (98), LEV 
3000mg (101), placebo 
(95) 
178:116 16-75 SPS/CPS  
GTCS 
≥ 2 
Shorvon et al 
(2000)(114)  
Parallel 
(12) 
LEV 1000mg (106), LEV 
2000mg (106), placebo 
(112) 
157:167 16-65 SPS/CPS  
GTCS 
 2 
 
Betts et al 
(2000)(115) 
Parallel 
(24) 
LEV 2000mg (42), LEV 
4000mg (38), placebo (39) 
73:46 16-70 SPS/CPS  
GTCS 
 3 
 
Ben-Menachem et 
al (2000)(116) 
Parallel 
(12) 
LEV 3000mg (181), 
placebo (105) 
137:149 16-70 CPS 1 
Boon et al 
(2002)(117) 
Crossover 
(2x12) 
LEV 2000mg (202), 
placebo (200) 
157:167 16-65 SPS/CPS  
GTCS 
≥ 3 
Tsai et al 
(2006)(118) 
Parallel 
(12) 
LEV 2000mg (47), placebo 
(47) 
42:52 16-60 SPS/CPS  
GTCS 
 3 
 
Peltola et al 
(2009)(119) 
Parallel 
(12) 
LEV 1000mg (79), placebo 
(79) 
99:59 12-68 SPS/CPS  
GTCS 
 3 
 
Zhou et al 
(2008)(120) 
Parallel 
(12) 
LEV 3000mg (13), placebo 
(11) 
13:11 16-70 SPS/CPS  
GTCS 
 2 
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Study Study 
design 
(weeks of 
treatment*) 
Daily treatment (number 
of subjects allocated) 
Male:Female Age range 
(years**) 
Type of 
epilepsy 
Number of 
concomitant 
AEDs 
(specified 
where stated) 
Xiao et al 
(2009)(121) 
Parallel 
(12) 
LEV 3000mg (28), placebo 
(28) 
24:36 17-60 SPS/CPS  
GTCS 
 2 
(PHT, CBZ, 
PHB, PRM, 
VPA, TPM, 
GBP, LMG) 
Oxcarbazepine       
Barcs et al 
(2000)(122) 
Parallel 
(24) 
OXC 600mg (168), OXC 
1200mg (177), OXC 
2400mg (174), placebo 
(173) 
341:351 15-65 SPS/CPS  
GTCS 
 3 
Pregabalin       
French et al 
(2003)(123) 
Parallel 
(12) 
PRB 50mg (88), PRB 
150mg (86), PRB 300mg 
(90), PRB 600mg (89), 
placebo (100) 
218:235 12-75 SPS/CPS  
GTCS 
 3 
Arroya et al 
(2004)(124) 
Parallel 
(12) 
PRB 150mg (99), PRB 
600mg (92), placebo (96) 
145:142 17-73 SPS/CPS  
GTCS 
 3 
 
Beydoun et al 
(2005)(125) 
Parallel 
(12) 
PRB 200mg TDS (111), 
PRB 300mg BD (104), 
placebo (98) 
156:156 17-82 SPS/CPS  
GTCS 
 4 
 
Lee et al 
(2009)(126) 
Parallel 
(12) 
PRB 600mg (119), placebo 
(59) 
86:92  18 SPS/CPS  
GTCS 
 4 
(CBZ, VPA, 
TPM, LTG, 
PHB, OXC) 
Tiagabine       
Uthman et al 
(1998)(127) 
Parallel 
(20) 
TGB 16mg (61), TGB 32mg 
(88), TGB 56mg (57), 
placebo (91) 
58:42 12-77 SPS/CPS  
GTCS 
 3 (PHT, CBZ, 
PHB, PRM) 
Kalviainen et al  
(1998)(128) 
Parallel 
(22) 
TGB 30mg (77), placebo 
(77) 
90:64 16-75 SPS/CPS  
GTCS 
 6 (CBZ, CLZ, 
PHT, VPA, 
VGB) 
Topiramate       
Tassinari et al 
(1996)(129) 
Parallel 
(12) 
TPM 600mg (30), placebo 
(30) 
24:6 18-65 SPS/CPS  
GTCS 
 2 
Ben-Menachem et 
al (1996)(130) 
Parallel 
(13) 
TPM 800mg (28), placebo 
(28) 
23:5 19-63 SPS/CPS  
GTCS 
 2 
Faught et al 
(1996)(131) 
Parallel 
(16) 
TPM 200mg (45), TPM 
400mg (45), TPM 600mg 
(46), placebo (45) 
143:38 19-68 SPS/CPS  
GTCS 
 2 
(CBZ, PHT) 
Privitera et al 
(1996)(132) 
Parallel 
(18) 
TPM 600mg (48), TPM 
800mg (48), TPM 1000mg 
(47), placebo (47) 
152:38 18-68 SPS/CPS  
GTCS 
 2 
Sharief et al 
(1996)(133) 
Parallel 
(11) 
TPM 400mg (23), placebo 
(24) 
40:7 18-65 SPS/CPS  
GTCS 
 2 
(CBZ, PHT, 
VPA, PHB, 
PRD) 
Yen et al 
(2000)(134) 
Parallel 
(14) 
TPM 300mg (23) , placebo 
(23) 
19:27 18-54 SPS/CPS  4 
(CBZ, VPA, 
LTG, PHT) 
Vigabatrin       
French et al 
(1996)(135) 
Parallel 
(12) 
VGB 3000mg (93), 
placebo (90) 
80:102 18-60 CPS  
GTCS 
 2 
(CBZ, PHT) 
Bruni et al 
(2000)(136) 
Parallel 
(36) 
VGB 3000mg [mean] (58), 
placebo (53) 
61:50 18-50 CPS  
GTCS 
 2 
 
Zonisamide       
Schmidt et al 
(1993)(137) 
Parallel 
(12) 
ZNS 500mg [mean] (71), 
placebo (68) 
81:58 18-59 CPS  3 
(CBZ, PHT, 
VPA, PHB, 
PRM) 
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Study Study 
design 
(weeks of 
treatment*) 
Daily treatment (number 
of subjects allocated) 
Male:Female Age range 
(years**) 
Type of 
epilepsy 
Number of 
concomitant 
AEDs 
(specified 
where stated) 
Faught et al 
(2001)(138) 
Crossover 
(20) 
ZNS 100mg, 200mg, 
400mg (118), placebo (85) 
104:99 13-68 SPS/CPS  
GTCS 
 2 
(CBZ, PHT, 
VPA, PHB, 
PRM) 
Brodie et al 
(2004)(139) 
Parallel 
(12) 
ZNS 400mg (73), placebo 
(71) 
85:59 18-59 SPS/CPS  
GTCS 
 2 
(CBZ, PHT, 
VPA, PHB, 
PRM) 
Sackarelles et al 
(2004)(140) 
Parallel 
(12) 
ZNS 500mg [mean] (78), 
placebo (74) 
101:51 17-68 CPS  
GTCS 
 2 
(CBZ, PHT, 
PHB, PRM) 
Brodie et al 
(2005)(141) 
Parallel 
(24) 
ZNS 100mg (56), ZNS 
300mg (55), ZNS 500mg 
(118), placebo (120) 
232:171 12-77 SPS/CPS  
GTCS 
 4 
(CBZ, CLB, 
GBP, LTG, 
PHB, PHT, 
TPM, VPA) 
 
*Weeks of treatment refers to the double-blind period consisting of both the titration-to-target and target-
stabilisation phases. 
 
**Due to the methodology used in categorising trials within PubMed and Embase, the inclusion criteria of ‘all 
adults 19+ years’ and ‘adults 18 to 64 years’ also included a small number of studies which enrolled both 
adults and children (see page 121 for further detail) 
 
For those studies where more than one dose of the active agent was compared against placebo, the dose 
underlined reflects the dose for which data were extracted from the trial to permit comparison. 
 
SPS = simple partial onset seizure; CPS = complex partial onset seizure; GTCS = secondary generalised 
tonic-clonic seizure 
 
GBP = gabapentin; LCS = lacosamide; LMG = lamotrigine; LEV = levetiracetam; OXC = oxcarbazepine; 
PRB = pregabalin; VPA = sodium valproate; TGB = tiagabine; TPM = topiramate; VGB = vigabatrin; ZNS = 
zonisamide 
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Table 5: Characteristics of additional studies included within the AED network meta-
analysis 
Study Study 
design 
(weeks of 
treatment) 
Daily treatment (number 
of subjects allocated) 
Male:Female Age range 
(years) 
Type of 
epilepsy 
Number of 
concomitant 
AEDs 
(specified 
where stated) 
Active-controlled studies 
Vigabatrin and Valproic Acid 
Brodie et al 
(1999)(84)  
Parallel 
(12) 
VGB 2000mg to 400mg 
(108) 
VPA 1000mg to 2000mg 
(107) 
106:109 12-78 SPS/CPS  
GTCS 
CBZ 
Gabapentin and Vigabatrin 
Lindberger et al 
(2000)(142) 
Parallel (8) GBP 2400mg to 3600mg 
(50) 
VGB 2000mg to 4000mg 
(52) 
51:51 13-68 SPS/CPS  2 
 
Lamotrigine and Pregabalin 
Baulac et al 
(2010)(112) 
Parallel 
(17) 
LTG 300mg to 400mg 
(141), PRB 300mg to 
600mg (152) 
155:138 18-82 SPS/CPS  3 
 
*Weeks of treatment refers to the double-blind period consisting of both the titration-to-target and target-
stabilisation phases. 
 
For those studies where more than one dose of the active agent was compared against placebo, the dose 
underlined reflects the dose for which data were extracted from the trial to permit comparison. 
 
SPS = simple partial onset seizure; CPS = complex partial onset seizure; GTCS = secondary generalised 
tonic-clonic seizure 
 
GBP = gabapentin; LCS = lacosamide; LMG = lamotrigine; LEV = levetiracetam; OXC = oxcarbazepine; 
PRB = pregabalin; VPA = sodium valproate; TGB = tiagabine; TPM = topiramate; VGB = vigabatrin; ZNS = 
zonisamide 
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4.6.2 Comparison of effect size 
4.6.2.1 Frequentist Meta-Analysis 
The results of the standard meta-analysis of placebo-controlled 
trials (stratified by drug) demonstrated that each AED was more 
efficacious than placebo in reducing seizure events by >50% from 
baseline (see Figure 17) with an overall OR 3.78 (95% CI 3.14 to 
4.55) (see Figure 19). For the efficacy endpoint, there was low to 
moderate evidence of heterogeneity (tau-squared = 0.15; I-
squared = 46%) which was attributable to specific AED drug class 
(levetiracetam, pregabalin, tiagabine and zonisamide). Similarly, 
meta-analysis of tolerability indicated a greater overall odds of 
premature withdrawal due to the development of adverse effects 
for all AEDs vs. placebo (OR 3.27, 95% CI 2.37 to 4.52) (see 
Figure 18 and Figure 20), with moderate evidence of heterogeneity 
(tau-squared = 0.45; I-squared = 55%), again attributable to 
specific AED class (tiagabine, topiramate and zonisamide). Based 
on these data there was no strong evidence favouring any one 
particular AED over another on the basis of efficacy, although 
oxcarbazepine appeared to be the least well tolerated. 
 
No evidence of significant heterogeneity in efficacy or tolerability 
(P < 0.05) was detected in different trials of the same drug 
following a review of the l’Abbé plots with the possible exception of 
pregabalin (efficacy analysis Cochran Q = 15.36, p = 0.002). A 
review of the Funnel plots did not reveal concerns regarding 
publication bias (see Figure 21 and Figure 22 for the efficacy and 
tolerability analyses, respectively). 
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Figure 17: Forest plot (RevMan v5.0) of the odds ratios for efficacy (50% responder 
rate) of randomized controlled trials comparing an AED vs. placebo as add-on 
treatment for refractory epilepsy, respectively.  
The black squares represent the odds ratio for individual studies of AED vs. placebo and the horizontal line 
represents the 95% confidence interval of the odds ratio. The black diamond represents the random-effects 
pooled odds ratio for studies reporting on the same AED where its width represents the 95% confidence 
intervals. Estimates to the right of the vertical line (i.e. odds ratio >1) are indicative of a statistically 
significant increase in efficacy, relative to placebo, in patients randomized to the active intervention. 
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Figure 17: (see above for description) 
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Figure 18: Forest plot (RevMan v5.0) of the odds ratios for tolerability (withdrawal 
from treatment due to an intolerable adverse event) of randomized controlled trials 
comparing an AED vs. placebo as add-on treatment for refractory epilepsy, 
respectively.  
The black squares represent the odds ratio for individual studies of AED vs. placebo and the horizontal line 
represents the 95% confidence interval of the odds ratio. The black diamond represents the random-effects 
pooled odds ratio for studies reporting on the same AED where its width represents the 95% confidence 
intervals. Estimates to the right of the vertical line (i.e. odds ratio >1) are indicative of a statistically 
significant increase in withdrawal rate, relative to placebo, in patients randomized to the active intervention. 
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Figure 18: (see above for description) 
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Figure 19: Summary Forest plot (RevMan v5.0) of the odds ratio for efficacy (50% 
responder rate) of randomized controlled trials comparing an AED vs. placebo as add-
on treatment for refractory epilepsy 
 
 
 
Figure 20: Summary Forest plot (RevMan v5.0) of the odds ratio for tolerability 
(withdrawal from treatment due to an intolerable adverse event) of randomized 
controlled trials comparing an AED vs. placebo as add-on treatment for refractory 
epilepsy 
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Figure 21: Funnel plot (RevMan v5.0) of randomised controlled trials comparing each 
AED versus placebo as add-on treatment for refractory epilepsy for the efficacy 
endpoint 
 
 
Chapter 4: Research Project One – Antiepileptic drugs for Refractory Epilepsy 
     - 109 - 
 
Figure 22: Funnel plot (RevMan v5.0) of randomised controlled trials comparing each 
AED versus placebo as add-on treatment for refractory epilepsy for the tolerability 
endpoint 
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4.6.2.2 Bayesian Network Meta-Analysis: efficacy, tolerability and 
prescribing hierarchy 
The median OR estimates, for the efficacy and tolerability 
endpoints, generated by the Bayesian random-effects network 
meta-analysis are given in Table 6. As a minimally-informative 
prior was used, these closely resemble those generated from the 
Frequentist random-effects meta-analysis (see Table 7 and Table 
8 for the efficacy and tolerability endpoints, respectively).  
 
No evidence of significant inconsistency (using Bucher’s test) was 
detected between directly-observed and inferred-treatment effects 
within the loop identified in Figure 16 for either efficacy (P = 0.26) 
or tolerability (P = 0.22).  
 
For both outcomes, the model showed reasonable goodness of fit 
to the data (number of data points) as determined by the posterior 
mean of the residual deviance [efficacy = 86.0 (84), 95% CrI 62.8, 
115.9, P = 0.419; tolerability = 77.6 (80), 95% CrI 57.9, 100.5, P = 
0.555]. A visual assessment of the trace plots (history) and time 
series (density) plots also did not reveal cause for concern 
regarding inconsistency. 
 
In contrast to the frequentist meta-analysis, network meta-analysis 
allows the ordering of AEDs according to efficacy and tolerability. 
Based on the odds ratios estimated, there was an approximately 
two-fold difference in short term efficacy (based on the 50% 
responder rate), lacosamide being the least and topiramate the 
most efficacious at the doses evaluated (see Figure 23). There 
was an approximately five-fold difference in short term tolerability 
with valproate being the best and oxcarbazepine being the least 
well tolerated at the doses evaluated (see Figure 24), however, 
due to the overlapping 95% CrI associated with these ORs the 
clinical relevance may not be as large or significant as suggested.  
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As treatment decisions for refractory partial epilepsy may be based 
on a balance between efficacy and tolerability, NNT and NNH 
values were calculated for each drug.  
 
A quantitative trade-off analysis found that four agents (valproate, 
levetiracetam, gabapentin and vigabatrin) demonstrated the best 
combination of short term efficacy and tolerability (see Figure 25). 
Though similarly effective, oxcarbazepine was less well tolerated 
than all other agents. The remaining agents (topiramate, 
pregabalin, tiagabine, zonisamide, lamotrigine and lacosamide) 
demonstrated intermediate short term efficacy and tolerability. 
 
4.6.2.3 Cost minimisation analysis 
With consideration to the number of possible AED combinations / 
permutations, and following discussion of the results with a 
representative from the neurology service at NHNN, it was decided 
that a formal cost effectiveness analysis would not be appropriate. 
Based on the logistics of prescribing in clinical practice, such as 
the strategy of AED prescribing incorporating patient specific 
factors (e.g. pregnancy), and the complex prescribing history of 
AEDs over the last 20 years, such analysis would contain too 
many confounding factors and override its merits. It was thus 
agreed that the trade-off analysis should include acquisition cost 
alongside efficacy and tolerability (see Table 9).  
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Table 6: Trade-off analysis – comparative efficacy and tolerability of the antiepileptic 
drugs (AED).  
Results are presented as the odds ratios (OR) [and their corresponding 95% credible interval (CrI) values] 
for the column-defining agent compared with the OR for the row-defining agent. For efficacy, ORs higher 
than 1 favour the column-defining treatment (e.g. the OR for efficacy for LEV compared with VPA is 1.09). 
For tolerability, ORs less than 1 favour the row-defining treatment. Results are statistically significant where 
the 95% CrI for the corresponding OR do not cross 1. To obtain ORs for comparison in the opposite 
direction, reciprocals should be taken (i.e. the OR for efficacy for VPA compared with LEV is 1/1.09 = 0.92) 
 
         Efficacy [response rate] (95% CrI)   
 
Comparison AED  
 
Tolerability [withdrawal rate] (95% CrI) 
 
VPA 
0.93 
(0.36, 
2.38) 
0.74 
(0.23, 
2.62) 
0.81 
(0.24, 
3.11) 
2.04 
(0.59, 
8.41) 
1.26 
(0.29, 
8.41) 
1.06 
(0.33, 
3.81) 
1.82 
(0.43, 
8.69) 
0.88 
(0.25, 
3.11) 
1.48 
(0.44, 
5.64) 
0.57 
(0.16, 
2.21) 
1.22 
(0.41, 
3.59) 
 
VGB 
0.80 
(0.38, 
1.77) 
0.89 
(0.40, 
2.16) 
2.21 
(0.86, 
5.96) 
1.37 
(0.44, 
4.87) 
1.62 
(0.56, 
2.56) 
1.98 
(0.65, 
6.51) 
0.95 
(0.42, 
2.14) 
1.61 
(0.71, 
3.95) 
0.62 
(0.25, 
1.64) 
1.23 
(0.26, 
4.77) 
0.97 
(0.35, 
2.46) 
 
GBP 
1.13 
(0.50, 
2.54) 
2.72 
(1.16, 
6.90) 
1.70 
(0.56, 
5.70) 
1.48 
(0.70, 
2.98) 
2.48 
(0.82, 
7.79) 
1.19 
(0.52, 
2.56) 
2.07 
(0.89, 
4.68) 
0.80 
(0.31, 
1.92) 
3.98 
(0.69, 
22.30) 
3.17 
(0.88, 
13.41) 
3.38 
(0.99, 
13.66) 
 
LMG 
2.46 
(1.09, 
5.92) 
1.52 
(0.53, 
4.90) 
1.33 
(0.68, 
2.48) 
2.20 
(0.75, 
6.63) 
1.07 
(0.49, 
2.12) 
1.84 
(0.86, 
3.86) 
0.69 
(0.29, 
1.66) 
3.47 
(0.60, 
15.44) 
2.84 
(0.77, 
8.58) 
2.96 
(0.91, 
8.20) 
0.90 
(0.21, 
2.63) 
 
TPM 
0.63 
(0.19, 
2.09) 
0.53 
(0.24, 
1.09) 
0.92 
(0.29, 
2.87) 
0.42 
(0.18, 
0.93) 
0.74 
(0.32, 
1.69) 
0.28 
(0.11, 
0.69) 
2.84 
(0.45, 
15.02) 
2.28 
(0.59, 
8.34) 
2.41 
(0.68, 
8.80) 
0.70 
(0.16, 
2.66) 
0.85 
(0.26, 
2.54) 
 
TGB 
0.86 
(0.28, 
2.32) 
1.48 
(0.36, 
5.55) 
0.69 
(0.21, 
1.97) 
1.21 
(0.37, 
3.56) 
0.46 
(0.13, 
1.43) 
1.09 
(0.23, 
4.39) 
0.88 
(0.29, 
2.28) 
0.93 
(0.35, 
2.27) 
0.29 
(0.08, 
0.73) 
0.32 
(0.14, 
0.83) 
0.38 
(0.13, 
1.13) 
 
LEV 
1.67 
(0.63, 
4.82) 
0.81 
(0.43, 
1.49) 
1.40 
(0.73, 
2.75) 
0.53 
(0.25, 
1.17) 
13.42 
(2.20, 
66.34) 
10.75 
(2.66, 
37.18) 
11.27 
(3.21, 
38.06) 
3.32 
(0.77, 
12.13) 
3.90 
(1.20, 
12.68) 
4.56 
(1.20, 
17.88) 
12.20 
(4.21, 
35.40) 
 
OXC 
0.48 
(0.16, 
1.32) 
0.83 
(0.27, 
2.43) 
0.37 
(0.10, 
0.98) 
2.43 
(0.47, 
11.54) 
1.97 
(0.61, 
6.02) 
2.04 
(0.73, 
6.35) 
0.61 
(0.15, 
2.06) 
0.70 
(0.26, 
2.01) 
0.83 
(0.27, 
3.12) 
2.17 
(1.02, 
5.51) 
0.18 
(0.06, 
0.64) 
 
ZNS 
1.71 
(0.86, 
3.71) 
0.66 
(0.29, 
1.55) 
2.56 
(0.52, 
12.22) 
2.09 
(0.66, 
6.51) 
2.19 
(0.80, 
6.71) 
0.65 
(0.18, 
2.08) 
0.78 
(0.29, 
2.23) 
0.94 
(0.29, 
3.17) 
2.42 
(1.00, 
5.96) 
0.20 
(0.07, 
0.65) 
1.10 
(0.40, 
2.89) 
 
PBG 
0.38 
(0.16, 
0.90) 
2.41 
(0.41, 
10.82) 
1.93 
(0.51, 
6.06) 
2.00 
(0.62, 
6.17) 
0.59 
(0.14, 
1.96) 
0.67 
(0.24, 
2.04) 
0.83 
(0.24, 
2.83) 
2.16 
(0.84, 
5.40) 
0.17 
(0.05, 
0.61) 
0.98 
(0.31, 
2.61) 
0.88 
(0.30, 
2.51) 
 
LCS 
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Table 7: Comparison of odds ratio estimates generated from the frequentist random-
effects meta-analysis and the Bayesian network meta-analysis for the efficacy 
endpoint 
 Frequentist MA Bayesian Network MA 
Intervention Mean Odds Ratio (95% CI) Mean Odds Ratio (95% CrI) 
Sodium Valproate NA 3.83 (1.15 – 11.62) 
Vigabatrin 2.99 (1.79 – 5.00) 3.50 (1.76 – 6.65) 
Gabapentin 3.13 (1.78 – 5.50) 2.76 (1.50 – 5.22) 
Lamotrigine 2.84 (1.77 – 4.54) 3.12 (1.87 – 5.42) 
Topiramate 6.37 (3.66 – 11.08) 7.71 (4.02 – 15.36) 
Tiagabine 4.46 (1.29 – 15.39) 4.75 (1.88 – 13.55) 
Levetiracetam 3.95 (2.71 – 5.76) 4.11 (2.80 – 6.01) 
Oxcarbazepine 7.02 (4.11 – 5.76) 6.87 (2.76 – 18.39) 
Zonisamide 3.20 (2.15 – 4.76) 3.30 (1.98 – 5.32) 
Pregabalin 5.74 (2.44 – 13.50) 5.73 (3.36 – 9.85) 
Lacosamide 2.13 (1.46 – 3.10) 2.17 (1.12 – 4.30) 
 
 
Table 8: Comparison of odds ratio estimates generated from the frequentist random-
effects meta-analysis and the Bayesian network meta-analysis for the tolerability 
endpoint 
 Frequentist Meta-Analysis Bayesian Network Meta-
Analysis 
Intervention Mean Odds Ratio (95% CI) Mean Odds Ratio (95% CrI) 
Sodium Valproate NA 1.65 (0.44 – 7.62) 
Vigabatrin 2.07 (0.75 – 5.75) 2.00 (0.88 – 5.43) 
Gabapentin 1.72 (0.70 – 4.22) 1.96 (0.87 – 4.51) 
Lamotrigine 5.19 (2.02 – 13.37) 6.32 (2.71 – 21.16) 
Topiramate 4.66 (1.77 – 12.26) 5.68 (2.54 – 11.49) 
Tiagabine 4.46 (0.95 – 20.92) 4.65 (1.82 – 12.49) 
Levetiracetam 1.71 (1.16 – 2.53) 1.80 (1.09 – 2.98) 
Oxcarbazepine 21.07 (11.38 – 39.01) 21.86 (8.51 – 56.21) 
Zonisamide 2.30 (1.23 – 4.29) 3.96 (2.12 – 8.60) 
Pregabalin 3.93 (2.27 – 6.79) 4.29 (2.22 – 9.09) 
Lacosamide 3.72 (1.95 – 7.10) 3.85 (1.75 – 8.75) 
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Figure 23: Box plot (WinBUGS) of the risk ratios (RR) of AEDs vs. placebo as 
estimated by the network meta-analysis for the efficacy (50% responder rate) 
endpoint.  
The individual plots represent the 95% credible interval (horizontal black line either side of the green box) 
and the interquartile range (green box, representing where 25% to 75% of the data lies); the vertical black 
line reflects the median RR. A larger RR is indicative of a greater proportion of patients achieving a 50% 
reduction in seizure frequency, relative to placebo. Where the 95% credible interval crosses the line of unity, 
this is indicative of a non-statistically significant difference to placebo. AEDs are listed in descending rank 
order. 
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Figure 24: Box plot (WinBUGS) of the risk ratios (RR) of AEDs vs. placebo as 
estimated by the network meta-analysis for the tolerability (premature 
discontinuation) endpoint.  
The individual plots represent the 95% credible interval (horizontal black line either side of the green box) 
and the interquartile range (green box, representing where 25% to 75% of the data lies); the vertical black 
line reflects the median RR. A larger RR is indicative of a greater proportion of patients withdrawing from 
treatment prematurely, relative to placebo. Where the 95% credible interval crosses the line of unity, this is 
indicative of a non-statistically significant difference to placebo. AEDs are listed in descending rank order. 
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Figure 25: Quantitative trade-off analysis – a comparison of the number needed to 
treat vs. number needed to harm (with 95% credible intervals) for efficacy (50% 
responder rate) and tolerability (withdrawal rate), endpoints respectively.  
Drugs in the lower right of the plot (i.e. low NNT and high NNH) are highly efficacious and well tolerated; 
conversely, drugs in the upper left of the plot (i.e. high NNT and low NNH) are less effective and poorly 
tolerated. Note that equal weighting of the efficacy and tolerability endpoints has been applied (i.e. the same 
emphasis is placed on achieving a 50% reduction in seizure rate in one patient as for incurring a premature 
withdrawal due to an intolerable adverse effect in another) 
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Table 9: Trade-off analysis – summary rank of treatment (clinical vs. cost). *AEDs 
currently protected under patent within the UK 
 Rank Efficacy Tolerability Cost* 
1 Oxcarbazepine Sodium Valproate Levetiracetam 
2 Topiramate Levetiracetam Gabapentin 
3 Pregabalin Gabapentin Sodium Valproate 
4 Tiagabine Vigabatrin Lamotrigine 
5 Levetiracetam Lacosamide Pregabalin 
6 Sodium Valproate Pregabalin Vigabatrin* 
7 Zonisamide Zonisamide Tiagabine* 
8 Vigabatrin Tiagabine Oxcarbazepine* 
9 Lamotrigine Lamotrigine Lacosamide* 
10 Gabapentin Topiramate Zonisamide* 
11 Lacosamide Oxcarbazepine Topiramate* 
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4.6.3 Principal Findings 
This systematic review, frequentist meta-analysis and network meta-
analysis with supportive quantitative trade-off analysis provides the 
most comprehensive and explicit assessment of the short-term 
comparative efficacy and tolerability of AEDs licensed for the 
adjunctive management of chronic refractory partial epilepsy with or 
without secondary generalization. The frequentist meta-analysis 
demonstrated that all AEDs were superior to placebo in preventing 
seizures. However, there was a dearth of published, randomised 
clinical trials that directly compared one AED with another. Using a 
Bayesian hierarchical model to conduct a mixed-treatment network 
meta-analysis, levetiracetam, vigabatrin, sodium valproate and 
gabapentin emerged as agents with the best combination of short 
term efficacy and tolerability, with the caveat that vigabatrin is 
recognized as being associated with serious visual disturbance with 
chronic use. 
 
4.6.4 Relation to Previous Studies 
Five meta-analyses and a narrative review exist related to this 
question, which have produced conflicting results, partly due to 
differences in methodology and inclusion criteria. Marson et al. (89, 
93) included 13 published and 15 unpublished randomised controlled 
trials, comparing six AEDs against placebo (gabapentin, lamotrigine, 
tiagabine, topiramate, vigabatrin, and zonisamide), concluding that 
there was a lack of conclusive evidence to determine a prescribing 
hierarchy accounting for differences in efficacy or tolerability. Shorvon 
et al. (143) subsequently included 36 published articles (including 
randomized controlled trials in full and abstract form), comparing eight 
AEDs against placebo, again reaching the same conclusion. Otoul et 
al. (144) later updated the meta-analysis conducted by Marson et al. 
by comparing the six AEDs indirectly against levetiracetam. No 
restrictions were placed regarding age of patients. Unlike the previous 
two reviews, the authors here found levetiracetam to demonstrate 
significant efficacy compared with gabapentin and lamotrigine. No 
significant differences regarding tolerability profile were noted 
between the seven AEDs evaluated. 
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In contrast, the present analysis, using a treatment network, did not 
demonstrate levetiracetam to possess a significantly more effective 
profile although it was one of four AEDs which showed a trend 
towards better efficacy and tolerability. 
 
Beyenburg et al. (145) conducted a meta-analysis of modern AEDs to 
determine the true effect of each agent in reducing seizure frequency 
not attributable to other factors, principally placebo response. 
Although the search period was similar to that of the present study, 
the inclusion of both adults and children resulted in a larger number of 
eligible studies. The key finding of this paper was the estimation of a 
placebo-corrected difference of 21% (95% CI 19% to 24%; P 
<0.0001). This is akin to value calculated within the present study of 
16%; the difference is likely to be the result of differences in the 
inclusion criteria. 
 
Rheims et al. (146) more recently conducted a meta-analysis in adult 
patients investigating the different parameters which may determine 
response to treatment. The number of publications and AEDs 
included were again greater than the present study as a result of the 
inclusion criteria permitting AEDs currently under investigation, or not 
indicated for refractory focal epilepsy. The authors concluded that 
although responder rate increased over the years for the placebo 
arm, a parallel increase was also observed in the active arm. Further, 
the use of last observation carried forward (LOCF) data 
overestimated the responder rate and analysis of efficacy at the level 
of doses for each AED did not reveal statistically significant 
differences. 
 
Lastly, Devinsky and Cramer commended the use of meta-analysis 
as the best available technique in the absence of comparative trial 
data.(147) However, this predated the availability of the more 
advanced network meta-analysis methodology. As such, the present 
analysis utilised a common placebo-corrected value, calculation of 
intention-to-treat dataset, and assessment of each AED at the most 
clinically relevant dose incorporating a Bayesian paradigm, an 
approach which is recommended for its clinical relevance,(148) with a 
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trade-off analysis to determine a treatment hierarchy. Prior overviews 
have supported the validity of network meta-analysis for indirect 
treatment comparisons provided certain conditions are met,(149) with 
emerging examples of its application in several disease areas.(150-
154) 
 
4.6.5 Strengths and Weaknesses of the Methodology 
Using frequentist methodology, previous attempts to determine a 
comparative review were unsuccessful.(145) This was the first 
analysis within the epilepsy field to utilise Bayesian statistics. 
Relevant trials were identified via explicit systematic review and the 
analysis conformed to PRISMA recommendations.(25) The efficacy 
outcome selected within this analysis is universally accepted as an 
informative outcome measure concerning AED efficacy 
(CHMP/EWP/566/98 Rev. 2).(155) All studies included in the present 
analysis were fully published unlike the previously published meta-
analyses (Marson et al.)(89) where over 50% (15/29) of included 
studies were unpublished; this stricter criteria was included to 
minimise the risk of heterogeneity as full trial methodology could be 
determine upon assessment for inclusion. Furthermore, the present 
analysis only included agents which are currently licensed in the UK 
for the adjunctive treatment of refractory epilepsy to strengthen the 
clinical utility of the findings generated. The criterion of single-dose 
extraction for analysis was supported by Rheims et al.(146) Lastly, a 
multiple treatment comparison design was utilised which allowed both 
direct and indirect comparisons via the construction of a treatment 
network unlike frequentist meta-analysis.(156) 
 
Multiple treatment options exist in epilepsy but, in common with many 
other therapeutic areas, treatment comparisons may be missing and / 
or there may be preferences toward certain comparators (including 
placebo).(157) These were features of the current analysis where of 
the 65 possible comparisons between the 11 AEDs (and placebo), 
only 13 were conducted and all but three were placebo-controlled 
trials. A major reason for the lack of direct active comparator trials is 
that regulatory authorities such as the Committee for Medicinal 
Products for Human Use (on behalf of the EMA), do not require such 
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trials to be conducted as a condition of the marketing authorisation of 
a new drug. Note, this distinction is different to denying patients to 
any form as treatment as subjects included within the RCTs were on 
a background of AEDs; however the comparator was placebo rather 
than an active agent.  
 
The recently published guideline on clinical investigation of medicinal 
products in the treatment of epileptic disorders continues to 
recommend that add-on studies (the addition of a new AED to 
existing therapies) should be of randomised, double-blind, placebo-
controlled, parallel group study design,(155) although the guideline 
also recommends that as more AEDs are approved for the add-on 
indication, comparative trials may be considered and that an 
evaluation of efficacy of such agents may be conducted through 
meta-analysis. Despite the above recommendation, AEDs continue to 
be trialled and receive regulatory approval on the basis of placebo-
controlled studies (with background treatment permitted), as 
highlighted by recent approval of eslicarbazepine and retigabine 
which continue to compound the situation. In the absence of prior 
active-comparator trial, guidance from NICE for example does not 
make recommendations about the selection or sequence of AED 
therapy with regard to specific drugs within the categories of older 
and newer AEDs.(90) An additional and crucial problem which arises 
from the absence of a prevailing treatment hierarchy in the presence 
of multiple therapeutic options is that the number of legitimate active 
comparator trials for any new AED becomes very large indeed, in 
itself providing an additional obstacle to comparator trials of new 
agents. Thus indirect comparisons, through network meta-analysis 
such as the one conducted here, might not only help develop rational 
treatment hierarchies based on existing therapies but also inform on 
the choice of high priority comparator agents for future trials of new 
AEDs. 
 
Nevertheless, it is also important to take note of several important 
limitations. First, although individual trials only provide information 
over a short period of time (typically 8 to 16 weeks), this is the 
duration of follow-up required to meet regulatory criteria. The findings 
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should be extrapolated to longer term use with caution, particularly as 
some drugs, for example vigabatrin, are recognized as being 
associated with the development of adverse effects with long term 
use.  
 
Second, the trials included in this analysis spanned 19 years during 
which time the available services and the management of epilepsy 
has changed. Importantly, the patient population recruited to more 
recent trials may have more refractory or ‘drug resistant’ epilepsy 
than patients recruited to earlier studies who were exposed to fewer 
previously licensed therapies. Also, it is possible that the aetiology of 
epilepsy has changed over the period 1990-2010; for example, 
epilepsy is an associated consequence of head traumas secondary to 
road traffic accidents, an issue which has been addressed by 
improved road safety. Statistical tests for heterogeneity (tau-squared 
and I-squared) considered that the patient populations were 
sufficiently similar to generate overall estimates, values noted as 
mild-moderate and moderate, respectively for the efficacy and 
tolerability endpoints. This point has been investigated in detail by 
Beyenburg et al.(145) who recently conducted a meta-analysis of 
modern AEDs, concluding that meta-regression showed no difference 
in effects between studies published before 2001 vs. 2001 and later 
for 50% reduction in seizure (Z = -0.50, P = 0.62) or seizure freedom 
(Z = -0.52, P = 0.60).The year 2001 was chosen to reflect the 
comparison of first vs. second generation AEDs. Beyenburg et al. 
also sought to explore whether or not factors such as number of past 
AEDs trialled or highest dose studied vs. all available doses had an 
influence on seizure-free outcome. However they concluded that 
insufficient data were available from the published manuscripts to 
enable such analyses. Nonetheless, the inclusion of multiple doses 
for each AED, specifically those at the higher end, may potentially 
skew the overall results with regards to increasing the incidence of 
premature discontinuation due to treatment-related adverse events 
without a corresponding increase in responder rate. Such 
heterogeneity would appear on Forest plot analyses as wider 
confidence / credible intervals and may reduce the validity of the 
results and limit generalisation of the findings. On this basis, despite a 
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reduction in overall patient numbers within the meta-analysis, it was 
decided to include data only for the dose closest to that prescribed in 
clinical practice for each AED.  
 
Third, it is plausible that using the target of 50% reduction in seizure 
as the efficacy endpoint for a refractory cohort is unjustified and not 
reflective of clinical practice, for example, in patients who have failed 
to respond to 2-3 medicines the clinical community would suggest 
that a lower threshold of response be considered acceptable. 
Currently however, the 50% responder rate is an endpoint which is 
endorsed by regulatory authorities such as the EMA, which does not 
take into account the duration and / or severity of seizures. As such, 
any analyses would be required to conform to these criteria.  
 
Fourth, although it was an intention from the outset to restrict the 
analysis to the adult population, a number of studies actually included 
a mixed population of adults and children (with one as low as ≥ 2 
years) without sub-grouping their results. Nonetheless, as the 
majority of data relates to investigation in adults the conclusions 
drawn should remain relevant to the use of AEDs in the adult 
population only.  
 
Fifth, this analysis only provides a non-specific estimate for 
withdrawal rates due to an intolerable adverse effect rather than firm 
conclusions on the severity of a specific adverse effect, such as 
ataxia, or the incidence of serious / rare adverse effects such as 
Steven-Johnson syndrome or suicidal tendency. Furthermore, 
although the inclusion criteria specified a double-blind design to 
promote robustness of the findings, it is appreciated that patients 
randomised to active therapy may become aware that they are 
receiving active treatment due the emergence of treatment-related 
adverse effects, such as sedation.  
 
Sixth, the studies included may be limited in their ability to report on 
adverse effects as the studies were primarily designed and powered 
to address the effectiveness of the AED under investigation and had 
a maximum duration of 24 weeks.(158)   
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Seventh, in specifying such strict inclusion criteria to ensure higher 
quality trials were included in the quantitative analysis, it was 
necessary to exclude trials investigating AEDs used in routine clinical 
practice today, such as carbamazepine.  
 
Finally, data within this analysis only relate to the use of AEDs for the 
treatment of patients with chronic refractory partial epilepsy and 
should not be extrapolated to patients with other forms of epilepsy, 
such as primary generalised. As for any medication, prescribing 
decisions should take into account specific contraindications and 
advice on prescribing in special groups such as women of 
childbearing age. 
 
The present study included data from publications in English 
language only. The decision to not include data from publications in 
languages other than English (LOE) was made based on the 
conclusions reached by the Canadian Agency for Drug and 
Technologies in Health (CADTH) and the UK National Institute of 
Health Research (NIHR) (review of impact of language restrictions on 
systematic reviews). First, the CADTH performed a systematic review 
of meta-analyses of conventional medicines, comparing those that did 
and those that did not include publications in LOE concluding that 
they could find no evidence of a systematic bias from the use of 
language restrictions.(34) Second, a Health Technology Appraisal (on 
behalf of the NIHR) also found that language restrictions did not bias 
the results of systematic reviews of conventional medicines, even 
after sensitivity analyses were conducted, noting that the results do 
not appear to be influenced by statistical heterogeneity or publication 
bias.(159) 
 
Finally, as carbamazepine is widely recommended and accepted as 
being the first-line option for patients with partial-onset seizures,(160) 
we believe that the non-inclusion of this particular AED within this 
analysis should not limit its findings. 
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4.6.6 Implications for Clinical Practice 
This review is focused on the most common form of epilepsy seen in 
clinical practice, partial onset seizure with or without secondary 
generalisation in the refractory setting. The stimulus for this stems 
from the lack of a guideline which provides explicit detail on how each 
agent licensed for this indication should be prescribed relative to one 
another. 
 
Although it is widely accepted that the best model of providing 
answers with the highest clinical relevance would be from a large-
scale multiple comparison head-to-head trial, the costs associated 
with such a model render the chances of this transpiring to be very 
small. The present study attempts to provide a response to one of the 
limitations of current trial methodology as specified within the 
discussion of the recent publication by Beyenburg et al. (145) – ‘given 
the absence of double-blind, placebo-controlled comparative AED 
trials, we could not compare the efficacy among individual AEDs’ – by 
generating a treatment network utilising a Bayesian framework 
supplemented by a quantitative trade-off analysis using pre-specified 
efficacy and tolerability parameters as well as acknowledging the 
current acquisition costs of each agent. In order to generate a robust 
and simplified network from which to permit translation into a 
treatment hierarchy, a single dose per AED was extracted for the 
analysis. This strategy follows the results of Rheims et al. (146) 
where an analysis of dose selection resulted in mostly non-significant 
difference for the primary endpoint (50% reduction in seizure 
frequency). In light of these data, such analyses were not repeated 
and instead data reporting for the dose investigated which most 
closely reflects that in current clinical practice were extracted for each 
AED. 
 
Until conduct of an independent large-scale RCT, herein the chapter 
is reported a methodologically and statistically rigorous analysis of 
AEDs currently available in the UK to assist clinical decision-making. 
An overview of the strengths and weaknesses of the methodology 
used is detailed above in section 4.6.5. 
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Lastly, an important implication of the findings is that although it is 
clear that the modern AEDs are more effective than placebo when 
used as adjunctive therapy for refractory focal epilepsy, they are of 
limited efficacy (in comparison with older agents) and are correlated 
with an increase in treatment-related intolerable adverse effects as 
well as cost. The current strategies for developing, investigating and 
licensing of AEDs thus require re-evaluation. 
 
Interestingly, this area of work continues to be of interest as evident 
by an NMA undergoing editorial review by the Annals of Medicine, 
July 2017 (SANN-2016-0302). In the submitted analysis, the authors 
aim to compare the relative efficacy and tolerability of the second and 
third generation AEDs for refractory epilepsy using NMA 
methodology. The 50% responder rate was again selected as the 
efficacy outcome whilst the tolerability outcome was more focussed 
on the exploring the incidence of dizziness and somnolence rather 
than a more general withdrawal as used in the present analysis. 
Presentation of outcome was again in the format of odds ratio (OR) 
and their 95% credible interval (CrI) as obtained from NMA, however 
ranking was determined via an analysis of surface under the 
cumulative ranking curve (SUCRA), which is an alternative strategy to 
a plot of number needed-to-treat (NNT) vs. number needed-to-harm 
(NNH). The outcomes were broadly similar to the current study with 
topiramate suggested as being significantly more effective than 
placebo, eslicarbazepine acetate, perampanel, pregabalin, 
zonisamide, gabapentin and lamotrigine with respect to 50% RR (all 
OR > 1). With regards to tolerability, patients who were managed by 
eslicarbazepine acetate, perampanel, oxcarbazepine, topiramate and 
pregabalin were more likely to suffer from dizziness compared to 
those who receive placebo (all OR > 1). Levetiracetam appeared to 
possess the best overall balance of efficacy and tolerability (SUCRA 
= 0.769, 0.743, 0.604 and 0.659), which concurs with the present 
analysis (see Figure 25, which plots levetiracetam in the lowest right 
hand corner indicating the best trade-off as lowest NNT and highest 
NNH profile).    
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Although the authors of the recent [currently unpublished] study 
utilised a slightly different methodology for determining the trade-off 
between efficacy and tolerability i.e. SUCRA vs. a plot of NNT / NNH, 
the results are in keeping with the findings of within this chapter. It is 
also interesting that independent interest has been shown in a variant 
trade-off assessment within the same field and specific area as 
presented here. The results of the present project therefore remain 
relevant with the recent NMA adding little to this field than previously 
established here. 
 
4.7 Summary 
This systematic review and Bayesian network meta-analysis highlights 
the paucity of long-term prospective randomised active comparator 
trials of AEDs currently licensed for refractory epilepsy. In comparison 
with the five previously published meta-analyses reporting on this topic 
and building on the recommendations issued by NICE, the use of 
indirect treatment comparisons indicated that levetiracetam, vigabatrin, 
gabapentin, and sodium valproate demonstrated the best combination 
of short term efficacy and tolerability, whereas oxcarbazepine, while 
equally effective, was the least well tolerated in the short term.  
 
As the use of carbamazepine is widely recommended and accepted as 
being an effective first line option for patients with partial onset focal 
seizures, despite there being no trials investigating this agent within 
the present analysis, clinical practice has dictated this agent to 
demonstrate a good balance of efficacy and tolerability in both the 
short and long term.  
 
With the exception of vigabatrin which is associated with visual field 
defects in long term use, in the absence of evidence definitively 
indicating the clinical superiority or tolerability of one AED over 
another, we suggest that other factors such as acquisition cost, dosing 
regimen, licensing indications and contraindications be the differential 
in selecting among these AEDs.  
 
The logical next step for future trials would be the commissioning of 
multiple active comparisons, similar to the SANAD study in primary 
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generalized epilepsy and partial epilepsy.(86, 87) Until regulators 
mandate greater use of such trials, network meta-analysis 
incorporating mixed treatment models and the hierarchical trade-off 
analysis may provide the only available source of useful information on 
comparative efficacy and safety of treatments for epilepsy and other 
common diseases. 
 
An independent review exploring the characteristics and 
methodological quality of network / indirect meta-analyses conducted 
over the last 10 years has recently been published.(161) As part of this 
analysis the quality of the above publication has been graded as 
moderate – high in accordance with the AMSTAR (a measurement tool 
to assess systematic reviews) and ISPOR (international society of 
pharmacoeconomics and outcomes research) criteria.  
 
This work has been published in the British Journal of Pharmacology 
2013; 76(5): 649-667 (doi: 10.1111/bcp.12083) and meets the criteria 
for inclusion on the NIHR Centre for Reviews and Dissemination (CRD) 
Database of Abstracts of Reviews and Effects (DARE).  
 
4.8 Implications of Research 
This publication utilised a novel trade-off analysis to comparatively 
determine the key efficacy and safety / tolerability parameters of 
treatments for refractory epilepsy in the absence of a large scale all-
encompassing randomised controlled clinical trial. The findings from 
this area of research were published and communicated locally via the 
area prescribing committee. The results have been read with interest 
and the NMA model has served as a template / reference point within 
the region for the use of new AEDs that have come to the UK market 
since, including eslicarbazepine, retigabine and perampanel (see 
Figure 26), all of which appear to possess a similar (and not superior) 
efficacy profile to those previously available (as compared with Figure 
17).  
 
The introduction of newer agents, as demonstrated with 
eslicarbazepine as a variant of oxcarbazepine, within North Central 
London are therefore more rigorously assessed with a conservative 
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uptake compared with adjacent regions as a result of this research 
project (see Figure 27). A locally developed prescribing hierarchy lists 
(following the failure of first-line gabapentin or valproic acid) the 
preferred second-line choices being levetiracetam > topiramate > 
lacosamide > zonisamide with consideration to the balance of NNT vs. 
NNH and cost.  
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Figure 26: Expanded analysis forest plot (RevMan v5.0) of the odds ratios for efficacy 
(50% responder rate) of randomized controlled trials comparing an AED vs. placebo 
as add-on treatment for refractory epilepsy, respectively.  
The black squares represent the odds ratio for individual studies of AED vs. placebo and the horizontal line 
represents the 95% confidence interval of the odds ratio. The black diamond represents the random-effects 
pooled odds ratio for studies reporting on the same AED where its width represents the 95% confidence 
intervals. Estimates to the right of the vertical line (i.e. odds ratio >1) are indicative of a statistically 
significant increase in efficacy, relative to placebo, in patients randomized to the active intervention.  
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Figure 27: Sum of issue quantity (June 2012 – May 2017) for (a) oxcarbazepine, and 
its newer equivalent (b) eslicarbazepine, within general practice across the London 
health economy 
Based on the NMA findings in Figure 26, where the efficacy (50% responder rate) for eslicarbazepine is 
lower than that for oxcarbazepine (Figure 17), the NCL area prescribing committee could not justify the 
addition of eslicarbazepine to the local formulary. The total issue quantity for eslicarbazepine within NCL 
compared with the other four London CCGs is therefore considerably lower. Source: 
https://openprescribing.net   
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5.0 Chapter 5: Research Project Two – Angiotensin-II 
Receptor Antagonists for the Management of 
Hypertension and Heart Failure 
 
5.1 Introduction 
The second research project introduces the concept of a cost-utility 
analysis as the trade-off assessment was expanded from efficacy and 
safety / tolerability to efficacy and cost. A systematic review and 
frequentist meta-analysis of all published studies will be performed, 
comparing losartan and candesartan as the two leading angiotensin II 
receptor antagonists for the management of hypertension and heart 
failure. Data will be abstracted from RCTs of head-to-head design to 
obtain estimates on their relative efficacy and safety with a view to 
determine the trade-off with cost-effectiveness. The use of a 
frequentist rather than Bayesian meta-analysis will be suitable for this 
project as only trials investigating both agents in a direct comparison 
will be identified. Further, the cost-utility method will be suitable as both 
agents are from the same pharmacological class and therefore 
regarded as clinically interchangeable.  
 
The goal for this project is to disseminate the outcomes via NHS 
channels to influence prescribing across the UK, including guides for 
clinicians and patients.  
 
5.2 Literature Review 
5.2.1 Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality worldwide (162), despite advances in diagnosis and 
management. Hypertension is a major risk factor for CVD, and a risk 
factor for the development of heart failure. The goal of hypertension 
therapy is to reduce blood pressure (BP) to less than 140/90 mmHg in 
elderly patients and to less than 130/85 mmHg in the young or middle-
aged and in patients with diabetes mellitus irrespective of age (163). 
Patients with symptomatic chronic heart failure (CHF) have reduced 
cardiac output, characteristic symptoms of dyspnoea, orthopnoea and 
decreased exercise capacity, and have a high risk of death and 
hospitalisation (164).  
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5.2.2 Current Management 
Although angiotensin-converting enzyme (ACE) inhibitors are a well-
established class of treatment, some patients are unable to tolerate 
them. In recent years, angiotensin II receptor antagonists (AIIRAs) 
have emerged as an alternative option for targeting and inhibiting the 
renin-angiotensin-aldosterone system (RAAS) by selectively blocking 
the AT1 subtype (165). AIIRAs exert a similar antihypertensive effect to 
ACE inhibitors (166, 167); however, their specificity avoids major ACE 
inhibitor-related adverse effects, such as cough and angioedema, 
which are believed to result from non-specific interference of bradykinin 
metabolism (168). Compared with losartan (Cozaar; MSD, Whitehouse 
Station, NJ, USA), the first AIIRA to receive a marketing authorisation 
for the management of hypertension, candesartan (Amias; Takeda, 
New York, NY, USA), the current market leader, has a slower 
dissociation rate from the AT1 receptor (169), potentially providing it 
with a longer-acting antihypertensive effect.  
 
5.3 Rationale for this Research Project 
The UK National Health Service (NHS) in 2010 spent in excess of £250 
million per annum on AIIRAs for the treatment of hypertension and 
heart failure; with candesartan cilexetil (Amias®; Takeda) dominating 
the market. Until recently both agents were comparably priced, 
however, as losartan potassium was the first AIIRA to receive a 
Marketing Authorisation, generic preparations of this agent are 
emerging at a fraction of the cost to its branded equivalent, Cozaar® 
(MSD). This research project explores the potential health benefits and 
compromises that a trade-off for a cheaper generic medicine would 
bring, through an exploration of its cost-effectiveness compared with a 
more expensive ‘on patent’ alternative.  
 
5.4 Collaboration 
All work related to the systematic review and frequentist meta-analysis 
within this chapter of the thesis was undertaken by me. Systematic 
review support was provided by Dr Grosso in the form of a second 
independent check against the proforma. The cost-utility model was 
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built and executed by Dr Scott with clinical information obtained from 
the meta-analysis. Subsequent analyses were interpreted and 
circulated by me with support from Dr Grosso.  
 
5.5 Protocol 
5.5.1 Systematic Review 
Relevant randomised trials were searched for within the Cochrane 
Central Register of Controlled Trials (Cochrane Library 2009, issue 
2), which contains the Hypertension and Heart Group’s specialist 
register, Medline (1950–March 2010), and Embase (1980–February 
2010). The search terms and limits are provided below (see section 
5.5.4).  
 
In addition to the database search strategy, the reference lists of 
identified manuscripts were manually hand-searched to identify 
additional relevant studies. To formulate and ensure optimal reporting 
of the systematic review and meta-analysis, the established PRISMA 
statement was followed (170). A summary of the studies identified, 
screened, assessed for eligibility and included for analysis is 
summarised in Figure 28 and Figure 29 for the hypertension and 
heart failure indications, respectively.   
 
5.5.1.1 Inclusion Criteria 
Hypertension 
Trials were included if they were of randomised, double-blind, 
active-controlled design (investigating candesartan and losartan), 
provided they recruited adult patients (> 18 years), were of parallel 
or cross-over design, and the treatment period was of at least 4 
weeks duration. 
 
Heart Failure 
Trials were included if they were of randomised, double-blind, 
active-controlled design (investigating candesartan and losartan), 
provided they recruited adult patients (> 18 years) with a left 
ventricular ejection fraction (LVEF) not exceeding 40%, were of 
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parallel or cross-over design, and the treatment period was of at 
least 4 weeks duration. 
 
5.5.1.2 Exclusion Criteria 
Studies were excluded if they were open-label, observational, or 
not fully published (e.g. only presented at conference proceedings 
or solely available in abstract form). Non-English language 
publications were also excluded (in accordance with the findings 
described in section 4.6.5) as were trials which permitted the use 
of other therapies which may have confounded the clarity of the 
outcomes of the drug being assessed (e.g. calcium channel 
blockers). Trials which used a conditional design where patients 
were allocated treatment only if they showed a pre-determined 
response to treatment during a baseline period before 
randomisation were also excluded.  
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Figure 28: The PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) flow diagram of studies identified from the systematic 
review for inclusion in the meta-analysis for hypertension   
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Figure 29: The PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) flow diagram of studies identified from the systematic 
review for inclusion in the meta-analysis for heart failure   
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5.5.2 Endpoints 
The primary efficacy endpoints for extraction from the hypertension 
trials were the mean change from baseline in trough (24 hours post-
dose) diastolic blood pressure (DBP) and systolic blood pressure 
(SBP). The primary efficacy endpoint for extraction from the heart 
failure trials was a composite of cardiovascular death and 
hospitalisation admission for management of heart failure. As safety / 
tolerability profiles for the two agents overlap due to them being from 
the same class, this endpoint was not assessed.  
 
5.5.3 Quality Assessment and Data Collection 
Data from systematic reviews or previous meta-analyses were not 
used to enable the collection of data from original sources; however, 
any such publications identified served as a comparator to ensure 
that all relevant studies had been included within this review. 
Secondary searches were conducted from the reference lists of 
manuscripts identified. To minimise bias, references and abstracts 
retrieved by the search were reviewed by me and validated by Dr 
Grosso. The same process applied to the selection of potentially 
relevant publications against the pre-specified inclusion and exclusion 
criteria. Important clinical and methodological study characteristics 
were extracted onto a standard form, checked and recorded to 
ensure consistency.  This included:  
 
1) Characteristics of trial participants (including age, gender, 
ethnicity, and diagnosis) 
2) Study design and regime of intervention 
3) Details of intervention (including type, dose, and duration) 
4) Details of outcome measure (baseline, peak and trough for SBP 
and DBP).  
 
Any discrepancies or lack of agreement between the two reviewers 
were referred to a third independent investigator (ADH) for arbitration. 
An assessment of risk of bias (using established criteria) (27) was 
also undertaken. All analyses were based on intention-to-treat data. 
For any trials that reported data using a per-protocol analysis, 
intention-to-treat values were calculated. 
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5.5.4 Search Terms 
See Table 10 and Table 11 for a list of the search terms and limits 
applied when conducting the database search.  
 
Table 10: Search strategy used to determine eligible published trials for the 
hypertension and heart failure analysis 
 Search term 
01. Losartan [MeSH] 
02. Candesartan$.tw 
03. Candesartan cilexetil [MeSH] 
04. Hypertension [MeSH] 
05. Heart failure [MeSH] 
06. 1 AND (2 OR 3) AND 4 
07. 1 AND (2 OR 3) AND 5 
08. 6 OR 7 
 
 
Table 11: Limits applied to each database as part of the systematic review for the 
hypertension and heart failure analysis 
Database Limits applied 
PubMed Humans; Randomised controlled trial; English; all adult: 19+ years 
Cochrane Nil 
Embase Full text; Human; English language ; Article OR Erratum; Adult <18 to 64 years> OR aged 
<65 years+  
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5.5.5 Statistical Analysis – Frequentist Meta-Analysis 
A random-effects ‘frequentist’ meta-analysis (38, 171) was 
conducted, to compare outcomes, reported as the weighted mean 
difference; therefore estimates meta-analysed over multiple trials are 
considered as average treatment effects. The choice of random-
effects is in keeping with previous analyses where the protocol and 
patient population for each study included vary slightly.  
 
To evaluate heterogeneity of the effect estimates the Cochran Q (Chi-
squared) and Higgins I-squared statistics were calculated (48). Refer 
to section 3.5.7 for further details on these.  
 
To generate the Forest plots, Funnel plots and l’Abbé plots, 
StatsDirect® v.2.7.7 (Altrincham, Cheshire, UK) was used. 
 
5.5.6  Economic Analysis – Cost-Utility Analysis (CUA) 
[This section of the research project was performed by MS] 
 
A 10-year CUA of adopting losartan or candesartan using a Markov 
state transition model (see Figure 30) was developed using 
Microsoft Excel (Microsoft Corporation, 2007) by Dr Scott in 
consultation with Dr Grosso and me. Structurally, the model 
assumes that all patients can be in one unique health state in a 
given cycle [one of: ‘Well’, ‘Coronary Heart Disease (CHD)’, ‘Stroke’ 
and ‘Death’] with the entire cohort initially in the ‘Well’ state. A 10-
year time horizon and annual cycle length was used for comparison 
of the costs and health outcomes for patients with essential 
hypertension, from the viewpoint of the UK National Health Service 
(NHS). Development of primary disease and subsequent quality-
adjusted survival was considered in the model.  Refer to section 
10.3 (Appendix III) for further detail on the CUA model.  
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Figure 30: Markov State Transition diagram used for the cost-utility analysis.  
The patient cohort all start in state A (‘Well’) and can transition annually to the coronary heart disease 
(CHD) and cerebrovascular disease states (B and C) denoted by the arrows, or they can survive or die 
from either myocardial infarction (MI) or stroke events from states B and C, respectively, or die from 
other causes. The time horizon of the model is 10 years 
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Non-fatal 
MI 
Non-fatal 
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Dead 
C 
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5.6 Findings 
5.6.1 Hypertension 
Overall, eight studies fulfilled the inclusion criteria for hypertension 
representing 9 comparisons and 3,619 patients (172-179). A summary 
of the characteristics of the studies included within this review is given 
in Table 12. Of the nine comparisons, two compared low-dose losartan 
with low-dose candesartan (50mg versus 8mg); two compared low-
dose losartan with mid-dose candesartan (50mg versus 16mg); two 
compared high-dose losartan with mid-dose candesartan (100mg 
versus 16mg); and three compared high-dose losartan with high-dose 
candesartan (100mg versus 32mg). The primary efficacy endpoint data 
were extracted from these studies and pooled in a meta-analysis 
(StatsDirect® 2.7.7; Altrincham, Cheshire, UK) to estimate the 
weighted average reduction in DBP and SBP from baseline in the two 
treatment groups (see Figure 31 and Figure 32). 
 
These analyses estimate a between-treatment difference of -1.89 
mmHg (95% CI -2.29 to -1.48) for trough DBP and -2.96 mmHg (95% 
CI -3.60 to -2.32) for trough SBP in favour of candesartan. Overall, the 
nine comparisons generated an I-squared statistic of 32.6% for the 
trough DBP and 52.4% for trough SBP indicating that although the 
results are statistically significant, there is a mild-to-moderate degree of 
heterogeneity between the individual studies when combined.  
 
For the purpose of the CUA, the meta-analysis was re-performed using 
only the three later studies which investigated both AIIRAs at their 
respective maximal licensed doses to derive a point estimate based on 
data reporting on comparative doses (see Figure 33 and Figure 34). 
This produced a between-treatment difference of -1.96 mmHg (95% CI 
-2.40 to -1.51) for trough DBP and -3.00 mmHg (95% CI -3.79 to -2.22) 
for trough SBP in favour of candesartan. As trough SBP is a more 
robust predictor of stroke and adverse cardiovascular outcome 
[Framingham model] this value was used the analysis.  
 
Further detail of data extracted from the eligible studies to populate the 
meta-analysis are provided in Table 16. 
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Table 12: Characteristics of studies included within the meta-analysis for hypertension 
Study Study design  
(weeks of treatment) 
Daily treatment dose  
(number of subjects) 
Subjects 
Diagnosis  Sex 
(Male:Female) 
Mean age 
(range) 
Ethnicity  
(Non-black:Black) 
Hypertension studies 
Andersson OK and Neldam S (1998)(172)  Parallel, non-forced titration (8) Losartan 50mg (83), Candesartan 8mg (82), 
Candesartan 16mg (84), placebo (85) 
Mild-
moderate 
 
188:146 60 (20-80) 334:0 
Lacourcière Y et al (1999)(177)  Parallel, Forced titration (8) Losartan 100mg (115), Candesartan 16mg 
(116), placebo (37) 
Mild-
moderate  
 
165:102 55 (20-80) 261:6 
Gradman AH et al (1999)(175)  Parallel, non-forced titration (8) Losartan 50/100mg (170), Candesartan 
16/32mg (162) 
 
Moderate 191:141 54 (18-80) 291:41 
Manolis AJ et al (2000)(178)  Parallel, non-forced titration (12) Losartan 50/100mg (461), Candesartan 
8/16mg (458), Losartan+hydrochlorthiazide 
50+12.5mg (232) 
 
Mild-
moderate 
608:553 51 (20-80) 635:526 
Bakris G et al  
(2001)(174)  
Parallel, Forced titration (8) Losartan 100mg (332), Candesartan 32mg 
(322) 
 
Moderate 380:274 54 (18-80) 541:113 
Vidt DG et al  
(2001)(176)  
Parallel, Forced titration (8) Losartan 100mg (304), Candesartan 32mg 
(307) 
 
Moderate 358:253 55 (18-80) 490:121 
Willemsen JM et al (2004)(179)  Cross-over, non-forced (4) Losartan 50mg, Candesartan 16mg, placebo 
(total n=13) 
 
Mild-
moderate 
8:5  52 (39-58) NR 
Baguet JP et al 
(2006)(173)  
Parallel, non-forced titration (6) Losartan 50mg (89), Candesartan 8mg (87), 
placebo (80) 
 
Mild-
moderate 
153:103 54 (18-75) NR 
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Table 13: Characteristics of studies included within the meta-analysis for heart failure 
Study Study design  
(weeks of treatment) 
Daily treatment dose  
(number of subjects) 
Subjects 
Diagnosis  Sex 
(Male:Female) 
Mean age 
(range) 
Ethnicity  
(Non-black:Black) 
Heart Failure studies 
Candesartan 
Granger CB et al (2003)(180)  Parallel (146)  Candesartan 32mg (1,013), placebo (1,015) LVEF ≤ 40%; 
NYHA II-IV 
 
1382:646 67 (NR) 1955:73 
McMurray JJV et al (2003)(181)  Parallel (178) Candesartan 32mg (1,276), placebo (1,272) LVEF ≤ 40%; 
NYHA II-IV 
 
2006:542 64 (NR) 2421:127 
Granger CB et al (2000)(182)  Parallel (12) Candesartan 16mg (179), placebo (91) LVEF ≤ 40%; 
NYHA II-IV 
 
186:84 65 (58-74) NR 
Losartan 
Konstam MA et al (2009)(183)  Parallel Losartan 50mg (1,927), Losartan 150mg 
(1,913) 
LVEF ≤ 40%; 
NYHA II-IV 
 
2691:1149 66 (56-73) NR 
Pitt B et al (2000)(184)  Parallel Losartan 50mg (1,578), Captopril 150mg 
(1,574) 
LVEF ≤ 40%; 
NYHA II-IV 
 
2185:966 72 NR 
Pitt B et al (1997)(185)  Parallel Losartan 50mg (352), Captopril 150mg (370) LVEF ≤ 40%; 
NYHA II-IV 
 
482:240 74 688:34 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Forest plot of the weighted mean difference (WMD) for absolute difference 
in trough diastolic blood pressure from baseline to end of study period (4 to 12 weeks) 
of randomised controlled trials comparing losartan with candesartan as monotherapy 
for the treatment of mild-to-moderate hypertension.  
The black squares represent the WMD for individual studies and the horizontal line represents the 
associated 95% confidence interval. The diamond and horizontal line within it represents the random-effects 
pooled WMD and its corresponding 95% confidence interval. Estimates to the left of the vertical line (i.e. 
WMD < 0) are indicative of a significant difference in trough diastolic blood pressure in favour of 
candesartan. Statistical significance is inferred where the confidence interval does not cross the vertical line 
of unity 
 
 
 
  
 
Effect size meta-analysis plot [random effects]
-15 -10 -5 5 10
Vidt et al (2001) - 100mg vs 32mg
Bakris et al (2001) - 100mg vs 32mg
Gradman et al  (1999) - 100mg vs 32mg
Manolis et al (2000) - 100mg vs 16mg
Lacourciere et al (1999) - 100mg vs 16mg
Willemsen et al (2004) - 50mg vs 16mg
Andersson & Neldam (1998) - 50mg vs 16mg
Baguet et al (2006) - 50mg vs 8mg
Andersson & Neldam (1998) - 50mg vs 8mg
  0  
DL pooled weighted mean difference = -1.886694  (95% CI = -2.292048 to -1.48134)   favours candesartan      favours losartan  
DL pooled weighted mean difference = -1.89 (95% CI = -2.29 to -1.48) 
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Figure 32: Forest plot of the weighted mean difference (WMD) for absolute difference 
in trough systolic blood pressure from baseline to end of study period (4 to 12 weeks) 
of randomised controlled trials comparing losartan with candesartan as monotherapy 
for the treatment of mild-to-moderate hypertension.  
The black squares represent the WMD for individual studies and the horizontal line represents the 95% 
confidence interval of the WMD. The diamond and horizontal line within it represents the random-effects 
pooled WMD and its corresponding 95% confidence interval. Estimates to the left of the vertical line (i.e. 
WMD < 0) are indicative of a significant difference in trough systolic blood pressure in favour of 
candesartan. Statistical significance is inferred where the confidence interval does not cross the vertical line 
of unity 
 
 
 
 
 
 
 
 
 
 
 
 
Effect size meta-analysis plot [random effects]
-30 -20 -10 10
Vidt et al (2001) - 100mg vs 32mg
Bakris et al (2001) - 100mg vs 32mg
Gradman et al  (1999) - 100mg vs 32mg
Manolis et al (2000) - 100mg vs 16mg
Lacourciere et al (1999) - 100mg vs 16mg
Willemsen et al (2004) - 50mg vs 16mg
Andersson & Neldam (1998) - 50mg vs 16mg
Baguet et al (2006) - 50mg vs 8mg
Andersson & Neldam (1998) - 50mg vs 8mg
  0  
DL pooled weighted mean difference = -2.958292  (95% CI = -3.600601 to -2.315982)     favours candesartan       favours losartan  
DL pooled weighted mean difference = -2.96 (95% CI = -3.60 to -2.32) 
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Figure 33: Forest plot of the weighted mean difference (WMD) for absolute difference 
in trough diastolic blood pressure from baseline to end of study period (4 to 12 weeks) 
of randomised controlled trials comparing losartan with candesartan at their maximum 
licensed doses as monotherapy for the treatment of mild-to-moderate hypertension.  
The black squares represent the WMD for individual studies and the horizontal line represents the 95% 
confidence interval of the WMD. The diamond and horizontal line within it represents the random-effects 
pooled WMD and its corresponding 95% confidence interval. Estimates to the left of the vertical line (i.e. 
WMD < 0) are indicative of a significant difference in trough diastolic blood pressure in favour of 
candesartan. Statistical significance is inferred where the confidence interval does not cross the vertical line 
of unity 
 
 
  
 
Effect size meta-analysis plot [random effects]
-3.0 -2.5 -2.0 -1.5 -1.0 -0.5
Vidt et al (2001) - 100mg vs 32mg
Bakris et al (2001) - 100mg vs 32mg
Gradman et al  (1999) - 100mg vs 32mg
  0  
DL pooled weighted mean difference = -1.960107  (95% CI = -2.407149 to -1.513065) favours candesartan (<0) 
DL pooled weighted mean difference = -1.96 (95% CI = -2.41 to -1.51) 
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Figure 34: Forest plot of the weighted mean difference (WMD) for absolute difference 
in trough systolic blood pressure from baseline to end of study period (4 to 12 weeks) 
of randomised controlled trials comparing losartan with candesartan at their maximum 
licensed doses as monotherapy for the treatment of mild-to-moderate hypertension.  
The black squares represent the WMD for individual studies and the horizontal line represents the 95% 
confidence interval of the WMD. The diamond and horizontal line within it represents the random-effects 
pooled WMD and its corresponding 95% confidence interval. Estimates to the left of the vertical line (i.e. 
WMD < 0) are indicative of a significant difference in trough systolic blood pressure in favour of 
candesartan. Statistical significance is inferred where the confidence interval does not cross the vertical line 
of unity 
 
 
 
 
 
 
 
 favours candesartan (<0) 
DL pooled weighted mean difference = -3.00 (95% CI = -3.79 to -2.22) 
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5.6.2 Base-Case Cost-Utility Model 
The base-case Markov model used a generic losartan 100mg retail 
price of £6.47 (28-day pack price) compared with the list price of 
£16.13 for candesartan 32mg (28-day pack price) at a moderate 
baseline risk (SBP 165mmHg) in a cohort of men and women aged 
65 years (see Table 14).  
 
The difference in mean trough SBP between candesartan and 
losartan was obtained from the meta-analysis (-3.00mmHg). The 
estimated ICERs for male and female patients with ‘moderate’ risk 
were £44,930 and £53,804, respectively, demonstrating the cost-
effectiveness of losartan relative to candesartan at current generic 
acquisition costs over a 10-year horizon.  
 
 
5.6.3 Heart Failure 
Overall, six studies were identified for heart failure; three studies 
reporting on losartan and three studies reporting on candesartan. No 
published head-to-head studies were found (see Table 13). In the 
absence of comparative trials directly comparing the efficacy of 
candesartan versus losartan in CHF, a qualitative analysis of the key 
studies was undertaken as an alternative to a quantitative meta-
analysis (see section 5.7.2). As the only common comparator was 
placebo and there are no head-to-head studies comparing the two 
AIIRAs, a NMA to generate indirect comparative estimates was not 
considered appropriate.   
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Table 14: Cost and utility parameters used in the base-case utility model comparing 
candesartan and losartan for the treatment of hypertension 
Parameter Base-case value Source 
Annual drug cost of candesartan (32mg) £193.56 BNF (2009)(186) 
Annual drug cost of generic losartan (100mg) £77.64 TEVA Pharmaceuticals (187) 
Projected annual drug cost of generic losartan (100mg) £10.56 Expert Opinion  
Annual cost of stroke survivor [cost in first year] £2,163 (8,046)* NICE Guideline CG034(188) 
Annual cost of MI survivor [cost in first year] £500 (4,448)* NICE Guideline CG034(188) 
Utility weight of stroke survivor 0.63 NICE Guideline CG034(188) 
Utility weight of MI survivor [first year] 0.88 (0.76) NICE Guideline CG034(188) 
Treatment effect difference (incremental reduction in SBP) -3.00 mmHg Meta-Analysis 
*cost inflated to 2009 base case; (MI) myocardial infarction; (SBP) systolic blood pressure 
 
 
Table 15: Variation of ICER with baseline risk when comparing candesartan and losartan for 
the treatment of hypertension 
Baseline risk/SBP ICER (£/QALY) 
Generic losartan  
(£77.64 per annum) 
Projected generic price 
(£10.56 per annum) 
Males 
Mild (140 mmHg) £52,644 £87,946 
Moderate (165 mmHg) £44,930 £74,901 
High (180 mmHg) £41,469 £69,076 
Females 
Mild (140 mmHg) £85,244 £142,449 
Moderate (165 mmHg) £53,804 £91,368 
High (180 mmHg) £41,591 £71,430 
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Table 16: Data extracted from clinical trials included within the meta-analysis for hypertension 
Study & design Losartan Candesartan 
 Mean (max) 
dose 
Baseline SBP [95% CI] DBP [95% CI] Mean (max) 
dose 
Baseline SBP [95% CI] DBP [95% CI] 
Lacourcière Y et al 
(1999)(177)  
– Forced titration 
– week 8 
 
100mg 
(from 50mg 
at week 4) 
[n=115] 
153.0/100.2 
mmHg 
Peak -10.3mmHg  
[-12.6 to -8.0] 
 
Trough -
8.2mmHg  
[-10.7 to -5.7] 
Peak -7.7mmHg 
[-9.3 to -6.2] 
 
Trough -
5.8mmHg  
[-7.5 to -4.1] 
16mg 
(from 8mg 
at week 4) 
[n=116] 
155.1/101.8 
mmHg 
Peak -
14.5mmHg 
[-16.8 to -12.3] 
 
Trough -
12.4mmHg 
[-14.8 to -10.0] 
Peak -9.4mmHg 
[-10.9 to -7.9] 
 
Trough -
8.2mmHg 
[-9.9 to -6.5] 
Gradman AH et al 
(1999)(175) 
– Not forced 
titration 
– week 8 
 
100mg 
(from 50mg 
at week 4) 
[n=170; 
56% not 
forced] 
154.1/100.5 
mmHg 
Peak -14.4mmHg 
[-16.8 to -12.1] 
 
Trough -
10.0mmHg 
[-12.2 to -7.8] 
Peak -9.6mmHg 
[-11.1 to -8.2] 
 
Trough -
8.9mmHg 
[-10.1 to -7.6] 
32mg 
(from 16mg 
at week 4) 
[n=162; 
52% not 
forced] 
152.9/100.3 
mmHg 
Peak -
16.5mmHg 
[-18.8 to -14.1] 
 
Trough -
11.9mmHg 
[-14.1 to -9.6] 
Peak -
12.6mmHg 
[-14.0 to -11.1] 
 
Trough -
11.0mmHg 
[-12.3 to -9.8] 
Bakris G et al 
(2001)(174) 
– CLAIM study 
– Forced titration 
– week 8 
100mg 
(from 50mg 
at week 2) 
[n=332] 
152.0/99.9 
mmHg 
Peak -12.6mmHg 
[not reported] 
 
Trough -
9.8mmHg 
[not reported] 
Peak -
10.1mmHg 
[not reported] 
 
Trough -
8.7mmHg 
[not reported] 
32mg 
(from 16mg 
at week 2) 
[n=322] 
152.6/100.1 
mmHg 
Peak -
15.2mmHg 
[not reported] 
 
Trough -
13.3mmHg 
[not reported] 
Peak -
11.6mmHg 
[no CI] 
 
Trough -
10.9mmHg 
[no CI] 
Vidt DG et al 
(2001)(176) 
– CLAIM II study 
– Forced titration 
– week 8 
100mg  
(from 50mg 
at week 2) 
[n=304] 
152.2/100.2 
mmHg 
Peak -12.0mmHg 
[not reported] 
 
Trough -
10.1mmHg 
[not reported] 
Peak -9.5mmHg 
[not reported] 
 
Trough -
9.1mmHg 
[not reported] 
32mg 
(from 16mg 
at week 2) 
[n=307] 
153.6/100.4 
mmHg 
Peak -
15.5mmHg 
[not reported] 
 
Trough -
13.4mmHg 
[not reported] 
Peak -
12.9mmHg 
[no CI] 
 
Trough -
10.5mmHg 
[no CI] 
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Study & design Losartan Candesartan 
 Mean (max) 
dose 
Baseline SBP [95% CI] DBP [95% CI] Mean (max) 
dose 
Baseline SBP [95% CI] DBP [95% CI] 
Andersson OK and 
Neldam S 
(1998)(172) 
– No titration 
– week 8 (low dose) 
50mg 
[n=83] 
168/104 
mmHg 
Peak -19mmHg 
[not reported] 
 
Trough -
11.0mmHg 
[not reported] 
-12mmHg 
[not reported] 
 
Trough -
7.0mmHg 
[not reported] 
8mg 
[n=82] 
169/102 
mmHg 
Peak -16mmHg 
[not reported] 
 
Trough -
14.0mmHg 
[not reported] 
Peak -10mmHg 
[no CI] 
 
Trough -
9.0mmHg 
[no CI] 
Andersson OK and 
Neldam S 
(1998)(172) 
– No titration 
– week 8 (high 
dose) 
50mg 
[n=83] 
168/104 
mmHg 
Peak -19mmHg 
[no CI] 
 
Trough -
11.0mmHg 
[no CI] 
Peak -12mmHg 
[no CI] 
 
Trough -
7.0mmHg 
[no CI] 
16mg 
[n=84] 
168/103 
mmHg 
Peak -20mmHg 
[no CI] 
 
Trough -
14.0mmHg 
[no CI] 
Peak -12mmHg 
[no CI] 
 
Trough -
10.0mmHg 
[no CI] 
Baguet et al 
(2006)(173) 
– No titration 
– week 6  
50mg 
[n=89] 
161/101 
mmHg 
Trough -
8.8mmHg 
[no CI] 
Trough -
5.1mmHg 
[no CI] 
8mg 
[n=87] 
160/101 
mmHg 
Trough -
10.8mmHg 
[no CI] 
Trough -
7.3mmHg 
[no CI] 
Willemsen et al  
(2004)(179) 
– No titration 
– week 4 
50mg 
[n=4] 
168/105 
mmHg 
Trough -23mmHg 
[no CI] 
Trough -
16mmHg 
[no CI] 
16mg 
[n=4] 
168/105 
mmHg 
Trough -
30mmHg 
[no CI] 
Trough -
18mmHg 
[no CI] 
Manolis AJ et al 
(2000)(178) 
– Not forced 
titration 
– week 12 
100mg 
(from 50mg 
at week 6) 
[n=449; 
47% had 
dose 
increased] 
153.0/101.6 
mmHg 
Trough -
14.4mmHg 
SD=11.7 
[-15.5 to -13.3] 
Trough -
12.4mmHg 
SD=7.2 
[-13.0 to -11.7] 
 
16mg 
(from 8mg 
at week 6) 
[n=462; 
45% had 
dose 
increased] 
152.7/101.6 
mmHg 
Trough -
15.8mmHg 
SD=12.2 
[-16.9 to -14.7] 
 
Trough -
13.1mmHg 
SD=7.6 
[-13.8 to -12.4] 
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5.6.4 Sensitivity analyses 
To determine an accurate understanding of the potential ICERs, MS 
assisted in the modelling of four alternative scenarios using one-way 
sensitivity analyses from the base-case model (see Table 15).  
 
Variation in baseline risk 
The baseline risk was varied by increasing the cohort pre-treatment 
SBP in the range 140-180mmHg. The cost-effectiveness of 
candesartan decreased as the baseline risk lowered, as would be 
expected as the value of treatment reduces when fewer patients 
develop disease (see Figure 35). The range of ICERs is £41,469 to 
£52,644 for male patients and £41,591 to £85,244 for female patients.  
 
Variation in hypertensive effectiveness 
The cost-effectiveness variations from the base-case for male and 
female patients at the limits of the 95% confidence intervals for the 
trough SBP were identified using a random effects meta-analysis (-
2.22 to -3.79 mmHg). The ICERs were £71,049 and £87,015 for a 2.22 
mmHg SBP reduction in male and female patients, respectively, and 
£44,930 and £53,804 for a 3.79 mmHg SBP reduction in male and 
female patients, respectively. Therefore, within the identified pooled 
range of statistical uncertainty, losartan remained the most cost-
effective treatment strategy. Figure 36 shows variation of the ICER with 
a wider range of trough SBP reduction (treatment effectiveness 
difference) with all other base case parameters left unchanged. For the 
ICER to fall below the UK perceived threshold of cost-effectiveness 
(£30,000 per QALY), the trough SBP differential between candesartan 
and losartan would have to be greater than 5 mmHg (in favour of 
candesartan). 
 
Projected pricing for losartan 
Using previous experience of generic market prices following patent 
expiry, it was anticipated that the acquisition cost of generic losartan 
may drop to £0.88 per pack of 28 tablets. Based on this figure, the 
base-case ICER would further increase to £74,901 and £91,368 for 
male and female patients, respectively, in favour of losartan. At this 
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generic price, candesartan becomes increasingly unfavourable from a 
cost-effectiveness point of view whilst it remains under patent 
protection and holds its current price (see Section 5.7.7 for further 
detail post candesartan patent expiry).  
 
Variation in age 
Variation in the cost-effectiveness with changes in the cohort starting 
age for male and female patients was also modelled. The ICER at 35 
years of age was £151,140 and £369,075 for male and female 
patients, respectively, decreasing to the base-case values at age 65. 
Figure 37 shows variation in ICER with starting age of the cohort in the 
range 35-65 years for males and females. Throughout the wide range 
of initial ages, losartan dominated candesartan establishing its position 
as the most cost-effective intervention of the two.   
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Figure 35: Incremental cost-effectiveness ratios (ICERs) of candesartan compared 
with losartan versus baseline hypertension risk.  
Results are displayed for males and females at two generic losartan prices: Price 1 (£77.64 per annum) and 
Price 2 (£10.56 per annum). At all risk levels and for both genders the ICER is greater than £30,000 per 
QALY indicating that losartan is dominant (i.e. the more cost-effective option)  
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Figure 36: One-way sensitivity analysis on the incremental cost-effectiveness ratio 
(ICER) of candesartan relative to losartan versus difference in relative anti-
hypertensive effect on systolic blood pressure (SBP) of candesartan relative to 
losartan.  
Within the range 0-5 mmHg difference between the effectiveness (reduction in SBP) of both agents the 
ICER is greater than £30,000 per QALY indicating that losartan is dominant (i.e. the more cost-effective 
option) 
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Figure 37: One-way sensitivity analysis on the incremental cost-effectiveness ratio 
(ICER) of candesartan relative to losartan versus cohort starting age in the age range 
35-65 years for males and females.  
The curves demonstrate losartan as being dominant across all age ranges (i.e. losartan is cost-effective 
irrespective of starting age) in accordance with the UK perceived threshold of cost-effectiveness at £30,000 
per QALY 
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5.7 Summary 
5.7.1 Hypertension 
This analysis provides a comprehensive overall estimate of the 
between-treatment difference in efficacy (reduction in BP) for 
candesartan as compared with losartan. A between-treatment 
difference of -1.96 mmHg (95% CI -2.40 to -1.51) for trough DBP and -
3.00 mmHg (95% CI -3.79 to -2.22) for trough SBP in favour of 
candesartan was observed in comparative studies at their maximal 
licensed doses.  
 
Based on the calculated BP-differential and using a 10-year Markov 
model, it was estimated that the cost per QALY gained would exceed 
£40,000 if candesartan was used in preference to losartan. The base-
case model used a cohort of patients with moderate CHD / CVD risk 
(baseline SBP of 165 mmHg) and the results demonstrate cost-
effectiveness of losartan with ICERs [for candesartan] of £44,930 and 
£53,804, for male and female patients, respectively.  
 
Sensitivity analyses suggest that the case for losartan adoption holds 
across plausible variation in CHD and CVD risk, relative hypertension 
reducing effect, gender and patient cohort starting age. This case is 
strengthened further in a situation where the acquisition cost of the 
generic drug falls further, as is the case once a number of generic 
manufacturers come to market creating a competitive market, or if the 
patient is female, younger, or mildly hypertensive. In addition, the 
population level benefit achieved by reducing BP could be attained by 
using cheaper low-dose combination therapy regimens.  
 
5.7.2 Heart Failure 
In the absence of comparative trials directly comparing the efficacy of 
candesartan versus losartan in CHF, a qualitative analysis of the key 
studies was undertaken as an alternative to a quantitative meta-
analysis.  
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Candesartan 
The CHARM-Alternative study (180) was a placebo-controlled 
randomised trial of candesartan in 2028 patients with a LVEF ≤ 40% 
who were intolerant of an ACE inhibitor (72% cough, 13% symptomatic 
hypotension, 12% renal dysfunction). The primary composite end-point 
was significantly reduced with candesartan (334 ⁄ 1,013) in comparison 
with placebo (406 ⁄ 1,015) [hazard ratio (HR) 0.77, 95% CI 0.67–0.89; p 
= 0.0004]. This corresponds to a relative risk reduction (RRR) of 23% 
(absolute difference = 7%) and a number needed to treat (NNT) of 14 
(i.e. 14 patients need to be treated for the duration of the study to 
prevent one patient from dying of a cardiovascular event or being 
hospitalised for treatment of heart failure). The primary end-point was 
powered to a statistically significant level by the reduction in hospital 
admission for CHF [HR 0.68, 95% CI 0.57–0.81; p < 0.0001] as the 
reduction in cardiovascular death was non-significant [HR 0.85, 95% CI 
0.71–1.02; p = 0.072]. 
 
The CHARM-Added study (189) (ACE-Inhibitor + candesartan versus 
ACE-Inhibitor + placebo) recruited 2,548 patients with an LVEF ≤ 40% 
who were receiving an optimal-tolerated dose of an ACE-inhibitor. The 
primary composite end-point (cardiovascular death and hospital 
admission for HF) was significantly reduced with candesartan (483 ⁄ 
1,276) in comparison with placebo (538 ⁄ 1,272) (HR 0.85, 95% CI 
0.75–0.96, p = 0.011). This corresponds to an RRR of 16% (absolute 
difference = 4.4%) and an NNT of 23. A statistically significant 
reduction was observed for both components of the primary endpoint: 
cardiovascular death [HR 0.84, 95% CI 0.72–0.98; p = 0.029] and 
hospital admission for CHF [HR 0.83, 95% CI 0.71–0.96; p = 0.014]. 
The composite secondary end-point of all-cause mortality or first CHF 
hospitalisation was also significantly reduced in the candesartan group 
[HR 0.87, 95% CI 0.78–0.98; p = 0.021]. Of note, at baseline, 55% of 
patients randomised to receive dual therapy were taking a beta-
blocker, whilst only 17% were also taking spironolactone [aldosterone 
antagonist]. With regards to safety, of the 74 patients treated with 
candesartan + ACE inhibitor who were also taking spironolactone, 
three (4%) developed serum potassium levels > 6 mmol ⁄ l compared 
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with one of 71 (1%) in the placebo group (number needed to harm = 
33). 
 
Losartan 
In comparison, the recently published HEAAL study (183) [low-dose 
losartan (50 mg daily) vs. high-dose losartan (150 mg daily)] recruited 
3,846 patients with an LVEF ≤ 40% and a documented intolerance to 
an ACE inhibitor. The proportion of patients who met the primary 
composite end-point (death and admission for HF) was 43% (losartan 
150 mg) versus 46% (losartan 50 mg), which was regarded as a 
modest yet significant benefit (HR 0.90, 95% confidence intervals 
0.82–0.99; p = 0.027). In comparison with the CHARM-Added study, at 
baseline, 72% of patients randomised to both arms were taking a beta-
blocker, and 38% were also taking an aldosterone antagonist. Overall, 
the authors reported superiority of losartan 150 mg once daily over 50 
mg once daily for the treatment of CHF. With regards to safety, 
losartan 150 mg daily compared with 50 mg daily was noted to cause a 
significant reduction in glomerular filtration rate (6.1 ml ⁄ min vs. 1.9 ml ⁄ 
min; p < 0.001, respectively). The incidence of premature 
discontinuation from therapy as a result of hyperkalaemia, 
hypotension, renal impairment and angioedema was non-significantly 
different between the two arms (p = 0.20, p = 0.65, p = 0.22, and p = 
0.12, respectively). The investigators put forward the hypothesis that 
up-titrating the dose of losartan as monotherapy may provide equally 
favourable results to a combination of ACE inhibitor and ARB as 
demonstrated in the CHARM-Added study. 
 
UK Licensing 
Both losartan and candesartan hold a marketing authorisation for the 
treatment of essential hypertension and CHF (in patient with an LVEF 
≤ 40%). Two key differences in their licensing criteria are noted:  
i. Essential hypertension: candesartan is indicated for adults 
only, whereas losartan is also indicated for children and 
adolescents aged 6–18 years; and 
ii. CHF: candesartan is indicated for use as monotherapy or in 
combination with an ACE inhibitor (following disease 
progression, incompatibility, or contraindication), whereas 
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losartan is only indicated as monotherapy in place of an 
ACE inhibitor. 
 
5.7.3 Strengths and Limitations 
The use of a trade-off analysis in estimating the comparative cost-
effectiveness of these two AIIRAs has several strengths. First, all 
data included within this analysis were extracted from robust trials 
which met strict inclusion criteria. The requirement of a randomised, 
double-blinded, controlled trial ensured that the final dataset would be 
subject to the least possible amount of bias. Second, the efficacy 
outcome selected (reduction in SBP) is well accepted as an 
informative outcome measure concerning hypertension and risk factor 
for the development of CVD. Third, all included study manuscripts 
were published in full allowing for intention to treat analyses.  
However, the results obtained from this methodology are subject to 
the limitations that are inherent in any meta-analysis. First, individual 
prospective studies only provide information over a short period of 
time (4–12 weeks) whilst the implications are extrapolated for life-long 
therapy. Second, excluding trials that have not been published may 
exaggerate the treatment effects observed as publications tend to 
favour those with positive results. Third, pooling of data from trials 
with differences in trial design, methodology and patient groups may 
result in a heterogeneous dataset from which conclusions are drawn. 
However, such differences in patient groups may serve to strengthen 
the meta-analysis by allowing generalisability of the results to a 
broader group. Furthermore, the use of a random-effects model and 
tests to identify the presence of significant heterogeneity aid to 
minimise and highlight the impact of such effect. Fourth, this analysis 
was restricted to data relating to the adult population; therefore it 
cannot be directly extrapolated to patients under the age of 18 years, 
although this is not a common target population for the management 
of hypertension or heart failure. Fifth, doses employed within the 
clinical trials are not always consistent with those used in clinical 
practice, therefore limiting the external validity of these data. To 
minimise the extent of this, only data comparing high-dose losartan 
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with high-dose candesartan were used in the subsequent CUA. 
Finally, data within this analysis only relates to the use of losartan and 
candesartan for the treatment of hypertension in patients with no 
other comorbidities and therefore should be extrapolated with caution 
in such patients.  
To ensure a robust analysis, best evidence was used, including the 
well validated Framingham risk equations as criteria for the 
development of disease and subsequent mortality in the CUA. The 
model was developed by an experienced health economists, 
however, is subject to some caveats. The model calculates only the 
first episode of MI or stroke events and the subsequent quality of life 
and costs associated with survivors. It does not consider that stroke 
patients may experience a fatal MI or vice versa. Whilst a fully 
probabilistic model may have been constructed, for ease of 
understanding and presentation it was decided to use deterministic 
analyses allowing for uncertainty using sensitivity analysis. This 
showed, that under plausible variation in key parameter values using 
one-way sensitivity analyses, that losartan remains the more cost-
effective of the two studied AIIRAs. 
 
5.7.4 Place in therapy for AIIRAs 
Currently, there are 11 ACE inhibitors and seven AIIRAs available in 
the UK (186). The UK NICE offers guidance on the use of these 
drugs in the following areas: CHF, hypertension, MI (secondary 
prevention), type II diabetes and chronic kidney disease.  
Where either an ACE inhibitor or an AIIRA is indicated, NICE 
recommends that an ACE inhibitor is routinely the drug of choice on 
the basis that there is a more robust evidence-base for their use. A 
recent review also suggested that AIIRAs may be less effective than 
even cheaper ACE inhibitors for MI protection (190). However, a 
meta-analysis has suggested that AIIRAs are indeed as effective as 
ACE inhibitors on the risk of MI, cardiovascular mortality and total 
mortality and also concluded that they may even be slightly more 
protective than ACE inhibitors on the risk of stroke (191). As CHD is 
more common than cerebrovascular disease it seems reasonable that 
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ACE inhibitors remain first-line in all (except perhaps in some high-
risk groups).  
For the treatment of hypertension, if either an ACE inhibitor or an 
AIIRA is indicated, the NICE recommendation stipulates using a drug 
that can be taken once-daily, is generically prescribed and minimises 
cost (188). For heart failure, combined treatment with both an ACE 
inhibitor and an AIIRA currently has a limited role. For patients with 
heart failure who remain symptomatic despite the use of a diuretic, 
beta-blocker and ACE inhibitor, options include to either add in an 
aldosterone antagonist, an AIIRA or hydralazine combined with a 
nitrate (192). Routine treatment with an ACE inhibitor in combination 
with an AIIRA is not recommended as recent publications have found 
little evidence to support this (193, 194). A recently published meta-
analysis regarding the use of an AIIRA in combination with an ACE 
inhibitor concluded that there was no clear survival benefits 
associated with the combination treatment strategy.(195) 
 
5.7.5 AIIRA prescribing recommendations 
The recommendation from this analysis is that generic losartan be 
initiated in all patients indicated for an AIIRA in both hypertension and 
heart failure. AIIRAs should not routinely be combined with ACE 
inhibitors and primarily be used in patients who are ACE-inhibitor 
intolerant. For existing patients on candesartan for hypertension it is 
recommended that patients are changed to losartan except in the rare 
scenario of prior intolerance to losartan. For existing patients on 
candesartan for heart failure where not already on maximal target 
dose, AIIRA dose escalation is encouraged. If a patient on 
candesartan is due for dose escalation, it is recommended that 
changing to losartan is considered at this point unless intolerant. 
Where a patient is on maximal dose candesartan for heart failure, it is 
recommended that the decision to switch be considered on a case-
by-case basis by the responsible physician. 
5.7.6 Dosing 
The losartan dose used in hypertension should be 50mg or 100mg 
daily depending on whether the existing AIIRA dose is at the lower or 
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upper end of its dosing schedule. A dose of 150mg daily is 
recommended as the target dose for heart failure; although this is 
currently outside of the manufacturers Marketing Authorisation (off-
label), it is supported by clinical data.  
 
5.7.7 Post candesartan patent expiry 
The patent protection for candesartan is in place until December 
2012. Following this point, it is highly likely that a number of generic 
manufacturers will launch their version of generic candesartan 
against a similar pricing strategy to that seen with generic losartan. 
Given that it is common practice for patent holders to submit requests 
for patent extensions and typically receiving a 6 month extension, the 
anticipated UK availability date for generic candesartan would be 
circa summer 2013. As generic losartan has been on the market 
since 2011 it will initially still represent the lowest price and most cost-
effective treatment option for hypertension and heart failure, however 
over a period of 12 month the prices of the two treatments will likely 
become comparable. In this situation, the cost utility analysis 
described above would become obsolete with prescribing favouring 
candesartan owing to its greater reduction in blood pressure.  
 
5.8 Conclusion 
Although candesartan, the most widely prescribed AIIRA, reduces both 
SBP and DBP to a greater extent when compared with losartan, this 
does not translate to a cost-effective reduction based on an 
assessment of its efficacy (using the validated Framingham model) 
compared with current and near future acquisition costs of losartan 
alongside perceived NHS affordability thresholds. No robust evidence 
supporting the superiority of candesartan over losartan in the treatment 
of heart failure was found. A recommendation of the analysis is 
therefore to adopt generic losartan as the AIIRA of choice, for new and 
existing patients, which could, based on 2009 prescribing figures in 
primary care alone, save the UK NHS approximately £200 million per 
annum. This saving may be enhanced as the acquisition price of 
generic losartan reduces over time, and further expanded following the 
availability of generic candesartan at a similar price to generic losartan. 
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This work has been published in the International Journal of Clinical 
Practice 2011; 65(3): 253-263 (doi: 10.1111/j.1742-
1241.2011.02633.x) and meets the criteria for inclusion on the NIHR 
Centre for Reviews and Dissemination (CRD) Database of Abstracts of 
Reviews and Effects (DARE). 
 
This work was also identified by the NHS Economic Evaluation 
Database and cited on their website, reference 
CRD/NHSEED/22011000527, citing the following comments: 
 A justification for the selection of comparators was given 
 The selection of clinical data was well carried out 
 The cost categories were consistent with the perspective and 
data sources reflecting the UK NHS setting 
 An appropriate incremental approach was used to synthesis the 
costs and benefits 
 The cost-effectiveness framework was conventional and the 
clinical analysis was very well conducted 
 The authors conclusions appear to be robust 
 
5.9 Implications of Research 
The findings from this area of research were published, communicated 
locally and circulated nationally. Local guidelines, clinician and patient 
letters were written to support prescribing and treatment switching. See 
section 10.3.2 to 10.3.5 for further details. See section 5.9.1 for 
implications on prescribing and spend.  
 
5.9.1 Implications on prescribing and spend 
Further to the publication of the above finding in the International 
Journal of Clinical Practice (March 2011), the circulation of above 
letters to clinicians and patients permitted the actionable roll-out of 
the results of the research project. Using data publically available 
from the NHS Business Services Authority (Prescription Services 
Division) as hosted on www.data.gov.uk it is possible to track the 
monthly spend on each medicine line by GP practice within the UK.  
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The change in prescribing illustrations below highlights: (1) the effect 
of the publication and resultant shift in AIIRA agent being prescribed 
to losartan, from 8,000 items per quarter in March 2011 to 14,000 
items per quarter in June 2012 (see Figure 38); and (2) the 
consequence of this shift in prescribing on spend upon availability of 
a generic medicine within the market place, with spend on other 
ARBs reducing from £120,000 per quarter in March 2011 to £40,000 
per quarter in June 2012 (see Figure 39). Following the loss of patent 
protection for candesartan it would be expected that a number of 
generic manufacturers will launch their version of generic 
candesartan against a similar pricing strategy to that seen with 
generic losartan. This will immediately result in a reduction in spend 
(NIC) as per losartan in Figure 39. Given the favourable efficacy 
profile observed with candesartan compared with losartan, in the 
scenario where both are similarly priced as generics it is anticipated 
that prescribing will revert back to generic candesartan in the higher 
risk patients and generic candesartan placed as first-line for new 
patients where an AIIRA is indicated.  
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Figure 38: Volume (number of items) of angiotensin-receptor blockers (ARBs) issued 
by General Practitioners and other primary care prescribers in England and Wales 
(2008-2012).  
The highlighted date of March 2011 indicates publication of the analysis and findings, which correlates with 
a change in prescribing trend (i.e. the number of items of losartan doubles over a period of 12 months whilst 
other ARBs decline). The R
2
 values are indicative of the linear trendline March 2010-March 2011 vs. March 
2011-September 2012. 
  
R
2
 = 0.953 
R
2
 = 0.745 
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Figure 39: Spend (net ingredient cost) of angiotensin-receptor blockers (ARBs) issued 
by General Practitioners and other primary care prescribers 2008-2012.  
The highlighted area indicates the rapid decline in spend on candesartan and other ARBs post publication 
of the analysis and findings. 
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6.0 Chapter 6: Research Project Three – 
Antimuscarinics and newer agents for the 
Management of Overactive Bladder syndrome 
 
6.1 Introduction 
This third research project reintroduces the use of Bayesian NMA and 
continues with the trade-off methodology based on multiple efficacy 
and tolerability endpoints. Between completion of the first research 
project and commencement of this third project, the Bayesian 
statistical technique has become adopted by NICE although 
traditionally used for simpler comparisons. The Bayesian NMA will be 
undertaken to comparatively assess data from all published RCTs 
comparing the antimuscarinics for overactive bladder meeting strict 
criteria, including head-to-head design where available, in order to 
obtain estimates on their relative efficacy and safety. Certain studies 
were conducted with a design to meet regulatory criteria whilst also 
attempting to be clinically useful, i.e. comparison to placebo and 
introducing an active comparator. The use of a Bayesian analysis 
rather than the frequentist analysis is therefore suitable as a number of 
published three-arm trials have investigated these agents in a direct 
head-to-head comparison thus permitting the construction of a network 
treatment loop. This design will require the coding for the Bayesian 
analysis to be completely revised to that used in the AED research 
project. 
 
The goal for this project is a hybrid of the first and second projects, to 
utilise the Bayesian NMA supported by the trade-off analysis in order 
to create a hierarchy for the range of medicines within this specific 
class. This hierarchy would then be used to influence prescribing at the 
local specialist centres as well as across the local health economy. To 
ensure a robust and clinically relevant analysis based on learning from 
project one, consultation with a methodological and clinical expert was 
undertaken. 
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6.2 Literature Review 
6.2.1 Overactive Bladder syndrome 
Overactive bladder (OAB) is defined by the International Continence 
Society as urinary urgency, usually accompanied by frequency and 
nocturia, with or without urgency urinary incontinence (UUI), in the 
absence of urinary tract infection (UTI) or other obvious 
pathology.(196) This is a widespread, chronic illness that affects the 
lives of millions of people worldwide at all ages. The incidence 
increases with age, with a prevalence of up to 31% in women and 42% 
in men > 75 years.(197) OAB has a major impact on quality of life,(198) 
as well as imposing a substantial socio-economic burden, with direct 
annual costs comparable to that of other chronic diseases such as 
diabetes mellitus.(199)  
 
Several treatment options are available for OAB including bladder and 
behavioural training, pharmacologic treatment and surgical 
therapies.(200) Oral antimuscarinics represent the mainstay of 
pharmacologic treatment for the management of OAB. They are 
recognised to be effective in the improvement of OAB symptoms and 
have a good safety profile.(201)  
 
6.3 Quantitative Analysis 
6.3.1 Current practice guidance 
The utilisation of systematic reviews and meta-analysis of the 
urological literature is proposed as a crucial step in improving the 
quality of urological patient care(202) with decisions based on a 
balance of benefits, potential harm and costs.  
 
Despite the publication of a NICE Clinical Guideline and several 
systematic reviews and meta-analyses of pharmacological treatment 
for OAB within the last few years, no clear differences in efficacy 
between antimuscarinics were found.(203-205)  
 
The aim of this quantitative trade-off analysis is to compare the 
clinical efficacy and tolerability of the most widely used pharmacologic 
treatments for OAB, and to determine an overall hierarchy to guide 
clinicians.   
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6.4 Collaboration 
All work undertaken within this chapter of the thesis was undertaken by 
me. Systematic review support was provided by Dr Grosso in the form 
of a second independent check against the proforma. Advice on the 
appropriate use of WinBUGS coding and analysis of findings was 
provided by Dr Welton with all analyses performed by me.  
 
6.5 Protocol 
6.5.1 Search strategy 
The literature search was undertaken according to the guidelines of 
the Centre for Reviews and Dissemination and Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA)(206) 
statement further to the publication by Maman K et al.(205) To 
identify randomised controlled trials (RCTs) analysing the efficacy 
and safety of pharmacologic treatments for OAB, a systematic 
literature search was conducted using Medline (Ovid), Embase (Ovid) 
and the Cochrane Central Register of Controlled Trials on 08 June 
2014. Refer to Table 17, Table 18 and Table 19, respectively for a full 
list of search terms.  
 
6.5.2 Eligibility criteria 
This review considered all published RCTs which investigated the 
efficacy and safety of pharmacological treatments in the management 
of OAB. Case reports, case series, and database studies were 
excluded from the review. Although the use of language restriction 
was not found to bias outcomes (as discussed in section 4.6.5), no 
language restriction or geographical restriction were applied here. All 
publications from 2000 onwards were included in the original search 
by Maman et al which was supplemented to 08 June 2014 for 
inclusion in the search. Only fully published articles were included. 
Letters, abstracts, conference posters, literature reviews and 
unpublished manuscripts were excluded. 
 
Reviewed studies enrolled adults (≥ 18 years of age) diagnosed with 
OAB. Studies among patients with neurogenic detrusor overactivity 
and men with lower urinary tract symptoms associated with benign 
prostatic hyperplasia were excluded. Further exclusions were studies 
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investigating pharmacological treatment in a single sex population or 
which incorporated a surgical intervention. Refer to Table 20 for full 
list of inclusion and exclusion criteria for studies eligible for the mixed-
treatment comparison (MTC) analysis. 
 
This review included studies on medicines licensed for the 
management of OAB within the UK at doses within their Marketing 
Authorisation which fulfilled the above inclusion and exclusion criteria.  
 
6.5.3 Outcome measures 
To be eligible, a study had to report a measure of efficacy and / or 
safety of OAB treatment over a minimum of 12 weeks. The efficacy 
endpoints, specified a priori, were (1) micturition frequency and (2) 
urgency urinary incontinence (UUI) episodes, both as per 24 hours. 
Studies that reported their results as weekly episodes were converted 
to an average number of episodes per 24 hours. The safety 
endpoints, specified a priori, were the number of patients reporting (1) 
dry mouth and (2) constipation, over the treatment period. These 
endpoints were validated by a Consultant within this field to ensure 
clinical relevance.  
 
6.5.4 Study selection 
Publications identified through the electronic searches were assessed 
independently for relevance by me and validated by Dr Grosso. Any 
disagreement between reviewers was resolved by discussion and 
consensus. In a second step, the reviewers read the full text of the 
retrieved references and selected the articles that met the inclusion 
criteria. The articles finally selected for the review were checked to 
identify different articles related to the same study. The selection 
process was recorded in accordance with the PRISMA flowchart 
process (see Figure 40). 
 
6.5.5 Quality assessment and assessment of bias 
Abstracts and full text articles were retrieved from the search, with 
potentially relevant publications selected against the pre-specified 
inclusion and exclusion criteria. To ensure consistency of data 
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extraction for each study, a structured form was used. The articles 
were retrieved by me and verified by Dr Grosso. The risk of bias 
assessment was also undertaken by me and then independently 
verified by Dr Grosso using criteria associated with sequence 
generation, allocation concealment, baseline comparability, blinding, 
follow-up, and selective reporting, as recommended by the Cochrane 
Collaboration (Chapter 8: Assessing risk of bias in included 
studies).(36) Disagreements between reviewers were resolved by 
discussion and consensus. 
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Table 17: Search strategy used in MEDLINE (Ovid) for the analysis of antimuscarinics 
for the management of OAB syndrome (search date range: 2013 week 24 to current; 
searched on 08 June 2014) 
ID Searches Results 
1 exp Urinary Bladder, Overactive/ 2403 
2 exp Urinary Incontinence/ 26156 
3 exp Urinary Incontinence, Urge/ 540 
4 or/1-3 27911 
5 exp Muscarinic Antagonists/ 49017 
6 (solifenacin or Vesicare or Vesikur or Vesiker or Vesitirim).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
360 
7 (tolterodine or Detrusitol or Detrusitol XL or Detrol or Detrol LA).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
813 
8 (mirabegron or YM-178 or Betanis or betmiga).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
103 
9 (darifenacin or Enablex or Emselex).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, protocol supplementary concept, 
rare disease supplementary concept, unique identifier] 
286 
10 (fesoterodine or Toviaz).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
137 
11 (oxybutynin or Ditropan or Lyrinel XL).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
1257 
12 (propiverine or Detrunorm).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
268 
13 (trospium or Regurin or Flotros or Sanctura or Tropez or Trosec or 
Spasmex).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
234 
14 or/5-13 50411 
15 Randomized controlled trials as Topic/ or randomized controlled trial.mp 103516 
16 Random allocation/ or random allocation.mp 81879 
17 Or/15-16 184540 
18 4 and 14 and 17 131 
19 Limit 18 to (humans) 130 
20 Limit 19 (2013 week 1 to current) 8 
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Table 18: Search strategy used in EMBASE (Ovid) for the analysis of antimuscarinics 
for the management of OAB syndrome (search date range: 2013 week 24 to current; 
searched on 08 June 2014) 
ID Searches Results 
1 exp overactive bladder/ 8561 
2 exp urge incontinence/ 4642 
3 exp urinary urgency/ 3767 
4 Exp urine incontinence/ 51599 
5 Or/1-4 57827 
6 exp muscarinic receptor blocking agent/ 56069 
7 (solifenacin or Vesicare or Vesikur or Vesiker or Vesitirim).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
1352 
8 (tolterodine or Detrusitol or Detrusitol XL or Detrol or Detrol LA).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
2993 
9 (mirabegron or YM-178 or Betanis or betmiga).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
310 
10 (darifenacin or Enablex or Emselex).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
1120 
11 (fesoterodine or Toviaz).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
522 
12 (oxybutynin or Ditropan or Lyrinel XL).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
4739 
13 (propiverine or Detrunorm).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
1234 
14 (trospium or Regurin or Flotros or Sanctura or Tropez or Trosec or Spasmex).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
protocol supplementary concept, rare disease supplementary concept, unique 
identifier] 
1217 
15 or/6-14 58983 
16 randomized controlled trial/ 343012 
17 Random allocation.mp or randomization/ 63302 
18 Or/16-17 397197 
19 5 and 15 and 18 501 
20 Limit 19 to (humans) 489 
20 Limit 20 (2013 week 1 to current) 54 
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Table 19: Search strategy used in The Cochrane Library for the analysis of 
antimuscarinics for the management of OAB syndrome (search date range: 2013 
week 24 to current; searched on 08 June 2014) 
ID Search Hits 
#1 MeSH descriptor Urinary Bladder, Overactive explode all trees 314 
#2 MeSH descriptor Urinary Incontinence, Urge explode all trees 81 
#3 overactive near/3 bladder 992 
#4 Urge near/3 incontinence 579 
#5 (#1 OR #2 OR #3 OR #4) 1375 
#6 MeSH descriptor Muscarinic Antagonists explode all trees 597 
#7 solifenacin or Vesicare or Vesikur or Vesiker or Vesitirim 177 
#8 tolterodine or Detrusitol or Detrusol XL or Detrol or Detrol LA 447 
#9 mirabegron or YM-178 or Betanis 46 
#10 darifenacin or Enablex or Emselex 71 
#11 fesoterodine or Toviaz 114 
#12 oxybutynin or Ditropan or Lyrinel XL 403 
#13 propiverine or Detrunorm 96 
#14 trospium or Regurin or Flotros or Sanctura or Tropez or Trosec or Spasmex 130 
#15 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) 1439 
#16 (#5 AND #15) 731 
#17 Limit #16 (2013 week 1 to current; Trials; Cochrane Group) 103 
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Table 20: List of inclusion and exclusion criteria for the mixed-treatment analysis of antimuscarinics for the management of OAB syndrome 
  Efficacy Safety 
Inclusion criteria 
Publication status Published Published 
Study Design  Randomised Controlled trial,  
Double-blind  
Randomised Controlled trial, 
Double-blind  
Patient population  OAB patients only OAB patients  only 
Results population FAS, ITT FAS, ITT, SAF 
Intervention  Studies comparing two or more of 
the following treatments: darifenacin, 
solifenacin, tolterodine, mirabegron, 
fesoterodine, oxybutynin, trospium 
or placebo.  
Studies comparing two or more of the 
following treatments: darifenacin, 
solifenacin, tolterodine, mirabegron, 
fesoterodine, oxybutynin, trospium or 
placebo.  
Duration  Minimum 12 weeks  Minimum 12 weeks  
Outcomes  Independent endpoints 
1. Change from baseline of the 
number of micturition / 24h 
2. Change from baseline of the 
number of UUI / 24h  
1. Number of patients experiencing 
dry mouth 
2. Number of patients experiencing 
constipation  
Exclusion criteria 
 1. Studies that are unpublished or 
in abstract / conference form 
only 
2. Studies with less than two arm 
treatments 
3. Studies comparing combined 
treatments 
4. Flexible-dose studies 
5. Studies with included a surgical 
paradigm 
6. Studies vs. placebo patch  
7. No standard error, standard 
deviation, variance or 
confidence interval around 
estimates of mean changes 
1. Studies that are unpublished or 
in abstract / conference form only 
2. Studies with less than two arm 
treatments 
3. Studies comparing combined 
treatments 
4. Flexible-dose studies 
5. Studies with included a surgical 
paradigm 
6. Studies vs. placebo patch  
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Figure 40: The PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) flow diagram of studies identified from the systematic review for 
inclusion in the network meta-analysis for management of overactive bladder 
syndrome 
 
 
 
165 potentially relevant studies identified from 
updated search for retrieval from the following 
electronic databases: 
 54       EMBASE (Ovid) 
 8         MEDLINE (Ovid) 
 103    Cochrane [CENTRAL] 
    
21 studies met the pre-specified inclusion criteria 
for full-text review and MTC analysis 
188 studies excluded for the following reasons: 
 39  Duplications between databases 
 41    Unpublished studies* 
 9 Reviews 
 2 Pre-specified outcome not reported 
 12 Duration < 12 weeks 
 4 Included women only 
 3 FAS / ITT analysis not reported 
 3 Failed to meet quality assessment criteria 
 3 Flexible-dosing design 
 4 Pooled analysis 
 4 Post-hoc analysis 
 3 Extension study 
 3 Single-blind design 
 11 Pharmacokinetic analysis 
 8 Included a surgical paradigm 
 9 Combination treatment 
 3 Abstract / Conference publication only 
 20 Population not OAB 
 6 IMP not licensed within the UK 
 1 Topical treatment 
 
*5 studies re-included from Maman et al. review as 
full-text publications  
44 studies identified by Maman et al (2013) 
209 studies assessed against the inclusion criteria 
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6.5.6 Data analysis: Mixed Treatment Comparison (MTC) 
A Bayesian mixed-treatment comparison (MTC) was conducted to 
estimate the relative efficacy and safety of all eligible pharmacological 
treatments compared with placebo, including all indirect comparisons. 
This was supplemented by a trade-off analysis of the pre-specified 
endpoints to establish an overall rank for each of the four parameters 
under investigation. Analyses were conducted for the general OAB 
population using reported full analysis dataset (FAS) or intention to 
treatment (ITT) population data. For each population, a random-
effects model was used at the level of trials.  
 
6.5.6.1 MTC code 
The treatment effects from the MTC model were estimated using 
WinBUGS,(207) with the code adapted from the NICE Evidence 
Synthesis Technical Series Documents 2 and 3. (61-63) As the 
data were not normally distributed within the studies included, the 
MTC model was coded for binomial likelihood within a random 
effects model. The model for the efficacy outcomes is reflective of 
continuous data, whilst the model for the tolerability outcomes is 
reflective of dichotomous data. The median of the posterior 
distribution were taken as the point estimate and the 2.5th and 
97.5th centiles provided the 95% credible interval (CrI). Refer to 
Figure 41 and Figure 42 for the WinBUGS codes created and used 
for the efficacy and tolerability outcomes, respectively.  
 
6.5.6.2 MTC model 
Unlike the code used for the AED chapter, a non-informative prior 
was selected for this MTC analysis. This was on the basis that no 
beliefs were in place prior to the analysis regarding the value of 
each effect size. Forty thousand iterations were used for each 
chain in the Bayesian analysis following a burn-in of 20,000. 
Convergence was assessed via visual assessment of trace plots. 
The visual assessment was corroborated through assessment of 
the ratio of the Monte Carlo error (MCe). Goodness of fit of the 
model was also assessed through analysis of the posterior mean 
of the sum of the residual deviance contributions of each data 
point.(62, 68)  
Chapter 6: Research Project Three – Antimuscarinics and newer agents for the Management of Overactive 
Bladder syndrome 
     - 182 - 
 
6.5.6.3 Endpoints 
For the efficacy endpoints, the treatment effect was the mean 
difference in the change from baseline for each treatment 
compared with placebo, under a binomial distribution for each arm. 
For the safety endpoint, the number of events reported in each 
treatment of a given trial was assumed to follow a binomial 
distribution with parameters n, the number of patients in a 
treatment arm, and p, the ‘‘true’’ probability of adverse events for 
each treatment. Placebo was used as the reference comparator for 
estimating the MTC models.  
 
Posterior median values and 95% CrI are reported for mean 
differences in changes in symptoms from baseline to week 12 
between treatments and odds ratios (ORs) for adverse events. A 
result was considered statistically significant when it had a 
probability of at least 97.5%. For example, a treatment was 
considered significantly more efficacious than placebo for 
reduction in number of micturition episodes per 24 hours if the 
probability of the difference in change in micturition frequency 
being negative was at least 97.5% (i.e. if the upper limit of the 95% 
CrI around the difference was less than zero).  
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Figure 41: WinBUGS model for the OAB network meta-analysis (efficacy endpoint) 
# Binomial likelihood, identity link 
# Randomeffects model for multi-arm trials 
 
model{                                 #PROGRAM STARTS 
 
for(i in 1:ns){                        #LOOP THROUGH STUDIES 
     w[i,1] <- 0        #Adjustment for multi-arm trials is zero for 
control arm 
     delta[i,1] <- 0                #Treatment effect is zero for control 
arm 
     mu[i] ~ dnorm(0,.0001)            #Vague priors for all trial baselines 
 
for (k in 1:na[i]) {                #LOOP THROUGH ARMS 
 var[i,k] <- pow(se[i,k],2)     #Calculate variances 
 prec[i,k] <- 1/var[i,k]        #Set precisions          
 y[i,k] ~ dnorm(theta[i,k],prec[i,k]) #Binomial likelihood 
 theta[i,k] <- mu[i] + delta[i,k]  #Model for linear predictor 
 
#Deviance contribution 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
      } 
 
#Summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {               #LOOP THROUGH ARMS 
 
#Trial-specific LOR distributions 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
 
#Mean of LOR distributions, with multi-arm trial correction 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
 
#Precision of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k 
 
#Adjustment, multi-arm RCTs 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
 
#Cumulative adjustment for multi-arm trials 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
      } 
  }    
totresdev <- sum(resdev[])             #Total Residual Deviance 
d[1]<-0           #Treatment effect is zero for control arm 
 
#Vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)        #Vague prior for between-trial SD 
tau <- pow(sd,-2)      #Between-trial precision = (1/between-trial 
variance) 
 
# All pairwise comparisons Ranking 
for (c in 1:(nt-1)) { for (k in (c+1):nt) { diff[c,k] <- (d[c] - d[k] )}}  
for (k in 1:nt) { 
rk[k] <- nt+1-rank(d[],k)    # assumes events are “good”  
best[k] <- equals(rk[k],1)                     #Calculate probability that treat k is best 
}     #PROGRAM ENDS 
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Figure 42: WinBUGS model for the OAB network meta-analysis (tolerability endpoint) 
 
# Binomial likelihood, logit link 
# Randomeffects model for multi-arm trials 
 
model{                     # PROGRAM STARTS 
 
for(i in 1:ns){             # LOOP THROUGH STUDIES 
   w[i,1] <- 0      # adjustment for multi-arm trials is zero for control 
arm 
   delta[i,1] <- 0        # treatment effect is zero for control arm 
   mu[i] ~ dnorm(0,.0001)         # vague priors for all trial baselines 
 
for (k in 1:na[i]) {       # LOOP THROUGH ARMS 
   r[i,k] ~ dbin(p[i,k],n[i,k])   # binomial likelihood 
   logit(p[i,k]) <- mu[i] + delta[i,k]  # model for linear predictor 
   rhat[i,k] <- p[i,k] * n[i,k]   # expected value of the numerators 
 
#Deviance contribution 
    dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
      + (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } 
 
# Summed residual deviance contribution for this trial 
  resdev[i] <- sum(dev[i,1:na[i]]) 
  for (k in 2:na[i]) {        # LOOP THROUGH ARMS 
 
# Trial-specific LOR distributions 
      delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
 
# mean of LOR distributions (with multi-arm trial correction) 
      md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# Precision of LOR distributions (with multi-arm trial correction) 
      taud[i,k] <- tau *2*(k-1)/k 
 
# Adjustment for multi-arm RCTs 
      w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
 
# Cumulative adjustment for multi-arm trials 
      sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
   } 
 } 
totresdev <- sum(resdev[])       # Total Residual Deviance 
d[1]<-0        # treatment effect is zero for reference treatment 
 
# Vague priors for treatment effects 
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)    # between-trial precision = (1/between-trial variance) 
 
 
 
 
# Pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2 
for (c in 1:(nt-1)) {  for (k in (c+1):nt) { 
or[c,k] <- exp(d[k] - d[c]) 
lor[c,k] <- (d[k]-d[c]) 
} 
} 
 
# Ranking on relative scale 
for (k in 1:nt) { 
rk[k] <- rank(d[],k)    # assumes events are “bad” 
best[k] <- equals(rk[k],1)   #calculate probability that treat k is best 
} 
}     # PROGRAM ENDS 
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6.6 Findings (Systematic Review) 
6.6.1 Study selection 
The PRISMA flow diagram (see Figure 40) presents the study 
selection process with the reasons for exclusion. The updated 
database search revealed a potential 165 studies in addition to the 44 
studies identified by Maman et al (total of 209 studies). After 
removing duplicates (39 studies), 170 references were obtained for 
full text review and screening against the inclusion and exclusion 
criteria. This resulted in excluding a further 149 articles (total of 188 
studies excluded) which resulted in 21 studies which fulfilled the 
eligibility criteria for the MTC analysis. These 21 studies enrolled 
21,855 patients of which 18,863 patients represented allocations to 
treatment arms of a medicine and dose licensed within the UK.(208-
227)  
 
6.6.2 Study characteristics 
The main characteristics of the studies included within the MTC 
analysis are documented in Table 21. Studies which met the inclusion 
/ exclusion criteria contained the following pharmacological 
treatments: 15mg darifenacin; 4mg and 8 mg fesoterodine; 50mg 
mirabegron; 10mg modified-release oxybutynin ; 5mg and 10mg 
solifenacin; 4mg immediate-release tolterodine; 4mg modified-release 
tolterodine; 40mg immediate-release trospium; 60 mg modified-
release trospium and placebo. All studies contained a minimum of 
two arms, where the control group could use an antimuscarinic 
(different drug, formulation, or dosage) or placebo. Figure 43 provides 
an overview of the treatment network, including the number of direct 
comparisons.  
 
6.6.3 Quality assessment of the included studies 
Using the Cochrane risk of bias assessment tool, none of the 21 trials 
included were identified at a high risk of bias for any of the domains; 
all studies were therefore included in the MTC analyses. The 
assessment for each study is described in Table 22 and Table 23 
below.  
  
  
Table 21: Characteristics of studies included within the mixed-treatment comparison analysis for overactive bladder syndrome 
Study Intervention Trial design Patient 
population 
No randomised 
patients 
Trial 
length 
(weeks) 
Chapple 2013 
(DRAGON)(208)  
 Mirabegron 25mg 
 Mirabegron 50mg 
 Mirabegron 100mg 
 Mirabegron 200mg 
 Tolterodine ER 4mg 
 Placebo 
Phase IIb, RCT, double-blind, double 
dummy, multicentre (Europe) 
OAB, ≥ 18 years 928 12 
Khullar 2013 
(SCORPIO)(209) 
 Mirabegron 50mg 
 Mirabegron 100mg 
 Tolterodine ER 4mg 
 Placebo 
Phase III, RCT, double-blind, multicentre 
(Europe, Australia) 
OAB, ≥ 18 years 1987 12 
Nitti 2013 (ARIES)(210)  Mirabegron 50mg 
 Mirabegron 100mg 
 Placebo 
Phase III, RCT, double-blind, double 
dummy, multicentre (US and Canada) 
OAB, ≥ 18 years 1329 12 
Herschorn 2013 
(CAPRICORN)(211) 
 Mirabegron 25mg 
 Mirabegron 50mg 
 Placebo 
Phase III, RCT, double-blind, double 
dummy, multicentre (Europe, US, 
Canada) 
OAB, ≥ 18 years 1306 12 
Yamaguchi 2014 (178-CL-
048)(212) 
 Mirabegron 50mg 
 Tolterodine tartrate 4mg 
 Placebo 
RCT, double-blind, multicentre (Japan) OAB , ≥ 20 years 1139 12 
Appell 2001(213)  Tolterodine IR 2mg BD 
 Oxybutynin ER 10mg 
RCT, double-blind, multicentre (USA) OAB 378 12 
Cardozo 2004(214)  Solifenacin 5mg 
 Solifenacin 10mg 
 Solifenacin 20mg 
RCT, double-blind, multicentre OAB, ≥ 18 years 907 12 
Chapple 2004(215)  Solifenacin 5mg 
 Solifenacin 10mg 
 Tolterodine 2mg BD 
 Placebo 
Phase IIIa RCT, double-blind, multicentre 
(North America & Europe) 
OAB, ≥ 18 years 1081 12 
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Study Intervention Trial design Patient 
population 
No randomised 
patients 
Trial 
length 
(weeks) 
Choo 2008(228)  Solifenacin 5mg 
 Solifenacin 10mg 
 Tolterodine IR 2mg BD 
Phase III RCT, double-blind, multicentre 
(Korea) 
OAB, ≥ 18 years 329 12 
Chu 2009(216)  Solifenacin 10mg 
 Placebo 
Phase III RCT, double-blind, multicentre 
(USA) 
OAB, ≥ 18 years 672 12 
Herschorn 2008(217)  Tolterodine ER 4mg 
 Placebo 
RCT, double-blind, multicentre (Canada, 
Europe) 
OAB, ≥ 18 years 617 12 
Herschorn 2010(218)  Fesoterodine 4/8mg 
 Tolterodine ER 4mg 
 Placebo 
RCT, double-blind, double dummy, 
multicentre (USA) 
OAB, ≥ 18 years 1712 12 
Homma 2003(219)  Tolterodine ER 4mg 
 Oxybutynin 3mg TDS 
 Placebo 
RCT, double-blind, multicentre (Japan) OAB, ≥ 20 years 608 12 
Kaplan 2011(220)  Fesoterodine 4mg/8mg 
 Tolterodine ER 4mg 
 Placebo 
RCT, double-blind, double dummy, 
multicentre (North & South America, 
Europe, Asia, Africa) 
OAB, ≥ 18 years 2417 12 
Nitti 2007(221)  Fesoterodine 4mg 
 Fesoterodine 8mg 
 Placebo 
RCT, double-blind, multicentre (USA) OAB, ≥ 18 years 836 12 
Staskin 2007(222)  Trospium chloride 60mg 
 Placebo 
RCT, double-blind, multicentre (USA) 
Subjects with 
OAB 
601 12 
Van Kerrebroeck 
2001(223) 
 Tolterodine IR 2mg BD 
 Tolterodine ER 4mg 
 Placebo 
RCT, double-blind, multicentre 
(Australasia, Europe, North America) 
OAB, ≥ 18 years 1529 12 
Yamaguchi 2007(224)  Solifenacin 5mg 
 Solifenacin 10mg 
 Propiverine 20mg 
 Placebo 
Phase III RCT, double-blind, multicentre 
(Japan) 
OAB, ≥ 20 years 1584 12 
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Study Intervention Trial design Patient 
population 
No randomised 
patients 
Trial 
length 
(weeks) 
Yamguchi 2011(225)  Fesoterodine 4mg 
 Fesoterodine 8mg 
 Placebo 
Phase III RCT, double-blind, multicentre 
(Asia) 
OAB, ≥ 20 years 951 12 
Zinner 2004(226)  Trospium 40mg 
 Placebo 
RCT, multicentre (USA) OAB, ≥ 18 years 512 12 
Zinner 2006(227)  Darifenacin 15 mg 
 Placebo 
RCT, double-blind, multicentre OAB, ≥ 18 years 432 12 
 
 
 
 
  
Table 22: Risk of bias assessment tool 
Study 
Questions 
Description 
Q1 Was randomisation carried out appropriately? 
Q2 Was the concealment of treatment allocation adequate? 
Q3 
Were the groups similar at the outset of the study in terms of prognostic 
factors? 
Q4 
Were the care providers, participants and outcome assessors blind to 
treatment allocation? 
Q5 Were there any unexpected imbalances in drop-outs between groups? 
Q6 
Is there any evidence to suggest that the authors measured more 
outcomes than they reported? 
Q7 
Did the analysis include an intention-to-treat analysis? If so, was this 
appropriate and were appropriate methods used to account for missing 
data? 
 
 
Table 23: Trials included within the analysis and their risk of bias assessment 
Study questions 
  Q1  Q2 Q3 Q4  Q5  Q6 Q7 
Chapple 2013 
(DRAGON)(208) 
Yes Yes Yes Yes No No Yes 
Khullar 2013 
(SCORPIO)(209) 
Yes Yes Yes Yes No No Yes 
Nitti 2013 
(ARIES)(210) 
Yes Yes Yes Yes No No Yes 
Herschorn 2013 
(CAPRICORN)(211) 
Yes Yes Yes Yes No No Yes 
Yamaguchi 2014 (175-
CL-048)(212) 
Yes Yes Yes Yes No No Yes 
Appell 2001(213) Unclear Unclear Yes Yes No No Yes 
Cardozo 2004(214) Unclear Unclear Yes Unclear No No Yes 
Chapple 2004(215) Unclear Unclear Yes Unclear No Yes Yes 
Choo 2008(228) Unclear Unclear Yes Unclear No No Yes 
Chu 2009(216) Yes Yes Yes Yes No No Yes 
Herschorn 2008(217) Unclear Unclear Yes Unclear No No Yes 
Herschorn 2010(218) Yes Yes Yes Unclear No No Yes 
Homma 2003(219) Yes Unclear Yes Yes No No Yes 
Kaplan 2011(220) Yes Unclear Yes Yes No No Yes 
Nitti 2007(221) Yes Unclear Yes Unclear No No Yes 
Staskin 2007(222) Unclear Unclear Yes Unclear No No Yes 
Van Kerrebroeck 
2001(223) 
Yes Unclear Yes Unclear No No Yes 
Yamaguchi 2007(224) Unclear Unclear Yes Unclear No No Yes 
Yamaguchi 2011(225) Unclear Unclear Yes Unclear No No Yes 
Zinner 2004(226) Yes Unclear Yes Unclear No No Yes 
Zinner 2006(227) Yes Unclear Yes Unclear No No Yes 
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Figure 43: Antimuscarinics included within the network meta-analysis / mixed-
treatment comparison.  
Each treatment represents a node within the star-shaped network. The lines between the nodes represent 
direct comparative data, where the number along the line indicates the number of studies for that particular 
link within the network. Each triangle represents a loop of direct comparative data which allows mixed 
treatment comparison.   
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6.7 Findings (Bayesian MTC) 
6.7.1 Efficacy 
6.7.1.1 Micturition per 24 hours 
The MTC analysis on micturition frequency was based on all 21 
studies (18,863 patients).(208-228) The mean (SD) baseline 
micturition frequency per 24 hours was 11.6 (±2.4). The median 
placebo-corrected difference from baseline to week 12 was 
statistically significantly different for all treatments except 
darifenacin 15mg (see Figure 44). 10mg modified-release 
oxybutynin demonstrated the greatest reduction in micturition 
frequency with a posterior median of the mean difference of -1.38 
(95% CrI -1.79 to -0.97) with 10mg solifenacin (-1.31; 95% CrI -1.55 
to -1.06) demonstrating the second greatest reduction. For the 
ranking analysis, 10mg solifenacin was assigned as the best agent 
(see Table 24) due to greater confidence in its estimate from the 
MTC analysis over 10mg modified-release oxybutynin, as evinced 
by narrower confidence intervals. 
 
6.7.1.2 Urinary urgency incontinence (UUI) per 24 hours 
The MTC analysis on UUI episodes was based on 17 studies 
(15,502 patients).(208-215, 217, 218, 220-222, 224, 225, 227) The 
mean (SD) baseline UUI per 24 hours was 3.7 (±2.1). The median 
placebo-corrected difference from baseline to week 12 was 
statistically significantly different for all treatments except 4mg 
immediate-release tolterodine, 4mg fesoterodine, 40mg immediate-
release trospium, and 15mg darifenacin (see Figure 45). 10mg 
solifenacin demonstrated the greatest reduction in number of UUI 
episodes with a posterior median of the mean difference of -0.91 
(95% CrI -1.25 to -0.56) with solifenacin 5mg (-0.67; 95% CrI -1.02 
to -0.32) and 10mg modified-release oxybutynin (-0.66, 95% CrI -
1.20 to -0.14) demonstrating joint second greatest reduction. For the 
ranking analysis, 10mg solifenacin was assigned as the best agent 
(see Table 25). 
  
Chapter 6: Research Project Three – Antimuscarinics and newer agents for the Management of Overactive 
Bladder syndrome 
     - 192 - 
6.7.2 Adverse events 
6.7.2.1 Dry mouth 
The MTC analysis on incidence of dry mouth was based on all 21 
studies (18,863 patients). (208-228) 50mg Mirabegron had an 
incidence of dry mouth similar to placebo (OR 0.75; 95% CrI 0.50 to 
1.16). All antimuscarinics were associated with a significantly higher 
risk of dry mouth compared with placebo and mirabegron (see 
Figure 46). For the ranking analysis, 50mg mirabegron was 
assigned as the best agent (see Table 26). 
 
6.7.2.2 Constipation 
The MTC analysis on incidence of constipation was based on 19 
studies (17,454 patients).(208, 209, 212-228) 50mg Mirabegron, 
10mg modified-release oxybutynin, and 4mg Fesoterodine  had a 
lower (not reaching significance) incidence of constipation 
compared with placebo. All other antimuscarinics were associated 
with a significantly higher risk of constipation (see Figure 47). For 
the ranking analysis, Fesoterodine 4mg was assigned as the best 
agent (see Table 27). 
 
6.7.3 Rank 
A summary of the ranking analysis for each of the four endpoints is 
presented in Table 28. Detailed distribution of probabilities (Rank-o-
gram) for each treatment being ranked at each of the possible 12 
positions is depicted in Figure 48 using the assumption that each 
endpoint is equally weighted to each other. Solifenacin and 
oxybutynin were among the most efficacious treatments, whilst 
mirabegron was the best tolerated.   
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Figure 44: Mean change from baseline (micturition frequency per 24 hours) versus 
placebo 
Box plots of the placebo-corrected mean difference of pharmacological treatments for OAB as estimated by 
the Bayesian MTC analysis regarding efficacy (micturition frequency per 24 hours). The individual plots 
represent the 95% credible interval (horizontal black line either side of the green box) and the interquartile 
range (green box, representing where 25% to 75% of the data lies); the vertical black line reflects the 
median placebo-corrected difference (MD). A larger MD (in the negative direction) is indicative of a greater 
treatment effect, relative to placebo. Where the 95% credible interval crosses the line of unity, this is 
indicative of a non-statistically significant difference to placebo..  
Table 24: Mean difference and rank order of the effect of treatment on micturition 
frequency per 24 hours 
Drug (dose) Mean difference 95% Credible 
Interval 
Rank 
Mirabegron 50mg OD -0.674 -0.865, -0.478 7 
Tolterodine MR 4 mg OD -0.571 -0.739, -0.416 9 
Tolterodine IR 2 mg BD -0.721 -1.040, -0.397 7 
Oxybutynin MR 10 mg OD -1.381 -1.792, -0.974 2 
Solifenacin  5 mg OD -0.960 -1.205, -0.698 4 
Solifenacin  10 mg OD -1.305 -1.552, -1.056 1 
Fesoterodine 8 mg OD -0.747 -0.967, -0.538 6 
Fesoterodine 4 mg OD -0.494 -0.860, -0.145 10 
Trospium 20 mg BD -1.080 -2.146, -0.122 3 
Trospium 60 mg OD -0.816 -1.312, -0.345 5 
Darifenacin 15 mg -0.355 -1.378, 0.608 11 
Mirabegron 50mg OD 
Tolterodine MR 4 mg OD 
Tolterodine IR 2 mg BD 
Oxybutynin MR 10mg OD 
Solifenacin 5 mg OD 
Solifenacin 10 mg OD 
Fesoterodine 8 mg OD 
Fesoterodine 4 mg OD 
Trospium 20 mg BD 
Trospium 60 mg OD 
Darifenacin 15 mg 
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Figure 45: Mean change from baseline (number of UUI episodes per 24 hours) versus 
placebo 
Box plots of the placebo-corrected mean difference of pharmacological treatments for OAB as estimated by 
the Bayesian MTC analysis regarding efficacy (UUI episodes per 24 hours). The individual plots represent 
the 95% credible interval (horizontal black line either side of the green box) and the interquartile range 
(green box, representing where 25% to 75% of the data lies); the vertical black line reflects the median 
placebo-corrected difference (MD). A larger MD (in the negative direction) is indicative of a greater 
treatment effect, relative to placebo. Where the 95% credible interval crosses the line of unity, this is 
indicative of a non-statistically significant difference to placebo.  
Table 25: Mean difference and rank order of the effect of treatment on UUI frequency 
per 24 hours 
Drug (dose) Mean difference 95% Credible 
Interval 
Rank 
Mirabegron 50mg OD -0.456 -0.658, -0.268 6 
Tolterodine MR 4 mg OD -0.374 -0.549, -0.190 7 
Tolterodine IR 2 mg BD -0.291 -0.701, 0.122 11 
Oxybutynin MR 10 mg OD -0.660 -1.196, -0.137 2 
Solifenacin  5 mg OD -0.672 -1.017, -0.322 2 
Solifenacin  10 mg OD -0.907 -1.246, -0.563 1 
Fesoterodine 8 mg OD -0.522 -0.764, -0.286 4 
Fesoterodine 4 mg OD -0.343 -0.697, 0.005 10 
Trospium 20 mg BD -0.405 -0.857, 0.053 7 
Trospium 60 mg OD -0.548 -1.089, -0.008 4 
Darifenacin 15 mg -0.406 -0.849, 0.050 7 
Mirabegron 50mg OD 
Tolterodine MR 4 mg OD 
Tolterodine IR 2 mg BD 
Oxybutynin MR 10mg OD 
Solifenacin 5 mg OD 
Solifenacin 10 mg OD 
Fesoterodine 8 mg OD 
Fesoterodine 4 mg OD 
Trospium 20 mg BD 
Trospium 60 mg OD 
Darifenacin 15 mg 
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Figure 46: Odds ratio (median) incidence of dry mouth relate to placebo 
Box plots of the placebo-corrected odds ratio (OR) of pharmacological treatments for OAB as estimated by 
the Bayesian MTC analysis regarding tolerability (dry mouth). The individual plots represent the 95% 
credible interval (horizontal black line either side of the green box) and the interquartile range (green box, 
representing where 25% to 75% of the data lies); the vertical black line reflects the median placebo-
corrected difference (MD). A larger OR (in the positive direction) is indicative of a greater adverse effect, 
relative to placebo. Where the 95% credible interval crosses the line of unity, this is indicative of a non-
statistically significant difference to placebo.  
 
Table 26: Odds ratio and rank order of the effect of treatment on dry mouth 
Drug (dose) Odds Ratio 95% Credible 
Interval 
Rank 
Mirabegron 50mg OD 0.7528 0.4982, 1.157 1 
Tolterodine MR 4 mg OD 3.479 2.793, 4.337 5 
Tolterodine IR 2 mg BD 5.545 4.153, 7.588 8 
Oxybutynin MR 10 mg OD 4.283 2.384, 8.221 7 
Solifenacin  5 mg OD 3.086 2.233, 4.318 3 
Solifenacin  10 mg OD 7.778 5.896, 10.550 10 
Fesoterodine 8 mg OD 7.896 5.852, 10.420 10 
Fesoterodine 4 mg OD 3.043 2.084, 4.323 3 
Trospium 20 mg BD 4.048 2.156, 7.986 7 
Trospium 60 mg OD 3.162 1.407, 7.724 4 
Darifenacin 15 mg 6.809 3.312, 14.610 9 
Mirabegron 50mg OD 
Tolterodine MR 4 mg OD 
Tolterodine IR 2 mg BD 
Oxybutynin MR 10mg OD 
Solifenacin 5 mg OD 
Solifenacin 10 mg OD 
Fesoterodine 8 mg OD 
Fesoterodine 4 mg OD 
Trospium 20 mg BD 
Trospium 60 mg OD 
Darifenacin 15 mg 
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Figure 47: Odds ratio (median) incidence of constipation relative to placebo 
Box plots of the placebo-corrected odds ratio (OR) of pharmacological treatments for OAB as estimated by 
the Bayesian MTC analysis regarding tolerability (constipation). The individual plots represent the 95% 
credible interval (horizontal black line either side of the green box) and the interquartile range (green box, 
representing where 25% to 75% of the data lies); the vertical black line reflects the median placebo-
corrected difference (MD). A larger OR (in the positive direction) is indicative of a greater adverse effect, 
relative to placebo. Where the 95% credible interval crosses the line of unity, this is indicative of a non-
statistically significant difference to placebo.  
 
Table 27: Odds ratio and rank order of the effect of treatment on constipation 
Drug (dose) Mean difference 95% Credible 
Interval 
Rank 
Mirabegron 50mg OD 1.412 0.812, 2.422 4 
Tolterodine MR 4 mg OD 1.496 1.106, 2.051 4 
Tolterodine IR 2 mg BD 1.534 1.005, 2.332 4 
Oxybutynin MR 10 mg OD 1.781 0.672, 4.492 5 
Solifenacin  5 mg OD 3.093 2.102, 4.784 8 
Solifenacin  10 mg OD 5.826 4.098, 8.260 10 
Fesoterodine 8 mg OD 2.394 1.661, 3.453 6 
Fesoterodine 4 mg OD 1.280 0.760, 2.187 1 
Trospium 20 mg BD 2.819 1.234, 6.222 7 
Trospium 60 mg OD 8.347 3.000, 32.370 11 
Darifenacin 15 mg 4.295 2.169, 9.677 9 
 
Mirabegron 50mg OD 
Tolterodine MR 4 mg OD 
Tolterodine IR 2 mg BD 
Oxybutynin MR 10mg OD 
Solifenacin 5 mg OD 
Solifenacin 10 mg OD 
Fesoterodine 8 mg OD 
Fesoterodine 4 mg OD 
Trospium 20 mg BD 
Trospium 60 mg OD 
Darifenacin 15 mg 
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Table 28: Trade-off analysis – summary rank of treatment (efficacy and tolerability) for 
the management of overactive bladder syndrome 
 
  Micturition / 
24hrs 
UUI / 24hrs Dry mouth Constipation 
Mirabegron 50mg OD 7 6 1 2 
Tolterodine MR 4mg OD 9 7 5 2 
Tolterodine IR 2mg BD 7 11 8 2 
Oxybutynin MR 10mg OD 2 2 6 5 
Solifenacin 5mg OD 4 2 2 8 
Solifenacin 10mg OD 1 1 10 10 
Fesoterodine 8mg OD 6 4 10 6 
Fesoterodine 4mg OD 10 10 2 1 
Trospium 20mg BD 3 7 6 7 
Trospium 60mg OD 5 4 4 11 
Darifenacin 15mg OD 11 7 9 9 
 
 
Table 29: Trade-off analysis – summary rank of treatment (clinical vs. cost)  
  Trade-Off 
(clinical) Rank 
Cost per 28-
days excl. VAT 
(BNF)(229)  
Cost Rank Revised Rank 
(Top 3) 
Mirabegron 50mg OD 3 27.06 4 -- 
Tolterodine MR 4mg OD 6 25.78 4 -- 
Tolterodine IR 2mg BD 8 2.65 2 2 
Oxybutynin MR 10mg OD 2 25.71 4 -- 
Solifenacin 5mg OD 1 25.78 4 3 
Solifenacin 10mg OD 4 33.52 5 3 
Fesoterodine 8mg OD 7 25.78 4 -- 
Fesoterodine 4mg OD 5 25.78 4 -- 
Trospium 20mg BD 5 23.77 3 -- 
Trospium 60mg OD 5 23.05 3 -- 
Darifenacin 15mg OD 9 25.48 4 -- 
Oxybutynin IR 5mg BD (2) 2.47 1 1 
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Figure 48: Trade-off analysis – rank-o-gram for each of the efficacy and tolerability 
endpoints 
Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among 
the 11 pharmacological agents (and placebo) for the management of overactive bladder. A higher 
probability at a rank of 12 is the most favourable for the efficacy endpoints (micturition and UUI, whilst a 
higher probability at a rank of 1 is the most favourable for the tolerability endpoints (dry mouth and 
constipation). For example, placebo demonstrated the number 1 rank for micturition and UUI indicating that 
it was the least effective for efficacy, however, placebo also had a rank of 1 for constipation indicating that it 
was the best tolerated for this safety endpoint.  
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6.7.4 Quality assessment of the MTC model 
For all four outcomes, the model showed reasonable goodness of fit to 
the data (number of data points) as determined by the posterior mean 
of the residual deviance [micturition = 52.7 (55), p = 0.564; UUI = 39.9 
(45), p = 0.689; dry mouth = 45.5 (54), p = 0.788; constipation = 40.6 
(50), p = 0.826].  
 
No evidence of significant inconsistency (Bucher’s test) was detected 
between directly observed and inferred treatment effects within the 
loop identified in Figure 43 for any of the four endpoints. A visual 
assessment of the trace plots (history) and time series (density) plots 
also did not reveal cause for concern regarding inconsistency. 
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6.8 Summary 
Based on the data from the 21 studies included within the analyses, 
the use of anticholinergics or mirabegron for the management of OAB 
reduces symptoms by a potentially clinically insignificant value. For 
example, for the micturition frequency per 24 hours endpoint, the 
greatest reduction was seen with oxybutynin (placebo corrected 
reduction of -1.38 against a mean baseline of 11.6 per 24 hours). 
Nonetheless, this MTC and trade-off analysis suggests that 10mg 
solifenacin  once daily is the most effective treatment for symptoms of 
OAB (reduction in micturition frequency and number of UUI episodes 
per 24 hours) compared with other agents available within the UK for 
this indication. However, 10mg solifenacin, along with 8mg 
Fesoterodine, were among the treatments with the highest incidence of 
dry mouth, and along with 60mg modified-release trospium, were 
among the treatments with the highest incidence of constipation. The 
agent with the most favourable tolerability profile was 50mg 
mirabegron, which was shown to be associated with a risk of dry 
mouth similar to placebo and significantly lower compared to all 
antimuscarinic drugs. This is unsurprising given its mechanism of 
action is different i.e. not acting on the anticholinergic pathway. The 
MTC also suggested that the risk of constipation was lower with 50mg 
mirabegron than most antimuscarinics (excluding tolterodine).  
 
This MTC analysis confirms the finding of previous systematic review 
and meta-analyses conducted by Chapple et al.,(203) and Maman et 
al.(205) The merits of this review over the previous two published in 
recent years are two-fold. First, it utilised a stricter inclusion and quality 
assessment criteria to increase the robustness of the finding of the 
MTC analysis; second, a quantitative trade-off assessment of 
treatments for each of the four endpoints investigated.  
 
The results of the present review differ from those reported by Buser et 
al.(204) specifically that solifenacin was estimated as being the most 
efficacious treatment in preference to trospium, oxybutynin and 
fesoterodine. The key reason for the differences is that Buser et al. 
included many treatments at doses which are unconventional and 
unlicensed. The authors note that this was done purely for the sake of 
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completeness with the corresponding results being incompletely 
understood and irrelevant to clinical practice. Irrespective of these 
differences in inclusion criteria, both meta-analyses suggest that there 
are few statistically significant important differences in efficacy 
between the agents, highlighting that 10 mg solifenacin ranked first 
with regards to efficacy (micturition frequency and UUI episodes) 
among pharmacological treatments included within the present 
analysis. 
 
6.8.1 Consideration of the trade-off analysis (oxybutynin modified-
release vs. immediate release) 
Although the results of the analysis reports oxybutynin modified-
release and solifenacin as being the agents possessing the best 
clinical outcomes (micturitions per 24 hours and UUI per 24 hours), 
with the exception of darifenacin, this difference relates to at best, 
one less micturition episode per 24 hours or one-half less UUI 
episode per 24 hours. On this basis, given the high cost of these two 
agents (currently marketed under a protected patent), it is unlikely 
that this difference constitutes a clinically meaningful difference to 
prescribe these in preference to the generic agents, which are equally 
efficacious.  
 
The authors of the Cochrane Collaboration review (2012) concluded 
the following: 
“Where the prescribing choice is between oral immediate-release 
oxybutynin or tolterodine, tolterodine might be preferred for reduced 
risk of dry mouth. If extended-release preparations of oxybutynin or 
tolterodine are available, these might be preferred to immediate-
release preparations because there is less risk of dry mouth. Between 
solifenacin and immediate-release tolterodine, solifenacin might be 
preferred for better efficacy and less risk of dry mouth. Solifenacin 5 
mg once daily is the usual starting dose, this could be increased to 10 
mg once daily for better efficacy but with increased risk of dry mouth. 
Between fesoterodine and extended-release tolterodine, fesoterodine 
might be preferred for superior efficacy but has higher risk of 
withdrawal due to adverse events and higher risk of dry mouth. There 
is little or no evidence available about quality of life, costs, or long-
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term outcome in these studies. There were insufficient data from trials 
of other anticholinergic drugs to draw any conclusions.” (230) 
 
Although oxybutynin immediate-release was not included within the 
current analysis as no studies met the inclusion criteria, it is worth 
highlighting the findings of the following reports which did not meet 
the inclusion criteria: 
 Minassiuan et al (2007) conducted a prospective, randomised, 
12-week, open-label study.(231) The primary endpoint was 
number of number of micturitions per 24 hours. Although an a 
priori sample size of 60 subjects per group was required the 
authors only manage to recruit 72 women due to recruitment 
difficulties. For this reason, the study was terminated prematurely; 
however, an analysis of the subjects recruited demonstrated no 
difference between the two groups. Although these results are not 
adequately powered to definitely answer the research question, it 
is consistent with the pharmacology that immediate-release 
preparation will not be therapeutically inferior to the modified-
release preparation.  
 Barkin et al (2004) conducted a multicentre, double-blind 6-week 
study.(232) Efficacy endpoints evaluated included micturition and 
UUI episodes. Of the 125 subjects randomised, the intention-to-
treat population comprised of 94 (75%), with tolerability 
assessment in all. Both treatments produced equivalent 
reductions in micturition and UUI episodes (p<0.001 vs. baseline), 
although more subjects in the immediate-release group reported 
adverse effects with dry mouth being the most common.  
 Versi et al (2000) conducted a multicentre, double-blind study of 
226 subjects to evaluate the efficacy and safety of the modified-
release preparation compared with the immediate-release 
preparation, with a particular emphasis on dry mouth.(233) 
Reductions in UUI episodes from baseline to end of treatment 
were 18.6 to 2.9 per week (83% decrease) and 19.8 to 4.4 per 
week (76% decrease) in the modified-release and immediate-
release groups, respectively (p=0.36). At equal doses, 
comparable proportions of patients in both groups reported the 
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absence of urge incontinence (p=0.85). The incidence of dry 
mouth in the study was shown to increase with dose in both 
groups, however, there was no significant difference between the 
two groups (47.7% and 59.1%, respectively (p=0.9) although time 
to first report of dry mouth was higher in the immediate-release 
group.  
 Anderson et al (1999) conducted a multicentre, randomised, 
double-blind, parallel study.(234) The primary endpoint was UUI 
episodes. A total of 97 women and 8 men were enrolled. The 
number of weekly UUI episodes decreased from 27.4 to 4.8 in the 
group taking the modified-release preparation compared with a 
decrease from 23.4 to 3.1 in the group taking the immediate-
release preparation (p=0.56) demonstrating no difference 
between the two formulations. Total incontinence episodes 
decreased from 29.3 to 6.0 and from 26.3 to 3.8, respectively 
(p=0.6), also showing no difference between the two formulations. 
Continence was achieved in 41% of subjects in the modified-
release preparation group compared with 40% of subjects in the 
immediate-release preparation group (p=0.9). Regarding 
tolerability, dry mouth was reported in 68% and 87% of subjects 
taking modified-release and immediate-release oxybutynin, 
respectively (p=0.04), and moderate-severe dry mouth in 25% 
and 46%, respectively (p=0.03).  
 
 
Although studies investigating oxybutynin immediate-release did not 
meet the inclusion criteria, the conclusions from the above qualitative 
assessment suggests that the conclusions drawn from oxybutynin 
modified-release within the trade-off analysis can be interchangeable 
with oxybutynin immediate-release.  
 
6.8.2 Consideration of the trade-off analysis vs. cost (Primary Care) 
The trade-off analysis (presented in Table 28) which considered 
clinical endpoints was updated with cost as an additional parameter. 
From this, a revised top 3 rank was established (see Table 29). With 
consideration to efficacy, tolerability and cost, the analysis suggests 
that oxybutynin immediate-release should be the first-line option, with 
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the modified-release preparation strictly reserved for patients who 
have demonstrated improvements in symptoms but report issues with 
compliance. Where oxybutynin is not appropriate, due to concerns 
regarding frailty, tolterodine may be considered an alternative first-line 
option. Although solifenacin performed the best on the trade-off 
analysis between efficacy and tolerability, due to its high cost relative 
to generic oxybutynin / tolterodine, the revised rank places this as 
second / third-line.  
 
6.8.3 Strengths and weaknesses 
The methods applied in this paper allow steps beyond conventional 
meta-analysis. The approach incorporates all available information 
from clinical trials while fully maintaining randomisation. A comparison 
of the various treatments available and a rank ordering is estimated. 
Finally, the quantitative trade-off assessment to produce a ranking for 
the efficacy and safety endpoints provides an evidence base for 
formal decision-analytic models.  
 
The use of stricter inclusion and quality assessment criteria has been 
utilised to overcome the limitation of the previously published reviews 
which included studies with poor reporting quality necessitating the 
authors to impute missing values (such as standard deviation).   
 
The safety dataset utilised for the MTC analysis was based on 
averaged data from the published manuscripts. It is therefore unclear 
how predictive these mean values are for the individual patients. 
Further, none of the studies reported whether, or how many, patients 
had two or more adverse events. Therefore, it was assumed that the 
occurrence of an adverse event was independent of the presence of 
another adverse event, although this situation might be more complex 
in clinical practice. Almost all studies published are fixed-dose trials; 
the few studies that did not clearly specify the dose regarding adverse 
events were excluded. This limitation is important, since in clinical 
practice the dose of a drug is often titrated, and flexible dose studies 
tend to report fewer adverse events.  
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One possible criticism of the current analysis is that the MTC analysis 
for the safety outcomes focused only on dry mouth and constipation, 
adverse events known to be associated with antimuscarinics and not 
associated with mirabegron. However, on the basis of pooled safety 
analyses for mirabegron showing no statistically significant 
differences compared with placebo for adverse events reported 
(except nasopharyngitis) the opinion put forward is that this limitation 
is upheld.  
 
The efficacy outcomes considered in this MTC were limited to 
micturition frequency and UUI episodes frequency, and did not 
include outcomes analysed in other reviews such as urgency, volume 
voided per micturition, or dry rate. Although urgency is an important 
symptom in OAB, measurement of this symptom is difficult due to the 
subjective nature of urgency. As several instruments can be used to 
measure this symptom it makes comparisons between studies 
challenging. The volume voided per micturition was not included as it 
was considered a surrogate outcome measure of less clinical 
relevance. Other efficacy outcomes such as number of patients with 
resolution of incontinence, mean change from baseline in daytime 
micturition frequency, night-time micturition frequency, and urgency-
driven micturition are also relevant but less frequently reported, and 
therefore they were not considered in this MTC. A further criticism 
may be that this study takes no account of adjunctive therapies such 
as bladder training or fluid management – these may have influenced 
the outcome of both the studies included and the data interpreted 
herein although each study would have balanced this as part of the 
patient characteristics. 
 
Despite the focus on objective data, the difference in the period of 
time on the open market for individual agents may have affected the 
volume of data for different agents. This may have impacted upon the 
study outcome and continues to be a limitation of NMA in general for 
the analysis of newer vs. older agents.  
 
Lastly, the baseline for this analysis was the systematic review 
reported by Maman et al in which studies published before 2000 were 
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not included to ensure greater homogeneity between study 
populations. This methodology was considered sound as pre-2000 
more patients were treatment naive and the definition of OAB was 
introduced in 2001. The drawback of this approach is that this 
analysis omits data on older treatments, specifically oxybutynin 
immediate-release which is used routinely in practice. 
 
6.8.4 Implications for clinical practice 
This review is focused on the most clinically relevant factors when 
considering treatment for symptoms of OAB as validated by a 
Consultant within this field. Although it is widely accepted that the 
best model of providing answers with the highest clinical relevance 
would be from a large scale multiple comparison head-to-head trial, 
MTC analysis are increasingly used to provide guidance in areas 
where a multitude of therapeutics options are available. An important 
implication of the findings is that solifenacin is the highest ranking 
treatment with regards to the trade-off analysis of clinical (efficacy 
and tolerability) parameters; however, when the absolute differences 
are considered in relation to cost of treatment, this revised analysis 
places solifenacin as a second-line option behind oxybutynin.  
 
6.8.5 Conclusion 
This analysis found that all treatments for OAB were associated with 
a reduction in symptoms; however, not all were statistically 
significant. Solifenacin 10mg was found to possess the best efficacy 
profile, whilst mirabegron possessed the most favourable tolerability 
profile. The Bayesian MTC methodology is a powerful tool for 
evidence-based health care evaluation, and when supplemented with 
a quantitative trade-off assessment, it has the ability to provide a 
reliable hierarchy of treatment options. The strength of the findings 
lies in the model being based on a robust dataset following principles 
from the PRISMA statement and the Cochrane Collaboration.  
 
6.9   Peer review 
Prior to performing the analysis in WinBUGS, the code was forwarded 
to Dr Nicky Welton (Reader in Statistical and Health Economic 
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Modelling; School of Social and Community Medicine, University of 
Bristol) for validation. Advice was provided on tidying up the lines of 
coding relating to inclusion of studies with three-arms as well as the 
performance of a number of further analyses: checking model fit / 
consistency; obtaining ranking probabilities / rank-o-gram; and 
including a table of treatment effect estimates. These were all 
performed.  
 
The initial protocol for this project as well as the draft manuscript was 
forwarded to Dr Wood (Consultant, Urology) for comment and clinical 
support. All advise and corrections provided were implemented. 
Beyond this, a draft manuscript in article formal was forward to Dr 
Welton for comment, from which all questions and comments were 
addressed. The result of the methodological and clinical collaboration 
was to improve the overall quality of the analysis and its conclusions. 
 
6.10 Translation of outcomes to current practice 
6.10.1 Trade-off analysis 
This assessment found that all treatments for OAB were 
associated with a similar level of efficacy and safety, with the 
exception of darifenacin. The trade-off analysis, with consideration 
to the efficacy and tolerability parameters (presented as rank-o-
grams), identified solifenacin as being the most favourable agent; 
however, the clinical significance between the ranks was minimal 
due to overlapping confidence intervals. When the trade-off 
assessment considered cost as an additional parameter, it was 
agreed with clinical consultation that oxybutynin and / or 
tolterodine immediate-release should be recommended as first-line 
options.  
 
It should be noted that the patent protection for solifenacin will 
cease in 2018/19 after which point it would be expected that 
generic (non-proprietary) products will be commercially available at 
a fraction of the existing cost. If the UK market price for solifenacin 
was to follow the same trend as seen for losartan, the price for 
one-month treatment of solifenacin would reduce from the current 
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price of £33.52 to circa £1.20 (excluding VAT) within 6 month of 
patent loss.  
 
In accordance with the Health & Social Care Information Centre 
Prescription Cost Analysis [England 2014 data], a total of 72,070 
thousand issues of solifenacin 10mg and 5 mg tablets were made 
in 2014 resulting in a total spend of £73,360,000. This particular 
medicine represents the highest value of in-class spend at 53% of 
the £137,275,000 total (BNF category 7.4.2). At a reduction in 
value in line with the proposal above (i.e. non-proprietary price of 
5% that of the branded Vesicare) at current issue level, spend 
would reduce to £3,668,000 resulting in a saving in the region of 
£70m. Until such time that a generic preparation of solifenacin is 
available, the use of oxybutynin or tolterodine immediate-release 
would represent more cost-effective first-line therapies on the 
basis of a simple cost-minimisation principle. Refer to sections 
6.10.2 and section 6.11 for current changes in practice. 
  
6.10.2 Implications of research 
The findings from this area of research were presented locally with 
the Area Prescribing Committee and associated Commissioners. A 
local guideline was written to influence and support prescribing 
(see section 6.10.3; NCL Guideline: Pharmacological management 
of OAB).  
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6.10.3 NCL Guideline: Pharmacological management of OAB  
 
 
 
North Central London 
Joint Formulary Committee 
 
 
 
 
 
 
 
 
 
 
Disclaimer 
This guideline is registered at North Central London (NCL) Joint Formulary Committee 
(JFC) and is intended solely for use by healthcare professionals to aid the treatment 
of patients within NCL.  However, clinical guidelines are for guidance only, their 
interpretation and application remain the responsibility of the individual clinician. If 
in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the 
manufacturer’s current prescribing information before treating individual patients. 
The authors and NCL JFC accept no liability for use of this information from this 
beyond its intended use. 
While we have tried to compile accurate information in this guideline, and to keep it 
updated in a timely manner, we cannot guarantee that it is fully complete and 
correct at all times. If you identify information within this guideline that is inaccurate, 
please report this to the admin@ncl-jfc.org.uk. If a patient is harmed as a 
consequence of following this guideline, please complete a local incident report and 
inform admin@ncl-jfc.org.uk. 
This guideline is not be to used or reproduced for commercial or marketing purposes. 
NCL JFC is funded by and provides advice to Acute Trusts and Clinical Commissioning 
Groups in NCL. 
  
Pharmacological management of 
Overactive Bladder (OAB) Syndrome 
in Primary Care 
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1. Target audience 
 Primary care GPs and practice nurses. 
 
2. Purpose 
To provide a treatment algorithm for the pharmacological management of 
Overactive Bladder Syndrome in Primary Care.  
The guidance is based on best available evidence, incorporating 
recommendations from NICE Clinical Guideline 171 (Urinary incontinence, 2013), 
NICE Technology Appraisal 290 (Mirabegron, 2013). The recommendations 
follow an independent review of the literature (level 1, grade A evidence) by the 
NCL JFC and consultation with key urology stakeholders. 
 
3. General treatment principles 
 When offering anti-cholinergic drugs to treat OAB consider co-existing 
conditions (for example, poor bladder emptying), use of existing medication 
affecting the total anti-cholinergic load and risk of adverse effects.  
 The exclusion of other pathologies including stones, infection or malignancy 
(where appropriate) is important. Refer to Section 3.1 for red flag 
symptoms requiring referral to secondary care 
 The use of bladder diaries to assess symptoms is recommended 
 Before OAB drug treatment starts, discuss with patients:  
o the likelihood of success and associated common adverse effects, and  
o the frequency and route of administration, and  
o that some adverse effects such as dry mouth and constipation may 
indicate that treatment is starting to have an effect, and  
o that they may not see the full benefits until they have been taking the 
treatment for 4 weeks   
o fluid and lifestyle advice (including caffeine and fluid reduction) 
 Prescribe the lowest recommended dose when starting a new OAB drug 
treatment 
 If OAB drug treatment is effective and well-tolerated, do not change the 
dose or drug 
 
3.1. Red flag symptoms requiring referral to Secondary Care 
 Visible haematuria 
 Recurrent or persistent UTI associated with haematuria in women aged ≥ 
40 years 
 Microscopic haematuria in women aged ≥ 50 years 
 Suspected malignant mass arising from the urinary tract 
 Abnormal DSE or PSA 
 Family history of bladder cancer 
 Loss of weight 
 Bone pain 
 Persistent bladder or urethral pain 
 Clinically benign pelvic mass 
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 Faecal incontinence 
 Suspected neurological disease 
 Voiding difficulty 
 Suspected or confirmed urogenital fistulae 
 Previous continence / pelvic cancer surgery 
 Previous pelvic radiation therapy 
 Suspected or confirmed acute kidney injury 
 
4. Drug selection principles 
 Offer oxybutynin immediate-release (not if frail or elderly) or tolterodine 
immediate-release first to  patients with OAB or mixed UI who have good 
performance status 
 If oxybutynin immediate-release is not effective or well tolerated, offer 
tolterodine immediate-release 
 Do not offer oxybutynin to patients with frailty (due to potential impact on 
cognitive function based on crossing of the blood-brain barrier); offer 
tolterodine immediate-release as the first-line agent or solifenacin if an anti-
cholinergic is indicated 
 Review treatment after 4 weeks (refer to section 5) 
 If immediate release anti-cholinergic treatment(s) for OAB or mixed UI are 
not effective or well tolerated, offer solifenacin  
 If solifenacin alone is not effective despite dose optimisation, and the patient 
is unsuitable for invasive procedures, consider treatment with a combination 
of solifenacin and mirabegron.  This combination has been shown to be 
effective at improving mean voided volume, micturition frequency and 
urgency.   
 Offer mirabegron, as an alternative, if anti-cholinergics are contra-indicated 
or clinically ineffective  
 Do not use flavoxate, propantheline, trospium, fesoterodine, tolterodine MR 
or imipramine for the treatment of urinary incontinence (UI) or OAB  
 Offer transdermal oxybutynin patches to patients unable to take oral 
medication 
 There is no reason to expect patches or modified-release preparations of 
anti-cholinergic drugs to be more effective  
 
4.1. Contraindications to antimuscarinic treatment 
 Myasthenia gravis 
 Significant bladder outflow obstruction 
 Urinary retention 
 Severe ulcerative colitis 
 Toxic megacolon 
 Gastrointestinal obstruction or intestinal atony 
 
4.2. Caution with antimuscarinic treatment 
Antimuscarinic treatment should be used with caution in the elderly 
(especially if frail), in those with autonomic neuropathy, hiatus hernia or 
reflux oesophagitis, and in those susceptible to angle-closure glaucoma.  
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Antimuscarinic treatment may worsen hyperthyroidism, coronary artery 
disease, congestive heart failure, hypertension, prostatic hyperplasia, 
arrhythmias and tachycardia. 
 
Several commonly prescribed medications that are not within the 
anticholinergic class have significant anticholinergic effects, which when 
taken with known anticholinergic medication can increase the risk of adverse 
effects and have the potential to cause anticholinergic syndrome. These 
include: 
 Antihistamines 
 Tricyclic antidepressants 
 Drugs for asthma and COPD 
 Cold preparations 
 Second generation antipsychotics (clozapine, olanzapine, quetiapine) 
 Hyoscine 
 
4.3. Antimuscarinic Syndrome 
A confusional state with characteristic features related to dysfunction of the 
autonomic parasympathetic (cholinergic) nervous system. Symptoms 
classified into systemic and CNS manifestations: 
 Systemic (peripheral) symptoms: blurred visions, photophobia, non-
reactive mydriasis, loss of accommodation response, flushed and dry skin, 
dry mouth, tachycardia, hypertension and fever. Gastrointestinal and 
urinary motility are frequently reduced. 
 CNS symptoms: delirium, agitation, disorientation and visual 
hallucinations. Ataxia, choreoathetosis, myoclonus and seizures may also 
occur without peripheral symptoms 
 
5. Reviewing Overactive Bladder drug treatment 
 Offer a face-to-face or telephone review 4 weeks after the start of each new 
OAB drug treatment. Ask the patient if they are satisfied with the therapy: 
o If improvement is optimal, continue treatment 
o If there is no or suboptimal improvement or intolerable adverse effects 
change the dose, or try an alternative OAB drug (see above), and review 
again 4 weeks later 
o Consider the use of objective measures such as bladder diaries, if feasible, 
to quantify the level of improvement  
 Offer review before 4 weeks if the adverse events of OAB drug treatment are 
intolerable  
 If second-line or third-line therapies are no more effective or tolerable than 
previous therapies revert to the previous and less expensive treatment and 
consider referral to secondary care  
 Offer a further face-to-face or telephone review if a patient’s condition stops 
responding optimally to treatment after an initial successful 4-week review 
 Due to concerns around risk of cognitive impairment, falls and all-cause 
mortality associated with anticholinergic use, review patients who remain on 
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long-term drug treatment annually (or every 6 months for patients over 75 
years).  
o Consider a ‘drug holiday’ for 4 weeks, and if successful discontinue 
treatment. Some patients will be able to manage their symptoms without 
long-term pharmacological therapy and have no further problems.  
o For those patients whose symptom control decline and were better 
managed whilst on treatment, restart. 
 STOP anti-cholinergic drugs where the following is suspected or being 
investigated: 
o Dementia (increased confusion, agitation) 
o Chronic glaucoma (acute exacerbation of glaucoma) 
o Chronic constipation (exacerbation of constipation) 
o Chronic prostatism (urinary retention) 
 If the patient wishes to discuss the options for further management (non-
therapeutic interventions and invasive therapy) refer to a specialist secondary 
care centre to arrange urodynamic investigation to determine whether 
detrusor over-activity is present and responsible for OAB symptoms 
o If detrusor over-activity is present and responsible for the OAB symptoms, 
refer the patient back to the centre that conducted the urodynamic 
investigation if the patient would like to consider invasive therapy [note: 
referral to another centre will likely result in repeat tests and investigations 
being conducted as the information can be difficult to interpret] 
o If detrusor over-activity is not present refer to secondary care for 
further discussion concerning future management 
 
6. Drug summary 
 If otherwise healthy: oxybutynin IR → tolterodine IR → solifenacin → 
mirabegron ± solifenacin 
 If frail / elderly: tolterodine IR → solifenacin → mirabegron ± solifenacin  
 If unable to swallow: transdermal oxybutynin 
 If contra-indicated to an anti-cholinergic: mirabegron 
 See Table 30 for quick reference to pharmacological therapies 
 See Appendix 1 for summary flow diagram. 
 
Table 30: OAB pharmacological therapy quick reference  
Name Initial dose Maximum 
dose 
Dosage adjustments* Main side effects 
Oxybutynin 
immediate-
release 
2.5mg - 5mg 
twice-daily or 
thrice-daily  
 
5mg four-
times daily 
Nil Dry mouth, 
constipation, 
blurred vision, 
dry eyes, 
cognitive 
impairment 
Tolterodine 
immediate-
release 
2mg twice-
daily 
2mg twice-
daily 
Reduce to 1mg twice-
daily if necessary to 
minimise side effects. 
Use with caution in 
Dry mouth, 
constipation, 
blurred vision, 
dry eyes 
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Name Initial dose Maximum 
dose 
Dosage adjustments* Main side effects 
severe renal 
impairment. 
Solifenacin 5mg once-
daily 
10mg once-
daily 
Dose should not 
exceed 5mg daily in 
severe renal 
impairment or 
moderate hepatic 
impairment or those 
on potent CYP3A4 
inhibitors. Should not 
be used in patients 
with severe hepatic 
impairment. 
Dry mouth, 
constipation, 
blurred vision, 
dry eyes, low rate 
of cognitive 
impairment 
Mirabegron 50mg once-
daily 
50mg once-
daily 
Dose should not 
exceed 25mg daily in 
moderate renal or 
hepatic impairment 
and those on potent 
CYP3A4 inhibitors. 
Should not be used in 
patients with severe 
renal or hepatic 
impairment. 
Tachycardia, 
urinary-tract 
infection 
Oxybutynin 
transdermal 
(Kentera) 
1 patch 
applied twice-
weekly to 
clean, dry 
unbroken skin 
on abdomen, 
hip or buttock 
(delivers 
3.9mg / 24 
hours) 
1 patch 
applied 
twice-
weekly 
Rotate application 
site. Use with caution 
in patients with renal 
or hepatic 
impairment. 
Skin irritation or 
pruritis, low 
incidence of dry 
mouth and 
constipation 
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Appendix 1: Summary of treatment recommendations 
  
Fit and 
healthy 
Frail or Elderly (≥ 75 
years old 
Patient 
Assessment 
Oxybutynin 
immediate-release 
Yes 
Able to take 
oral 
medication 
Able to take 
oral 
medication 
Transdermal 
oxybutynin 
Yes 
Contra-indication to 
anti-muscarinic 
Yes 
Mirabegron 
No 
No* 
Yes 
Ineffective or not 
tolerated despite dose 
optimisation 
No* 
Solifenacin 
Yes 
Ineffective despite dose 
optimisation 
Mirabegron ± 
Solifenacin 
No* 
Ineffective or not 
tolerated despite dose 
optimisation 
No* 
Yes 
Tolterodine 
immediate-release 
Ineffective or not 
tolerated despite 
dose optimisation 
Yes 
* Review effective treatment annually 
(or every 6 months in patient ≥ 75 years 
old) and consider a 4 week ‘drug free 
holiday’ to avoid chronic adverse effects 
Tolterodine 
immediate-release 
Not tolerated  
Mirabegron 
Yes 
No* 
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6.11 Qualitative Analysis (prescribing analysis) 
6.11.1 Review of practice 
Based on the large proportion of solifenacin prescribing identified 
from a review of HSCIC prescribing cost data, an analysis of 
change in practice was undertaken to determine the impact of the 
guideline and communication. Figure 49 identifies the change in 
solifenacin issued to patients in NHS Enfield from January 2014 
following the above analysis (draft version). The reduction in 
proportion from 35% to less than 20% corresponds to a reduction 
in spend of £140,000 per annum. Unfortunately the other four 
CCGs within the NCL region have not followed through to the 
same extent however it identifies the opportunity that £700,000 of 
saving per annum exists within NCL alone. The data presented in 
Figure 50 and Figure 51 highlight the corresponding reduction in 
oxybutynin modified-release prescribing, and increase in 
oxybutynin / tolterodine immediate-release prescribing, 
respectively.  
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Figure 49: Proportion of solifenacin issued (as a proportion of all antimuscarinics) 
within North Central London between May 2012 and March 2017.  
Practice begins to change following JfC discussion in January 2014; practice continues to modify further 
following draft guidelines in June 2014. Source: https://openprescribing.net    
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Figure 50: Proportion of oxybutynin modified-release issued (as a proportion of all 
antimuscarinics) within North Central London between May 2012 and March 2017.  
Practice begins to change following JfC discussion in January 2014; practice continues to modify further 
following draft guidelines in June 2014. Source: https://openprescribing.net   
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Figure 51: Proportion of oxybutynin and tolterodine immediate-release issued (as a 
proportion of all antimuscarinics) within North Central London between May 2012 and 
March 2017.  
Practice begins to change following JfC discussion in January 2014; practice continues to modify further 
following draft guidelines in June 2014. Source: https://openprescribing.net   
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6.12 Reflection of this project 
Further to the methodological work conducted previously (specifically 
the mixed treatment network meta-analysis for the antiepileptic 
drugs); it was considered important to ensure that this piece of work 
was not only a replication of methodological technique, but also to 
demonstrate growth in knowledge and analytical skills. To ensure 
this, two specific actions were taken as part of this research project: 
 
1. Validation and improvement of NMA technique: The work was 
forwarded to Dr Nicola Welton (University of Bristol) for peer 
review. This choice was made as Bristol University is renowned 
for its School of Social and Community Medicine which is host 
to academic leads in Medical Statistics and Epidemiology. Dr 
Welton is an expert in the field of network meta-analysis and 
Bayesian multiparameter evidence synthesis, which this project 
was based on. Furthermore, Dr Welton is Deputy Director of the 
NICE Clinical Guidelines Technical Support Unit, which is 
based at the School, and is co-author on the two Technical 
Support Documents referenced within the methodology section 
of this project. Validation of the NMA model from an expert in 
the field and comments on further analyses which were 
originally missing (see section 6.9) provides assurance of an 
understanding of the methodology, interpretation of results, and 
overall robustness of project. 
 
2. Translation to practice: The objective of this work was the 
development of a clinical guideline for the purpose of primary 
care clinicians, with the findings of the network meta-analysis 
shared with a Consultant Urologist who practices as part of a 
multi-disciplinary team (Urology, Uro-gynaecology and Care of 
the Elderly) where such treatment is frequently used. This was 
not done with the epilepsy group as part of research project one 
and therefore could be considered a limitation of the exercise. 
The particular choice of individual was made on the basis of 
familiarity with the processes of the Drugs and Therapeutics 
Committee, having conducted a number of submissions and 
being the recipient of challenging requests for information. The 
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inclusion of a respected clinician as part of the peer review, and 
known to the target audience, would ensure that the conclusion 
and recommendations carry value beyond an academic 
exercise.   
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7.0 Chapter 7: Research Project Four – Oral 
anticoagulants for prevention of stroke in atrial 
fibrillation 
 
7.1 Introduction 
This fourth research project continues with the use of Bayesian NMA, 
with the trade-off analysis encompassing a number of endpoints, 
including efficacy, safety and cost. Through collaboration with the 
Medical Statistics and Epidemiology Division (School of Social and 
Community Medicine, University of Bristol), this project also includes a 
formal cost-utility analysis, bespoke to the UK setting, to advise UK 
NHS policy.   
 
The use of a Bayesian meta-analysis rather than the traditional 
frequentist analysis is suitable for this project as again only a limited 
number of published trials have investigated these agents in a direct 
head-to-head comparison.  
 
The goal of this project is to consolidate techniques developed over 
projects one to three and apply them to an analysis of a more complex 
therapeutic area that features as a priority for the local and national 
NHS service. The findings of the NMA and outcomes of the trade-off 
analysis would be used to influence prescribing across the UK. To 
ensure a robust and clinically relevant analysis based on learning from 
earlier projects, formal collaboration with a methodological, health 
economics and clinical expert team will be undertaken. 
 
An additional goal for this project is to understand if any 
recommendations can be made on which of the agents under analysis 
should be prioritised to be trialled in a head-to-head manner. 
 
7.2 Literature Review 
7.2.1 Atrial fibrillation, stroke and myocardial infarction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia.(235) 
The prevalence of AF roughly doubles with each decade of age, 
rising to almost 9% at age 80-90 years.(236) AF substantially 
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 226 - 
increases (by up to five times) the risk of thromboembolic stroke 
(annual incidence 114 per 100,000) due to pooling of blood in the left 
atrium and systemic embolisation to the brain. More than 20% of the 
130,000 annual strokes in England and Wales are attributed to AF. 
Approximately one-third of stroke patients die in the first ten days, 
one-third recover in one month and one-third have disabilities 
needing rehabilitation making stroke the leading cause of adult 
disability. Patients with thromboembolic stroke from AF have higher 
mortality, morbidity and hospital stay than patients with other stroke 
subtypes.  
Since its launch in 1954 as a medicine for human use, warfarin 
remains an effective oral anticoagulant for the prevention of stroke in 
patients with AF,(237) however it is underused in clinical care given 
its cumbersome testing and monitoring requirements.   
 
Although the incidence and mortality of stroke continue to fall in the 
UK, the underutilisation of anticoagulation in patients with AF at high-
risk of stroke is a major gap in clinical care.(238) In patients with atrial 
fibrillation, antiplatelet and anticoagulant therapies are generally 
considered from the perspective of mitigation of stroke risk. However, 
the presence of atrial fibrillation is also associated with an 
approximately two-fold higher risk of future acute myocardial 
infarction,(239) whose annual incidence in England (130 and 55.9 per 
100,000 for men and women respectively)(240) is higher than that for 
stroke. 
  
7.2.2 Current usage and cost of warfarin in the NHS 
A 2007 Health Technology Assessment report stated that 
approximately 950,000 people (2% of the GP population) in the UK 
are prescribed warfarin; increasing by about 10% per year.(241) 
Warfarin-related bleeding is one of the top five reasons for 
hospitalisation for adverse drug effects in England,(242)  because of 
the narrow therapeutic index and numerous drug / dietary 
interactions. Although the approximate acquisition cost of warfarin is 
only £10 per patient per year, the requirement for therapeutic 
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monitoring to ensure optimal efficacy and to reduce the risk of 
bleeding, through hospital-, primary care-, or pharmacist-based 
anticoagulation clinics, or by home-monitoring with anticoagulant 
clinic support, increases the cost of warfarin treatment.  
 
The estimated annual cost of managing patients on warfarin in the 
NHS in England and Wales is approximately £90 million. A 2006 
NICE report estimated that 46% of patients who should be on 
warfarin are not receiving it, and that many receiving anticoagulation 
are not in optimal therapeutic range, perhaps because of concern 
about the risk and inconvenience of warfarin treatment.(243) 
 
7.2.3 Novel oral anticoagulants and their place in the NHS 
The class of novel (or non-vitamin-K antagonist) oral anticoagulants 
(NOACs) includes dabigatran (a direct inhibitor of clotting factor II), as 
well as rivaroxaban, apixaban, edoxaban, otamixaban and betrixaban 
(all factor X inhibitors). These agents have a more rapid onset and 
offset of action than warfarin, are therefore considered to have more 
predictable dosing requirements than warfarin, negating the need for 
therapeutic dose monitoring, increasing convenience and reducing 
overall cost.(244) However, the safety and efficacy of at least one of 
the NOACs (dabigatran) may vary according to achieved plasma 
concentrations, which may differ between individuals receiving the 
same dose,(245) suggesting a potential benefit from therapeutic dose 
monitoring (TDM). If this is proved to be the case, the consequence 
would be an increase in the overall cost of treatment.  
Over recent years these drugs have been evaluated in clinical trials 
as an alternative to warfarin for the prevention of stroke in patients 
with AF (for which warfarin is given lifelong); as an alternative to 
LMWH for prevention of VTE in high-risk patients undergoing major 
orthopaedic surgery as well as those being hospitalised with acute 
medical conditions (for which LMWH is given to cover the high-risk 
period); as an alternative to a period of LMWH and then warfarin for 
acute treatment of a first VTE (usually for 6 months); as well as for 
secondary prevention after a first episode of VTE, for which there is 
currently no widely used treatment. 
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The estimated annual acquisition cost per patient of new 
anticoagulants is substantially higher than that of warfarin and will 
remain so until patent expiry (for example, 2020 for rivaroxaban). 
However, the higher acquisition cost could be offset by the reduced 
need for therapeutic monitoring through anticoagulation services, by 
increased effectiveness, or by improved safety. Potential limitations of 
NOACs include class- and drug-specific cautions / contraindications, 
potential for sub-therapeutic dosing, reduced adherence due to lack 
of regular monitoring, absence of, or limited experience with 
antidotes, as well as the added cost of maintaining stocks of 
numerous different anticoagulants and the potential for prescribing 
errors due to unfamiliarity. 
 
7.3 Rationale for undertaking this research 
Limitations of the previous evidence base (and shortfalls in previous 
attempts at evidence synthesis) make rational selection from the now 
wide range of available oral anticoagulants difficult for NHS 
commissioners, doctors and patients. Much of the existing NICE 
guidance in this area is limited to technology appraisals of the 
individual agents (for example, TA170 for rivaroxaban). 
Clinical trials in this area have the following limitations: 
 Few, if any, trials have made direct comparisons of NOAC drugs 
with one another. This is a recurrent theme in the licensing of new 
drugs as there is no regulatory requirement for the Pharmaceutical 
Industry to undertake this. This limitation may be addressed 
through the use of network meta-analysis to estimate the 
comparative efficacy and safety of agents, which have been tested 
against a common comparator; in this case, warfarin. 
 Different rates of sub-therapeutic anticoagulation with warfarin 
within trials (as measured by the time spent in the therapeutic 
range) may have artificially inflated the apparent efficacy or 
deflated potential safety / tolerability concerns of the newer agents. 
This limitation may be addressed to some extent by investigating 
the relation of average time in therapeutic range (TTR) with efficacy 
within the network meta-analysis framework.  
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Prior synthesis research in this area has the following limitations: 
 Some meta-analyses preceded the publications of potentially 
influential trials 
 Failure to fully incorporate evidence on the adverse effects of oral 
anticoagulants by including data from all trials, regardless of 
indication, to maximise power and provide the most robust 
evidence on the balance between benefit and harm 
 The lack of cost-effectiveness analyses relevant to England and 
Wales (i.e. the UK NHS setting) 
 
Thus, it was agreed that there is a need for an up-to-date 
comprehensive evidence synthesis of all competing treatments to 
inform the rational choice of a minimum set of oral anticoagulants 
needed by the NHS for the main therapeutic indications to avoid 
unnecessary over-stocking and to reduce the risk of prescription error 
due to unfamiliarity. A working group between UCL and University of 
Bristol was created with a proposal drafted and submitted to the NIHR 
Health Technology Assessment (HTA) for funding. Following review by 
the HTA Clinical Evaluation and Trials Board, the research project was 
successfully awarded £242,550 (HTA – 11/92/17).  
The work undertaken within this project also falls within the MRC 
ConDuCT (collaboration and innovation for difficult or complex 
randomised controlled trials) Hub, specifically ‘evidence synthesis and 
expected value of information for prioritisation of RCTs’.  
 
7.3.1 Research aim 
To determine what is / are the best oral anticoagulant(s) for 
prevention of stroke in atrial fibrillation; and for primary prevention, 
treatment and secondary prevention of venous thromboembolic 
disease. Note, the aim of this thesis relates only to stroke prevention 
in AF, as the area of the project that I was directly involved in. 
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7.3.2 Research objectives 
The specific objectives of this research project were: 
 To identify the most effective, safe and cost-effective 
anticoagulant for stroke prevention in AF, and consider whether 
the evidence is consistent across important patient subgroups 
(for example presence of comorbidities, age, etc.) 
 To identify optimal anticoagulation strategies for use by Acute 
Trust Drugs & Therapeutics Committees or Area Prescribing 
Committees, based on the best drug(s) for each of the main 
therapeutic indications 
 To estimate the value of conducting further research on the 
cost-effectiveness of these drugs, for example recommendation 
and identification of conducting a head-to-head trial of two or 
more new anticoagulants 
 
7.4 Collaboration 
Owing to the size of the review, a Project Board was established to 
undertake the NIHR funded Health Technology Assessment. The 
Project Board comprised of five key teams: (1) systematic review; (2) 
methodology; (3) clinical; (4) health economics; and (5) patient partner. 
Tasks undertaken by me relate to systematic review and clinical 
aspects, specifically: contribution to the pre-study protocol and grant 
applications; undertaking the systematic review, data extraction and 
assessment of data for the AF review; provision of clinical and 
pharmaceutical expertise to advise the health economics team; and 
supporting interpretation of the results in relation to clinical practice. 
The working group convened on a regular basis for 15 months over the 
course of the project. The execution of data derived from the 
systematic review within the Bayesian NMA was performed by the 
methodology team. The cost-effectiveness analyses were performed 
by the health economics team.  
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7.5 Protocol (Quantitative Analysis) 
7.5.1 Systematic Review 
A systematic review, with network meta-analysis, of randomised 
controlled trials addressing the question relevant to the study 
objectives was undertaken.  
This review was undertaken in accordance with the Centre for 
Reviews and Dissemination (CRD) guidelines for undertaking 
systematic review,(246) and the Cochrane Handbook for Systematic 
Reviews of Interventions,(27) (as updated online during 2011: see 
www.cochrane-handbook.org). This review was prospectively 
registered in the PROSPERO database 
(http://www.crd.your.ac.uk/prospero), with registration number 
CRD42013005324. Related reviews were assigned registration 
numbers CRD42013005331 and CRD42013005330.   
 
7.5.2 Search strategy 
Scoping searches conducted during protocol development identified 
some previously published NMAs of oral anticoagulants. Studies 
included in these NMAs were rescreened against the eligibility criteria 
and a search was developed to identify any additional studies 
published beyond the search dates of the most recent NMAs in each 
population.(247) 
The search strategy identifying studies for the review of stroke 
prevention in AF was run on 12 March 2014 and updated on 15 
September 2014. The search strategy covered the period 2010 to 
September 2014 and included terms for AF, the interventions and 
comparators of interest and a filter added to focus the search on 
RCTs.  
Relevant randomised trials were searched for within MEDLINE and 
PREMEDLINE In-Process & Other Non-Indexed Citations, EMBASE 
and The Cochrane Library. In keeping with the strategy of Chapter 
6.0 (section 6.5.2), no restrictions on language were applied for this 
search. Duplicate records (identified by title, authors, journal citation 
and date published) were removed. The principal search strategy is 
outlined in Table 31.  
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Owing to the size of the team involved in this project, unlike the 
previous three areas, data from studies in progress, unpublished 
research and research reported in the grey literature from 
www.clinicaltrials.gov (to September 2012) was also obtained. The 
reference lists of retrieved studies and relevant review articles were 
screened. The NHS Economic Evaluation Database (NHS EED) and 
NICE Technology Appraisals records were searched. 
 
7.5.2.1 Search terms 
Table 31 provides a list of the search terms and limits applied when 
conducting the database search.  
 
Table 31: Search strategy used in MEDLINE (in-process & other non-indexed 
citations – current week) and MEDLINE (1950 to present) for the analysis of 
NOACs for the prevention of stroke in AF (search date 20 March 2014; 
updated 15 September 2014)  
 Search term Results 
01. tachycardia, supraventricular/ or tachycardia, ectopic atrial/ 5,440 
02. Atrial fibrillation/ 33,510 
03. ((atrial or atrium or auricular) adj3 fibrillat$).ti,ab. 38,980 
04. Heart fibrillat$.ti,ab. 42 
05. (supraventricul$ adj3 (arrhythmi$ or tachycardia$)).ti,ab. 7,547 
06. ((atrial or atrium) adj3 (tachycardia$ or arrhythmi$)).ti,ab. 6,888 
07. (atrial adj3 tachyarrhythmi$).ti,ab. 1,210 
08. Atrial flutter/ 4,944 
09. ((atrial or auricular) adj3 flutter$).ti,ab. 5,382 
10. Or/1-9 59,756 
11. exp *anticoagulants/ 94,278 
12. exp *coumarins/ 24,265 
13. Warfarin/ 14,307 
14. exp vitamin k/ai [antagonist and inhibitors] 1,534 
15. Thrombin/ai [antagonist and inhibitors] 3,372 
16. Factor Xa/ai [antagonist and inhibitors] 2,197 
17. Aspirin/ 37,712 
18. (anticoagula$ or anti-coagula$).ti. 21,584 
19. (oral anticoagula$ or oral anti-coagula$).ti.ab. 7,768 
20. (coumarin$ or coumadin$ or warfarin or marevan or dicoumarol 
or dicoumarin or dicumarin or dicumarol or acenocoumarol or 
phenindione or aldocumar).ti,ab. 
26,479 
21. (factor Xa adj2 (antagonist$ or inhibitor$)).ti,ab. 1,502 
22. (factor 10a adj2 (antagonist$ or inhibitor$)).ti,ab. 2 
23. (factor IIa adj2 (antagonist$ or inhibitor$)).ti,ab. 29 
24. ((vitamin K or vitamin-k) adj2 (antagonist$ or inhibitor$)).ti,ab. 2,080 
25. (dabigatram or pradaxa or BIBR1048 or Apixaban or Eliquis or 
BMS-562247-01 or Edoxaban or Lixiana or savaysa or DU- 
176b or betrixaban or PRT-054021 or PRT0504021 or 
rivaroxaban or xarelto or BAY-59739 or Erixaban or 
D0913).ti,ab. 
1,330 
26. (NOAC or NOACS).ti,ab. 152 
27. (aspirin or acetyl-salicylic acid or acetylsalicylic acid).ti,ab. 42,763 
28. Or/11-27 175,520 
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 Search term Results 
29. 10 and 28 6,721 
30. Letter/ 829,317 
31. Editorial/ 348,841 
32. News/ 159,841 
33. exp historical article/ 318,220 
34. Anecdotes as topic/ 4,508 
35. Comment/ 572,414 
36. Case report/ 1,665,104 
37. (letter or comment$).ti. 94,907 
38. Or/30-37 3,300,100 
39. randomized controlled trial/ or Randomized Controlled Trials as 
Topic/ or random$.ti,ab. 
835,720 
40. 38 not 39 3,270,043 
41. Animals/ not humans/ 3,807,926 
42. exp Animals, Laboratory/ 714,413 
43. exp Animal Experimentation/ 6,188 
44. exp Models, Animal/ 407,073 
45. exp rodentia/ 2,629,200 
46. (rat or rats or mouse or mice).ti. 1,097,935 
47. Or/40-46 7,662,407 
48. 29 not 47 5,201 
49. Systematic review/ 0 
50. Meta-analysis/ 45,623 
51. (meta analy$ or metaanaly$ or metanaly$ or meta 
regression).ti,ab. 
61,909 
52. ((systematic$ or evidence$) adj2 (review$ or overview$)).ti,ab. 71,965 
53. (reference list$ or bibliograph$ or hand search$ or manual 
search$ or relevant journals).ab. 
24,936 
54. (search strategy or search criteria or systematic search or study 
selection or data extraction).ab. 
26,492 
55. (search$ adj4 literature).ab. 26,789 
56. (medline or pubmed or cochrane or embase or psychlit or 
psyclit or psychinfo or cinahl or science citation index or bids or 
cancerlit).ab. 
82,698 
57. Cochrane.jw. 10,337 
58. ((multiple treatment$ or indirect or mixed) adj2 
comparison).ti,ab. 
901 
59. Or/49-58 186,127 
60. randomized controlled trial.pt. or randomized controlled trial/ or 
Randomized Controlled Trials as Topic/ 
452,445 
61. controlled clinical trial.pt. 87,837 
62. Randomi#ed.ab. 343,274 
63. Placebo.ab. 151,447 
64. Drug therapy.fs. 1,674,296 
65. Randomly.ab. 208,182 
66. Trial.ab. 297,177 
67. Groups.ab 1,328,911 
68. Or/60-67 3,312,451 
69. clinical trials as topic.sh. 168,554 
70. Trial.ti. 123,158 
71. Or/60-63,65,69-70 946,554 
72. 59 or 71 1,075,719 
73. 48 and 72 1,764 
74. Limit 73 to yr=”2010-current” 728 
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7.5.2.2 Quality Assessment and Data Collection 
Two reviewers independently screened the results of the searches 
by title and abstract (initially by me and verified by Mr Okoli). 
Disagreements were resolved through consensus or referral to a 
third reviewer where necessary (Ms Davies). The full text articles of 
all potentially relevant reports were obtained and assessed 
independently against the eligibility criteria. Multiple reports of the 
same study were collated and mapped under the primary 
publication. 
 
Data extraction was undertaken against dedicated forms which were 
piloted initially on a small selection of studies to ensure their 
appropriateness. Data were extracted from the trial reports by me 
and checked by a second for all studies. Disagreements were 
resolved through consensus or by referral to a third reviewer where 
necessary (as above). The following data were extracted: study 
details (identifier, study design, location, year, length of follow-up, 
industry sponsorship); participant details (number of participants, 
age, gender); intervention details (drug name, dose, timing); 
comparator details; details relevant to risk-of-bias assessment 
(including adherence to and withdrawal from randomised allocation); 
and effect modifiers. Multiple reports from a study informed a single 
data extraction form. Data were extracted and managed using 
Microsoft Access® 2013 software (Microsoft Corporation, Redmond, 
WA, USA). 
 
Data were extracted in dichotomous form based on the full 
randomised samples, as number of events in intervention and 
control groups and numbers of participants. Details of follow-up time 
was collected (e.g. participant-years in each treatment group) as 
well as estimates of hazard ratios (HRs) and their confidence 
intervals (CIs) when available. 
 
7.5.2.3 Assessment of Risk of Bias 
Risk of bias in studies was assessed using the Cochrane Risk of 
Bias Tool.(36) Assessments were carried out by me and 
independently checked by Mr Okoli. All disagreements were 
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resolved through consensus or by referral to a third reviewer where 
necessary, as per section 7.5.2.2. 
 
7.5.3 Selection of data 
7.5.3.1 Choice of Interventions 
To perform the NMA each intervention group from each trial was 
allocated to a category. Each intervention category formed a ‘node’ 
within the treatment network. Separate nodes were created for 
different doses or frequencies of administration for the oral 
anticoagulants. The different forms of vitamin K antagonists were 
assigned to one node term (i.e. warfarin); however three sub-nodes 
under the term were created to account for INR range 2-3, INR 
range 3-4, and other. Due to the number of intervention categories 
(or treatment nodes), clear labelling was necessary. 
 
7.5.3.2 Choice of Time Points 
For trials where outcome data were presented at multiple time 
points the longest period of follow-up was taken. 
 
7.5.4 Eligibility criteria 
7.5.4.1 Study Design 
Trials were included if they were of phase II or phase III randomised 
controlled design, and using either a superiority or non-inferiority 
design. 
 
7.5.4.2 Participants 
Adults (≥18 years) eligible for oral anticoagulation or antithrombotic 
treatment with a diagnosis of non-valvular atrial fibrillation (AF) were 
included. Trials in participants only eligible for parenteral (injected) 
anticoagulation were excluded. Unless otherwise specified, 
anticoagulation services may have been delivered in hospital, 
primary care, pharmacy-based clinics or through home monitoring 
and telephone support. The review was not limited to NHS 
anticoagulation services.  
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7.5.4.3 Inclusion criteria: Interventions and Comparators 
Five oral NOACs were the focus of the review: dabigatran 
(Pradaxa®); apixaban (Eliquis®); edoxaban (Lixiana®); betrixaban 
(pending Marketing); and rivaroxaban (Xarelto®). 
 
NOACs not considered within this review and reasons for exclusion 
were: erixaban (current stage of development was unclear); 
ximelagatran (withdrawn due to liver toxicity); darexaban (YM150) 
and AZD0837 (both discontinued in early development phase); 
LY517717 and letaxaban (TAK442) (no available information on 
clinical development for both); and otamixaban (parenteral 
formulation only in development therefore likely to be a treatment for 
VTE and not AF).  
 
The aim of the systematic review was to inform the network meta-
analysis (NMA), therefore the comparator interventions were 
determined to ensure that they would provide information on the 
relative effectiveness of the interventions of interest. Comparators 
were chosen based on the possibility of informing indirect evidence 
on the relative effectiveness of oral anticoagulants, and on the 
‘distance’ of these comparators from our interventions of interest in 
the network, which relates to the likely increase in precision in the 
estimates of relative effectiveness of the oral anticoagulants. 
 
Specific comparators for the prevention of stroke in AF were:  
 therapeutic doses of warfarin or other VKA [with optimal 
international normalised ratio (INR) range 2–4] 
 aspirin 
 clopidogrel 
 
7.5.4.4 Exclusion criteria 
Studies evaluating fixed-dose administration of warfarin were 
excluded. Studies evaluating warfarin with suboptimal target INR 
compared with UK guidelines were also excluded from the main 
analyses but combined with studies evaluating warfarin with 
standard target INR in sensitivity analyses. 
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7.5.5 Outcome measures 
The key outcomes addressed in the NMA are marked with an asterisk 
(*) in the list below. These were chosen based on three 
considerations: (1) their clinical importance; (2) the consistency or 
reporting across studies included in the network; and (3) the number 
of data that were available for inclusion in NMAs. The choice was 
based on agreement by the clinical contributors to the research 
project (Prof Hingorani, Dr Sofat, and I). 
 
Where outcome data were not presented directly, they were 
computed or substituted, using data for other outcomes using 
assumptions that were considered to be clinically reasonable, as 
guided by the clinical contributors to the research project. For 
example, where data could not be extracted for outcome ‘stroke or 
SE’, the data for ‘all stroke’ was used. Where CRB was not reported 
but both major bleeding and CRNM bleeding events were, the total 
number of events across these categories was used. This was 
performed by me and the data verified by Mr Okoli.  
    
7.5.5.1 Outcomes: Prevention of stroke in Atrial Fibrillation 
Data were sought on the following outcomes:  
 Stroke or systemic embolism (SE)* 
 All stroke 
 Ischaemic stroke (major ischaemic stroke or minor ischaemic 
stroke)* 
 Fatal stroke 
 Non-fatal stroke 
 Haemorrhagic stroke (major haemorrhagic stroke or minor 
haemorrhagic stroke) 
 Any bleeding 
 Minor bleeding 
 Major bleeding* 
 Clinically relevant non-major (CRNM) bleeding 
 Clinically relevant bleeding (CRB)* (defined as CRNM bleeding 
or major bleeding) 
 Intracranial bleeding* 
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 Extracranial major bleeding 
 Extracranial minor bleeding 
 Fatal bleeding 
 Bleeding from surgical site 
 Thrombocytopenia 
 Myocardial infarction (MI)* 
 Transient ischaemic attack (TIA) 
 Arterial event 
 Quality-of-life outcomes 
 Hospital admission 
 Death (cardiovascular) 
 All-cause mortality* 
 
7.5.6 Quantitative (Statistical) Analysis 
For each analysed outcome in each review, a frequentist meta-
analysis of ‘direct evidence’ and a Bayesian NMA of ‘direct and 
indirect evidence’ were performed. Results from individuals studies 
are presented in forest plots, arranged within each possible pairwise 
analysis (e.g. one NOAC versus another NOAC).  
 
7.5.6.1 Undertaking the Quantitative Analysis 
The networks were plotted to illustrate the data structure for each 
review and outcome. In these plots, the size of the node for each 
intervention is proportional to the number of patients randomised to 
that intervention. When direct evidence comparing two interventions 
was available, these two interventions are connected by a line 
where its thickness is proportional to the number of patients who 
contributed to the comparison. The intervention labels were 
formatted as follows: 
 
 Licensed doses of NOACs are written in bold typeface; these 
are interventions of primary interest.  
 Interventions that were excluded from the primary analysis 
labels are presented in square brackets. Such exclusions are 
because (1) they were not considered to be of interest to inform 
health decisions in the UK (e.g. warfarin interventions using sub-
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therapeutic INR ranges); or (2) the total number of events was 
zero, so they are uninformative; or (3) they do not connect with 
the other trials in the network. 
 Excluded interventions that were included in sensitivity analyses 
are marked with an asterisk (*) under section 7.5.5.1. 
 
In previous chapters of this thesis the random-effects model of the 
Frequentist meta-analysis was used, however for this analysis the 
fixed-effect model was used. This was agreed by the Project Board 
following a review of preliminary analyses focussing on 
heterogeneity concluding that trial protocols and patient groups 
were sufficiently similar across all studies owing to the nature of 
strict diagnosis driving the inclusion criteria.(49)  
All meta-analyses were performed within a Bayesian framework, 
using freely available WinBUGS software version 1.4.3 (MRC 
Biostatistics Unit, Cambridge, UK) and code.(248) As in section 6.0, 
the MTC model was coded for binomial likelihood owing to the 
endpoints of interest being discrete and not continuous. In 
supplementary analyses for some outcomes it was agreed that 
hazard ratios (HRs) would be modelled rather than odds ratios 
(ORs) as this more accurately describes the outcomes of risk being 
non-cumulative. 
Convergence of the Markov chains was assessed as in previous 
chapters via visual examination of trace plots. Goodness of fit was 
also assessed by calculating the posterior mean residual deviance.  
 
7.5.6.2 Investigation of heterogeneity 
Subgroup analyses were planned to examine the extent to which 
patient- and study-level characteristics explain between-study 
heterogeneity. Important characteristics were pre-specified as age, 
gender, ethnicity / race, body mass index (BMI) or weight, renal 
status or creatinine clearance, blood pressure, diabetes mellitus, 
hypertension, previous thrombotic event, liver disease, chronic heart 
failure, cancer, pregnancy, intervention dose, average TTR in the 
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warfarin group, and summary assessment of risk of bias for each 
outcome.  
Clinically relevant factors for AF trials were CHADS2, CHADS2 
VASC, HAS-BLED, history of previous stroke or TIA and previous 
MI.  
It is expected that investigation of between-study variation using 
these characteristics could not be studied in most cases due to the 
lack of multiple trials of the same pairwise comparison, although 
some sensitivity analyses for the review of stroke prevention in 
patients with AF could be conducted. 
 
7.5.6.3 Investigation of inconsistency 
The validity of a NMA depends on the assumption that there is no 
effect modification of the pairwise intervention effects or, that the 
prevalence of effect modifiers is similar in the different studies. For a 
clinical and epidemiological judgement of the plausibility of this 
assumption an assessment was undertaken to determine whether 
or not the trials were similar in ways that might modify treatment 
effect, based on the pre-specified list of potential effect modifiers 
(see section 7.5.6.2).  
Direct and indirect estimates generated from the analysis will be 
presented for comparison. The extent of the disagreement between 
the direct and indirect estimates can be used as a local measure of 
inconsistency for that comparison. [Note that for the vast majority of 
comparisons there was either only direct evidence or only indirect 
evidence, so that the NMA estimates correspond to one of these]  
 
7.6 Data Extraction  
A bespoke database was created using Microsoft Access (Microsoft® 
Office Access 2003, Microsoft Corporation) to ensure that data 
extraction was undertaken in a systematic manner. The process of 
data extraction is described in section 10.4 (Appendix IV) and section 
10.5 (Appendix V).  
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7.7 Protocol (Cost-Effectiveness Analysis) 
The following section was led by the health economics working group 
with input from the clinical team in identifying key assumptions and 
conditions.  
 
7.7.1 Research Questions 
The clinical and health economics working groups of the project 
board had particular interest in identifying the answer to the following 
question: “What is the most cost-effective first-line anticoagulant 
in the prevention of ischaemic stroke in patients with AF?” 
The aim was to evaluate cost-effectiveness from an NHS perspective. 
Costs and outcomes were to be modelled over the expected lifetime 
of patients. The models were designed to synthesise evidence on a 
number of parameters [e.g. incidence of ischaemic stroke, relative 
treatment efficacy, adverse events (AEs), costs, etc.] in order to 
estimate the relative cost-effectiveness of treatment options. The 
‘model inputs’ are based on a variety of evidence sources. These 
include routine data on drug costs and observational studies of the 
long-term costs and quality of life (i.e. utilities) in AF. 
The AF model was constructed in R version 3.02 (The R Foundation 
for Statistical Computing, Vienna, Austria)(249) and performed by the 
health economics team with input from the clinical team. All NMA 
were conducted in WinBUGs.(58) 
 
7.7.2 Patient Population 
The clinical team considered patients with non-valvular AF who were 
eligible for anticoagulation. No distinction was made between 
paroxysmal, persistent and permanent AF. The RCTs identified in the 
systematic review did not distinguish between AF type; however, 
patients with paroxysmal AF are less likely to be included in RCTs 
than those with other AF types. The results from the cost-
effectiveness analysis are therefore most applicable to patients with 
persistent and permanent AF.  
The patients considered by the model were those receiving first-line 
anticoagulation at the age of 70 years, based on the mean age 
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observed in the RCTs identified in the systematic review [mean age 
70 years, standard deviation (SD) 8 years], and consider costs and 
benefits over a lifetime. As assumption of a 60:40 split in favour of 
males was made, as indicated by recruitment into the RCTs. 
7.7.3 Interventions 
The first-line treatments for AF included within the cost-effectiveness 
analysis (CEA), alongside their standard or licensed doses, are listed 
in Table 32. To ensure relevance to the NHS, only licensed 
treatments and doses within the UK were included within the analysis. 
Although a few small RCTs have compared betrixaban with warfarin 
in AF, there was not enough evidence to include it in the economic 
model. Standard of care for patients with AF, before the introduction 
of NOACs, was warfarin, and remains the comparator.(250) 
The clinical team (based on current practice) agreed that treatment 
switching may occur as a result of treatment failure, indicated by 
ischaemic stroke or serious AEs, such as intracranial haemorrhage 
(ICH). It was also agreed that for patients on warfarin as first-line 
treatment, the only second-line intervention available was assumed to 
be no treatment. In practice this would mean that for patients on a 
NOAC first-line treatment, second-line treatment may be either 
warfarin or no treatment, with no treatment being the only third-line 
option. These rules are illustrated in Figure 52, where the events that 
may lead to treatment switching are indicated. 
 
7.7.4 Outcomes  
Results on total costs and quality-adjusted life-years (QALYs) are 
presented, both discounted at 3.5%, as agreed by the clinical and 
health economics teams. This discount is made on the basis that 
future costs and benefits will be valued less by society in the future 
than the value at present day. The use of a uniform rather than 
differential (or variable) discount over a future time period as well as 
the value of 3.5% is commonly used for economic modelling in 
developed countries such as the UK and USA. These modelling 
terms are currently used by NICE as part of their Technology 
Appraisal program, based on the recommendations of the UK 
Treasury.(251)  
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The health economics team undertook probabilistic analyses, for 
which model parameters are given probability distributions to reflect 
uncertainty in their values.(252) The results are summarised with the 
expected costs, expected QALYs and expected net monetary benefit 
(NMB) for a range of willingness to pay per additional QALY gained 
(where expected values are an average over the joint distribution of 
the model parameters). The outcomes are aligned with NICE’s 
willingness-to-pay threshold of £20,000–30,000 per QALY.(72)  
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Table 32: First-line NOAC and licensed doses  (used to inform the CEA); Source – 
BNF 67 (229) 
Intervention Dose / Target INR Time on 
treatment 
Apixaban 2.5mg twice daily (elderly) 
5mg twice daily 
Lifetime 
Dabigatran 110mg twice daily (elderly) 
150mg twice daily 
Lifetime 
Rivaroxaban 20mg once daily Lifetime 
Warfarin Variable dose to INR 2-3 Lifetime 
 
 
 
 
 
Figure 52: Treatment strategies and switching / discontinuation rules (events that may 
lead to treatment switching are indicated next to the arrows) 
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7.7.4.1 AF Model Structure 
[This section of the research project was performed by the health 
economics team and is therefore included for information only] 
The discrete-time Markov multistate model structure (see Figure 53) 
used a cycle length of 3 months, as in other recently published 
models.(253-255) The model was run for a cohort starting at age 70 
years using a lifetime time horizon with a cut-off at 100 years. 
Patients were initially assigned to first-line treatment, which may be 
warfarin or a NOAC. There is a probability of switching to another 
therapy or discontinuing treatment entirely (see Figure 52). 
Each of the treatment strategies has the same model structure but 
with different costs, utilities and event probabilities. From any state, 
a patient can have a clinically relevant (extracranial) bleed, an ICH, 
an ischaemic stroke, a MI, a TIA, a SE, can discontinue or switch 
treatment because of these events or die. These events are similar 
to those used in earlier published models.(255, 256) The primary 
difference to previous models is that this analysis does not 
distinguish between minor and major ischaemic stroke, as there was 
limited evidence from the RCTs to estimate the relative rates of 
these events. Non-clinically relevant minor bleed events were also 
not included as it is assumed that this will not have a significant 
impact on costs, quality of life or future risks. As in most previous 
models, memory states are used to record a history of the most 
important previous events. 
The model assumes that SE and TIA have only short-term effects 
on future risks, costs and utilities, whereas ischaemic stroke, ICH, 
other CRB and MI have long-term consequences that must be 
modelled. Up to four major events are therefore recorded and 
assumed to affect future risks, costs and utilities. For example, 
patients with MI + ICH will have different risks, costs and utilities to 
patients with MI or ICH alone. Unlike the Wisloff 2013 model,(257) 
the current model does not distinguish between bleed locations, 
such as gastrointestinal and other types of bleed. Based on 
agreement from the clinical team members, it was assumed that the 
greatest impact on risks, costs and effects is captured by the broad 
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definition of ‘clinically relevant bleeds’, as reported in the RCTs. In 
total, the current model has 17 states, including a well state (‘AF 
Well’) and death.  
At any cycle, patients can switch treatments to second-line or no 
treatment. All adverse health events increase the probability of 
treatment switching. An ICH is assumed to always lead to treatment 
switching. Patients are assumed to always switch treatment from 
dabigatran to warfarin if they experience a MI as a result of recent 
findings suggesting a link between dabigatran and MI risk.(258) 
Whether or not patients switch treatment after an ischaemic stroke 
depends on whether it was due to treatment failure or non-
compliance. It was assumed that this was due to treatment failure 
but that only a proportion of patients will switch treatment following 
an ischaemic stroke. 
In the Markov model, future state transitions depend only on the 
current state in which the patient is (and not past history). However, 
the age of the cohort will increase with each cycle and mortality risk 
increases accordingly, based on general population life tables. 
There is no available evidence to suggest treatment effects change 
with age or that they depend on event history. The model therefore 
makes the assumption that treatment effects are independent of age 
and event history. 
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Figure 53: Markov model for AF. Patients can experience transient events (TIA or SE) but stay in the same health state, with possibly 
changed treatment, thereafter; (B) other clinically relevant bleed; (S) ischaemic stroke 
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7.7.5 Inputs for the CEA model for AF 
7.7.5.1 Cost of Pharmacotherapy 
[Guidance on the inputs for the following section of the research 
project was provided by me to the health economics team] 
To ensure relevance to the NHS the costs of medicines were based 
on the current version of the British National Formulary (BNF) at the 
time, March 2014, edition 67.(229) The most economical pack sizes 
were used to inform on the price. Although in practice various areas 
of the NHS receive medicines at discounted prices against the BNF 
reference cost (particular in secondary care), these discounts are 
confidential and are not usually applicable in the primary care 
setting where the majority of prescribing and supply of these 
medicines for AF is delivered. As these are all under patent the 
validity of the model will hold true for a number of years. 
Edoxaban does not currently have a list price within the UK, 
therefore for the base case analysis it was assumed that it would be 
price matched to dabigatran. As all of the NOACs are taken orally, it 
was assumed that there are no administration or monitoring costs. 
This follows the costing report in AF of Ali et al.(259) Average drug 
and monitoring cost of warfarin comes from a costing report by 
NICE68 and is cited in the study by Kansal et al.(255)  
The unit costs of drugs are assumed to be fixed as they are known, 
so that point estimates, rather than distributions, were entered into 
the models. Given that the administration and monitoring costs of 
warfarin are variable (dependant on setting and level of monitoring 
required) and therefore present a level of uncertainty, in the 
absence of other information a uniform distribution was assumed 
ranging from 50% to 150% of the costs specified within the NICE 
costing report.(243) A sensitivity analysis for the assumed cost of 
warfarin monitoring was also performed.  
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Table 33: Drug dose, duration and costs for the prevention of stroke in AF 
Intervention Dose 
per day 
(mg) 
Mg per 
tablet 
No. 
in 
pack 
Cost 
(£) per 
pack 
Cost 
(£) per 
day 
Administration 
cost (£) 
Cost (£) per 
3-month 
cycle AF 
model 
Apixaban 10 
5 
5 
2.5 
56 
60 
61.50 
65.90 
2.20 
2.20 
0.00 
0.00 
200.42 
200.44 
Dabigatran 300 
220 
150 
110 
60 
60 
65.90 
65.90 
2.20 
2.20 
0.00 
0.00 
200.44 
200.44 
Rivaroxaban 20 20 60 210.00 2.10 0.00 191.63 
Warfarin Variable Variable 100 Variable Variable sensitive 105.13* 
* Values were inflated from the 2013-14 Office for National Statistics (ONS) Consumer Price Inflation Index 
for Medical Services (DKC3) and placed in a uniform distribution ~(52.57, 157.70) and (210.26, 630.79) on 
the cost per 3-month and annual cycles, respectively.(260)  
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7.7.5.2 Cost of Atrial Fibrillation and Anticoagulant-related events 
(Acute Phase)  
All costs of acute and chronic care were inflated to 2013–14 values 
using the Office for National Statistics (ONS) Consumer Price 
Inflation Index for Medical Services (DKC3).(261) Acute 
management costs for SE, MI, TIA, and CRB come from the 2012–
13 NHS reference costs.(262) The reference costs for MI account 
for only direct hospitalisation; we assumed that total costs would be 
double this amount to account for follow-up costs.(263) Acute 
management costs for ischaemic stroke and ICH come from a study 
of patients with AF on a UK stroke registry.(264) The health 
economics team assumed a normal distribution for the mean acute 
costs, with SDs defined by the standard errors of the source data. 
 
7.7.5.3 Cost of Atrial Fibrillation and Anticoagulant-related events 
(Chronic Phase)  
Long-term management costs of stroke (ischaemic stroke or ICH) 
also come from the UK stroke registry (264). This registry stratified 
the severity of ischaemic strokes by disability (non-disabling, 
moderately disabling, totally disabling); their annual costs and SDs 
were averaged, weighted by the number of events. As in the study 
by Kansal et al.,(255) the same cost for ICH as for ischaemic stroke 
were assumed. Normal distributions are assumed, with SDs defined 
by the standard errors of the source data. 
 
7.7.5.4 Utilities  
The AF model used utility weights combined with survival to 
estimate QALYs. Utility weights are anchored at 1 (best health) and 
0 (as bad as death), such that a year spent in an intermediate health 
state with a utility weight of 0.5 would be considered equivalent to 6 
months in the best health state with a utility value of 1. The models 
have a number of acute health events that affect patients for a short 
period, followed by a partial or full recovery and a number of chronic 
health states from which patients do not recover.  
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Utilities were identified from a previous NICE technology appraisal 
submission on rivaroxaban (253). The rivaroxaban technology 
appraisal submission conducted a systematic literature search for 
evidence on EQ-5D (European Quality of Life-5 Dimensions) utility 
index in health states related to AF. 
 
7.8 Findings (Quantitative Analysis: Stroke prevention in AF) 
7.8.1 Systematic Review 
A total of 1,852 records were identified from the various databases for 
the systematic review of stroke prevention in AF (see Figure 54). 
Twenty-three completed eligible RCTs were identified for inclusion in 
the review, with a total of 41 associated references for these trials. No 
ongoing trials were identified. A summary of the characteristics of the 
23 trials is presented in Table 34.  
Twenty of the trials were of multicentre design; two trials were 
conducted in two centres; and one trial was conduction in only one 
centre. The majority of the multicentre trials were conducted across 
several countries in North and South America, Europe, Asia, Russia 
and Israel, Australia and South Africa. The two-centre trials were 
conducted in one country: one in China and the other in Denmark. 
The single-centre trial was conducted in Denmark. Sixteen of the 
trials were Phase III studies and seven were Phase II studies. The 
number of patients randomised across the 23 trials ranged from 75 to 
21,105, with a total of 94,656 patients, of whom 97% (91,333) were 
from the Phase III studies. Thirteen studies: six Phase III and seven 
Phase II studies examined a NOAC. Four studies examined 
edoxaban, three each examined apixaban and dabigatran, two 
examined rivaroxaban and one examined betrixaban. 
Eligibility criteria for patient participation were similar across studies: 
all patients having non-valvular AF, whether new or existing, and 
including paroxysmal, persistent or permanent types. Diagnosis of AF 
was predominantly by electrocardiography. In a few cases, Holter 
recording, pacemaker or other intracardiac recording was used. This 
was important in reducing heterogeneity and the basis of using a 
fixed-effect model for the meta-analysis.  
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The mean age of included patients was reported in only 61% of the 
studies and this ranged from 63.3 to 81.5 years. The percentage of 
male patients was reported in 78% of the studies, and this varied 
significantly across the studies, ranging from 44.9% to 82.9%. Mean 
BMI was not often reported and ranged from 24.4 to 30.5 kg/m2. 
Percentage of patients with previous stroke, hypertension and chronic 
heart failure varied significantly across the studies, ranging from 5% 
to 63.8%, from 38% to 93.7%, and from 0% to 100%, respectively. 
Bleeding risk among patients was assessed predominantly with the 
CHADS2 scoring system. 
Warfarin was examined in all but two of the 23 of the included 
studies, against a NOAC in 12 studies, and against aspirin in nine 
studies. Standard intensity warfarin (INR 2–3) was examined by all of 
the studies, although in a few studies the warfarin arm was a mixture 
of low intensity (INR < 2) and standard intensity, in unknown 
proportions. Across all of the studies, mean TTR for warfarin ranged 
from 45.1% to 83% of the treatment duration. One study(265) 
compared both low intensity warfarin (INR < 2) and standard intensity 
(INR 2.5–3.5) dicoumarol with aspirin, but the mean TTR was not 
reported for the standard intensity dicoumarol arm. The doses of 
NOACs examined were edoxaban 30 mg, 45 mg, and 60 mg once 
daily and 30 mg and 60 mg twice daily; apixaban 2.5 mg and 5 mg 
twice daily; dabigatran 50 mg, 110 mg, 150 mg and 300 mg twice 
daily; rivaroxaban 15 mg and 20 mg once daily; and betrixaban 40 
mg, 60 mg and 80 mg once daily. Examined aspirin dosages ranged 
from 75 mg to 325 mg once daily. 
Treatment duration in the edoxaban and dabigatran studies was 
predominantly 3 months, although one study reported mean 
treatment durations of 24 months and another reported a median 
treatment duration of 29.8 months. Mean treatment duration for 
apixaban studies ranged from 13.1 to 21.6 months and one study 
reported 3 months’ treatment duration. The two studies on 
rivaroxaban reported 30 months’ treatment duration and a mean 
treatment duration of 19.4 months, respectively. Mean treatment 
duration 4.9 months was reported in the betrixaban study. Treatment 
duration was similar for each comparator in almost all the NOAC 
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studies. Reported efficacy and safety outcome types were similar 
across studies and these were reported at the end of the treatment 
periods. All 23 studies reported data on stroke, 15 studies reported 
data on MI, 18 studies reported data on major bleeding, 12 studies 
reported data on CRB, and 18 studies reported data on all-cause 
mortality.  
Fifteen of the 23 studies, including all the NOAC studies, were 
sponsored by pharmaceutical companies. Six studies were funded by 
grants from medical research bodies although two of these grants 
contained contributions from a pharmaceutical company. Sponsor 
detail was not reported in two studies. In most of the pharmaceutical 
company sponsored studies, the sponsor(s) had influence on the 
study design, data management and analysis. 
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Figure 54: The PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) flow diagram of studies identified from the systematic review for 
inclusion in the meta-analysis for stroke prevention in AF 
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 Table 34: Characteristics of randomised controlled trials of NOACs included in the quantitative analysis of stroke prevention in AF 
 Study (centre 
type) [countries] 
Study type, Sponsor 
(Sponsor 
involvement) 
Age, 
eligibility 
(mean age, 
years) [% 
male] 
AF type No. 
randomised 
Interventions 
compared 
Treatment 
duration 
(months) 
Mean 
TTR 
(INR), 
% 
Outcomes Time of 
outcome 
assessment 
(months) 
ACTIVE W (265)  
 
(Multi-centre)  
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, Asia 
and South Africa] 
Phase III 
 
Sanofi Aventis and 
Bristol Myers Squibb 
 
(The sponsor 
contributed to the 
study design ‘but had 
no role in data 
collection, data 
analysis, data 
interpretation, 
or writing of the 
report’) 
 
≥ 18  
(70.2)  
 
[66.1] 
Non-
valvular 
 
ECG 
diagnosed 
6,706 Antiplatelet:  
 
1. Clopidogrel 
75mg + aspirin 
75-100mg once 
daily 
 
Warfarin: 
 
2. INR 2-3 (an 
equivalent VKA 
may have been 
used) 
Not stated 63.8 Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, MI 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, fatal 
bleeding, death (all 
causes) 
15.4 
AFASAK (266) 
 
(Two centres) 
 
[Denmark] 
 
Phase III 
 
NycoMed AS; Henrik 
Henriksen’s 
Foundation; Kathrine 
and Vigo Skovgaard’s 
Foundation; and 
Danish Medical 
Research Foundation 
 
(not stated) 
≥ 18  
(74.2)  
 
[53.6] 
Chronic 
non-
valvular 
 
ECG 
diagnosed 
1,007 Warfarin: 
 
1. INR 2-3 
 
Antiplatelet: 
 
2. Aspirin 75mg 
daily 
 
3. Placebo once 
daily 
 
24 73 Efficacy: all stroke, 
fatal stroke, minor 
ischaemic stroke, 
TIA 
 
Safety: bleeding, 
death (all causes) 
24 
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AFASAK II (267) 
 
(Single centre) 
 
[Denmark] 
 
Phase III 
 
Danish Heart 
Foundation; NycoMed 
DAK; DuPont 
Pharma; Danish 
Foundation for 
Medical Research; 
other non-industry 
funders 
 
(not stated) 
≥ 18  
(74.2)  
 
[60] 
Chronic 
non-
valvular 
 
ECG 
diagnosed 
677 Warfarin: 
 
1. 1.25mg/day 
fixed dose 
 
2. 1.25mg/day 
fixed dose plus 
aspirin 
300mg/day 
 
3. INR 2-3 
 
Antiplatelet: 
 
4. Aspirin 300mg 
daily 
 
42 73 Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, fatal stroke, 
stroke or SE, TIA, MI 
 
Safety: major 
bleeding, minor 
bleeding, intracranial 
bleeding, death (all 
causes) 
42 
AF-ASA-VKA-
CHINA (268) 
 
(Two centres) 
 
[China] 
Phase III 
 
Grant from talent pool 
subject of Shanghai 
Shi Dong Hospital 
 
(not applicable) 
≥ 80  
(NR)  
 
[NR] 
Persistent 
and 
permanent 
non-
valvular 
 
Confirmed 
by the case 
history and 
ECG 
110 Warfarin: 
 
1. INR 1.6-2.5 
 
Antiplatelet: 
 
2. Aspirin 100mg 
daily 
 
24 NR Efficacy: stroke or 
SE, ischaemic 
stroke, MI 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, fatal 
bleeding, death (all 
causes) 
1, 6, 12, 18, 
24 
AF-DABIG-VKA-
JAPAN (269) 
 
(Multi-centre) 
 
[Japan] 
Phase II 
 
Boehringer Ingelheim 
 
(The sponsor was 
involved in the trial) 
≥ 20  
(NR)  
 
[NR] 
Paroxysmal 
persistent 
or 
permanent 
non-
valvular 
 
ECG 
diagnosed 
174 Dabigatran: 
 
1. 110mg bd 
 
2. 150mg bd 
 
Warfarin: 
 
3. INR 2-3 (INR ≥ 
1.6 to ≤ 2.6 in ≥ 
70 years) 
 
3 NR Efficacy: stroke or 
SE 
 
Safety: all bleeding, 
major bleeding, 
composite CRB 
3 
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AF-EDOX-VKA-
ASIA (270) 
 
(Multi-centre) 
 
[Taiwan, South 
Korea, Hong 
Kong and 
Singapore] 
Phase II 
 
Daiichi Sanyo Co. 
 
(The sponsor ‘had 
influence on the study 
design, data 
management and 
analysis, and key 
decisions’) 
18-80  
(65.1) 
 
[65.4] 
Non-
valvular 
 
ECG 
diagnosed 
 
CHADS2 ≥ 
1 
235 Edoxaban: 
 
1. 30mg daily 
 
2. 60mg daily 
 
Warfarin: 
 
3. INR 2-3 
 
3 
(edoxaban) 
 
6 (warfarin) 
45.1 Efficacy: stroke or 
SE 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, 
CRNM bleeding 
3 
AF-EDOX-VKA-
JAPAN (271) 
 
(Multi-centre) 
 
[Japan] 
Phase II 
 
Daiichi Sanyo Co. 
 
(The sponsor ‘had 
input on the study 
design and data 
analysis and 
interpretation of the 
results, and wrote he 
clinical study report’) 
≥ 20 
(NR) 
 
[NR] 
Non-
valvular 
 
ECG 
diagnosed 
 
CHADS2 ≥ 
1 
536 Edoxaban: 
 
1. 30mg daily 
 
2. 45mg daily  
 
3. 60mg daily 
 
Warfarin: 
 
4. INR 2-3 
 
3 83 (≥ 
70 
years)  
 
73 (< 
70 
years)  
Efficacy: stroke or 
SE 
 
Safety: all bleeding, 
major bleeding, 
CRNM bleeding, 
composite CRB 
3 
AF-EDOX-VKA-
MULTI (272) 
 
(Multi-centre) 
 
[North America, 
Chile, Europe and 
Russia] 
Phase II 
 
Daiichi Sanyo Co. 
 
(not clear) 
18-85 
(65.1) 
 
[62.1] 
Persistent 
non-
valvular 
 
ECG 
diagnosed 
 
CHADS2 ≤ 
2 
 
1,146 Edoxaban: 
 
1. 30mg daily 
 
2. 65mg daily  
 
3. 30mg bd 
 
4. 60mg bd 
 
Warfarin: 
 
5. INR 2-3 
 
3 49.7 Efficacy: stroke or 
SE, MI, hospital 
admission 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, 
CRNM bleeding, 
composite CRB, 
death 
(cardiovascular) 
3 
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AF-VKA-ASA-
CHINA (273) 
 
(Multi-centre) 
 
[China] 
 
Phase III 
 
10
th
 National Five-
Year Project of China 
 
(not applicable) 
50-80 
(NR) 
 
[NR] 
Non-
valvular 
 
Diagnosis 
based on 
medical 
history, 
ECG and / 
or Holter 
recordings 
690 Warfarin: 
 
1. INR 2.1-2.5 
 
2. INR 1.6-2.0  
 
Antiplatelet: 
 
3. Aspirin 200mg 
daily 
 
24 
(mean 15) 
NR Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, TIA 
 
Safety: major 
bleeding,  minor 
bleeding, CRNM 
bleeding, composite 
CRB, death 
(cardiovascular) 
24 
ARISTOTLE 
(274-284) 
 
(Multi-centre) 
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, Asia 
and South Africa] 
Phase III 
 
Bristol-Myers Squibb 
and Pfizer 
 
(The trial was 
designed in 
conjunction with the 
Sponsors and ‘the 
primary analyses 
were performed both 
at BMS and the Duke 
Clinical Research 
Institute’) 
 
≥ 18 
(median 
70) 
 
[64.7] 
Non-
valvular or 
flutter 
 
ECG 
diagnosed 
18,201 Apixaban: 
 
1. 5mg bd  
 
(2.5mg bd in 
participants with 
more than one of 
≥ 80 years, ≤ 
60kg, serum 
creatinine level of 
≥ 1.5mg/dL) 
 
Warfarin: 
 
2. INR 2-3  
 
21.6 
(median) 
62.2 Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, stroke or SE, 
MI 
 
Safety: all bleeding, 
major bleeding, 
composite CRB, 
intracranial bleeding, 
death (all causes) 
21.6 
(median for 
intracranial 
bleeding) 
ARISTOTLE-J 
(285) 
 
(Multi-centre) 
 
[Japan] 
Phase II 
 
Pfizer and Bristol-
Myers Squibb 
 
(not clear) 
≥ 20  
(70.3) 
 
[82.9] 
Non-
valvular 
 
Diagnosis 
based on 
ECG, 
Holter 
recroding 
or 
intracardiac 
electrogram 
222 Apixaban: 
 
1. 2.5mg bd 
 
2. 5mg bd  
 
Warfarin: 
 
3. INR 2-3 (INR 
2-2.6 in ≥ 70 
years) 
 
3 60 Efficacy: stroke or 
SE, ischaemic 
stroke, TIA 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, 
CRNM bleeding, 
composite CRB, 
death (all causes) 
3 
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AVERROES 
(270, 275, 276, 
286) 
 
(Multi-centre) 
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, Asia 
and South Africa] 
 
Phase III 
 
Bristol-Myers Squibb 
and Pfizer 
 
(The Sponsors was 
involved in the 
design, data 
collection and 
analysis)  
≥ 50  
(70) 
 
[58.5] 
Non-
valvular 
 
ECG 
diagnosed 
5,599 Apixaban: 
 
1. 5mg bd 
 
(2.5mg bd if > 80 
years or ≤ 60kg / 
renal status)  
 
Antiplatelet 
(Aspirin): 
 
2. 81-324mg 
daily 
 
13.1 
(median) 
NR Efficacy: all stroke, 
stroke or SE, 
ischaemic stroke, 
haemorrhagic 
stroke, MI 
 
Safety: major 
bleeding, minor 
bleeding, CRNM 
bleeding, intracranial 
bleeding, fatal 
bleeding, death 
(cardiovascular), 
death (all causes) 
13.1 
(median) 
BAFTA (286) 
 
(Multi-centre) 
 
[UK] 
 
Phase III 
 
The Medical 
Research Council UK 
and supported by 
MidRec and the 
Primary Care 
Research Trust 
 
(The Sponsors had 
no direct role in study 
design, data 
collection, analysis or 
interpretation, writing 
the report, or decision 
to submit for 
publication) 
≥ 75  
(81.5) 
 
[54.6] 
Non-
valvular or 
atrial flutter 
 
ECG 
diagnosed 
973 Antiplatelet 
(Aspirin): 
 
1. 75mg daily 
 
Warfarin: 
 
2. INR 2-3 
 
32.4 
(mean) 
67 Efficacy: all stroke, 
MI 
 
Safety: major 
bleeding, death (all 
causes) 
32.4  
(mean) 
Chinese ATAFS 
(287) 
 
(Multi-centre) 
 
[China] 
 
Phase III 
 
(not disclosed) 
40-80 
(63.3) 
 
[59.7] 
Non-
valvular 
704 Antiplatelet 
(Aspirin): 
 
1. 150-160mg 
daily 
 
Warfarin: 
 
2. INR 2-3 (INR 
1.6-2.5 in > 75 
years) 
 
NR NR Efficacy: all stroke 
 
Safety: death (all 
causes) 
19  
(median) 
 
[range 2-24] 
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ENGAGE AF-
TIMI-48 (288, 
289) 
 
(Multi-centre) 
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, Asia 
and South Africa] 
 
Phase III 
 
Daichii Sankyo 
Pharma Development 
 
(not clear) 
≥ 21 
(NR) 
 
[61.9] 
Non-
valvular 
 
ECG 
diagnosed 
 
CHADS2 ≥ 
2 
 
21,105 Edoxaban: 
 
1. 30mg daily 
 
2. 60mg daily  
 
(half dose where 
creatinine 
clearance is 30-
50 ml/min, ≤ 
60kg, or 
concomitant use 
of verapamil or 
quinidine or 
dronedarone) 
 
Warfarin: 
 
3. INR 2-3 
 
29.8 
(median) 
64.9 Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, fatal stroke, 
stroke or SE, MI 
 
Safety: major 
bleeding, minor 
bleeding, fatal 
bleeding, intracranial 
bleeding, CRNM 
bleeding, composite 
CRB, death 
(cardiovascular), 
death (all causes) 
29.8 
(median) 
EXPLORE-Xa 
(279) 
 
(Multi-centre) 
 
[USA, Canada 
and Germany] 
 
Phase II 
 
Portolo 
Pharmaceuticals, 
South San Francisco 
 
(not stated) 
≥ 18  
(73) 
 
[66.5] 
New or 
existing 
non-
valvular or 
atrial flutter 
 
Diagnosis 
based on 
ECG, 
Holter 
recroding, 
rhythm 
strip, 
pacemaker 
or other 
intracardiac 
reading 
508 Betrixaban: 
 
1. 40mg daily 
 
2. 60mg daily  
 
3. 80mg daily 
 
Warfarin: 
 
4. INR 2-3 
 
4.9  
(mean) 
63.4 Efficacy: all stroke 
 
Safety: all bleeding, 
major bleeding, 
minor bleeding, 
CRNM bleeding, 
composite CRB, 
death (all causes) 
4.9  
(mean) 
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J-ROCKET AF 
(290) 
 
(Multi-centre) 
 
[Japan] 
 
Phase III 
 
Bayer Yakuhin Ltd 
 
(The funder was 
‘responsible for trial 
design and study data 
collection’) 
≥ 20  
(71.1) 
 
[80.6] 
Non-
valvular 
 
ECG 
diagnosed 
1,280 Rivaroxaban: 
 
1. 15mg daily 
(10mg daily if 
creatinine 
clearance 30-49 
ml/min) 
 
Warfarin: 
 
2. INR 2-3 (INR 
1.6-2.6 in ≥ 70 
years) 
 
30 65 Efficacy: all stroke, 
ischaemic stroke, 
haemorrhagic 
stroke, stroke or SE, 
MI 
 
Safety: composite 
CRB, death 
(cardiovascular), 
death (all causes) 
30 
PATAF (265)  
 
(Multi-centre) 
 
[Netherlands] 
 
Phase III 
 
Prevention fund 
(grant 002817010), 
Zorgonder-Zoek, 
Netherlands 
 
(not stated) 
≥ 60  
(74.8) 
 
[44.9] 
Chronic or 
intermittent 
 
ECG 
diagnosed 
729 Warfarin: 
 
1. INR < 2 
 
2. INR 2.5-3.5 
 
(some patients 
received other 
coumarins – 
pheonprocoumon 
or 
acenocoumarol)  
 
Antiplatelet 
(Aspirin): 
 
3. 150mg daily 
 
32.4 
(mean) 
NR Efficacy: all stroke, 
ischaemic stroke, 
arterial event 
 
Safety: death 
(cardiovascular), 
death (all causes) 
32.4 
(mean) 
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PETRO (291) 
 
(Multi-centre) 
 
[USA, Denmark, 
Netherlands and 
Sweden] 
 
 
Phase II 
 
Boehinger Ingelheim 
 
(the funder ‘was 
responsible for the 
statistical analysis 
conducted according 
to a prospectively 
designed plan 
approved by the 
steering committee’) 
≥ 18 
(69.5) 
 
[81.9] 
Permanent, 
persistent 
and 
paroxysmal 
non-
valvular 
with 
coronary 
arterial 
disease 
 
Diagnosis 
not 
explained 
502 Dabigatran: 
 
1. 50mg bd 
 
2. 50mg (+ 
aspirin 81mg) bd 
 
3. 50mg (+ 
aspirin 325mg) 
bd 
 
4. 150mg bd 
 
5. 150mg (+ 
aspirin 81mg) bd 
 
6. 150mg (+ 
aspirin 325mg) 
bd 
 
7. 300mg bd  
 
8. 300mg (+ 
aspirin 81mg) bd 
 
9. 300mg (+ 
aspirin 325mg) 
bd 
 
Warfarin: 
 
10. INR 2-3 
 
3 57.2 Efficacy: stroke or 
SE 
 
Safety: all bleeding, 
major bleeding, 
composite CRB 
3 
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RE-LY (292, 293) 
 
(Multi-centre) 
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, Asia 
and South Africa] 
 
 
Phase III 
 
Boehinger Ingelheim 
 
(the Sponsor 
contributed to the 
design, conduct, and 
reporting of the study) 
≥ 18 
(71) 
 
[63.6] 
Non-
valvular 
 
ECG 
diagnosed 
 
Mean 
CHADS2 = 
2.1 
 
18,113 Dabigatran: 
 
1. 110mg bd 
 
2. 150mg bd 
 
Warfarin: 
 
10. INR 2-3 
 
24 
(mean) 
64 Efficacy: stroke or 
SE, ischaemic 
stroke, 
haemorrhagic 
stroke, MI, PE, 
hospital admission 
 
Safety: major 
bleeding, minor 
bleeding, intracranial 
bleeding, 
extracranial minor 
bleeding, death 
(cardiovascular), 
death (all causes) 
 
24 
(mean) 
ROCKET-AF 
(294-297) 
 
(Multi-centre) 
 
[North and South 
America, Europe, 
Russia, Israel, 
Australia, New 
Zealand, Asia and 
South Africa] 
 
Phase III 
 
Johnson & Johnson, 
Bayer 
 
(the Sponsor was not 
involved in the 
coordination of the 
trial, data 
management or 
analyses) 
≥ 18 
(median 
73) 
 
[60.3] 
Non-
valvular 
 
ECG 
diagnosed 
 
Mean 
CHADS2 ≥ 
2 
 
14,264 Rivaroxaban: 
 
1. 20mg daily 
(15mg daily if 
creatinine 
clearance 30-49 
ml/min) 
 
Warfarin: 
 
2. INR 2-3 
19.4  
(median) 
55 Efficacy: all stroke, 
stroke or SE, MI 
 
Safety: major 
bleeding, CRNM 
bleeding, composite 
CRB, fatal bleeding, 
intracranial bleeding, 
death (all causes) 
 
19.4 
(median) 
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SPAF II (298) 
 
(Multi-centre) 
 
[USA] 
 
Phase III 
 
The Division of Stroke 
an Trauma, National 
Institute of 
Neurological 
Disorders and Stroke 
 
(not clear) 
Not clear 
(NR) 
 
[NR] 
Non-
valvular 
1,100 Warfarin: 
 
1. INR 2-4.5 (in < 
75 years) 
 
2. INR 2-4.5 (in > 
75 years)  
 
Antiplatelet 
(Aspirin): 
 
3. 325mg daily 
(in < 75 years) 
 
4. 325mg daily 
(in > 75 years) 
 
37.2  
(mean for 
< 75 years) 
 
24 
(mean for 
> 75 years) 
NR Efficacy: stroke or 
SE, ischaemic 
stroke, MI, TIA 
 
Safety: intracranial 
bleeding, death (all 
causes) 
 
27.6 
(mean) 
WASPO (299) 
 
(Multi-centre) 
 
[UK] 
 
 
Phase III 
 
Not declared 
>80 and 
<90  
(median 
83) 
[47] 
Permanent 
non-
valvular 
75 Warfarin: 
 
1. INR 2-3 
 
Antiplatelet 
(Aspirin): 
 
2. 300mg daily  
 
12 69.2 Efficacy: all stroke, 
TIA 
 
Safety: death (all 
causes) 
 
12 
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7.8.2 Time in Therapeutic Range (TTR) for warfarin 
Table 35 indicates what the comparator intervention, target INR and 
(where reported) mean TTR was for the studies that included a 
warfarin intervention arm. Sixteen (73%) of these studies reported 
mean TTR, which varied substantially (from 45.1% to 83%) between 
studies.  
 
Table 35: Mean TTR for warfarin in stroke prevention in AF 
Study Interventions that were compared 
with warfarin 
Warfarin INR Mean 
TTR 
(INR), % 
ACTIVE W (265)  Antiplatelet (clopidogrel 75mg + 
(aspirin 75-100mg) once daily 
2-3 63.8 
AFASAK (266) Aspirin 75mg once daily,  
Placebo once daily 
2-3 73 
AFASAK II (267) Aspirin 300mg once daily 2-3 73 
AF-ASA-VKA-CHINA (268) Aspirin 100mg once daily 1.6-2.5 NR 
AF-DABIG-VKA-JAPAN (269) Dabigatran 110mg or 150mg twice 
daily 
2-3  
(≥1.6 to ≤2.6 in ≥ 
70 years) 
NR 
AF-EDOX-VKA-ASIA (270) Edoxaban 30mg or 60mg once daily 2-3 45.1 
AF-EDOX-VKA-JAPAN (271) Edoxaban 30mg, 45mg or 60mg once 
daily 
2-3  
(1.6 to 2.6 in ≥ 70 
years) 
83 (≥ 70) 
73 (< 70) 
AF-EDOX-VKA-MULTI (272) Edoxaban 30mg or 60mg once daily,  
Edoxaban 30mg or 60mg twice daily 
2-3 49.7 
AF-VKA-ASA-CHINA (273) Aspirin 200mg once daily 2.1-2.5 NR 
ARISTOTLE (274-284) Apixaban 5mg twice daily 2-3 62.2 
ARISTOTLE-J (285) Apixaban 2.5mg or 5mg twice daily 2-3  
(2 to 2.6 in ≥ 70 
years) 
60 
BAFTA (286) Aspirin 75mg once daily 2-3 67 
Chinese ATAFS (287) Aspirin 150mg to 160mg once daily 2-3  
(1.6 to 2.6 in > 75 
years) 
NR 
ENGAGE AF-TIMI-48 (288, 289) Edoxaban 30mg or 60mg once daily 2-3 64.9 
EXPLORE-Xa (279) Betrixaban 40mg or 60mg or 80mg 
once daily 
2-3 63.4 
J-ROCKET AF (290) Rivaroxaban 15mg once daily 2-3  
(1.6 to 2.6 in ≥ 70 
years) 
65 
PATAF (265)  Aspirin 150mg once daily 2.5-3.5 NR 
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Study Interventions that were compared 
with warfarin 
Warfarin INR Mean 
TTR 
(INR), % 
PETRO (291) Dabigatran 50mg, or 50mg + aspirin 
81mg, or 50mg + aspirin 325mg, or 
150mg, or 150mg + aspirin 81mg, or 
150mg + aspirin 325mg, or 300mg, or 
300mg + aspirin 81mg, or 300mg + 
aspirin 325mg (all twice daily) 
2-3 57.2 
RE-LY (292, 293) Dabigatran 110mg or 150mg twice 
daily 
2-3 64 
ROCKET-AF (294-297) Rivaroxaban 20mg once daily 2-3 55 
SPAF II (298) Aspirin 325mg once daily 2-4.5 NR 
WASPO (299) Aspirin 300mg once daily 2-3 69.2 
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7.8.3 Risk of bias 
A risk of bias assessment was undertaken for each included study 
using the Cochrane assessment tool against each domain (see Table 
36). Each assessment was made by me and verified by Mr Okoli.    
 
The assessments ranged from low to high risk of bias; however it was 
difficult to judge some studies as a result of inaccessibility of study 
protocols. For most of the outcomes assessed in the studies, all 
randomised patients were either accounted for in the analysis, or in 
some cases a small number of patients were unaccounted for with 
reasons judged likely to be unrelated to the outcome.  
 
The majority of the studies were judged to be at low risk of bias for 
allocation concealment and incomplete outcome data. The majority of 
the studies were judged to be at a low or unclear risk of bias for 
sequence generation. Randomisation sequence across the low-risk 
studies was predominantly computerised. Most studies were also 
judged to be of low risk of bias for blinding of outcome assessment, 
with three studies judged to be at high risk of bias in this domain. 
Fourteen studies were judged to be at high risk of bias for blinding of 
participants and personnel, mainly because they were open-label. 
Where studies were blinded for different dose groups of a novel 
anticoagulant, but not in the comparison of these to warfarin, we 
assigned a high risk of bias because the principal contribution of the 
study to our analyses would be the comparison of warfarin with the 
licensed dose of the anticoagulant. Risk-of-bias judgements for 
studies contributing to analyses of each outcome are presented 
graphically in the sections that follow. 
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Table 36: Risk of bias assessment for NOAC studies included within the analysis of stroke prevention in AF 
Study Sequence generation 
(SG) 
Allocation 
concealment (AC) 
Blinding of 
participants and 
personnel (BPP) 
Blinding of outcome 
assessments (BOA) 
Incomplete outcome 
data (IOD) 
Selective Reporting 
(SR) 
ACTIVE W (265)  L  
‘Patients were 
randomised by an 
automated central 
interactive voice-
response system, in a 1 
: 1 ratio, to receive 
clopidogrel plus aspirin 
or oral anticoagulation 
therapy’ 
L 
By means of a central, 
interactive, voice 
response system 
H 
Treatment was open, 
with blinded 
adjudication of 
outcomes 
L 
‘All major outcomes 
were adjudicated by a 
blinded committee and 
all strokes were 
adjudicated by 
neurologists’ 
 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
AFASAK (266) L 
‘The patients were 
randomised to receive 
warfarin, aspirin 75 mg 
od, or placebo. They 
received consecutive 
numbers, which 
corresponded to 
numbered packages 
containing the study 
medication, the order of 
which was determined 
by computer generated 
randomisation’ 
 
L 
‘They received 
consecutive numbers, 
which corresponded to 
numbered packages 
containing the study 
medication, the order 
of which was 
determined by 
computer-generated 
randomisation’ 
 
H 
‘Warfarin was given 
openly, but the aspirin 
and placebo arms were 
double-blind. The 
warfarin tablets looked 
different from the aspirin 
and placebo tablets, 
which were 
indistinguishable’  
U 
No information on 
blinding of outcome 
assessors 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
AFASAK II (267) 
 
L 
‘According to a computer-
generated sequence, 
eligible participants were 
assigned to daily 
treatment’ 
U 
No information on 
whether or note and 
how treatment was 
concealed 
H 
This was an open-label 
study 
L 
‘All end-points were 
evaluated by an end-
point committee 
unaware of treatment 
status. The committee 
consisted of two 
neurologists and two 
cardiologists’ 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
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AF-ASA-VKA-
CHINA (268) 
 
U 
‘A total of 110 patients 
met the inclusion criteria 
and were randomly 
divided into warfarin 
study and aspirin control 
groups’ 
H 
No information and no 
indication of treatment 
allocation concealment 
H 
No details, but 
monitoring of INR 
implies the study was 
open-label 
H 
No information, and no 
indication of blinding 
outcome assessors 
L 
Small numbers of 
missing data in the two 
randomised arms and 
the number missing in 
each arm seem to be 
balanced; also with 
comparable reasons 
for the missing data. It 
is unlikely that missing 
data are related to the 
outcome 
U 
Study protocol not 
found 
AF-DABIG-VKA-
JAPAN (269) 
 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
U 
Available information is 
from a preliminary 
report and not a 
published article. 
Therefore no 
information to enable 
judgement 
AF-EDOX-VKA-
ASIA (270) 
 
L 
‘Via Fisher Automated 
Clinical Trials System 
(FACTS)’ 
L 
‘Block randomisation 
was done by FACTS; 
Cenduit produced the 
randomisation 
schedule; which was 
kept confidential until 
the end of the study’ 
H 
‘The investigator, 
patients and sponsor 
were blinded to the 
dose of edoxaban, but 
not to the identity of 
edoxaban and 
warfarin’ 
L 
‘The independent CEC, 
which was blinded to 
study treatments, 
adjudicated all bleeding 
events and 
thromboembolic events 
(stroke, systemic 
embolic event, MI) 
during the study’ 
L 
Only one person with 
missing outcome data 
L 
All outcomes are 
reported as per 
protocol 
AF-EDOX-VKA-
JAPAN (271) 
 
L 
‘Treatment was 
assigned using the 
biased coin method’ 
U 
‘Patients were 
randomised using the 
specifications of 
dynamic allocation 
procedures’ 
H 
‘This was a 
multicentre, 
randomised, dose-
ranging study of 
edoxaban (double-
blind to dose) and 
open-label warfarin’ 
U 
‘Secondary endpoints 
consisted of 
thromboembolic 
events including stroke 
assessed by an 
independent Event 
Assessment 
Committee’ 
L 
Some missing data 
with reasons although 
the number of missing 
data are quite minimal 
and unlikely related to 
the outcome 
L 
All outcomes are 
reported as per 
protocol 
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AF-EDOX-VKA-
MULTI (272) 
 
 
L 
‘The randomisation 
schedule was generated 
by an independent 
biostatistician who was 
not part of the study 
team. Using a central, 
interactive, automated 
telephone system’ 
L 
‘Using a central, 
interactive, automated 
telephone system, 
eligible patients who 
provided written 
informed consent were 
randomly allocated’  
H 
‘The study was double 
blind with respect to 
edoxaban dose, but 
open-label for 
randomisation between 
edoxaban and warfarin’  
U 
For efficacy outcomes: 
‘Stroke confirmed by 
CT or sutopsy; TIA 
confirmed by a 
neurologist’ 
 
L 
For safety outcomes: 
‘Suspected bleeding 
events were assessed 
by an independent 
blinded adjudication 
committee’ 
L 
Very minimal missing 
data in three arms (1 
patient); otherwise all 
patients were 
accounted for in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
AF-VKA-ASA-
CHINA (273) 
 
 
L 
‘Stratified block 
randomisation’ 
U 
Not enough 
information: ‘After 
giving signed informed 
consent, patients who 
met the inclusion criteria 
were enrolled and 
randomly allocated to 
one of three study 
groups according to a 
stratified block 
randomisation’  
U 
‘In the warfarin groups, 
an initial dose of 1–
3mg/day of warfarin was 
prescribed after the 
baseline INR values 
were measured’. ‘In the 
aspirin group, a fixed 
dose of 200 mg/day of 
aspirin was used’ 
U 
Not clearly described 
‘Medical records from 
all potential events were 
further reviewed by a 
five-physician clinical 
outcomes committee’ 
U 
A total of 96 patients 
withdrew from the study 
after randomisation but 
the remaining 690 
patients were all 
included in the analysis 
 
 
U 
Study protocol not 
found 
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ARISTOTLE 
(274-284) 
 
L 
’Randomisation was 
stratified according to 
whether patients had 
received warfarin 
previously 
and according to clinical 
site’ 
 
U 
‘An algorithm 
was provided to 
manage temporary 
discontinuations of the 
study drug around the 
time of interventional 
procedures while 
maintaining 
concealment 
of the group 
assignments’ 
 
L 
‘An algorithm was 
provided to manage 
temporary 
discontinuations of the 
study drug around the 
time of interventional 
procedures while 
maintaining 
concealment 
of the group 
assignments’ 
 
L 
‘The primary and 
secondary efficacy and 
safety outcomes were 
adjudicated on the basis 
of prespecified criteria 
by a clinical events 
committee whose 
members were not 
aware 
of study-group 
assignments’ 
 
L 
For efficacy outcomes: 
No missing outcome 
data 
 
U 
For bleeding 
outcomes: Some 
missing outcome data 
with reason which 
appear to be similar in 
the groups. However, it 
is not clear whether or 
not the reasons for the 
missing outcome data 
are related to the 
outcome 
L 
All outcomes are 
reported as per 
protocol 
ARISTOTLE-J 
(285) 
 
 
U 
‘Patients were 
randomised in a 1 : 1 : 1. 
The 
randomisation 
assignment 
method (Pocock et al.) 
incorporated trial site and 
warfarin status 
(experienced 
or naive) as factors’ 
 
U 
Not enough 
information. ‘On the first 
day of study drug dosing 
(week 0), patients were 
randomised in a 1 : 1 : 1 
fashion’ 
 
H 
‘This was a 
randomised, partially 
blinded study comparing 
high double-blinded 
doses of apixaban with 
open-label warfarin’ 
 
L 
‘An independent 
blinded end-point 
committee adjudicated 
all reported bleeding 
and efficacy events’ 
 
L 
Few outcome missing 
data with reasons. 
Reasons 
almost balance out 
across 
groups and it is unlikely 
that the reasons are 
related to the outcome 
 
L 
All outcomes are 
reported as per 
protocol 
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AVERROES 
(270, 275, 276, 
286) 
 
L 
‘Randomisation was 
performed with the use 
of a 24-hour central, 
computerised, automated 
voice-response system’ 
L 
‘Randomisation was 
performed with the use 
of a 24-hour central, 
computerised, 
automated 
voice-response system’ 
L 
‘In keeping with the 
double-dummy design, 
patients who were 
assigned to receive 
apixaban also received 
an 
aspirin placebo, and 
those 
assigned to receive 
aspirin 
also received an 
apixaban 
placebo’ 
L 
‘All outcomes were 
adjudicated by a 
committee whose 
members were unaware 
of the treatment 
assignments. Cases of 
stroke and ICH were 
adjudicated by 
neurologists’ 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
BAFTA (286) 
 
 
L 
‘Within each stratum, 
randomly permuted 
blocks 
of eight were generated 
to 
produce allocation tables’ 
 
L 
‘Primary care 
physicians telephoned 
for 
the treatment allocation 
when they had an 
eligible 
patient’ 
 
H 
‘BAFTA was a 
prospective randomised 
open-label trial’ 
 
L 
‘Clinical details on 
possible primary events 
were sent to two 
independent 
neurologists 
who were blind to 
treatment allocation’ 
 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
Chinese ATAFS 
(287) 
 
U 
‘The randomised study 
of efficacy and safety of 
antithrombotic therapy in 
non-valvular AF: warfarin 
compared with aspirin’ 
 
U 
No information on 
whether or not and how 
treatment allocation was 
concealed 
 
U 
No information on 
whether or not 
participants and 
personnel were blinded 
to treatment 
 
U 
No information on 
blinding of outcome 
assessors 
 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
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ENGAGE AF-
TIMI-48 (288, 
289) 
 
L 
‘Randomisation was 
performed with the use 
of a central, 24-hour, 
interactive, computerised 
response system’ 
 
L 
‘Randomisation was 
performed with the use 
of a central, 24-hour, 
interactive, 
computerised 
response system’ 
 
L 
‘Each patient received 
two sets of study drugs: 
either active edoxaban 
and a placebo matching 
warfarin, or a placebo 
matching edoxaban and 
active warfarin’ 
 
L 
‘An independent 
clinical end-point 
committee, whose 
members were unaware 
of the study assignment, 
adjudicated all deaths 
and suspected 
cerebrovascular events, 
systemic embolic 
events, MIs, bleeding 
events, and hepatic 
events’ 
 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
EXPLORE-Xa 
(279) 
 
U 
‘Patients were 
randomly assigned 
(1 : 1 : 1 : 1 allocation) 
A dynamic randomisation 
was used to assign and 
balance patients by 
country, 
concurrent aspirin use, 
and 
antecedent warfarin’ 
 
U 
Not enough 
information. ‘Patients 
were randomly assigned 
(1 : 1 : 1 : 1 allocation)’ 
 
H 
‘Assignment to 
betrixaban or warfarin 
was not blinded, but the 
betrixaban dose was 
double-blinded’ 
 
L 
‘An independent 
adjudicator, blinded to 
treatment groups, 
adjudicated all major 
bleeds, CRNM bleeds, 
strokes, MI, other SE 
and 
deaths’ 
 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
J-ROCKET AF 
(290) 
L 
No details provided but 
assumed to follow robust 
design of the ROCKET 
AF 
study 
 
L 
No details provided 
but assumed to follow 
robust design of the 
ROCKET AF study 
 
L 
‘As part of the 
doubledummy 
design, patients in 
each group also 
received a 
tablet of either titrated 
warfarin placebo or 
rivaroxaban placebo, 
respectively, to preserve 
the treatment blind’ 
 
U 
‘An independent 
clinical end-point 
committee adjudicated 
all 
suspected strokes, SEs, 
MIs, deaths, and 
bleeding 
events contributing to 
the 
prespecified end-points’ 
 
L 
Very few missing 
data. Unlikely to 
influence 
the true outcome 
 
L 
All outcomes are 
reported as per 
protocol 
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PATAF (265)  
 
L 
Randomisation was 
computer generated 
 
L 
‘Patients eligible for 
standard anticoagulation 
were randomly assigned 
(centrally, by telephone)’ 
 
U 
‘Patients were single 
blinded for the two 
intensities of 
anticoagulant’ 
 
L 
‘End-point 
ascertainments were 
blinded for treatment. 
Events were 
independently 
reviewed by two 
members 
of the (neurological, 
cardiological, vascular, 
ophthalmological and 
internal medicine) event 
committees (or three, in 
case of disagreement’ 
 
U 
Some missing data 
and although with 
similar 
reasons across groups, 
the missing numbers in 
the groups are not 
balanced 
 
U 
Study protocol not 
found 
PETRO (291) 
 
 
 
U 
‘The PETRO study was 
a randomised trial of 
patients with AF at high 
risk for thromboembolic 
events’ 
U 
Not enough 
information 
‘Randomisation was 
stratified in the ratio 
6 : 9 : 9 : 4 (50-, 150- 
and 
300-mg dabigatran, and 
warfarin, respectively)’ 
 
H 
‘The trial was 
doubleblind 
with respect to 
dabigatran dose but 
open-label for 
concomitant aspirin 
treatment’ 
 
U 
For efficacy outcome: 
No information but the 
outcomes may have 
been blinded 
 
L 
For bleeding outcome: 
‘An independent 
adjudication committee 
blinded to treatment 
evaluated all bleeding 
events’ 
 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
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RE-LY (292, 293) 
 
 
L 
‘After providing written 
informed consent, all trial 
participants were 
randomly 
assigned to receive one 
of 
two doses of dabigatran, 
or to receive warfarin, 
by means of a central, 
interactive, automated 
telephone system’ 
 
L 
By means of a central, 
interactive, automated 
telephone system 
 
H 
‘RE-LY was a 
randomised trial 
designed 
to compare two fixed 
doses of dabigatran, 
each 
administered in a 
blinded 
manner, with open-label 
use of warfarin’ 
 
L 
‘Each primary and 
secondary outcome 
event 
was adjudicated by two 
independent 
investigators 
who were unaware of 
the 
treatment assignments’ 
 
L 
All patients were 
included in the 
analyses 
L 
All outcomes are 
reported as per 
protocol 
ROCKET-AF 
(294-297) 
 
L 
’Randomisation was 
performed with the use of 
a central 24-hour, 
computerised, automated 
voice-response system’  
L 
’Randomisation was 
performed with the use 
of a central 24-hour, 
computerised, 
automated voice-
response system’  
L 
‘Patients were randomly 
assigned to receive 
fixed-dose rivaroxaban 
or adjusted dose 
warfarin. Patients in 
each group also 
received a placebo 
tablet in order to 
maintain blinding’  
U 
‘An independent clinical 
end-point committee 
applied protocol 
definitions to adjudicate 
all suspected cases of 
stroke, SE, MI, death 
and bleeding events that 
contributed to the pre-
specified end-points’  
L 
Very few missing 
outcome data but with 
reasons which appear to 
balance across groups. 
Unlikely that the missing 
data are related to the 
true outcome  
L 
All outcomes are 
reported as per 
protocol 
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SPAF II (298) 
 
 
L 
Randomisation was 
done separately at each 
clinical site by computer 
U 
Not enough 
information: ‘The 
randomisation 
sequence could not be 
pre-reviewed’ 
H 
Both patient and 
investigator were 
aware of therapy 
assignment 
L 
For neurological 
efficacy outcomes: ‘All 
suspected neurological 
events were evaluated 
by an on-site study 
neurologist and verified 
by an events committee; 
evaluation was based 
on review of original 
medical records, from 
which information about 
therapy assignment had 
been removed’ 
 
H 
For safety outcomes: 
No details on blinding 
of outcome 
assessment 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
WASPO (299) 
 
 
 
L 
‘Randomisation was 
prepared from a 
computer-generated 
random numbers 
programme’ 
L 
‘Randomisation was 
performed by opening 
sealed envelopes in 
numbered sequence’ 
H 
This was an open-label 
study 
H 
No information and no 
indication of blinding 
L 
All patients were 
included in the 
analyses 
U 
Study protocol not 
found 
 
(H) high risk; (L) low risk; (U) unclear risk 
Quotations from the publication articles are denoted by inverted commas 
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7.8.4 Results on clinical effectiveness and safety 
The 27 different interventions considered in the 23 trials are listed in 
Table 37 and Table 38, which show the number of patients analysed 
and the number of outcome events for each outcome reported in 
each trial. NMAs were performed for seven outcomes:  
 stroke or SE 
 ischaemic stroke 
 MI 
 major bleeding 
 CRB 
 intracranial bleeding  
 all-cause mortality 
Arms that were considered not to provide any evidence of interest to 
inform health decisions in the UK were excluded from the analyses. 
Specifically, the warfarin arm with INR range 1.6–2 from the AF-VKA-
ASA-CHINA trial (273), the warfarin arm with INR range of < 2 from 
PATAF (265), the placebo arm from AFASAK (266), and the two 
warfarin arms with a fixed daily dose from AFASAK II (267) were 
excluded.  
Two independent nodes were defined for warfarin interventions, 
labelled as ‘warfarin (INR 2–3)’ and ‘warfarin (INR 3–4)’, respectively. 
The first of these formed the reference treatment across all networks 
in the AF review as this is the UK standard of care. The ‘warfarin (INR 
2–3)’ node included the trials with a therapeutic INR range of 2–3 
(e.g. ACTIVE W (300), AFASAK (266)), as well as some interventions 
with an INR range of 2.5–3.5 (AF-EDOX-VKA-ASIA (270) and PATAF 
(265)) or 2.0–4.5 (SPAF II (298)). In other trials the INR range for 
some patients in the warfarin arm was sub-therapeutic (< 2.0), so that 
the total INR range was 1.6–3.0. These interventions were excluded 
from the main analysis, but merged with the INR 2–3 node in a 
sensitivity analysis. As a consequence, there were three two-arm 
trials (J-ROCKET AF (290), Chinese ATAFS (287) and AF-ASA-VKA-
CHINA (268)) that were included only in sensitivity analyses. 
Two independent nodes were defined for antiplatelet interventions 
(‘aspirin’ or ‘aspirin plus clopidogrel’), using the cut-off point of 150 
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mg, with the understanding that daily doses above that were 
appropriate for stroke prevention in AF, whereas lower doses were 
appropriate for secondary prevention of cardiovascular events. The 
dose range considered in the AVERROES trial (273, 301-303) (81–
324 mg od) was much wider than in any other trial, and we included 
this intervention in the lower-dose node (< 150 mg once daily) 
because patients from that study had received a low daily dose. As a 
sensitivity analysis, the AVERROES trial was excluded from the 
network. Finally, the main analysis used a binomial model, assuming 
equal follow-up times across arms within trials and ignoring some 
variations in how results were reported. A separate analysis was 
performed for all outcomes taking into account the differences in 
duration of follow-up within and between trials, and the differences in 
the definition of event used across trials (e.g. total number of events 
vs. first events only). 
Due to the scale of this project the results are presented as follows for 
each of the seven outcomes.  
 First, network plots are provided to illustrate the comparisons 
of interventions made in the different trials (see Figure 56 to 
Figure 64).  
 Second, efficacy and safety outcomes reported from the 
randomised controlled trials for stroke prevention in AF (see 
section 7.8.4.1 to 7.8.4.7).  
 Third, the risk-of-bias assessments are illustrated, specific to 
the outcome for each trial included in the network.  
 Fourth, results tables are presented for each intervention 
compared with the reference treatment (warfarin with a target 
INR range of 2–3).  
 Fifth, results tables are presented for pairwise comparisons 
among licensed doses of the NOACs. For both sets of results 
tables, posterior median ORs and 95% credible intervals from 
Bayesian fixed-effects analyses are shown, although the latter 
are referred to as CIs for convenience. In these tables results 
are presented separately for any available direct evidence, for 
any indirect comparisons that can be made (excluding the 
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direct evidence) and for the NMA (which combines the direct 
and the indirect evidence). Comparisons from the NMA with a 
ratio between interval limits of > 9 were considered 
‘imprecisely estimated’ and are presented at the bottom of 
each table (calculation of indirect evidence was not 
undertaken for imprecisely estimated comparisons).  
 Sixth, a summary of results across outcomes is provided, in 
the form of a ‘rank-o-gram’, which illustrates the probability 
that each treatment is best, second best, and so on, for each 
outcome (see section 7.8.5.1) 
 Lastly, forest plots of all contributing data, with ORs calculated 
using standard frequentist methods are presented in section 
(see section 10.6; Appendix VI: Forest Plots (stroke 
prevention in AF). 
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Table 37: List of interventions (for the NMA) examined by included randomised 
controlled trials in stroke prevention in AF 
 
NMA 
reference 
number 
Intervention 
1 Warfarin (INR 2-3) 
2 Warfarin (INR 1.6-3.0) 
3 Warfarin (INR 3-4) once daily 
4 Antiplatelet (<150mg once daily) 
5 Antiplatelet (≥150mg once daily) 
6 Dabigatran (50mg twice daily) + aspirin (81mg twice daily) 
7 Dabigatran (50mg twice daily) + aspirin (325mg twice daily) 
8 Dabigatran (150mg twice daily) + aspirin (81mg twice daily) 
9 Dabigatran (150mg twice daily) + aspirin (325mg twice daily) 
10 Dabigatran (300mg twice daily) + aspirin (81mg twice daily) 
11 Dabigatran (300mg twice daily) + aspirin (325mg twice daily) 
12 Apixaban (2.5mg twice daily) 
13 Apixaban (5mg twice daily) 
14 Dabigatran (50mg twice daily) 
15 Dabigatran (110mg twice daily) 
16 Dabigatran (150mg twice daily) 
17 Dabigatran (300mg twice daily) 
18 Betrixaban (40mg once daily) 
19 Betrixaban (60mg once daily) 
20 Betrixaban (80mg once daily) 
21 Edoxaban (30mg once daily) 
22 Edoxaban (45mg once daily) 
23 Edoxaban (60mg once daily) 
24 Edoxaban (30mg twice daily) 
25 Edoxaban (60mg twice daily) 
26 Rivaroxaban (15mg once daily) 
27 Rivaroxaban (20mg once daily) 
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Table 38: Summary of list of outcomes reported and patient numbers from the 
included randomised controlled trials in stroke prevention in AF 
 
 No. 
Studies 
No. 
patients 
No. 
events 
Transient ischemic attack (TIA) 6 3767 60 
All stroke 14 72149 2541 
Stroke or systemic embolism 16 90427 3161 
Ischemic stroke 8 50131 1406 
Minor ischemic stroke 1 1007 3 
Haemorrhagic stroke 7 49626 331 
Fatal stroke 4 23762 285 
Pulmonary embolism 1 18113 43 
Bleeding 14 28921 6225 
Major bleeding 12 43481 7627 
Minor bleeding 19 84736 4265 
Fatal bleeding 4 42069 214 
Extra-cranial minor bleeding 1 18113 956 
Intra-cranial bleeding 7 74265 722 
MI 12 89632 1345 
Hospital admission 2 19256 7211 
Death (cardiovascular) 6 47628 2766 
Death (all causes) 17 91867 6526 
Arterial event 2 909 13 
Clinically Relevant Non Major Bleed 10 38776 6045 
Composite Clinically relevant bleeding 12 58126 9293 
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Figure 56: NOAC systematic review – Atrial fibrillation network plot (simple) 
 
 
 
Figure 57: NOAC systematic review – Atrial fibrillation network plot (all stroke) 
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Figure 58: NOAC systematic review – Atrial fibrillation network plot (ischaemic stroke)  
 
 
 
Figure 59: NOAC systematic review – Atrial fibrillation network plot (haemorrhagic 
stroke) 
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Figure 60: NOAC systematic review – Atrial fibrillation network plot (all bleeding) 
 
 
 
Figure 61: NOAC systematic review – Atrial fibrillation network plot (major bleeding) 
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Figure 62: NOAC systematic review – Atrial fibrillation network plot (all death) 
 
 
 
Figure 63: NOAC systematic review – Atrial fibrillation network plot (CRNM bleeding) 
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Figure 64: NOAC systematic review – Atrial fibrillation network plot (composite 
clinically relevant bleeding) 
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Table 39: Efficacy outcomes reported from the randomised controlled trials (stroke prevention in AF): number of events for each outcome at 
trial level 
 
Study 
Study 
size 
TIA All 
stroke 
Stroke 
or SE 
Ischaemic 
stroke 
Minor 
ischaemic 
stoke 
Major 
ischaemic 
stroke 
Haemorrhagic 
stroke 
Fatal 
stroke 
PE MI Hospital 
admission 
ACTIVE W 
(265) 
6,706  159  132   20   59  
AF-ASA-VKA-
CHINA (268) 
101   18 14      5  
AF-DABIG-
VKA-JAPAN 
(269) 
166   1         
AF-EDOX-
VKA-ASIA 
(270) 
234   0         
AF-EDOX-
VKA-JAPAN 
(271) 
519   1         
AF-EDOX-
VKA-MULTI 
(272) 
1,143   11       5 12 
AF-VKA-ASA-
CHINA (273) 
440 13 10  9   1     
AFASAK (266) 671 2 20   1   4    
AFASAK II 
(267) 
339 3 19 22 8   2 2  8  
ARISTOTLE 
(274-284) 
18,140  449 477 337   118   192  
ARISTOTLE-J 
(285) 
218 1  3 1      0  
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AVERROES 
(270, 275, 276, 
286) 
5,599  154 164 128   15   52  
BAFTA (286) 973  94        30  
Chinese 
ATAFS (287) 
704  23          
ENGAGE AF-
TIMI-48 (288, 
289) 
21,026  958 1,016 804   169 239  443  
EXPLORE-Xa 
(279) 
508  2  2      0  
J-ROCKET AF 
(290) 
1,278  31 33 24   7   4  
PATAF (265) 272  7  7 2 5    5  
PETRO (291) 515   2         
RE-LY (292, 
293) 
18,113   519 389   71  43 270 7,199 
ROCKET-AF 
(294-297) 
14,236  405 575 310      227  
SPAF II (298) 1,100 25  67 63      34  
WASPO (299) 75 1 0          
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Table 40: Safety outcomes reported from the randomised controlled trials (stroke prevention in AF): number of events for each outcome at 
trial level 
 
Study 
Study 
size 
All 
bleeding 
Minor 
bleeding 
Major 
bleeding 
Fatal 
bleeding 
Extracranial 
minor 
bleeding 
Intracranial 
bleeding 
Arterial 
bleeding 
CRNM 
bleeding 
CRB Cardiovascular 
deaths 
All-
cause 
mortality 
ACTIVE W 
(265) 
6,706 1,199 1,049 194 18       317 
AF-ASA-VKA-
CHINA (268) 
101 14 9 3 2       4 
AF-DABIG-
VKA-JAPAN 
(269) 
166 45  3      14   
AF-EDOX-
VKA-ASIA 
(270) 
234 57 48 2     9 11   
AF-EDOX-
VKA-JAPAN 
(271) 
519 115  5     15 20   
AF-EDOX-
VKA-MULTI 
(272) 
1,143 114 52 13     49 62 8  
AF-VKA-ASA-
CHINA (273) 
440  25 8        11 
AFASAK 
(266) 
671 23          15 
AFASAK II 
(267) 
339  68 9   3     31 
ARISTOTLE 
(274-284) 
18,140 5,416  789   174   1,490  1,272 
ARISTOTLE-J 
(285) 
218 41 36 1     5 6  0 
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AVERROES 
(270, 275, 276, 
286) 
5,599  341 83 10  24  180 263 180 251 
BAFTA (286) 973   50        215 
Chinese 
ATAFS (287) 
704           12 
ENGAGE AF-
TIMI-48 (288, 
289) 
21,026  1,851 1,196 112  234  3,579 4,456 1,668 2,349 
EXPLORE-Xa 
(279) 
508 118 109 8     12 18  2 
J-ROCKET AF 
(290) 
1,278      15   262 8 12 
PATAF (265) 272       8   18 29 
PETRO (291) 515 88  4      36   
RE-LY (292, 
293) 
18,113  5,284 1,162  956 150    880 1,371 
ROCKET-AF 
(294-297) 
14,236   781 82  139  2,336 2,924  458 
SPAF II (298) 1,100      18     127 
WASPO (299) 75  10 3        3 
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7.8.4.1 Stroke or Systemic Embolism 
Sixteen studies reported the number of stroke or systemic 
embolism (SE) events, and the other seven trials reported the 
number of stroke events, so that the resulting network was based 
on data from all 23 trials, comparing a total of 26 interventions (see 
Figure 65).  
 
There were 3,217 stroke or SE events in total. Twenty studies 
were included in the main analysis, with the remaining three 
included only in sensitivity analyses. The thicker lines joining 
interventions, which mainly correspond with comparisons between 
licensed doses of NOACs and warfarin (INR 2–3) represent the 
larger (mainly Phase III) trials. Similarly, the larger green circles 
represent the interventions to which the largest number of patients 
were randomised. Importantly, there were no direct comparisons 
between different NOACs, although there were numerous 
comparisons between different doses of the same NOAC in mainly 
Phase II trials, and some such comparisons in larger trials. 
Therefore, comparisons between the effects of different NOACs 
need to be inferred from the network (indirect evidence). 
 
Table 41 shows risk-of-bias judgements for studies reporting 
stroke or SE. The studies were at mixed risks of bias: there were 
concerns about lack of blinding of participants for most trials, and 
about lack of allocation concealment and blinding of outcome 
assessment in some. 
 
Table 42 shows comparisons of licensed doses with warfarin (INR 
2–3), suggests that both low- and high-dose antiplatelet drugs 
increase the risk of stroke or SE compared with warfarin (INR 2–
3). Among NOACs, there was some evidence that apixaban [5 mg 
bd (bd)], dabigatran (150 mg bd), edoxaban (60 mg od) and 
rivaroxaban (20 mg od) reduce the risk of stroke or SE compared 
with warfarin (INR 2–3). Most other comparisons were imprecisely 
estimated. Comparisons among licensed doses of NOACs were 
almost all based on indirect evidence (see Table 43). Among the 
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comparisons that were not classified as imprecisely estimated, 
there was some evidence that edoxaban (60 mg once daily) and 
rivaroxaban (20 mg once daily) increase the risk of stroke or SE 
compared with dabigatran (150 mg twice daily). 
 
Results from a supplementary analysis taking into account the 
differences in duration of follow-up within and between trials, and 
the differences in the definition of event used across trials (e.g. 
total number of events vs. first events only), are presented in Table 
44 and Table 45. These values are very similar to those for ORs. 
 
As a post hoc sensitivity analysis, a fixed-effects meta-regression 
model was fitted using the mean TTR for warfarin patients (see 
Table 35) as a covariate and the mean log-odds ratio (log-OR) 
from each pairwise comparison (with warfarin as the reference 
category) as the response variable. There was little evidence of 
effect modification due to mean TTR (estimated coefficient 0.0021 
with 95% CI −0.07 to 0.08 per 1% increase). The model fit indices 
were very similar with and without the covariate. 
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Figure 65: Network plots for stroke or systemic embolism (stroke prevention in AF) [a represents excluded interventions 
that were included within the sensitivity analyses]
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Table 41: Trials included within the NMA and their risk of bias assessment for stroke 
or SE (stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
ACTIVE W (265) 1,4 + + - + + ? 
AFASAK (266) 1,4 + + - ? + ? 
AFASAK II (267) 1,5 + ? - + + ? 
AF-ASA-VKA-CHINA (268) 2,4 ? - - - + ? 
AF-DABIG-VKA-JAPAN (269) 2,15,16 ? ? ? ? ? ? 
AF-EDOX-VKA-ASIA (270) 1,21,23 + + - + + + 
AF-EDOX-VKA-JAPAN (271) 2,21,22,23 + ? - ? + + 
AF-EDOX-VKA-MULTI (272) 1,21,23,24,25 + + - ? + + 
AF-VKA-ASA-CHINA (273) 1,5 + ? ? ? ? ? 
ARISTOTLE (274-284) 1,13 + ? + + + + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
BAFTA (286) 1,4 + + - + + + 
Chinese ATAFS (287) 2,5 ? ? ? ? + ? 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
PATAF (265)  1,5 + + ? + ? + 
PETRO (291) 1,6,7,8,9,10,11,14,16,17 ? ? - ? + + 
RE-LY (292, 293) 1,15,16 + + - + + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
SPAF II (298) 1,5 + ? - + + ? 
WASPO (299) 1,5 + + - - + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 42: Results for stroke or SE (stroke prevention in AF); comparisons with 
warfarin (INR 2-3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) 1.99 (1.28 to 3.15) 1.88 (1.44 to 2.51) 
Antiplatelet (≥ 150mg daily) 1.61 (1.25 to 2.07) 1.61 (1.25 to 2.07) 
Apixaban (5mg bd) 0.79 (0.66 to 0.94) 0.79 (0.66 to 0.94) 
Dabigatran (110mg bd) 0.90 (0.74 to 1.10) 0.90 (0.74 to 1.10) 
Dabigatran (150mg bd) 0.65 (0.52 to 0.81) 0.65 (0.52 to 0.81) 
Edoxaban (30mg daily) 1.13 (0.97 to 1.32) 1.13 (0.97 to 1.32) 
Edoxaban (60mg daily) 0.86 (0.74 to 1.01) 0.86 (0.74 to 1.01) 
Rivaroxaban (20mg daily) 0.88 (0.74 to 1.03) 0.88 (0.74 to 1.03) 
 
Table 43: Results for stroke or SE (stroke prevention in AF); NOACs (licensed doses 
only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 0.82 (0.62 to 1.08) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.09 (0.87 to 1.39) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 1.11 (0.87 to 1.41) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 1.33 (1.02 to 1.75) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 1.35 (1.03 to 1.78) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 1.01 (0.80 to 1.27) 
 
Table 44: Results for stroke or SE (stroke prevention in AF); comparisons with 
warfarin (INR 2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Warfarin (INR 3-4) 0.58 (0.17 to 1.58) 
Antiplatelet (< 150mg daily) 1.82 (1.39 to 2.41) 
Antiplatelet (≥ 150mg daily) 1.58 (1.23 to 2.02) 
Apixaban (5mg bd) 0.79 (0.67 to 0.94) 
Dabigatran (110mg bd) 0.91 (0.75 to 1.11) 
Dabigatran (150mg bd) 0.66 (0.53 to 0.82) 
Edoxaban (30mg daily) 1.13 (0.98 to 1.31) 
Edoxaban (60mg daily) 0.87 (0.74 to 1.01) 
Rivaroxaban (20mg daily) 0.88 (0.75 to 1.03) 
 
Table 45: Results for stroke or SE (stroke prevention in AF); NOACs (licensed doses 
only) – sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 0.83 (0.63 to 1.10) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.10 (0.87 to 1.38) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 1.11 (0.88 to 1.40) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 1.32 (1.01 to 1.73) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 1.34 (1.02 to 1.76) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 1.01 (0.81 to 1.27) 
 
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 296 - 
 
7.8.4.2 Ischaemic Stroke 
Fourteen studies reported on 2,228 ischaemic stroke events, 
leading to a connected network comparing a total of 15 
interventions (see Figure 66). Twelve studies were included in the 
main analysis, with the remaining two included only in sensitivity 
analyses. The studies were at mixed risks of bias (see Table 46). 
There were concerns about lack of blinding of participants for most 
trials, and about lack of allocation concealment and blinding of 
outcome assessment in one trial (AF-ASA-VKA-CHINA,(268) only 
included in sensitivity analyses due to implementation of warfarin 
within non-standard INR range). 
 
Table 47 shows comparisons of all interventions with warfarin (INR 
2–3), suggests that both low- and high-dose antiplatelets increase 
the risk of ischaemic stroke compared with warfarin (INR 2–3). 
Among NOACs, there was some evidence that dabigatran (150 mg 
twice daily) reduces the risk of ischaemic stroke compared with 
warfarin, whereas edoxaban (30 mg once daily) increases that 
risk. There was little evidence that the risk of ischaemic stroke 
differed between licensed doses of NOACs (see Table 48). 
 
In a sensitivity analysis to take into account the differences in 
duration of follow-up, NMA results were as presented in Table 49 
and Table 50. These values are very similar to those for ORs. 
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Figure 66: Network plots for ischaemic stroke (stroke prevention in AF) [a represents 
excluded interventions that were included within the sensitivity analyses] 
  
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 298 - 
 
Table 46: Trials included within the NMA and their risk of bias assessment for 
ischaemic stroke (stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
ACTIVE W (265) 1,4 + + - + + ? 
AFASAK II (267) 1,5 + ? - + + ? 
AF-ASA-VKA-CHINA (268) 2,4 ? - - - + ? 
AF-VKA-ASA-CHINA (273) 1,5 + ? ? ? ? ? 
ARISTOTLE (274-284) 1,13 + ? + + + + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
PATAF (265)  1,5 + + ? + ? + 
RE-LY (292, 293) 1,15,16 + + - + + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
SPAF II (298) 1,5 + ? - + + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 47: Results for ischaemic stroke (stroke prevention in AF); comparisons with 
warfarin (INR 2-3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) --- 2.52 (1.62 to 3.99) 
Antiplatelet (≥ 150mg daily) 2.00 (1.51 to 2.67) 2.00 (1.51 to 2.67) 
Apixaban (5mg bd) 0.92 (0.74 to 1.14) 0.92 (0.74 to 1.14) 
Dabigatran (110mg bd) 1.14 (0.90 to 1.44) 1.14 (0.90 to 1.44) 
Dabigatran (150mg bd) 0.76 (0.58 to 0.98) 0.76 (0.58 to 0.98) 
Edoxaban (30mg daily) 1.44 (1.21 to 1.71) 1.44 (1.21 to 1.71) 
Edoxaban (60mg daily) 1.01 (0.84 to 1.21) 1.01 (0.84 to 1.21) 
Rivaroxaban (20mg daily) 0.93 (0.74 to 1.16) 0.93 (0.74 to 1.16) 
 
Table 48: Results for ischaemic stroke (stroke prevention in AF); NOACs (licensed 
doses only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 0.83 (0.59 to 1.16) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.10 (0.83 to 1.46) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 1.01 (0.74 to 1.38) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 1.33 (0.97 to 1.83) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 1.22 (0.87 to 1.73) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 0.92 (0.69 to 1.23) 
 
Table 49: Results for ischaemic stroke (stroke prevention in AF); comparisons with 
warfarin (INR 2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 2.46 (1.59 to 3.92) 
Antiplatelet (≥ 150mg daily) 1.94 (1.47 to 2.59) 
Apixaban (5mg bd) 0.92 (0.75 to 1.15) 
Dabigatran (110mg bd) 1.12 (0.89 to 1.42) 
Dabigatran (150mg bd) 0.76 (0.59 to 0.99) 
Edoxaban (30mg daily) 1.43 (1.22 to 1.69) 
Edoxaban (60mg daily) 1.01 (0.84 to 1.20) 
Rivaroxaban (20mg daily) 0.92 (0.74 to 1.15) 
 
Table 50: Results for ischaemic stroke (stroke prevention in AF); NOACs (licensed 
doses only) – sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 0.83 (0.59 to 1.15) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.09 (0.83 to 1.44) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 1.00 (0.73 to 1.35) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 1.32 (0.96 to 1.80) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 1.21 (0.86 to 1.70) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 0.92 (0.69 to 1.22) 
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7.8.4.3 Myocardial Infarction 
Fifteen studies reported 1,334 MI events, leading to a network of 
16 interventions (see Figure 67). Thirteen studies were included in 
the main analysis, with the other two included only in sensitivity 
analyses. The studies were at mixed risks of bias (see Table 51). 
There were concerns about lack of blinding of participants for most 
trials, and about lack of allocation concealment and blinding of 
outcome assessment in some. 
 
 
Table 52 shows weak evidence that dabigatran (110 mg twice 
daily), dabigatran (150 mg twice daily) and Edoxaban (30 mg once 
daily) increase the risk of MI compared with warfarin (INR 2–3), 
and weak evidence that rivaroxaban (20 mg once daily) decreases 
risk of MI compared with warfarin (INR 2–3). None of the 
interventions was superior or inferior to warfarin (INR 2–3). The 
pairwise comparisons of licensed NOACs, presented in Table 53, 
show weak evidence that dabigatran (150 mg twice daily ) 
increases the risk of MI compared with Apixaban (5 mg twice 
daily), and evidence that rivaroxaban (20 mg once daily) reduces 
the risk of MI compared with Dabigatran (150 mg twice daily). 
Results were similar in a sensitivity analysis, taking into account 
the differences in duration of follow-up within and between trials, 
and the differences in the definition of event used across trials 
(e.g. total number of events vs. first events only) (see Table 54 and 
Table 55).  
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Figure 67: Network plots for MI (stroke prevention in AF) [a represents excluded 
interventions that were included within the sensitivity analyses]  
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Table 51: Trials included within the NMA and their risk of bias assessment for MI 
(stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
ACTIVE W (265) 1,4 + + - + + ? 
AFASAK II (267) 1,5 + ? - + + ? 
AF-ASA-VKA-CHINA (268) 2,4 ? - - - + ? 
AF-EDOX-VKA-MULTI (272) 1,21,23,24,25 + + - ? + + 
ARISTOTLE (274-284) 1,13 + ? + + + + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
BAFTA (286) 1,4 + + - + + + 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
PATAF (265)  1,5 + + ? + ? + 
RE-LY (292, 293) 1,15,16 + + - + + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
SPAF II (298) 1,5 + ? - - + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 52: Results for MI (stroke prevention in AF), comparisons with warfarin (INR 2-
3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) 1.00 (0.47 to 2.10) 1.01 (0.64 to 1.61) 
Antiplatelet (≥ 150mg daily) 1.38 (0.94 to 2.03) 1.38 (0.94 to 2.03) 
Apixaban (5mg bd) 0.87 (0.66 to 1.15) 0.87 (0.66 to 1.15) 
Dabigatran (110mg bd) 1.32 (0.97 to 1.79) 1.32 (0.97 to 1.79) 
Dabigatran (150mg bd) 1.29 (0.96 to 1.75) 1.29 (0.96 to 1.75) 
Edoxaban (30mg daily) 1.22 (0.97 to 1.53) 1.22 (0.97 to 1.53) 
Edoxaban (60mg daily) 0.96 (0.75 to 1.22) 0.96 (0.75 to 1.22) 
Rivaroxaban (20mg daily) 0.80 (0.61 to 1.04) 0.80 (0.61 to 1.04) 
 
Table 53: Results for MI (stroke prevention in AF), NOACs (licensed doses only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 1.48 (0.98 to 2.22) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.10 (0.76 to 1.58) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 0.92 (0.63 to 1.34) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 0.74 (0.50 to 1.09) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 0.62 (0.41 to 0.93) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 0.84 (0.59 to 1.20) 
 
Table 54: Results for MI (stroke prevention in AF), comparisons with warfarin (INR 2-
3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 1.01 (0.64 to 1.61) 
Antiplatelet (≥ 150mg daily) 1.36 (0.93 to 2.01) 
Apixaban (5mg bd) 0.88 (0.67 to 1.16) 
Dabigatran (110mg bd) 1.31 (0.96 to 1.77) 
Dabigatran (150mg bd) 1.30 (0.96 to 1.77) 
Edoxaban (30mg daily) 1.22 (0.97 to 1.52) 
Edoxaban (60mg daily) 0.96 (0.76 to 1.22) 
Rivaroxaban (20mg daily) 0.80 (0.62 to 1.04) 
 
Table 55: Results for MI (stroke prevention in AF), NOACs (licensed doses only) – 
sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 1.48 (0.98 to 2.23) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.09 (0.76 to 1.57) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 0.91 (0.62 to 1.33) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 0.74 (0.49 to 1.08) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 0.62 (0.41 to 0.92) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 0.84 (0.59 to 1.19) 
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7.8.4.4 Major Bleeding 
Eighteen studies reporting 4,314 major bleeding events, leading to 
a network of 24 interventions (see Figure 68). Seventeen studies 
were included in the main analysis, with the remaining study 
included only in sensitivity analyses. These studies were at mixed 
risks of bias (see Table 56). There were concerns about lack of 
blinding of participants for most trials, and about lack of allocation 
concealment and blinding of outcome assessment in some. 
 
 
There was weak evidence that antiplatelet therapy (< 150 mg once 
daily) reduced major bleeding compared with warfarin (INR 2–3). 
There was evidence that apixaban (5 mg twice daily), dabigatran 
(110 mg twice daily), Edoxaban (30 mg once daily) and edoxaban 
(60 mg once daily) reduced major bleeding risk compared with 
warfarin (INR 2–3) (see Table 57). Comparisons among licensed 
doses of NOACs, presented in Table 58, suggest that Dabigatran 
(150 mg twice daily) increases risk of major bleeding compared 
with apixaban (5 mg twice daily), whereas rivaroxaban (20 mg 
once daily) increases risk of major bleeding compared with 
apixaban (5 mg twice daily) and edoxaban (60 mg once daily). 
 
In a sensitivity analysis to take into account the differences in 
duration of follow-up, NMA results were as presented in Table 59 
and Table 60, and show very similar results. Another sensitivity 
analysis involved fitting a fixed-effects meta-regression model 
using the mean TTR for warfarin patients (see Table 35) as a 
covariate and the mean log-OR from each pairwise comparison 
(with warfarin as the reference category) as the response variable. 
No evidence of an effect modification was found according to 
mean TTR (estimated coefficient 0.04 with 95% CI −0.03 to 0.12 
per 1% increase). The model fit indices yielded almost identical 
values for the models with and without the covariate. 
 
  
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 306 - 
 
 
 
Figure 68: Network plots for major bleeding (stroke prevention in AF) [a represents 
excluded interventions that were included within the sensitivity analyses] 
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Table 56: Trials included within the NMA and their risk of bias assessment for major 
bleeding (stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
ACTIVE W (265) 1,4 + + - + + ? 
AFASAK II (267) 1,5 + ? - + + ? 
AF-ASA-VKA-CHINA (268) 2,4 ? - - - + ? 
AF-DABIG-VKA-JAPAN (269) 2,15,16 ? ? ? ? ? ? 
AF-EDOX-VKA-ASIA (270) 1,21,23 + + - + + + 
AF-EDOX-VKA-JAPAN (271) 2,21,22,23 + ? - ? + + 
AF-EDOX-VKA-MULTI (272) 1,21,23,24,25 + + - + + + 
AF-VKA-ASA-CHINA (273) 1,5 + ? - ? ? ? 
ARISTOTLE (274-284) 1,13 + ? + + ? + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
BAFTA (286) 1,4 + + - + + + 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
PETRO (291) 1,6,7,8,9,10,11,14,16,17 ? ? - + + + 
RE-LY (292, 293) 1,15,16 + + - + + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
WASPO (299) 1,5 + + - - + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 57: Results for major bleeding (stroke prevention in AF), comparisons with 
warfarin (INR 2-3)  
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) 1.00 (0.56 to 1.77) 0.75 (0.52 to 1.06) 
Antiplatelet (≥ 150mg daily) 1.07 (0.82 to 1.42) 1.07 (0.82 to 1.42) 
Apixaban (5mg bd) 0.71 (0.61 to 0.81) 0.71 (0.61 to 0.81) 
Dabigatran (110mg bd) 0.80 (0.69 to 0.93) 0.80 (0.69 to 0.93) 
Dabigatran (150mg bd) 0.94 (0.81 to 1.08) 0.94 (0.81 to 1.08) 
Edoxaban (30mg daily) 0.46 (0.40 to 0.54) 0.46 (0.40 to 0.54) 
Edoxaban (60mg daily) 0.78 (0.69 to 0.90) 0.78 (0.69 to 0.90) 
Rivaroxaban (20mg daily) 1.03 (0.89 to 1.18) 1.03 (0.89 to 1.18) 
 
Table 58: Results for major bleeding (stroke prevention in AF), NOACs (licensed 
doses only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 1.33 (1.09 to 1.62) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.11 (0.92 to 1.35) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 1.45 (1.19 to 1.78) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 0.84 (0.69 to 1.02) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 1.10 (0.90 to 1.34) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 1.31 (1.07 to 1.59) 
 
Table 59: Results for major bleeding (stroke prevention in AF), comparisons with 
warfarin (INR 2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 0.76 (0.53 to 1.08) 
Antiplatelet (≥ 150mg daily) 1.07 (0.82 to 1.41) 
Apixaban (5mg bd) 0.72 (0.62 to 0.82) 
Dabigatran (110mg bd) 0.81 (0.70 to 0.93) 
Dabigatran (150mg bd) 0.94 (0.82 to 1.07) 
Edoxaban (30mg daily) 0.47 (0.41 to 0.55) 
Edoxaban (60mg daily) 0.79 (0.70 to 0.90) 
Rivaroxaban (20mg daily) 1.02 (0.89 to 1.18) 
 
Table 60: Results for major bleeding (stroke prevention in AF), NOACs (licensed 
doses only) – sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 1.31 (1.08 to 1.59) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.10 (0.91 to 1.33) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 1.43 (1.17 to 1.75) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 0.84 (0.70 to 1.02) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 1.09 (0.90 to 1.33) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 1.30 (1.07 to 1.57) 
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7.8.4.5 Clinically Relevant Bleeding 
Twelve studies reporting 9,556 clinically relevant bleeding (CRB) 
events, leading to a network of 23 interventions (see Figure 69). 
Eleven studies were included in the main analysis, with the 
remaining study included only in sensitivity analyses. These 
studies were at mixed risks of bias (see Table 61), the concerns 
being due to a lack of blinding of participants for most trials.  
 
Results presented in Table 62 suggest that antiplatelet therapy (< 
150 mg once daily) reduces CRB compared with warfarin (INR 2–
3). Note that the licensed dose for antiplatelet therapy for AF is ≥ 
150 mg once daily: no studies provided data for that dose for CRB. 
Among NOACs, there was evidence that apixaban (5 mg twice 
daily), edoxaban (30 mg once daily) and edoxaban (60 mg once 
daily) reduce CRB compared with warfarin (INR 2–3). However, 
edoxaban (30 mg twice daily) and edoxaban (60 mg twice daily) 
increased CRB compared with warfarin (INR 2–3). Among licensed 
NOACs (see Table 63), there was evidence that edoxaban (60 mg 
once daily) and rivaroxaban (20 mg once daily) increase CRB 
compared with apixaban (5 mg twice daily) and that rivaroxaban 
(20 mg once daily) increased CRB compared with edoxaban (60 
mg once daily).  
 
Results from a supplementary analysis of HRs rather than ORs 
show very similar results (see Table 64 and Table 65). 
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Figure 69: Network plots for CRB (stroke prevention in AF) [a represents excluded 
interventions that were included within the sensitivity analyses] 
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Table 61: Trials included within the NMA and their risk of bias assessment for CRB 
(stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
AF-DABIG-VKA-JAPAN (269) 2,15,16 ? ? ? ? ? ? 
AF-EDOX-VKA-ASIA (270) 1,21,23 + + - + + + 
AF-EDOX-VKA-JAPAN (271) 2,21,22,23 + ? - ? + + 
AF-EDOX-VKA-MULTI (272) 1,21,23,24,25 + + - + + + 
ARISTOTLE (274-284) 1,13 + ? + + ? + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
PETRO (291) 1,6,7,8,9,10,11,14,16,17 ? ? - + + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 62: Results for CRB (stroke prevention in AF), comparisons with warfarin (INR 
2-3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) --- 0.59 (0.45 to 0.77) 
Antiplatelet (≥ 150mg daily) 0.67 (0.60 to 0.75) 0.67 (0.60 to 0.75) 
Apixaban (5mg bd) 0.59 (0.54 to 0.64) 0.59 (0.54 to 0.64) 
Dabigatran (110mg bd) 1.09 (0.37 to 3.04) 1.09 (0.37 to 3.04) 
Dabigatran (150mg bd) 0.84 (0.77 to 0.90) 0.84 (0.77 to 0.90) 
Edoxaban (30mg daily) 1.97 (1.04 to 3.67) 1.97 (1.04 to 3.67) 
Edoxaban (60mg daily) 2.76 (1.46 to 5.17) 2.76 (1.46 to 5.17) 
Rivaroxaban (20mg daily) 1.03 (0.95 to 1.11) 1.03 (0.95 to 1.11) 
 
Table 63: Results for CRB (stroke prevention in AF), NOACs (licensed doses only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.24 (1.09 to 1.42) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 1.53 (1.33 to 1.75) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 1.23 (1.10 to 1.37) 
 
Table 64: Results for CRB (stroke prevention in AF), comparisons with warfarin (INR 
2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 0.59 (0.46 to 0.76) 
Apixaban (5mg bd) 0.67 (0.60 to 0.75) 
Edoxaban (30mg daily) 0.59 (0.55 to 0.64) 
Edoxaban (45mg daily) 1.09 (0.37 to 3.01) 
Edoxaban (60mg daily) 0.83 (0.77 to 0.90) 
Edoxaban (30mg bd) 1.98 (1.05 to 3.71) 
Edoxaban (60mg bd) 2.78 (1.46 to 5.20) 
Rivaroxaban (20mg daily) 1.03 (0.95 to 1.11) 
 
Table 65: Results for CRB (stroke prevention in AF), NOACs (licensed doses only) – 
sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.24 (1.09 to 1.42) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 1.53 (1.33 to 1.74) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 1.23 (1.10 to 1.37) 
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7.8.4.6 Intracranial Bleeding 
Eight studies reporting a total of 757 intracranial bleeds, leading to 
a network of 10 interventions (see Figure 70). Seven studies were 
included in the main analysis, with the remaining study included 
only in sensitivity analyses. These studies were at mixed risks of 
bias (see Table 66), the concerns being due to a lack of blinding of 
participants and, in one study, lack of blinding of outcome 
assessment. 
 
 
There was strong evidence that Apixaban (5mg twice daily), 
dabigatran (110mg twice daily), dabigatran (150mg twice daily), 
edoxaban (30mg once daily), edoxaban (60 mg once daily) and 
rivaroxaban (20 mg once daily) reduced risk of intracranial 
bleeding compared with warfarin (INR 2–3) (see Table 67). For 
each of these NOAC doses except rivaroxaban (20 mg once daily), 
the estimated reduction in risk was > 50%. There was weak 
evidence that risk of intracranial bleeding was increased for 
rivaroxaban (20 mg once daily) compared with apixaban (5 mg 
twice daily), dabigatran (150 mg twice daily) and edoxaban (60 mg 
once daily) (see Table 68). Analysing HRs rather than ORs led to 
similar results (see Table 69 and Table 70). 
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Figure 70: Network plots for intracranial bleeding (stroke prevention in AF) [a 
represents excluded interventions that were included within the sensitivity analyses] 
  
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 315 - 
 
Table 66: Trials included within the NMA and their risk of bias assessment for 
intracranial bleeding (stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
AFASAK II (267) 1,5 + ? - + + ? 
ARISTOTLE (274-284) 1,13 + ? + + ? + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
RE-LY (292, 293) 1,15,16 + + - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
ROCKET-AF (294-297) 1,27 + + + ? + + 
SPAF II (298) 1,5 + ? - - + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 67: Results for intracranial bleeding (stroke prevention in AF), comparisons with 
warfarin (INR 2-3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) --- 0.50 (0.21 to 1.23) 
Antiplatelet (≥ 150mg daily) 0.39 (0.13 to 0.98) 0.39 (0.13 to 0.98) 
Apixaban (5mg bd) 0.42 (0.30 to 0.58) 0.42 (0.30 to 0.58) 
Dabigatran (110mg bd) 0.31 (0.19 to 0.47) 0.31 (0.19 to 0.47) 
Dabigatran (150mg bd) 0.40 (0.27 to 0.59) 0.40 (0.27 to 0.59) 
Edoxaban (30mg daily) 0.31 (0.21 to 0.43) 0.31 (0.21 to 0.43) 
Edoxaban (60mg daily) 0.46 (0.33 to 0.62) 0.46 (0.33 to 0.62) 
Rivaroxaban (20mg daily) 0.65 (0.46 to 0.91) 0.65 (0.46 to 0.91) 
 
Table 68: Results for intracranial bleeding (stroke prevention in AF), NOACs (licensed 
doses only)  
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 0.96 (0.58 to 1.60) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.09 (0.69 to 1.70) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 1.55 (0.97 to 2.49) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 1.13 (0.69 to 1.87) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 1.61 (0.96 to 2.72) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 1.43 (0.90 to 2.26) 
 
Table 69: Results for intracranial bleeding (stroke prevention in AF), comparisons with 
warfarin (INR 2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 0.50 (0.21 to 1.20) 
Antiplatelet (≥ 150mg daily) 0.39 (0.14 to 0.97) 
Apixaban (5mg bd) 0.42 (0.30 to 0.58) 
Dabigatran (110mg bd) 0.31 (0.19 to 0.46) 
Dabigatran (150mg bd) 0.41 (0.27 to 0.59) 
Edoxaban (30mg daily) 0.31 (0.21 to 0.43) 
Edoxaban (60mg daily) 0.46 (0.34 to 0.62) 
Rivaroxaban (20mg daily) 0.66 (0.47 to 0.91) 
 
Table 70: Results for intracranial bleeding (stroke prevention in AF), NOACs (licensed 
doses only) – sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 0.97 (0.57 to 1.58) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.09 (0.70 to 1.71) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 1.55 (0.97 to 2.48) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 1.13 (0.70 to 1.87) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 1.62 (0.96 to 2.74) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 1.43 (0.91 to 2.25) 
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7.8.4.7 All-Cause Mortality 
Eighteen studies reported 6,479 all-cause mortality events, leading 
to a network of 15 interventions (see Figure 71). Fifteen studies 
were included in the primary analysis, with the remaining study 
included only in sensitivity analyses. These studies were at mixed 
risks of bias (see Table 71), the concerns being due to a lack of 
blinding of participants for most studies, and about lack of 
allocation concealment and blinding of outcome assessment in 
some studies. 
 
Table 72 suggests that all NOAC doses with comparisons that 
were not imprecisely estimated [apixaban (5 mg twice daily), 
dabigatran (110 mg twice daily), dabigatran (150 mg twice daily), 
edoxaban (30 mg once daily), edoxaban (60 mg once daily) and 
rivaroxaban (20 mg once daily)] were associated with a reduced 
risk of all-cause mortality compared with warfarin (INR 2–3). There 
was little evidence that the risk of all-cause mortality differed 
between licensed doses of NOACs (see Table 73). Analysing HRs 
rather than ORs produced similar results (see Table 74 and Table 
75). 
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Figure 71: Network plots for all-cause mortality (stroke prevention in AF) [a represents 
excluded interventions that were included within the sensitivity analyses] 
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Table 71: Trials included within the NMA and their risk of bias assessment for all-
cause mortality (stroke prevention in AF) 
 
Study Interventions SG AC BPP BOA IOD SR 
ACTIVE W (265) 1,4 + + - + + ? 
AFASAK (266) 1,4 + + - ? + ? 
AFASAK II (267) 1,5 + ? - + + ? 
AF-ASA-VKA-CHINA (268) 2,4 ? - - - + ? 
AF-VKA-ASA-CHINA (273) 1,5 + ? - ? ? ? 
ARISTOTLE (274-284) 1,13 + ? + + + + 
ARISTOTLE-J (285) 1,12,13 ? ? - + + + 
AVERROES (270, 275, 276, 286) 4,13 + + + + + + 
BAFTA (286) 1,4 + + - + + + 
Chinese ATAFS (287) 2,5 ? ? ? ? + ? 
ENGAGE AF-TIMI-48 (288, 289) 1,21,23 + + + + + + 
EXPLORE-Xa (279) 1,18,19,20 ? ? - + + + 
J-ROCKET AF (290) 2,26 + + + ? + + 
PATAF (265)  1,5 + + ? + ? + 
RE-LY (292, 293) 1,15,16 + + - + + + 
ROCKET-AF (294-297) 1,27 + + + + + + 
SPAF II (298) 1,5 + ? - - + ? 
WASPO (299) 1,5 + + - - + ? 
 (-) high risk of bias; (+) low risk of bias; (?) unclear risk of bias; (AC) allocation of concealment; 
(BOA) blinding of outcome; (BPP) blinding of participants and personnel; (IOD) incomplete 
outcome data; (SG) sequence generation; (SR) selective reporting. 
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Table 72: Results for all-cause mortality (stroke prevention in AF), comparisons with 
warfarin (INR 2-3) 
Comparison with warfarin (INR 
2-3) 
Direct evidence, 
OR (95% CI) 
NMA, OR (95% CI) 
Antiplatelet (< 150mg daily) 1.02 (0.75 to 1.38) 1.08 (0.88 to 1.33) 
Antiplatelet (≥ 150mg daily) 1.04 (0.87 to 1.25) 1.04 (0.87 to 1.25) 
Apixaban (5mg bd) 0.88 (0.79 to 0.98) 0.88 (0.79 to 0.98) 
Dabigatran (110mg bd) 0.91 (0.80 to 1.04) 0.91 (0.80 to 1.04) 
Dabigatran (150mg bd) 0.88 (0.77 to 1.01) 0.88 (0.77 to 1.01) 
Edoxaban (30mg daily) 0.86 (0.78 to 0.96) 0.86 (0.78 to 0.96) 
Edoxaban (60mg daily) 0.91 (0.82 to 1.01) 0.91 (0.82 to 1.01) 
Rivaroxaban (20mg daily) 0.83 (0.69 to 1.00) 0.83 (0.69 to 1.00) 
 
Table 73: Results for all-cause mortality (stroke prevention in AF), NOACs (licensed 
doses only) 
Licensed NOACs only Direct 
evidence, OR 
(95% CI) 
NMA, OR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) - 1.00 (0.84 to 1.19) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) - 1.03 (0.89 to 1.20) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) - 0.94 (0.76 to 1.17) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) - 1.03 (0.87 to 1.22) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) - 0.94 (0.74 to 1.18) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) - 0.91 (0.73 to 1.13) 
 
Table 74: Results for all-cause mortality (stroke prevention in AF), comparisons with 
warfarin (INR 2-3) – sensitivity analysis using HRs instead of ORs 
Comparison with warfarin (INR 2-3) HR (95% CI) 
Antiplatelet (< 150mg daily) 1.07 (0.88 to 1.30) 
Antiplatelet (≥ 150mg daily) 1.04 (0.87 to 1.24) 
Apixaban (5mg bd) 0.89 (0.80 to 0.99) 
Dabigatran (110mg bd) 0.91 (0.80 to 0.99) 
Dabigatran (150mg bd) 0.89 (0.78 to 1.01) 
Edoxaban (30mg daily) 0.88 (0.80 to 0.97) 
Edoxaban (60mg daily) 0.92 (0.83 to 1.02) 
Rivaroxaban (20mg daily) 0.83 (0.69 to 1.00) 
 
Table 75: Results for all-cause mortality (stroke prevention in AF), NOACs (licensed 
doses only) – sensitivity analysis using HRs instead of ORs 
Licensed NOACs only HR (95% CI) 
Dabigatran (150mg bd) vs. apixaban (5mg bd) 1.00 (0.85 to 1.18) 
Edoxaban (60mg daily) vs. apixaban (5mg bd) 1.03 (0.90 to 1.20) 
Rivaroxaban (20mg daily) vs. apixaban (5mg bd) 0.94 (0.76 to 1.15) 
Edoxaban (60mg daily) vs. dabigatran (150mg bd) 1.03 (0.88 to 1.22) 
Rivaroxaban (20mg daily) vs. dabigatran (150mg bd) 0.93 (0.75 to 1.17) 
Rivaroxaban (20mg daily) vs. edoxaban (60mg daily) 0.90 (0.73 to 1.11) 
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7.8.5 Summary of results  
Results from the NMA suggest that a number of licensed doses of 
NOACs reduce the risk of the outcome of stroke or SE, major 
bleeding, CRB, intracranial bleeding and all-cause mortality 
compared with the reference treatment, warfarin (doses adjusted to 
maintain INR 2-3). There was evidence that edoxaban increased 
CRB compared with warfarin (INR 2-3). Risk of MI appeared higher 
for some NOACs than for warfarin (INR 2–3). Comparisons for some 
licensed NOAC doses, such as apixaban (2.5 mg twice daily) and 
betrixaban (40 mg once daily), could not be estimated precisely. 
 
Due to local protocols, several studies conducted in Asian countries 
considered a lower INR range for warfarin interventions in elderly 
patients. These were excluded from the main analysis but were 
included (merged with the reference treatment, warfarin INR 2–3) as 
a second sensitivity analysis for each outcome. This permitted the 
incorporation of a non-licensed dose of rivaroxaban (15 mg once 
daily) that was included in the J-ROCKET AF trial showing a reduced 
risk of stroke compared with warfarin (INR 1.6–3), with a median OR 
of 0.49 (95% CI 0.24 to 0.99). Apart from this, results showed the 
same trends as described above. 
 
The dose range for the antiplatelet arm in the AVERROES trial was 
unusually wide (81–324 mg once daily). Because some of the 
patients had received a dose that was below UK standard, it was 
agreed between the clinical collaborators of this project to merge this 
with the antiplatelets (< 150 mg once daily) node for the primary 
analysis. In a further sensitivity analysis for each outcome, this trial 
was excluded. Again, the results were not substantially different from 
those presented above.  
 
With regard to appraisal of the NMA model, no instances of lack of 
convergence among the Markov chains, poor model fit or poor model 
inconsistency were identified.  
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7.8.5.1 Trade-off Analysis 
The trade-off analysis, presented in the form of rank-o-grams, 
plotted the probability that each of the licensed interventions for AF 
is ranked best, second best, and so on, for preventing each 
outcome, are displayed in Figure 72 and Figure 73, for efficacy 
and safety, respectively.  
 
The non-NOAC interventions (warfarin, INR 2–3) and antiplatelet 
therapy (aspirin/clopidogrel, ≥ 150 mg once daily) were ranked 
least effective for stroke or SE and ischaemic stroke and were not 
among the best three interventions for any of the outcomes. 
Warfarin (INR 2–3) was also ranked as the least effective 
intervention to reduce the risk of intracranial bleeding. Among the 
licensed NOACs, apixaban (5 mg twice daily) was ranked as 
among the best interventions for major bleeding, intracranial 
bleeding, all-cause mortality, stroke or SE, ischaemic stroke and 
MI. Edoxaban (60 mg once daily) was ranked second for major 
bleeding and all-cause mortality. Except for all-cause mortality and 
MI, outcomes for rivaroxaban (20 mg once daily) were ranked less 
highly than those for apixaban (5 mg twice daily), dabigatran (150 
mg twice daily) and edoxaban (60 mg once daily). 
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Figure 72: Ranking of efficacy (Rank-o-gram) for licensed interventions examined in 
stroke prevention in AF 
Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among 
the NOACs (and warfarin). A higher probability (y-axis) at a rank of 1(x-axis) indicated the most favourable 
treatment for the plotted endpoint (stroke or SE, ischaemic stroke, or MI). 
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Figure 73: Ranking of safety (Rank-o-gram) for licensed interventions examined in 
stroke prevention in AF 
Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among 
the NOACs (and warfarin). A higher probability (y-axis) at a rank of 1(x-axis) indicated the most favourable 
treatment for the plotted endpoint (major bleeding, CRB, all-cause mortality, or IC bleeding). 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
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7.9 Findings (Cost-effectiveness analysis: Stroke prevention in AF) 
7.9.1 Introduction 
Further to section 7.7 where the protocol for the CEA is described, in 
this section the results of the CEA for first-line treatment of patients 
with AF are presented. This area of the research project was 
undertaken by the health economics team, with inputs for the model 
and sensitivity analyses informed by the clinical team members. 
Results are presented from Bayesian analyses with 95% credible 
[confidence] intervals.   
 
7.9.2 Summary from NMA 
Results from the NMA are summarised in Table 76.  
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Table 76: Mean HR and 95% Credible Intervals relative to warfarin from the NMA for 
each event and treatment (included in the CEA model) 
 
NOAC Ischaemic 
stroke 
TIA SE ICH Other 
CRB 
MI Death 
(all 
cause) 
Apixaban (5mg bd) 0.90 (0.72 
to 1.11) 
0.74 
(0.041 to 
3.26) 
0.65  
(0.33 to 
1.18) 
0.46  
(0.36 to 
0.58) 
0.82  
(0.70 to 
0.94) 
0.86  
(0.65 to 
1.10) 
0.89  
(0.8 to 
0.99) 
Dabigatran (150mg 
bd) 
0.75 (0.58 
to 0.97) 
2.68 
(0.062 to 
16.10) 
0.65 
(0.52 to 
0.80)  
0.36 
(0.26 to 
0.49) 
1.07 
(0.92 to 
1.24) 
1.27 
(0.93 to 
1.68) 
0.88 
(0.77 to 
1.00) 
Edoxaban (60mg 
daily) 
1.00 (0.83 
to 1.20) 
2.76 
(0.06 to 
15.80) 
0.58 
(0.30 to 
0.97)  
0.49 
(0.39 to 
0.61) 
0.88 
(0.82 to 
0.94) 
0.95 
(0.74 to 
1.19) 
0.92 
(0.83 to 
1.01) 
Rivaroxaban (20mg 
daily) 
0.92 (0.73 
to 1.13) 
2.68 
(0.063 to 
15.90) 
0.95 
(0.79 to 
1.13)  
0.65 
(0.46 to 
0.89) 
1.05 
(0.98 to 
1.13) 
0.79 
(0.61 to 
1.01) 
0.83 
(0.69 to 
0.99) 
Apixaban (2.5mg bd) 0.74 
(0.042 to 
3.37) 
0.76 
(0.041 to 
3.51) 
0.48 
(0.031 to 
1.97)  
2.78 
(0.06 to 
16.2) 
0.63 
(0.080 to 
2.06) 
1.01 
(0.049 to 
4.67) 
1.03 
(0.050 to 
5.03) 
Dabigatran (110mg 
daily) 
1.13 (0.89 
to 1.42) 
2.82 
(0.062 to 
16.40) 
0.90 
(0.73 to 
1.10)  
0.31 
(0.22 to 
0.43) 
0.94 
(0.81 to 
1.09) 
1.29 
(0.94 to 
1.71) 
0.91 
(0.80 to 
1.03) 
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 Table 77: Main assumptions in the AF model 
 Assumption 
1 Does not include minor non-clinically relevant bleeds as transient events 
2 No distinction between severity of ischaemic strokes (SE assumed to be a transient 
event without long-term consequence) 
3 Dose of Apixaban and dabigatran given does not reduce as patients age 
4 Bleeds and ICH (and with it, haemorrhagic stroke) have the same effect on future risk of 
death as stroke 
5 Patients switch to no treatment after ICH / haemorrhagic stroke 
6 Patients on dabigatran who experience an MI will always switch to warfarin (not another 
NOAC) 
7 Patients may switch from NOAC to warfarin or warfarin to no treatment after 
ischaemic stroke, bleed, SE or TIA  
8 Patients may discontinue warfarin treatment or switch from a NOAC to warfarin, even if 
they do not experience an event (due to lack of compliance) 
9 Warfarin arms from the RCTs identified in the systematic review are representative of 
the AF population in England and Wales  
10 Events rate and relative treatment effects are assumed not to vary with age 
11 Relative mortality rate in patients with AF relative to the general population does not 
vary with age 
12 Warfarin treatment costs over 3 months are taken from the NICE costing report. 
Uncertainty in this is represented using a uniform distribution from 50% to 150% of the 
NICE costing report estimate 
13 Assume no monitoring or administration costs for NOACs 
14 Assume post-ICH management costs to be similar to post-ischaemic stroke 
management costs 
15 Combined management costs for post-multiple event states (e.g. MI + stroke) to be the 
maximum of management costs for constituent events 
16 Assume quality of life for patients with a history of multiple events to be a multiplicative 
combination of QoL for constituent events  
17 All endpoints are equally weighted 
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7.9.3 Results of the cost-effectiveness model (AF) 
Assumptions made in the construction of the AF model are listed in 
Table 77. Total costs and QALYs for first-line anticoagulation strategy 
are presented in Table 78. Incremental costs and QALYs for each 
strategy compared with the established standard of care, warfarin 
(INR 2-3) is also given.  
 
Dabigatran (150mg twice daily) has the lowest expected total cost 
(£23,064), followed by apixaban (5 mg twice daily), edoxaban (60 mg 
once daily), warfarin (INR 2–3) and rivaroxaban (20 mg once daily), 
which has the highest expected total cost (£24,841). Expected costs 
are similar across all treatments, and there is a high degree of 
uncertainty around the costs for all treatments. 
 
Apixaban has the highest expected QALYs (5.49), followed by 
rivaroxaban (5.45), dabigatran and edoxaban (both with 5.41), and 
warfarin (INR 2–3) (5.16). The NOACs have similar expected QALYs, 
all of which are higher than for warfarin (INR 2–3). There is a high 
degree of uncertainty around the QALY estimates. 
 
At a willingness-to-pay threshold of £20,000 per QALY, all NOACs 
have positive expected incremental net benefit (INB) compared with 
warfarin (INR 2–3), suggesting that they may be a cost-effective use 
of NHS resources. Apixaban has the highest expected INB (£7,533), 
followed by dabigatran (£6,365), rivaroxaban (£5,279) and edoxaban 
(£5,212). Apixaban is the only NOAC for which the 95% CI around 
INB is positive, suggesting that apixaban is cost-effective compared 
with warfarin. These conclusions also hold at the higher threshold of 
£30,000. These assessments are made on non-discounted costs, 
using commercially available (i.e. non-commercially sensitive) prices. 
Based on experience that discounts for branded medicines within the 
same therapeutic class are generally similar, the above conclusions 
would continue to hold true.  
 
The analysis was undertaken on the assumption that each of the 
endpoints were weighted equally, i.e. one ischaemic stroke was equal 
to one SE, although the economic implications of each event were 
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modelled using data from the ONS and NHS reference costs. The key 
drivers of the results favouring apixaban (5mg twice daily) were the 
lower rates of MI, ICH and other CRB (see Table 76). Although it is 
acknowledged that all-cause mortality could from a patients’ 
perspective be regarded as the most important safety endpoint, it is 
possible that all-cause mortality is dominated by causes of death that 
are unrelated to the intervention so any benefit (or harm) will be 
concealed. Furthermore, the estimates generated from the CUA 
model carry a degree of uncertainty around the mean and 95% CrI 
values, which adds to the insensitivity and lack of specificity already 
present with the all-cause mortality outcome.  
 
For apixaban (5mg twice daily), the estimates for TIA, MI, ICH and 
other CRB all fall in favour of this particular NOAC, with ischaemic 
stroke and all-cause mortality estimates broadly similar to the others. 
More specifically, the high cost and disutility of ICH has a great 
influence on total costs, total QALYs and net benefits. Apixaban has a 
low rate of TIA; however the minimal impact of this event means that 
it is not a driving factor in the results. Although dabigatran has the 
lowest rate of ICH, the higher rate of MI offsets this benefit. 
 
Table 78: Cost-effectiveness of first-line treatment strategies for patients with AF 
Estimated costs 
and outcomes 
Warfarin  
(INR 2-3):  
mean (95% CI) 
Apixaban  
(5mg bd):  
mean (95% CI) 
Dabigatran 
(150mg bd): 
mean (95% CI) 
Edoxaban (60mg 
daily): mean 
(95% CI) 
Rivaroxaban 
(20mg daily): 
mean (95% CI) 
Expected total costs 
(£) 
24,418  
(12,189 to 
50,365)  
23,340  
(12,842 to 
45,753) 
23,064 
(12,674 to 
46,075) 
23,985  
(13,098 to 46,319) 
24,841  
(13,198 to 47,603) 
Expected QALYs 5.17  
(3.63 to 6.54)  
5.49  
(3.84 to 6.79) 
5.41  
(3.82 to 6.70) 
5.41  
(3.82 to 6.68) 
5.45  
(3.82 to 6.80) 
Expected 
incremental total 
costs (£) 
Reference  –1078  
(–7626 to 2568) 
–1354  
(–8049 to 2273) 
–433.4  
(–6430 to 3619)  
422.5  
(–4730 to 5104) 
Incremental 
expected QALYs 
Reference 0.3227  
(–0.01486 to 
0.8142)  
0.2505  
(–0.08034 to 
0.7025) 
0.2389  
(–0.1122 to 
0.6841) 
0.2851  
(–0.06816 to 
0.8096) 
Incremental 
expected net benefit 
(£20,000) 
Reference 7,533  
(489.9 to 18,228) 
6,365  
(-167.7 to 17,039) 
5,212 
(-893.8 to 14,826) 
5,279 
(-1,097 to 15,180) 
Incremental 
expected net benefit 
(£30,000) 
Reference 10,760  
(576.2 to 25,861) 
8,871 
(-597.3 to 23,402) 
7,601 
(-1,556 to 20,987) 
8,130 
(-1,399 to 22,819) 
Incremental results are relative to warfarin (INR 2-3); Figures are presented as mean (CI) 
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7.9.4 Results of the sensitivity analyses 
To explore whether or not results were sensitive to the assumed 
costs of warfarin, the extreme case in which there is no administration 
or monitoring costs for warfarin was reviewed first. This assumption 
found little effect on the conclusion that apixaban (5 mg twice daily) is 
the most cost-effective strategy (see Figure 74). The rationale for this 
exercise was to prove that if warfarin is not cost-effective with zero 
monitoring costs then it will not be cost-effective with monitoring costs 
greater than this. On this principle, sensitivity analyses with higher 
monitoring costs were not carried out. Similarly, the assumption that 
ICH and other CRBs have no effect on future mortality risk did not 
alter the conclusion that apixaban is most likely to be cost-effective 
(see Figure 75). 
 
Different treatment switching strategies were also explored. If patients 
switch to no treatment only when they experience an ICH or a MI (if 
on dabigatran), the results are similar to the primary analysis. If all 
patients switch treatments after ischaemic stroke, bleed, SE and TIA, 
in addition to the switching after ICH and MI (for dabigatran) then 
patients spend only a short time on a NOAC before switching to 
warfarin. In this scenario, it is perhaps unsurprising that warfarin is 
the most cost-effective strategy. Another switching strategy was also 
considered by which all patients switch after an ischaemic stroke or 
clinically relevant bleed, and none switch after a TIA or SE, and found 
that the results are similar to the primary analysis.  
 
For a comprehensive analysis, different initial ages (and 
corresponding doses) for the cohort were also explored. Apixaban (5 
mg twice daily) is the strategy that is most likely to be cost-effective, 
assuming an initial cohort age of 60 years. Lower doses of apixaban 
(2.5 mg twice daily) and dabigatran (110 mg twice daily) are 
recommended for elderly patients, and were compared in a sensitivity 
analysis (see Figure 76). The uncertainty is much greater in this 
comparison, but apixaban (2.5 mg twice daily) is most likely to be the 
most cost-effective first-line therapy for the prevention of stroke in AF.  
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Although there was a high degree of uncertainty in the inputs of the 
model, apixaban (5 mg twice daily) was identified with the highest 
probability of being the most cost-effective first-line treatment over a 
range of willingness-to-pay-per-QALY thresholds. The driver of this 
result is the generally lower rates of MI, ICH and other CRB on 
apixaban than the other NOACs. The assumptions made within the 
model are summarised in Table 77. The conclusion remained robust 
to a range of sensitivity analyses. The only sensitivity analysis found 
to affect the conclusion was the assumption about treatment 
switching strategy; if treatment switching is assumed to always occur 
after stroke, bleed, SE or TIA then warfarin was identified as the most 
cost-effective treatment. However, based on discussion between the 
clinical group members it was agreed that this extreme switching 
strategy was not considered realistic in practice. The costs of warfarin 
were taken from the NICE costing report (304). As a level of 
uncertainty is described in this estimate it was agreed that an extreme 
case scenario analysis should be performed in which it is assumed 
that warfarin treatment and monitoring incurs zero cost. Under this 
assumption apixaban (5mg twice daily) was still the most cost-
effective treatment. Apixaban and dabigatran may be given in lower 
doses to the elderly. It was assumed that all patients would receive 
the higher dose, and remain on it, even as they age, however, results 
were robust to a sensitivity analysis assuming only the lower doses of 
apixaban (2.5 mg twice daily) and dabigatran (110 mg twice daily) 
were administered. 
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Figure 74: Cost-effectiveness acceptability curves (CEAC) for sensitivity analysis 
assuming that the cost of warfarin treatment is zero 
 
 
 
 
 
Figure 75: Cost-effectiveness acceptability curves (CEAC) for sensitivity analysis 
assuming no effect of bleed or ICH on mortality risk 
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Figure 76: Cost-effectiveness acceptability curves (CEAC) for sensitivity analysis 
comparing lower doses of apixaban and dabigatran, as would be administered in older 
patients with AF 
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7.9.5 Limitations  
It was not possible to include betrixaban within the analyses due to 
lack of evidence; therefore no conclusions are made about the 
relative cost-effectiveness of betrixaban or other unlicensed 
treatments. An assumption was made that age determines mortality 
rate, but that other event rates and relative treatment effects do not 
depend on age. The effects of minor and major stroke are not 
distinguished within the model. Some previous models have done so 
(256, 305, 306) but the health economics team found that there was 
insufficient evidence to be able to estimate rates differently. It was 
assumed that SE is a transient event with no long-term 
consequences. Although there can be long-term consequences, such 
as limb loss, these are very rare, and as such one would not expect 
inclusion of these to affect the results. 
 
One notable potential limitation of the model is that there is no 
distinction between different types of AF. There is emerging evidence 
that there may be a ‘dose–response’ relationship in stroke risk with 
increasing ‘persistence’ of AF,(307) although others have suggested 
that risk of stroke is as high in paroxysmal patients with AF as with 
persistent or permanent AF.(308) The RCTs included in this review 
are likely to have recruited mostly persistent or permanent patients 
with AF, therefore the conclusions may not extend to patients with 
paroxysmal AF. 
 
There have been few analyses of NOACs for the prevention of stroke 
in AF in the UK population. Kansal et al.(255) found dabigatran to be 
cost-effective compared with warfarin and aspirin in the UK setting, as 
was the case in the current analysis. However, the authors did not 
include any other NOACs. The Bayer submission to NICE on 
rivaroxaban(253) found it be cost-effective compared with warfarin. 
This submission also found rivaroxaban and dabigatran to have 
equivalent effects but dabigatran to have higher costs, thus 
concluding that rivaroxaban is the most cost-effective. Within that 
analysis only rivaroxaban was compared with warfarin, which found 
close to a 60% probability that rivaroxaban was cost-effective in the 
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£20,000–30,000 threshold range, similar to the current analysis 
probability that a NOAC (apixaban) was most cost-effective. The 
Harrington et al.(309) model, conducted in the US setting, compared 
apixaban (5 mg twice daily), dabigatran (110 mg twice daily), 
rivaroxaban (20 mg once daily), and warfarin (variable dose), and 
found that apixaban had the highest expected QALYs, followed by 
dabigatran, rivaroxaban and warfarin. This concurs with the current 
analysis which also found apixaban to have the highest expected 
QALYs and that dabigatran and rivaroxaban would have higher 
expected QALYs than warfarin, although the high degree of 
uncertainty in the current results renders them compatible with the 
order found by Harrington et al. These authors also found apixaban 
and dabigatran to be cost-effective compared with warfarin, and other 
US studies found apixaban,(310) rivaroxaban(305) and 
dabigatran(256) to be cost-effective compared with warfarin. Although 
costs in the USA are not strictly comparable with those in the UK 
setting, it is promising to see that the results from the current analysis 
are in line with these earlier findings.  
 
7.10 Discussion and Conclusion 
7.10.1 Clinical effectiveness 
There was evidence that apixaban (5 mg twice daily), dabigatran 
(150 mg twice daily), edoxaban (60 mg once daily) and 
rivaroxaban (20 mg once daily) all reduce the risk of stroke or SE 
compared with warfarin (INR 2–3). Among the NOACs, there was 
evidence of a higher risk of stroke or SE with edoxaban and 
rivaroxaban than dabigatran.  
 
There was evidence that dabigatran reduces the risk of ischaemic 
stroke compared with warfarin, whereas edoxaban increases that 
risk. There was little evidence that the risk of ischaemic stroke 
differed between licensed doses of NOACs. 
 
There was weak evidence that the risk of MI is higher with 
dabigatran (110 mg twice daily), dabigatran (150 mg twice daily) 
and edoxaban (30 mg once daily) than warfarin (INR 2–3), and 
weak evidence that the risk of MI is lower with rivaroxaban (20 mg 
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once daily) than warfarin (INR 2–3). Among the NOACs, there was 
weak evidence that MI risk is higher with dabigatran (150 mg twice 
daily) than apixaban (5 mg twice daily), and lower with rivaroxaban 
(20 mg once daily) than dabigatran (150 mg twice daily). 
 
There was evidence that apixaban (5 mg twice daily), dabigatran 
(110 mg twice daily), edoxaban (30 mg once daily) and edoxaban 
(60 mg once daily) all reduced risk of major bleeding compared 
with warfarin (INR 2–3). Among the NOACs, there was evidence 
that risk of major bleeding is higher with dabigatran (150 mg twice 
daily) than apixaban (5 mg twice daily), and with rivaroxaban (20 
mg once daily) than apixaban (5 mg twice daily) and edoxaban (60 
mg once daily).  
 
There was evidence that the risk of CRB during antiplatelet 
therapy (aspirin < 150 mg once daily) is lower than with warfarin 
(INR 2–3). There was evidence that the risk of CRB with apixaban 
(5 mg twice daily), edoxaban (30 mg once daily) and edoxaban (60 
mg once daily) is also lower than with warfarin (INR 2–3). 
However, edoxaban (30 mg twice daily) and edoxaban (60 mg 
twice daily) increased CRB compared with warfarin (INR 2–3). In 
comparisons among NOACs, there was evidence that CRB with 
edoxaban (60 mg once daily) and rivaroxaban (20 mg once daily) 
is higher than with apixaban (5 mg twice daily), and that 
rivaroxaban (20 mg once daily) increases CRB compared with 
edoxaban (60 mg once daily). 
 
There was strong evidence that risk of intracranial bleeding was 
lower with apixaban (5 mg twice daily), dabigatran (110 mg twice 
daily), dabigatran (150 mg twice daily), edoxaban (30 mg once 
daily), edoxaban (60 mg once daily) and rivaroxaban (20 mg once 
daily) than warfarin (INR 2–3). For each of these NOACs [and 
doses], except for rivaroxaban (20 mg once daily), the estimated 
relative risk reduction for intracranial bleeding was > 50%. There 
was weak evidence that risk of intracranial bleeding is higher with 
rivaroxaban (20 mg once daily) than apixaban (5 mg twice daily), 
dabigatran (150 mg twice daily) and edoxaban (60 mg once daily). 
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Risk of all-cause mortality was lower with apixaban (5 mg twice 
daily), dabigatran (110 mg twice daily), dabigatran (150 mg twice 
daily), edoxaban (30 mg once daily), edoxaban (60 mg once daily) 
and rivaroxaban (20 mg once daily) than warfarin (INR 2–3), but 
there was little evidence of a difference between the licensed 
doses of NOACs for this outcome. 
 
7.10.1.1 Summary – Clinical Trade-off Analysis 
Overall, apixaban (5mg twice daily) was ranked as being 
among the best interventions for a wide range of the outcomes 
that were evaluated, including stroke or SE, MI, major bleeding, 
ICH and all-cause mortality. Edoxaban (60 mg once daily) was 
ranked second for major bleeding and all-cause mortality. 
Except for all-cause mortality, outcomes for rivaroxaban (20 mg 
once daily) were ranked less highly than several other NOACs. 
The non-NOAC interventions [warfarin (INR 2–3) and 
antiplatelet therapy (aspirin/clopidogrel ≥ 150 mg od)] were 
ranked worst for stroke or SE and were not among the best 
three interventions for any of the outcomes. Apixaban (2.5 mg 
twice daily) or betrixaban (40 mg once daily) were not included 
within the analyses because comparisons involving these 
interventions were imprecisely estimated. 
 
In the sensitivity analyses, results were similar when using HRs 
instead of ORs. Moreover, no evidence of effect modification 
according to mean TTR for patients on warfarin was found. An 
important limitation is that primary studies did not report the 
mean time above or below therapeutic range for warfarin arms. 
Therefore, it was not possible to address some clinically 
relevant questions regarding the impact of treatment settings 
for warfarin on stroke prevention, as well as on bleeding and 
other AEs. 
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7.10.2 Cost effectiveness 
Dabigatran (150 mg twice daily) has the lowest expected total cost 
(£23,064), followed by apixaban (5 mg twice daily), edoxaban (60 
mg once daily), warfarin (INR 2–3) and rivaroxaban (20 mg once 
daily), which had the highest expected total cost (£24,841). 
Expected costs are similar across all treatments, and there is a 
high degree of uncertainty around the costs for all treatments. 
 
Apixaban (5 mg twice daily) has the highest expected QALYs 
(5.49), followed by rivaroxaban (20 mg once daily) (5.45), 
dabigatran (150 mg twice daily) (5.42), edoxaban (60 mg once 
daily) (5.41) and warfarin (INR 2–3) (5.17). The NOACs have 
similar expected QALYs, all of which are higher than for warfarin 
(INR 2–3). There is a high degree of uncertainty around the QALY 
estimates. 
 
At a willingness-to-pay threshold of £20,000 per QALY, all NOACs 
have positive expected incremental net benefit (INB) compared 
with warfarin (INR 2–3), suggesting that they may be a cost-
effective use of NHS resources. Apixaban (5 mg twice daily) has 
the highest expected INB (£7533), followed by dabigatran (150 mg 
twice daily) (£6365), rivaroxaban (20 mg once daily) (£5279) and 
edoxaban (60 mg once daily) (£5212). Apixaban (5 mg twice daily) 
is the only NOAC for which the 95% CI around INB is positive, 
suggesting with confidence that apixaban is cost-effective 
compared with warfarin. These conclusions also hold at the higher 
threshold of £30,000. The key drivers of these results are the lower 
rates of MI, ICH and other CRB for apixaban (5 mg twice daily). 
 
7.10.2.1 Summary – Cost-Effectiveness Trade-off Analysis 
The CEAC indicates that apixaban (5 mg twice daily) has the 
highest probability of being the most cost-effective first-line 
therapy for AF, close to 60% in the £20,000–30,000 range of 
willingness-to-pay thresholds generally considered by NICE. 
Dabigatran (150 mg twice daily) has the highest probability of 
being cost-effective if the willingness-to-pay threshold is very 
low as a result of having the lowest expected total costs. 
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Warfarin (INR 2–3) and edoxaban (60 mg once daily) are 
unlikely to be cost-effective. Apixaban (5 mg twice daily) has 
the highest expected net benefit at a wide range of willingness-
to-pay thresholds. In conclusion, apixaban (5 mg twice daily) is 
likely to be the most cost-effective first-line therapy for AF, 
under the assumptions of the model. 
 
7.10.3 Analysis of the value of information for future research 
The optimal decision regarding the most cost-effective NOAC is 
most sensitive to the HRs comparing the NOACs, suggesting that 
a head-to-head trial comparing NOACs is of value. The decision is 
also sensitive to costs, the effect of past events on future HRs, and 
probabilities of treatment switching. A head-to-head trial could also 
provide information about baseline event rates, costs and 
switching probabilities. However, a study powered to measure all 
of these outcomes with sufficient precision would require a very 
large sample size, which may be prohibitively expensive. With 
these agents reaching the end of their patent protected period 
(dabigatran potentially available as a generic medicine as early as 
2018) it is highly unlikely that this is of commercial interest to any 
of the Pharmaceutical companies who have still yet to deliver peak 
sales.  
 
7.10.4 Strengths 
The strengths of this appraisal, undertaken as an NIHR Health 
Technology Assessment, includes its comprehensive coverage of 
all the therapeutic areas in which NOACs have been evaluated to 
date, using the same methodology [only AF reported here]. 
Previous analyses of comparative effectiveness have focused on 
individual therapeutic areas, making it more difficult to judge if one 
of the four licensed NOACs might emerge as a frontrunner in more 
than one therapeutic area. 
 
Additional strengths include careful appraisal of study quality; 
focus on clinically relevant end points; an evaluation of safety that 
considers evidence spanning all therapeutic areas together, to 
maximise power; the development of a treatment hierarchy for the 
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different anticoagulant indications, where the data allowed it; and a 
CEA that is relevant to the NHS. This was possible through setting 
up a HTA team that encompassed academics from the systematic 
review and health economics specialties as well as clinical and 
patient partners.  
 
7.10.5 Limitations 
The limitations of this NIHR Health Technology Assessment, as is 
the case for systematic reviews and meta-analysis, relate to 
shortfalls in the primary data on which the overview is based. 
These include: 
 No direct head-to-head comparisons between different NOAC 
drugs – all such comparisons were therefore based on indirect 
evidence derived from the networks 
 Economic analyses for long-term conditions such as AF make 
long-term projections on the basis of short-term trial evidence, 
observational data and clinically informed assumptions about 
plausible treatment pathways and health-state transitions. 
These assumptions and evidence limitations are discussed 
above.  
 The profile of patients entering trials may not be the same as 
those treated in practice, who may be older and have more 
comorbidities. Treatment benefits in such patients may be 
smaller, and rates of harm higher, than estimated by trials. 
 As for all new drugs, adverse effects that remained 
undetected during development may come to light with high-
volume use post licensing.  
 It is possible that patients treated with warfarin in practice are 
at higher risk of bleeding complications than those in trials 
because of a greater number of comorbidities and less 
stringent control of anticoagulation. However, concerns have 
also been raised previously that the time spent in the 
therapeutic range was suboptimal among patients in clinical 
trials who were assigned to warfarin. Thus, clinical trials could 
have underestimated both the benefits and the risks of 
warfarin treatment. 
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Several factors led to imprecision in the estimation of certain 
treatment effects. These included low rates of occurrence of 
certain end points; widespread use of composite end points, with 
low rates of occurrence of certain (more clinically relevant) 
components of the composite; as well as substantial inconsistency 
in the reporting of end points in different trials in the same 
therapeutic area, leading to a substantial number of missing end 
point data (see Table 39 and Table 40). Owing to the low event 
rates and lack of substantial replication of specific comparisons 
across studies, it was agreed that a fixed-effects models should be 
used for the NMA. This does not account for heterogeneity in 
treatment effects. Under fixed-effects models, the Bayesian 
analyses with vague priors will produce results very similar to 
frequentist analyses. 
The apparent efficacy of NOACs when compared with warfarin 
could be inflated if control of the INR was suboptimal among 
patients who were randomised to warfarin. For this reason, many 
of the studies reported time spent in the therapeutic range (TTR), 
as an index of anticoagulant control. This is a potentially important 
issue for the studies of stroke prevention in AF, for which 16 (73%) 
of the 22 studies that included a warfarin intervention arm reported 
mean TTR. There was substantial variation in TTR (from 45.1% to 
83%) between these studies. The pre-specified protocol for this 
health technology appraisal specified TTR as a potential modifier 
of NOAC treatment effect in trials in which warfarin was the 
comparator.  
In some situations, the need for anticoagulation monitoring with 
warfarin treatment may be viewed as a useful means to confirm 
adherence to anticoagulant therapy rather than as an 
inconvenience. This was an interesting point raised by the patient 
partner on the panel who suggested that an awareness of the 
activity of the medicine (i.e. INR testing) provides positive 
reassurance that the treatment is working and will reinforce 
patients taking their medicine, compared with NOACs which do not 
require routine testing or monitoring.  
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There is a suggestion that the efficacy and safety of dabigatran 
could be improved by monitoring of achieved drug levels, like with 
warfarin, because these exhibit wide inter-individual variation. This 
will reduce the convenience advantages of this NOAC and 
increase its cost compared with warfarin or other NOACs, however 
as this is not a requirement this was not modelled in the cost 
analyses. Only one of the studies included within the current 
review considered whether or not monitoring improves the efficacy 
and safety of NOACs: in a subsample of 9,183 patients in the RE-
LY trial,(245) ischaemic stroke and major bleeding both correlated 
with dabigatran plasma concentrations. Specific tests to measure 
the anticoagulation effects of NOACs are being developed but are 
not yet widely available(311) and routine coagulation tests such as 
prothrombin time and activated partial thromboplastin time are of 
limited use.(312, 313) It is therefore currently unclear whether or 
not the efficacy and safety profiles of NOACs can be improved by 
monitoring and dose adjustment. Monitoring may be particularly 
helpful in certain clinical situations (for example, in the peri-
operative period around planned or emergency surgery, or patients 
presenting with bleeding(313)) and in certain patients groups (for 
example, advanced age and renal impairment [outside of the 
range investigated by the clinical trials]). 
Finally, therapeutic decision making may be influenced by 
recognition that effective treatments for reversal of anticoagulation 
with NOACs are still under development. Promising results from 
early phase trials of medicines currently identified include: 
 Aripazine (PER-977; PER 977; ciraparantag) is a synthetic 
cationic molecule that binds unfractionated and LMWH, the 
factor Xa inhibitors edoxaban, rivaroxaban and apixaban, and 
the factor II inhibitor dabigatran, but not to warfarin.(314) In a 
Phase I trial involving 80 healthy volunteers, intravenous 
PER977 reversed the prolongation of whole blood clotting time 
induced by a single oral dose of edoxaban 60 mg in a dose-
dependent fashion, within 10–30 minutes of 
administration.238 Phase II clinical studies of this agent are in 
progress. 
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 Andexanet alpha (PRT4445; PRT064445) is a recombinant 
modified factor Xa molecule that acts as an antidote to factor 
Xa inhibitors through a decoy mechanism. A number of Phase 
III studies of this agent are under way.(315, 316) 
 Idarucizumab (BI 655075) is a humanised monoclonal 
antibody fragment that binds dabigatran to reverse its 
anticoagulant activity.(317, 318) Phase I/II studies of this 
agent have been completed. A Phase III study investigating 
reversal of anticoagulation in patients receiving dabigatran 
who have uncontrolled bleeding or who require emergency 
surgery or invasive procedures is under way. 
 
7.10.6 Future research 
Like most NMA of new therapies, the evidence on the comparative 
efficacy and safety of NOACs in this review has come exclusively 
from indirect comparisons; this again is a consequence in the 
absence of regulatory requirement to undertake head-to-head 
trials, although is more likely to be attributable to this new group of 
anticoagulants undergoing trial investigation at similar times before 
each has a chance to become standard practice and therefore a 
comparator. A mechanism by which to compare them whilst under 
development would have been useful to serve as a guide at the 
time of regulatory approval and launch. Among patients with AF, a 
long-term condition, the trials have also been of relatively short 
duration. As different manufacturers have developed each of the 
agents evaluated in this review on the premise that it will achieve a 
healthy market share and therefore financial return, it is highly 
unlikely that any head-to-head trials will be initiated by the industry 
for academic gain. 
 
Reliable estimation of the cost-effectiveness of NOACs in different 
clinical scenarios requires high-quality data on absolute event 
rates for the various efficacy and safety outcomes. NHS health 
record data could provide a rich source for information, but so far 
health record data have been insufficiently utilised for this purpose. 
As NHS Digital evolves within the UK this may be a possibility in 
the future.  
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Although NOACs were developed in part to supersede warfarin by 
obviating the need for therapeutic monitoring of anticoagulation, to 
improve convenience, recent studies have suggested that 
monitoring of drug levels may improve safety and efficacy of 
dabigatran treatment. Whether or not this is also the case for other 
NOACs is not known and is of course associated with an additional 
cost not factored within this analysis.  
 
The requirement for therapeutic drug monitoring with warfarin also 
serves as a means to assess adherence. Thus far, long-term 
adherence rates for NOACs (e.g. among patients with AF who may 
require anticoagulation for many years) have not been evaluated.  
 
The research needs identified by this review are therefore as 
follows: 
 To undertake one or more trials making direct comparisons 
between the most promising NOACs and NOAC doses, in 
situations typical of NHS clinical practice (potentially apixaban 
vs. rivaroxaban) 
 Information on long-term rates of the main efficacy and safety 
outcomes among patients receiving anticoagulants for AF 
(e.g. from registries or health record data) 
 Information on the role (if any) of therapeutic monitoring to 
enhance the safety and efficacy of NOACs 
 Information on long-term adherence rates in patients receiving 
NOACs for AF 
 
7.10.7 Summary 
This systematic review, Bayesian NMA, clinical trade-off analysis 
and CUA, provides the most comprehensive and up-to-date 
analysis of the benefits, safety issues, and cost implications for 
NOACs compared with warfarin for the prevention of stroke in AF. 
At licensed doses and at NHS prices, a number of NOACs are of 
net benefit compared with warfarin with apixaban being ranked the 
highest. A trial directly comparing NOACs would overcome the 
need for indirect comparisons to be made using NMA, however 
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this is unlikely to occur. Based on the NMA and CEA findings, 
apixaban emerged as the best intervention. This recommendation 
is supported by a registry study which found that patients treated 
with apixaban were associated with a lower risk of major or CRNM 
bleeding compared with warfarin.(319) 
 
This work has been published by the NIHR as part of their Health 
Technology Assessment programme: Volume 21, Issue 9 (March 
2017) and meets the criteria for inclusion on the NIHR Centre for 
Reviews and Dissemination (CRD) Register. 
  
7.10.8 Implications for clinical practice 
The findings from the NMA and CEA broadly suggest that all 
NOACs dominate warfarin for the prevention of stroke in AF. 
Overall, apixaban appears to be the most cost-effective NOAC 
owing to the highest expected QALY and greater confidence of the 
95% CI around the incremental net benefit estimate. However, the 
absolute values between NOACs are unlikely to be so significant 
so as to actively modify therapy for patients currently on treatment. 
Local guidelines will need to be drawn up in conjunction with 
clinical specialists and patient partners to determine the benefits of 
one NOAC over another in determining the favoured agent from 
the class.  
  
Chapter 7: Research Project Four – Oral anticoagulants for prevention of stroke in atrial fibrillation 
     - 346 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[BLANK PAGE] 
 
 
Chapter 8: Discussion 
     - 347 - 
8.0 Chapter 8: Discussion  
 
8.1 Summary 
The application of a quantitative trade-off analysis, including 
efficacy, safety, tolerability, and / or cost parameters, as a 
supplement to Frequentist or Bayesian meta-analysis, over a 
number of clinical specialities has successfully aided in the 
establishment of a hierarchy of treatments. This hierarchy has been 
used to change practice within a pilot site of the UK NHS resulting in 
cost savings or cost-avoidance without compromising on patient 
care. Indirect comparisons, generated through NMA as conducted 
across a number of clinical specialities within this thesis, not only 
help develop rational treatment hierarchies, but also inform on the 
choice of high priority comparator agents for direct head-to-head 
analysis in the form of an RCT. 
 
Findings from the quantitative trade-off analysis of antiepileptic 
drugs for refractory epilepsy and of antimuscarinics for overactive 
bladder syndrome have modified prescribing trends within North 
Central London, providing moderate cost avoidance and cost 
savings for the NHS. The findings from the meta-analysis and 
supporting cost-utility analysis of angiotensin receptor blockers for 
hypertension and heart failure have directed change in prescribing 
across the UK, providing a saving to the health economy of 
approximately £200 million without compromising patient safety. 
Lastly, the findings from the network meta-analysis and supporting 
cost-utility analysis of novel oral anticoagulants for prevention of 
stroke in AF are in the process of being circulated to support and 
standardise prescribing.  
 
8.2 General study findings 
The approval of new medicines currently entering the UK (and 
European) market is required to satisfy regulatory criteria. A 
selection of these are subject to additional commissioning 
assessment. Where more than one medicine from the same class is 
available and / or recommended this presents the clinician with a 
dilemma as to which to choose. This predicament affects the health 
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economy where choices are favoured towards newer, more 
expensive medicines on the basis that they must be more 
efficacious or better tolerated.  
The consideration of many treatments within the context of a meta-
analysis, in the absence of a head-to-head RCT, is becoming 
increasingly popular as clinicians and policy makers attempt to 
consider together and understand the results from multiple trials on 
the same topic. Although assumptions and considerations for such 
analyses are required from the clinical community, the methodology 
and execution of NMA were traditionally held in the realms of 
statisticians owing to the specialised software required. With the 
availability of WinBUGS, a publically available software, and clear 
technical guides, this may now be utilised by policy developers 
directly.  
The studies presented within this thesis provide a concept of 
clarification for clinicians in practice regarding the most appropriate 
use of medicines available on balance of safety and efficacy, and 
cost where analysed. To explore its applicability, a number of 
different medicines across a range of different conditions were 
selected on the basis of their clinical importance. This includes 
treatments for refractory epilepsy (partial seizures with secondary 
generalisation), hypertension, heart failure, overactive bladder 
syndrome, and atrial fibrillation.  
Across a range of specialities, the analyses within this thesis 
demonstrate that the data required for regulatory purposes are not 
sufficiently meaningful for clinical practice. The use of frequentist or 
Bayesian meta-analysis, with subsequent trade-off and / or cost-
effectiveness analysis, are able to produce clinically-relevant data to 
inform clinicians and prescribing committees responsible for the 
development of guidelines. Where network meta-analyses produce 
findings that suggest no significant difference between the 
medicines under review, it can be reasonably assumed that the 
clinically-relevant difference between such agents is also not 
significant. Under such assumption a trade-off analysis can be 
supported by a cost-minimisation analysis. Where network meta-
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analyses produce findings that are statistically significantly different, 
the trade-off analysis should be supported by a cost-utility analysis. 
These analyses can be used prospectively i.e. to prevent the 
unnecessary uptake of new medicines that do not appear to offer 
any clear added value over existing therapies, or retrospectively i.e. 
to disinvest in medicines currently available on hospital or general 
practice formularies owing to their low clinical value.  
Among the topics considered within this thesis, the findings from the 
trade-off analysis for Chapter 5: Research Project Two – 
Angiotensin-II Receptor Antagonists for the Management of 
Hypertension and Heart Failure, and for Chapter 6: Research 
Project Three – Antimuscarinics and newer agents for the 
Management of Overactive Bladder syndrome have been converted 
into meaningful guidance for clinicians, via the relevant prescribing 
committee. This has subsequently led to changes in prescribing 
practice and savings to the health economy without compromises in 
patient care. The findings from the trade-off analysis for Chapter 4: 
Research Project One – Antiepileptic drugs for Refractory Epilepsy 
were implemented differently owing to the complexity of the 
condition. The most practical application of the results was agreed 
as being a benchmark for future medicines licensed for the same 
indication thereby restricting formulary adoption pending clear 
benefits on efficacy, tolerability, or cost. Within the local economy, 
North Central London, this has prevented widespread use of newer 
agents brought to market since the publication of this work. The 
work undertaken within the last research project, Chapter 7: 
Research Project Four – Oral anticoagulants for prevention of stroke 
in atrial fibrillation, was more extensive for a comprehensive cost-
utility analysis to complement the trade-off analysis. Whilst changes 
in practice have yet to be implemented, the findings have been 
shared with the commissioners within North Central London and are 
being used to support the CCGs on the appropriate use of the 
newer NOACs compared with warfarin.  
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8.3 General study strengths and limitations 
Meta-analysis of data has been used to synthesise results for several 
decades. Interest in this methodology continues as it enables 
researchers to reconcile inconsistent or unclear findings from 
individual RCTs and reach a definitive answer to the research 
question of interest. As a result, meta-analysis can overcome a key 
limitation of small studies, lack of sufficient statistical power. 
 
The use of Bayesian network meta-analysis supplemented by trade-
off and, where applicable, cost-effectiveness analysis employed 
during this thesis extends the above principle in order to further clarify 
research questions still faced in clinical practice. This methodology 
has several strengths, although some important limitations are 
apparent, as outlined within each chapter. The general strengths and 
limitations in terms of data and study validity are discussed below.  
 
8.3.1 Data validity 
A reservation amongst the clinical community when using meta-
analysis techniques to infer treatment pathways is the quality of the 
primary data included. It is thus important to validate this step in 
accordance with robust processes.  
To mitigate these concerns, strict guidelines are available for authors 
undertaking systematic review and meta-analysis. The use of an a 
priori protocol and data extraction form ensure that data used are 
consistently obtained. Following the principles outlined within 
PRISMA, the integrity of the data is maintained through capture of the 
appropriate patient groups, including those lost to follow-up or 
excluded from treatment for the efficacy and safety endpoints of 
interest.(320) To maintain relevance to the original scope, i.e. 
applicability to the UK NHS, the data considered within each of the 
review areas are applicable to UK licensed medicines and doses. 
Additionally, the restriction of full-text articles only ensures that the 
validity of the data has been assessed by an impartial and 
independent editorial board.  
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It is important to highlight that the work undertaken within this thesis 
has been peer reviewed, with three of the four areas published in 
medical journals, indicating the validity of the research technique and 
resultant findings. The findings have also been used to develop 
guidelines and implemented in practice indicating the acceptance of 
this technique amongst the relevant clinical communities.  
 
8.3.2 Model validity 
For the Frequentist analyses, the commercially available StatsDirect® 
software was used, utilising fixed-effect and random-effects models 
as appropriate, and standard reporting functionality. For the Bayesian 
analyses, the freely available WinBUGS® package was used. Coding 
for the Bayesian model were adapted from the NICE DSU Technical 
Service Documents and verified by experts in Bayesian analyses as 
described with the respective chapters. To demonstrate robustness in 
the Bayesian coding, results from Frequentist analyses were also 
presented to highlight the degree of correlation between the direct 
comparisons. As this is commonplace in the published literature it 
was replicated within this thesis. The aim of this was to assure the 
reader of the strength in the model when interpreting the indirect 
comparison estimates generated.  
To further assure on the estimates generated, a range of 
assessments were undertaken as described in section 3.5.7 
(including funnel plot, l’Abbé plot, and Higgins I-squared) and section 
3.6.8 (including convergence, inconsistency and goodness-of-fit). 
 
8.3.3 Bayesian vs. Frequentist Model 
Bayesian and Frequentist methods both have advantages and 
disadvantages, with many similarities. The Frequentist analysis is 
used where data are available to enable direct comparisons. Where a 
framework is required to create indirect estimates the Bayesian 
analysis is used. When the sample size is large, Bayesian inferences 
often produce results for parametric models that are very similar to 
results produced by Frequentist methods. For all analyses conducted 
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within this thesis the sample sizes have been sufficiently large and 
uniform with a high degree of correlation between both methods.  
Specific advantages in the use of Bayesian analysis include: 
 Providing a principled way of combining prior information with 
new data within a solid decision framework (model). Previous 
information acquired is used to form a prior distribution for 
future analysis. All inferences logically follow Bayes’ theorem.  
 Providing exact inferences that are conditional on the 
dataset.  
 Providing interpretable estimates, i.e. the true parameter has 
a probability of 0.95 of falling in a 95% credible interval 
 Providing a convenient setting for a wide range of models, 
such as hierarchical (rank) models and missing data 
problems (indirect comparisons). 
 
Specific disadvantages in the use of Bayesian analysis include: 
 It does not advise users on how to select a prior, and there is 
no correct way to choose / use a prior. The Bayesian model 
therefore requires the user to possess skills in translating 
prior beliefs into a mathematically formulated prior. If a prior 
is used incorrectly, the results generated from the analysis 
may be misleading. 
 As posterior distributions are influenced by the use of priors, 
it may be difficult to obtain acceptance of the results from 
subject matter experts who do not agree with the validity of 
the chosen prior. 
 The analysis utilises a high degree of computational 
processing, particularly where the model includes a large 
number of parameters. The number of simulation / iterations / 
burn-in used may provide slightly different estimates, 
although this is less likely to be an issue where higher 
numbers (>10,000) are used.   
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8.3.4 Alternative Methods 
All analyses undertaken within this thesis used a fixed- or random-
effect model at the level of trials. The use of individual patient level 
data (IPD) instead of aggregate trial-level data in the execution of 
meta-analysis is an alternative methodology that could have been 
used. The use of aggregate data, defined as study level data 
obtained from study publications (or study authors), is traditional used 
when populating a dataset for meta-analysis. The use of IPD involves 
acquiring the raw individual level data for each study and used in the 
synthesis of the meta-analysis. In this technique, the same approach 
is used regarding performing the Frequentist or Bayesian meta-
analysis however the preceding systematic review includes the 
additional step of drawing data from the authors original files rather 
than the summary data presented within a publication. It is proposed 
that meta-analysis of IPD has many potential advantages, both 
statistically and clinically, over meta-analysis of aggregate data.(321) 
Key examples include: aggregate data not available, poorly reported, 
derived and presented differently across studies, and more likely to 
be published where statistically or clinically significant. IPD data may 
also contain more participants and outcomes than that reported, and 
have a longer follow-up time.  
IPD meta-analysis is not however without its disadvantages. In 
particular, this approach is resource intensive due to the substantial 
time (and costs) involved in contacting study authors, who then must 
be willing to part with their raw data. It would also be expected that 
dialogue with the author is required to clarify and resolve data issues. 
Additionally, there are concerns surrounding the applicability of ethics 
approval as handing of IPD may be akin to source data. Further, 
despite the best efforts of an author undertaking IPD meta-analysis, it 
may be possible that IPD is not available for all studies included. In 
this scenario an assessment will need to be undertaken to determine 
if the absence of IPD and use of aggregate data would bias the 
analysis. Lastly, it is important to acknowledge that the quality of IPD 
or aggregate data is dependent on the quality of the study itself.  
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The use of IPD meta-analysis was initially considered as part of the 
NIHR funded project (Chapter 7: Research Project Four – Oral 
anticoagulants for prevention of stroke in atrial fibrillation), however 
not followed through on balance of the perceived advantages 
compared with the complexity this technique would have added to the 
project.(322)  
 
8.4 Study novelty 
This research incorporates many novel features. First, this thesis 
describes a programme of studies that are of direct relevance to the 
health economy specifically related to medicines use. Second, the 
research undertaken within each chapter of the thesis describes the 
use of trade-off analysis using key efficacy and safety / tolerability 
end points based on clinical experience and implications for a 
hierarchy. Third, cost-effectiveness analysis are utilised (specifically 
cost-utility) which have been populated using UK relevant parameters 
and its outputs directly implemented within the NHS with consequent 
practice change.  
 
During the period over which this thesis was conducted, a handful of 
leading statistical methodology teams have also recently identified the 
value of Bayesian network meta-analysis supplemented by a rank 
assessment. Examples include a review of first- and second-
generation antidepressants,(323, 324) which would be similar to the 
review of AEDs undertaken in Chapter 4.0. 
 
8.5 Reflective Account 
The conduct of the various research projects within this thesis has 
provided me with the opportunity to translate many academic and 
clinical skills into practice. Over the course of the four research topics 
the complexity of the methodology increased requiring revision of the 
techniques both in coding and execution. The use of WinBUGS and 
network meta-analysis as a whole was a new experience; however its 
value has been accepted within the local medicines management 
committees once translated into clinically-relevant outputs such as 
guidelines or treatment hierarchies, made possible with the trade-off 
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technique.  The ability to derive more robust, clinically useful 
information from pooling studies allowed me to see how clinical 
practice can be influenced and updated. The thesis as a whole has 
provided me with an aptitude for bridging the gap between regulatory 
data and data required at the interface of clinical practice.  
 
The core principle of rankings from an NMA and their extrapolation to 
guide practice has been questioned recently in an article.(325) 
Although related, the trade-off technique presented within this thesis 
is not intended to generate model outputs to be used in an unqualified 
application. Conversely, the basis for establishing a rank follows 
request from clinical practice for clarity on specific parameters of 
interest in order to minimise uncertainty of the output. The result of 
this key difference being successful implementation of the findings, 
where applied.   
 
8.6 Further Work 
Numerous research projects could follow-on from this thesis. For 
example, the creation of a central database from published studies 
would be appropriate to enable meta-analysis (of a direct or indirect 
nature) upon the licensing of a new medicine within the same class. 
This could be automatically populated as part of the article 
submission process at the point of acceptance. The upload of data 
should be encouraged to include stratified and sub-group level data to 
enable sensitivity analysis if needed. The funding of such a system 
and requirement for journals to make their data available as a direct 
feed to this could be enforced as part of a legislative change in the 
regulatory process, for example an FDA and / or EMA requirement 
upon granting of the Marketing Authorisation. This database would be 
akin to the CPRD (Clinical Practice Research Datalink) currently 
established within the UK as a joint venture between the NIHR and 
the MHRA in order to improve drug safety, best practice and clinical 
guidelines. The CPRD is an example of how post-marketing 
surveillance programs are predominantly limited to safety monitoring, 
with the exception of those that are marketed under specific early 
access schemes.  
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The benefit of the above is that it would enable cumulative analysis to 
take place with data available in a standardised format, without the 
need for individuals to assess studies in detail to determine reporting 
as intention-to-treat, modified intention-to-treat, or per-protocol. This 
system would introduce a culture change in the contribution of 
cumulative analyses related to efficacy and place in therapy post-
marketing. The execution of systematic reviews and meta-analysis 
should continue to be undertaken by experts within this area of 
research to ensure rigour is applied to the methodology and its 
appropriateness. The integrity of data will also need to be validated 
although there is potential that this could be done centrally if 
commissioned by the NIHR.  
For certain medicines, the above methodology, Bayesian mixed 
treatment comparisons with trade-off analysis, is able to support the 
development of a rank order of medicines included within the scope, 
which in turn will describe the best agent based on efficacy and 
tolerability, second best agent etc. This may compound an issue 
already in existence; that the launch of certain medicines in clinical 
practice results in different patterns of prescribing compared with that 
examined and assessed within the clinical trial. The knowledge of a 
treatment being ranked, for example, third would from a guideline 
development perspective suggest that this should be positioned as 
third line, should a third choice be required. It is important to note that 
the trial data has not evaluated the use of these agents in sequential 
use and therefore the rank analysis findings are being extrapolated to 
infer that a third choice would deliver the same benefits and / or risks 
as being given third-line.  
To answer this question a quite separate research project of n-of-1 
studies would need to be raised. Having sought clarification from the 
MHRA, this would not constitute a clinical trial of an investigational 
medicinal product (CTIMP) as the medicines themselves would be 
used in accordance with their Marketing Authorisation with the trial 
being intra-subject. Given that this, like the projects undertaken within 
this thesis, is an academic rather than commercial exercise, in order 
to undertake this it would require administrative support from 
medicines management teams within Acute Trusts. To undertake this 
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formally, a potential expense lies on the availability of placebo- or 
active-matched stock in situations where subjective measures are the 
primary outcome. Such work on this is already underway at the 
National Hospital for Neurology and Neurosurgery (NHNN) where 
access to the new antiepileptic drug brivaracetam is being supplied 
on a named patient evaluation basis to patients in whom 
levetiracetam has previously been used but causing tolerability 
issues. On the basis of overlapping clinical pharmacology of these 
two agents, specific inclusion criteria set for the evaluation require a 
clinical response to levetiracetam and recording of off-target adverse 
effect(s), with outcomes evaluation for 6 months. A similar n-of-1 
study is being discussed for eslicarbazepine secondary to 
oxcarbazepine.  
 
8.7 Conclusion 
While the randomised double-blind controlled clinical trial is the 
undisputed gold-standard for assessing drug efficacy, such trials are 
expensive to commission, include a fixed number of comparators, 
and usually do not provide the necessary comparisons to the 
potential standard of care. Moreover, they include limited patient 
numbers and run for short periods leading to limited power and 
therefore generalisability of its findings. Although designed to address 
statistical power as part of the calculation of recruitment target, the 
implications for clinical practice may be considered insufficient with 
specific issues related to comparative efficacy and safety. Therefore, 
at the time of product launch, clinicians are often faced with limited 
data and relevance for any new medicine. Despite numerous 
advances in evidence-based medicine, this continues to be an on-
going gap.  
Critical appraisal of systematic reviews and meta-analyses are 
embedded within evidence based medicine at the top of the pyramid 
on the basis that they can provide important insight into the utility of 
the results to improve patient care. Provided the methodology is 
robust in determining the validity, magnitude and applicability of the 
primary studies in accordance with the Cochrane Collaboration tools 
(or equivalent), the results will be generated to be of clinical value.  
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Meta-analyses frequently appear in the appraisal processes used by 
commissioning agencies, such as NICE, however they are not a 
mandatory part of the regulatory process. The research projects 
undertaken within this thesis demonstrate the merits of Bayesian 
mixed treatment comparisons, and the potential that Bayesian and 
frequentist meta-analysis can be enhanced to develop trade-off and 
cost-utility analyses. Routine implementation of such analyses can 
help to avoid uncertainty at the point of prescribing and unnecessary 
spend on newer medicines with no benefit over cheaper, established 
alternatives.  
Although such system has great potential it will require investment 
and buy-in at the regulatory and research authority level 
internationally. It is however important to acknowledge that despite 
notable success, this system is subject to several limitation. First, 
individual prospective studies only provide information over a short 
period of time whilst the implications are extrapolated for life-long 
therapy. Second, excluding trials that have not been published may 
exaggerate the treatment effects observed. Third, although 
heterogeneity assessments are undertaken, pooling of data from 
trials with differences in trial design, methodology and patient groups 
may result in a heterogeneous dataset from which conclusions are 
drawn. However, such differences may serve to strengthen the meta-
analysis by allowing generalisability of the results to a broader group 
as will be seen in general practice outside of the confines of a clinical 
trial. Fourth, analysis of this type will be restricted to the data 
available e.g. adult population; therefore any findings will need to be 
mindful that they are not extrapolated to patients beyond certain 
criteria. Fifth, doses employed within the clinical trials are not always 
consistent with those used in clinical practice, including the use (or 
absence) of a dose-escalation phase and close monitoring for dose-
titration; the external validity of data may therefore be questionable, 
although it is sufficient to satisfy regulatory authorities. Finally, data 
within such analyses only relate to the use of the medicine under 
investigation for a specific place in therapy, generally first- or second-
line; the generalisability or extrapolation of data beyond this should be 
considered with caution.  
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In this thesis I investigated the utility of a trade-off analysis as an 
extension to meta-analysis to overcome some of the limitations in 
practice currently. Data available publically from published articles, as 
accessed via on-line database and journals, was used to quantify the 
efficacy and safety / tolerability of medicines which are licensed for 
the same indications. These data were then converted into odds ratio, 
hazard ratio and / or number needed to treat or harm for specific 
endpoints considered of clinical importance in order to conduct a 
trade-off analysis and determine a rank. Provided a system is created 
centrally that captures the primary data in an organised manner, this 
methodology can be effectively utilised to inform on the relative merits 
and harms of every new medicine as part of product launch, thereby 
indicating potential value over existing treatments. The building of 
data from historical publications could be executed as a programme 
of responding under the guidance of the Regional Medicines 
Optimisation Committees (RMOC) as part of implementation of 
quality, standardised care across the UK.  
Despite certain limitations with this type of analysis, something which 
is widely acknowledged with meta-analysis, given the efficiency and 
versatility of this method this could become a future standard 
following regulatory approval. This could facilitate a paradigm shift 
from the traditional model of trial-and-error, where new medicines are 
perceived to be better than existing medicines and receive uptake on 
this basis, to one of an informed rank. Improvement in prescribing 
trends and reductions in spend are crucial in order to achieve a 
sustainable National Health Service.  
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10.0 Appendices 
10.1 Appendix I: PRISMA templates 
 
 PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 77:  PRISMA flow diagram template (2009) 
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  PRISMA 2009 Checklist 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
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Section/topic  # Checklist item  
Reported 
on page #  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
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Section/topic  # Checklist item  
Reported 
on page #  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
 
  
Figure 78: PRISMA checklist template (2009) 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
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10.2 Appendix II: WinBUGS user guide  
 
Instructions for using WinBUGS (v14.0) 
Open the programme “WinBUGS14” 
Starting the process 
[Menu] File – Open – (Open “WinBUGS Template” file) 
 A template file with all the commands to run the analysis will open in a 
window.  
 
Adapt the command section 
Replace the following items between the first two blue arrows: 
 N (delta) = total number of trial arms (remember, active vs placebo will be 
entered as two arms) [2] 
 NS (mu) = total number of studies [1] 
 NT (d) = total number of different treatment option (including placebo 
which should be number 1) [5] 
 BR = baseline risk (i.e. background risk from population data OR pooled 
result from the placebo intervention) [2] 
 
The program will not run if all of these letters are not replaced with a number 
(N.B. the BR is in a small font) 
 
Adapt the data 
1. Open data sheet in Excel 
2. Highlight data only from excel sheet i.e. exclude the trial id, comparison, 
population (only r[], n[], t[], b[], s[] and m[] and data).  
3. Copy 
4. Go back to WinBUGS 
5. After the second arrow is the data highlight the data (not the word END) 
6. [Menu] Edit – Paste Special – Plain Text 
 
Adapt the run program 
Below the third arrow is the section “#initial 1” 
 Following “d=c(NA,-0.5,-1,-0.2),” repeat the numbers to equal the number 
of treatments, NA appears once only; e.g. if NT=8 then  
d=c(NA,-0.5,-1,-0.2,-0.5,-1,-0.2,-0.5),” a comma should be present after 
the closing bracket. 
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 Following “mu=c(…)” repeat the numbers to equal the number of studies. 
Ensure that a comma is not present after the final number before closing 
the bracket, but is present after the closing bracket. 
 Following “delta=c(…)” repeat the numbers to equal the number of trial 
arms. Ensure that a comma is not present after the final number before 
closing the bracket. In this entry, a comma is not present after the closing 
bracket. 
 
Running the program 1 
[Menu] Model – Specification 
 
Specification Tool 
Step 1 
 Highlight the word “model{“ after the first arrow 
 On the Specification Tool, Click “check model” 
 The status bar (bottom grey bar) should read “model is syntactically 
correct” 
 
Step 2 
 Highlight the row “r[], n[], t[], b[], s[] and m[]” 
 On the Specification Tool, click “load data” 
 The status bar (bottom grey bar) should read “data loaded” 
 
Step 3 
 On the Specification Tool, click “compile” 
 The status bar (bottom grey bar) should read “data compiled” 
 
Step 4 
 Highlight the row “list(” under #initial 1 
 On the Specification Tool, click load inits 
 The status bar (bottom grey bar) should read “model is initialized” 
 
Running the program 2 
[Menu] Model – Update 
 
Update Tool 
Step 5 
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 Change number of updates from 1000 to 20,000 (number of iterations 
performed to derive an average.  
 Click on “update” 
 The iteration box will scan from 0 to 20,000 
 
 
Running the program 3 
[Menu] inference – Sample 
 
Sample Monitor Tool 
Step 6 
 In the node box, enter the following (not the bit in the brackets), each type 
pressing set afterwards: 
 or (odds ratio) 
 rr (risk ratio) 
 sumdev (goodness of fit) 
 best (ranking) 
 rk (ranking) 
 Go back to the Update Tool 
 Click “update” 
 The iteration box will scan from 20,000 to 40,000 
 
 
Executing the program 
Go back to the Sample Monitor Tool 
 
Step 7 
 In the node box, enter an asterisk (shift+8) 
 Click “stats” 
 A node statistics window should open will all the results 
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Obtaining the results 
Go to the node statistics window 
 
Step 8 
 Place the cursor at the start of the word “node” 
 Select all text within the window by pressing “CTRL+A” 
 Copy all of the text by pressing “CTRL+C” 
 
Open up a blank Excel spreadsheet 
 
Step 9 
 Paste all of the text by pressing “CTRL+V” 
 This will copy all the data in columns B to J 
 In column A, next to the OR results, enter in the corresponding treatments 
(for 1, 2, 3, etc.) 
 In column K, row 1, add the heading “MCe/sd”  
 In K2, setup the rule to divide E2 by D2.  
 Drag this rule to apply to the whole of column K 
 Using the mouse, left-click on the “K” column button to highlight this 
column 
 Right-click mouse to access the menu and select “format cells” 
 Under “number – category” select percentage, changing the number of 
decimal places to zero before selecting OK.  
 The percentages displayed provide a figure (%) on how robust the 
computed figures are. All values should be less than 5%. If above 5%, go 
back to WinBUGS, locate the Update Tool, click on update to repeat the 
number of interations from 40,000 to 60,000. Proceed from Step 7 again.  
 Any entries where the sd value is zero should be manually entered as 
“0%”. 
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Interpreting the results 1 
 
Goodness of fit (Sumdev) 
“An analysis of how the observed value relates to that which is 
expected” 
 
Step 10 
 At the bottom of the data pasted will be a sumdev row, where the number 
in the C column will indicate how “good” the data is. This number should 
be in the region of N, the number of studies included in the analysis.  
 Below this box (should be empty), enter in the N value 
 To calculate a p-value to be more precise in the reporting of this goodness 
of fit analysis 
 Click on the empty box below the N value (still in column B) 
 Click on the “fx” button in the command bar 
 In the “search for a function box” type in “chi” 
 Select the option “CHIDIST” which will return the one-tailed 
probability of the chi-squared distribution 
 For the X value, select the sumdev value 
 For the Deg_freedom value, select the N value entered 
 Click OK 
 The p-value should be >0.05 to indicate that there is no statistically 
significant variation in the result that was observed from that which 
is expected.  
 
 
Interpreting the results 2 
Switch back to WinBUGS; the node statistics window should still be open. 
Click on the Sample Monitor Tool. 
 
Step 11 
 In the node box, enter “or” 
 Click “history” 
 Export these results for analysis; the line should be heavily distorted (up 
and down) and not a steady line. Copy and paste as appropriate into MS 
Word. 
 
Step 12 
 In the Sample Monitor Tool node box, “or” should still be present 
 Click “density” 
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 A series of graphs, akin to a normal distribution should appear. Copy and 
paste as appropriate into MS Word. 
 
Interpreting the results 3 
Go back to the node statistics window. 
[Menu] Inference – Compare 
 
Step 13 
 In the node box, enter “or” 
 Click “caterpillar” 
 A caterpillar plot will be generated representing the odds ratio of all 
interventions relative to each other visually.  
 The red line represents the baseline risk value entered in at the start of the 
program indicating where interventions need to be placed (with the 
confidence intervals) to be considered effective at a significant level.  
 
Step 14 
 In the node box, enter “rr” 
 Click “caterpillar” 
 A caterpillar plot will be generated representing the risk ratio of all 
interventions relative to each other visually.  
 Again, the red line represents the baseline risk value entered in at the start 
of the program indicating where interventions need to be placed (with the 
confidence intervals) to be considered effective at a significant level. 
These point estimates take into account all interventions included within 
the analysis and are the basis for the rank outcome.  
 
Interpreting the results 4 
 
Rank  
[Menu] Inference – Rank 
 
 The Rank Monitor Tool window will open 
 In the node box, enter “rk” 
 Click “set” 
 Go back to the Update Tool window and click “update” 
 The iteration box will scan from 40,000 to 60,000 (unless repeated earlier 
in Step 9) 
 Go back to the Rank Monitor Tool window 
 In the node box, “rk” should still be present 
 Click “histogram” 
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 Information on how the rank was established will be presented using 
histograms. 
 
Buchers test for inconsistency 
Use the worksheet in Excel. 
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10.2.1 Data entry for 3-arm MTC analysis (Research Project Three) 
Table 79: Efficacy endpoint 1; Mean number of micturition’s (voids) per 24 hours [change from baseline] 
Reference ID Comparison t[,1] t[,2] t[,3] t[,4] y[,1] y[,2] y[,3] y[,4] se[,1] se[,2] se[,3] se[,4] na[] 
Chapple 2013 (Dragon) P vs MIR50 v TOL4 1 2 3 NA -1.44 -2.08 -1.99 NA 0.251 0.191 0.329 NA 3 
Khullar 2013 (Scorpio) P vs MIR50 v TOL4 1 2 3 NA -1.37 -1.94 -1.57 NA 0.115 0.116 0.123 NA 3 
Nitti 2013 (Aries) P vs MIR50 1 2 NA NA -1.05 -1.66 NA NA 0.130 0.130 NA NA 2 
Herschorn 2013 (Capricorn) P vs MIR50 1 2 NA NA -1.18 -1.6 NA NA 0.170 0.120 NA NA 2 
Yamaguchi 2014(b) BJUI P vs MIR50 v TOL4 1 2 3 NA -0.86 -1.67 -1.4 NA 0.143 0.138 0.134 NA 3 
Appell 2001 TOL2 vs OXY10 4 5 NA NA -2.87 -3.53 NA NA 0.003 0.006 NA NA 2 
Cardozo 2004 P vs SOL5 vs SOL10 1 6 7 NA -1.59 -2.37 -2.81 NA 0.205 0.176 0.199 NA 3 
Chapple 2004 P vs SOL5 vs SOL10 vs TOL2 1 6 7 4 -1.2 -2.19 -2.61 -1.88 0.205 0.176 0.199 0.190 4 
Choo 2008 SOL5 vs SOL10 vs TOL2 
6 7 4 NA -2.18 -2.47 -2.14 NA 
0.249 0.259 0.248 
NA 3 
Chu 2009 P vs SOL10 
1 7 NA NA -1.50 -3.00 NA NA 0.200 0.200 NA NA 2 
Herschorn 2008 P vs TOL4 
1 3 NA NA -1.70 -2.30 NA NA 0.200 0.100 NA NA 2 
Herschorn 2010 P vs FES8 vs TOL4 
1 8 3 NA -1.50 -2.20 -2.1 NA 0.200 0.100 0.100 NA 3 
Homma 2003 P vs TOL4 
1 3 NA NA -1.10 -2.00 NA NA 0.200 0.100 NA NA 2 
Kaplan 2011 P vs FES8 vs TOL4 1 8 3 NA -2.13 -2.75 -2.48 NA 0.142 0.096 0.107 NA 3 
Nitti 2007 P vs FES 4 vs FES8 1 9 8 NA -1.08 -1.61 -2.09 NA 0.180 0.180 0.180 NA 3 
Staskin 2007 P vs TRO60 1 11 NA NA -1.99 -2.81 NA NA 0.160 0.150 NA NA 2 
Van Kerrebroeck 2001 P vs TOL2 vs TOL4 1 4 3 NA -2.20 -3.30 -3.50 NA 0.178 0.194 0.155 NA 3 
Yamaguchi 2007 P vs SOL5 vs SOL10 1 6 7 NA -0.94 -1.93 -2.19 NA 0.115 0.101 0.109 NA 3 
Yamaguchi 2011 P vs FES4 vs FES8 1 9 8 NA -0.59 -1.15 -1.25 NA 0.180 0.180 0.180 NA 3 
Zinner 2004 P vs TRO20 1 10 NA NA -1.29 -2.37 NA NA 0.350 0.350 NA NA 2 
Zinner 2006 P vs DAR15 1 12 NA NA -1.80 -2.20 NA NA 0.350 0.350 NA NA 2 
               No studies 21 
             No treatments 12 
             No arms 55 
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Table 81 continued. 
 
 
 
Events Sample size Treatment Baseline treatment Study Arm of study 
Reference ID Comparison r[] n[] t[] b[] s[] m[] 
Chapple 2013 (Dragon) P vs MIR50 v TOL4 -1.44 166 1 1 1 1 
Khullar 2013 (Scorpio) P vs MIR50 v TOL4 -1.37 480 1 1 2 1 
Nitti 2013 (Aries) P vs MIR50 -1.05 454 1 1 3 1 
Herschorn 2013 (Capricorn) P vs MIR50 -1.18 433 1 1 4 1 
Yamaguchi 2014(b) BJUI P vs MIR50 v TOL4 -0.86 368 1 1 5 1 
Appell 2001 TOL2 vs OXY10 -2.87 172 4 4 6 1 
Cardozo 2004 P vs SOL5 vs SOL10 -1.59 281 1 1 7 1 
Chapple 2004 P vs SOL5 vs SOL10 vs TOL2 -1.20 253 1 1 8 1 
Choo 2008 SOL5 vs SOL10 vs TOL2 -2.18 118 6 4 9 1 
Chu 2009 P vs SOL10 -1.50 309 1 1 10 1 
Herschorn 2008 P vs TOL4 -1.70 201 1 1 11 1 
Herschorn 2010 P vs FES8 vs TOL4 -1.50 334 1 1 12 1 
Homma 2003 P vs TOL4 -1.10 122 1 1 13 1 
Kaplan 2011 P vs FES8 vs TOL4 -2.13 462 1 1 14 1 
Nitti 2007 P vs FES 4 vs FES8 -1.08 266 1 1 15 1 
Staskin 2007 P vs TRO60 -1.99 300 1 1 16 1 
Van Kerrebroeck 2001 P vs TOL2 vs TOL4 -2.20 507 1 1 17 1 
Yamaguchi 2007 P vs SOL5 vs SOL10 -0.94 395 1 1 18 1 
Yamaguchi 2011 P vs FES4 vs FES8 -0.59 318 1 1 19 1 
Zinner 2004 P vs TRO20 -1.29 256 1 1 20 1 
Zinner 2006 P vs DAR15 -1.80 225 1 1 21 1 
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Table 80: Labels and codes used for each of the treatments included within the MTC analysis 
Label Drug (dose) Code 
P Placebo 1 
MIR50 Mirabegron 50mg OD 2 
TOL4 Tolterodine MR 4mg OD 3 
TOL2 Tolterodine IR 2mg BD 4 
OXY10 Oxybutynin MR 10mg OD 5 
SOL5 Solifenacin 5mg OD 6 
SOL10 Solifenacin 10mg OD 7 
FES8 Fesoterodine 8mg OD 8 
FES4 Fesoterodine 4mg OD 9 
TRO20 Trospium 20mg BD 10 
TRO60 Trospium 60mg OD 11 
DAR15 Darifenacin 15mg OD 12 
 
 
#Description of data inputs 
       # ns = Number of studies 
       # nt = Number of treatments (including placebo) 
       # t[,x] = Treatment indicator 
       # r[,x] = Number achieving response on HAM-D (50% improvement of scores from baseline) 
       # n[,x]= Number of all randomized patients (ITT) 
       # na[] = Number of arms in study 
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10.3 Appendix III: Supplementary Material for Research Project Two  
10.3.1 Cost-Utility Analysis model  
Baseline risk parameters (age, gender, SBP), smoking status, 
presence ⁄ absence of diabetes or atrial fibrillation (AF) and high-
density lipoprotein (HDL) levels and drug treatment effects on SBP 
were computed. A risk sub-model was then used to calculate the age- 
and sex-related probabilities of stroke and CHD risk for each year in 
the model, based on Framingham risk equations (326, 327). As noted 
by Wolf et al. (1991), SBP is an accurate predictor of stroke risk (327). 
Although, other studies have tried to improve the predictive value of 
outcomes beyond that which the well-established Framingham risk 
score could predict, a recent review showed that the studies were 
hampered by methodological flaws (328). Male and female cohorts 
were modelled separately by baseline risk according to SBP (mild 140 
mmHg, moderate 165 mmHg, high 180 mmHg) and subsequent 
mortality was calculated as a result of myocardial infarction (MI) and 
cerebrovascular events. 
 
To overcome the normal fixed temporal probability limitation of 
standard Markov models, annual time-dependent transition 
probabilities were calculated using look-up tables for age and gender-
related all-cause mortality from UK life tables and data from the MI ⁄ 
stroke mortality in the Framingham follow-up Study (329). Mortality was 
limited to 10 years post disease since the regression equations for 
stroke progression are valid only for a 10-year period. Half-cycle 
correction was used when calculating life-years (330).  
 
For a one thousand essential hypertension patient cohort simulation, 
given varying baseline risks of developing CHD and CVD, we 
calculated the following secondary economic outcomes: total and 
average costs per strategy, life-years gained, quality-adjusted life-
years (QALYs) gained and report the primary outcome of incremental 
cost-effectiveness ratios (ICERs) of the two treatments by calculating 
the ratio of the averaged incremental costs to incremental QALYs. An 
ICER value of £30,000 per QALY was used as an upper threshold for 
NHS cost-effectiveness.  
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Best estimates of disease-state costs and utility values for the base–
case model were estimated from the published literature. We 
considered the direct costs for drug acquisition and those associated 
with managing initial non-fatal stroke and CHD events as well as the 
costs for ongoing management, inflated from 2005 to 2009 base year 
values using the Hospital and Community Pay & Price Index (331). In 
line with the National Institute for Health and Clinical Excellence 
(NICE) Technology Appraisals, annual disease-state quality of life was 
estimated, assuming that MI survivors had higher utility after their initial 
events and stroke survivors had constant utility thereafter. Cost and 
health benefits were discounted at a rate of 3.5% in concordance with 
NICE Technology Appraisal guidance. We assume equal utility loss in 
both arms attributable to adverse treatment effects since we are 
comparing two drugs within the same class without proven evidence of 
any tolerability differences. The death state is associated with zero 
cost and utility. 
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10.3.2 UCLH Guidelines on ARBs for Hypertension and Heart Failure  
 
 
UCLH GUIDELINES ON ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) 
FOR HYPERTENSION AND HEART FAILURE 
  
In March 2010, losartan (Cozaar®) lost market exclusivity. This is the first of the 
angiotensin II receptor blockers (ARBs) to do so. This drug class currently incurs the 
fourth highest cost to the NHS in terms of drug expenditure. The cost of losartan 
50mg and 100mg has fallen to £3.77 (from £12.80) and £4.64 (from £16.18) 
respectively. Experience with other agents (e.g. ACE inhibitors) suggests the price will 
fall much further saving the NHS more than £50 million. However the total ARB 
spend in England was £272 million in England in 2008, with 6 ARBs (candesartan, 
eprosartan, irbesartan, olmesartan, telmisartan and valsartan) remaining on patent. 
If losartan were the primary ARB in the NHS more than £200 million could be saved 
per annum.  Locally, NHS London spends £35million a year on ARBs generating 
potential to achieve a £25 million saving.  
 
Within a class of drugs, all acting in the same way at the same receptor, there can be 
differences in required dose, dosing frequency, drug interactions, adverse event 
profiles and the pharmacopolitical environment (cost, licensing etc).  For ARBs, which 
are used in hypertension (usually in combination therapy) and heart failure, these 
differences are small, almost always clinically insignificant, and reflect minor dosing 
differences. They are all once a day drugs. In other words, the drugs are more or less 
clinically indistinguishable. With the recent HEAAL trial publication, a target dose for 
losartan in heart failure is now available at 150mg [unlicensed] per day. After a UCLH 
Use of Medicines Committee evidence review of ARBs, and in collaboration with 
Camden PCT, all ARBs except losartan have been removed from The Formulary. For 
patients on ARBs for hypertension, a pharmacist-led review policy is to be 
implemented. For patients on ARBs for stable heart failure where the patient is not 
on the maximum ARB dose, dose escalation is recommended and achieved by 
changing to losartan. The exception to this is the [rare] specific situation of prior 
losartan intolerance. For patients with severe heart failure and prone to frequent 
decompensations, changing medications could theoretically precipitate 
decompensation (although there is no published evidence that this is as significant 
problem). However, for such patients the decision to change will be left to the 
discretion of the patient's physician. 
 
Recommendations  
 New patients: Losartan is the only ARB to be initiated in all patients for both 
hypertension and heart failure. ARBs should only be prescribed if ACE-
inhibitor intolerant. 
 Existing patients for hypertension: 
o Patients admitted on branded ARBs will receive and be discharged 
on losartan (pharmacy-led review). Exceptions: prior documented 
intolerance to losartan. 
Existing patients for heart failure: 
o Where not already on maximal dose, ARB dose escalation is 
encouraged.  If a patient has the ARB dose escalated, the patient 
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should be changed to losartan (exception: prior documented 
intolerance to losartan). This should be performed under guidance 
of the responsible physician. Where the patient is on maximal dose 
ARB and it is not losartan, the existing ARB is continued and the 
decision to change left to the responsible physician. 
 The losartan dose used in hypertension will be 50mg or 100mg daily 
depending on whether the existing ARB dose is at the lower or upper end of 
its dosing schedule (see table). 150mg daily is the target dose for heart 
failure [unlicensed]. 
 
FAQ 
 
Isn’t candesartan more effective than losartan in heart failure and /or have a better 
evidence-base? 
There are no head-to-head studies comparing these agents so there is an absence of 
robust evidence in terms of ascertaining apparent superiority or inferiority of one 
agent over another. In terms of evidence base, in 2009, a larger study [involving 
losartan] with longer follow-up, called the HEAAL study, was published (the HEAAL 
trial recruited 3,846 patients and followed up for a median of almost 5 years; Charm-
Alternative [involving candesartan] recruited 2,028 with a median follow-up of about 
3 years) which also demonstrated a reduction in the rate of death or admission for 
heart failure in patients with heart failure, reduced left-ventricular ejection fraction, 
and intolerance to ACE inhibitors. It is, however, difficult to compare these two trials 
directly as Charm-Alternative was merely a placebo-controlled trial and only 55% of 
patients were taking a β -blocker; baseline β-blocker therapy was much greater (72%) 
in the active-comparator [low dose losartan] HEAAL study. A recent independent 
analysis concluded that based on these study differences the findings of HEAAL 
appear reasonably consistent with those of the CHARM-Alternative study.3 
 
What about the safety issue raised by some commentators of the ELITE II study, 
where losartan use was associated with increased mortality compared to placebo 
in patients prescribed beta-blockers. HEAAL had no placebo arm and cannot 
therefore rule out the possibility that losartan interacts with beta-blockers in 
patients with heart failure in a negative fashion? 
First, this finding was based on exploratory post-hoc sub-group analyses in a small 
(insufficiently powered) group of patients in ELITE II. Such data are interpreted as 
hypothesis-generating and not policy-defining. Second, this apparent difference was 
not seen if use was based on concomitant treatment with beta-blockers during the 
study which is more relevant. Third, patients on losartan and captopril also taking 
beta-blockers did better than most patients not on such treatment at randomisation 
during ELITE II. Fourth, the “interaction” between treatment effect and baseline 
beta-blocker use should be interpreted with caution given the small absolute number 
of patients receiving these drugs and potential bias related to the reasons for 
administering these agents. Fifth, the presence of an interaction was investigated in 
the subsequent OPTIMAAL study (see below) which showed no interaction between 
losartan and beta blockers with respect to survival. Sixth, many commentators now 
agree that these “findings” suggested from ELITE II analyses are likely to be spurious.  
Seventh, of note, baseline beta-blocker therapy was much greater in the HEAAL and 
OPTIMAAL studies (72 and 79% respectively) when compared to CHARM-Alternative 
(55%). Finally, there is no evidence from HEAAL of an inflated mortality rate in either 
arm. 
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Wasn’t losartan inferior to ACEi for post-MI heart failure (OPTIMAAL study)?  
5477 patients 50 years of age or older with confirmed acute myocardial infarction 
and heart failure during the acute phase or a new Q-wave anterior infarction or 
reinfarction, were randomly assigned and titrated to a [low] target dose of losartan 
(50 mg once daily) or [proven] captopril (50 mg three times daily) as tolerated in the 
OPTIMAAL study. The primary endpoint was all-cause mortality. There were 946 
deaths during a mean follow-up of 2.7 years: 499 (18%) in the losartan group and 447 
(16%) in the captopril group (relative risk 1·13 [95% CI 0·99—1·28], p=0·07) i.e. a non-
significant difference in the primary endpoint (total mortality) was observed. The 
incidence of reinfarction, revascularisation, and all-cause hospital admission were 
essentially identical between the two groups. The upper one-sided 95% confidence 
margin (1·25) for the relative risk of death from any cause was above the pre-
specified margin of 1·10 resulting in failure to satisfy the non-inferiority criterion.  
 
Valsartan and candesartan lose exclusivity within 2 years, is this worth all the 
effort? 
Patents are often extended and there is often a delay between total expiry and 
generic availability. Regardless, savings of several hundred million pounds that could 
be achieved during this time are far from insignificant. 
 
It would be easier to apply these guidelines for new patients only, won’t changing 
patients stabilized on treatment be too time consuming and risky? 
For patients treated for hypertension, no experts consulted at UCL Hospitals thought 
this unreasonable especially considering the wide inter- and intra-day variations in 
physiological blood pressure; most use will be as combination therapy as well. For 
patients with heart failure the guideline allows for clinical discretion and only 
suggests change during up-titration to target dose; a practice that is universally 
encouraged in heart failure.   
 
Why don’t you recommend changing all heart failure patients?   
The evidence for all ARBs in heart failure is robust, including evidence for losartan.  
The effect of ARBs in heart failure is a class effect. There are no head-to-head studies 
indicating superiority or inferiority of one agent over another.  Also, losartan is the 
only ARB where high dose has been shown to be more effective than low dose.  
Nevertheless, despite all the pharmacological data of equivalence, there may be 
small ‘dosology’ differences between ARBs.  Some heart failure patients are very 
unwell with short life expectancy.  It is possible that even slight changes such as may 
occur during an ARB change could tip patients into decompensation – or, of course, 
decompensation episodes could occur anyway and be blamed on the ARB change, 
preventing disclosure of other causes. 
 
High dose losartan for heart failure is not licensed. 
This is true, but sometimes the regulatory environment lags the evidence, and 
sometimes, such as when the drug is off patent, it may never catch up. Doctors use 
unlicensed drug/dose/indications frequently (such as generic clopidogrel in acute 
coronary syndrome), provided the reasons are sensible and robust. The UCLH Use of 
Medicines Committee has also advocated the use of 150mg losartan in heart failure.  
 
Are there any significant differences in drug-drug or drug-food interactions? 
No although aliskiren levels may be reduced by irbesartan. 
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What about combination drugs? 
Patients appreciate combination drugs (ARB + diuretic) as it reduces the total number 
of tablets per day to be taken.  However, the price premiums for combination drugs 
are too high so it is not cost-effective to prescribe them.  Any individuals on 
combination treatment will be changed to losartan plus equivalent dose diuretic.  
 
What are the precise dose comparisons with losartan? 
All 7 drugs are marketed in 3 doses (low, medium, high dose).  We recommend 
changing to low, medium or high dose losartan (see table).  During changing, there 
may be the opportunity to uptitrate the dose because higher doses of losartan are 
better in heart failure. 
 
Limiting medical prescribing is a threat to doctor autonomy. 
NHS resources are limited and getting more so.  Optimising cost-effective prescribing 
of ARBs will free up resources for other areas where there may be no alternatives, 
particularly new, expensive but effective treatments. 
 
What will the saving be? 
The savings of an England-wide change are in the region of £200 million per year, and 
£25million in London.  This saving will not, however, be sustained long term as other 
ARBs lose their patent (e.g. candesartan 2012) – but in an environment of fiscal 
tightening, this will free up resources for other essential services and drugs over the 
next few years. 
 
Will patients want to change? 
There is extensive experience of changing similar drugs both locally and nationally, 
e.g. in statins.  We have also developed a patient information leaflet to explain the 
justification and reasons for changing. When conducted sensitively, patients almost 
universally approve and consent to changing. 
 
Who contributed to these guidelines? 
Dr James Moon & Dr Simon Woldman, both Consultant Cardiologists; Dr Anthony 
Grosso & Mr Pritesh Bodalia, both Pharmacists; and Prof Raymond MacAllister & Prof 
Aroon Hingorani, both Consultant Clinical Pharmacologists, drafted these guidelines 
which were approved by the multidisciplinary Use of Medicines Committee (Drugs 
and Therapeutics Committee). 
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Appendix 
 
Table 1: Dose comparisons of ARBs in heart failure 
 
ARB Lower dose Intermediate dose Target dose 
Losartan 50mg 100mg 150mg [unlicensed] 
Candesartan 4mg 8-24mg 32mg 
Valsartan 80mg 120-280mg 320mg 
 
Table 2: Dose comparisons of ARBs in hypertension 
 
ARB Lower dose Intermediate dose Upper dose 
Losartan 50mg 50-100mg 100mg 
Candesartan 4mg 8-24mg 32mg 
Eprosartan 600mg 600mg 800mg 
Irbesartan 150mg 150mg 300mg 
Olmesartan 10mg 20mg 30-40mg 
Telmisartan 20mg 40mg 80mg 
Valsartan 80mg 120-280mg 320mg 
 
Note: These are not exact dose equivalent tables and lower doses may be 
appropriate for the elderly, patients with renal or hepatic impairment or if on 
concomitant diuretic treatment (see current British National Formulary or Summary 
of Product Characteristics for prescribing information). 
 
References 
1. McKelvie, R. Compared with low-dose losartan, high-dose losartan decreases risk of death or hospital admission for 
heart failure in people with heart failure who are intolerant to ACE inhibitors Evidence-Based Medicine April 2010 | 
volume 15 | number 2 
2. Grosso AM, Bodalia PN, MacAlliser RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-
effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, 
meta- and cost-utility analysis. Int J Clin Pract 2011; 65 (3): 253-263 
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10.3.3 GP Template Letter 
 
 
Patient name:      
 
DOB:     
 
Hospital admission date:     
 
Dear Doctor, 
 
Re: Angiotensin II Receptor Blockers (ARBs) 
 
We are writing to inform you that we have changed the above patient to losartan 
therapy during their recent hospital admission. In March 2010, losartan (Cozaar®) 
lost its patent. This is the first of the angiotensin II receptor blockers (ARBs) to do so. 
We estimate that if losartan were the primary ARB in the NHS more than £200 
million could be saved per annum. Locally, NHS London spend £35 million a year on 
ARBs generating the potential to achieve a £25 million saving. 
 
The UCLH Use of Medicines Committee (UMC) which includes representation from 
our local PCTs, has recently reviewed the evidence for ARBs and it has been agreed 
that we will change all patients prescribed a branded ARB for hypertension to generic 
losartan. The exception to this is the [rare] specific situation of prior losartan 
intolerance. For patients on ARBs for stable heart failure where the patient is not on 
the maximum ARB dose, we will have changed to losartan during dose escalation 
(our target dose for heart failure [150mg] is unlicensed, although it is evidence-
based). For patients with severe heart failure and prone to frequent 
decompensations, changing medications could theoretically precipitate 
decompensation (although there is no published evidence that this is a significant 
problem). However, for such patients the decision to change has been left to the 
discretion of the patients’ physician.  
 
We have informed the patient of this change and provided them with an information 
leaflet and 28 days supply of losartan tablets with the instruction to obtain further 
supplies from your surgery.  
 
If you would like to discuss this further, please contact the Medicines Management 
team on 0845 1555 000 extension 4340. Patients can phone our Medicines 
Information helpline on 0845 1555 000 extension 73500. 
 
Yours sincerely 
 
 
Mr Pritesh Bodalia 
On behalf of the UCLH UMC 
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10.3.4 Heart Failure Patient Information Leaflet (PIL) 
 
 
Patient Information: Changes to your heart failure medication  
 
This leaflet aims to explain the reasons why one of the medications to help with control of 
your heart failure has been changed. The UCLH Use of Medicines Committee is a group of 
specialist consultants, pharmacists and nurses that has a special interest in medicines. They 
regularly review the medicines we prescribe to check that we’re using the most effective 
ones. For conditions for which there are a number of similar medicines we also check that we 
are using the most cost-effective medicine (see below for more information). This group has 
recently reviewed the potential benefits of each of the medicines used to treat heart failure 
and it was agreed that losartan should be used in preference to candesartan, eprosartan, 
irbesartan, olmesartan, telmisartan or valsartan. 
 
We have changed your prescription to losartan 50mg, 100mg or 150mg to be taken once a 
day to help with your heart failure. If you have any questions about this change please 
contact our Medicines Information department on 0845 1555 000 extension 73500. This line 
is open between 10am to 5pm from Monday to Friday.  If you have any candesartan, 
eprosartan, irbesartan, olmesartan, telmisartan or valsartan at home please return them to 
your local chemist so that they can be disposed of. Do not take candesartan, eprosartan, 
irbesartan, olmesartan, telmisartan or valsartan AND losartan at the same time. 
 
Some reasons for the change: 
 
For many illnesses there are a number of similar medicines. The more expensive one is not 
necessarily better than less expensive ones. When there is more than one choice it is sensible 
for the doctor to prescribe the one that is the best value (or most cost-effective).  
 
We do not believe there is anything medically wrong with the medicine you have been using 
previously. But we do believe that losartan can give you the same results while also giving the 
NHS better value for money. 
 
If the new medicine does not suit you, your GP can change your prescription back to the 
medicine you have been taking. 
 
Frequently asked questions: 
Why change my medicine if my current one works fine? Your previous medicine was one of a 
number of very similar medicines. The newer medicine you have been given is currently the 
most cost-effective of this class and allows us to use these savings to help improve other NHS 
services. 
 
Is there any risk of side effects with the change? As with all medicines the risk is not zero but 
it is a small risk. If you do experience a side effect it is likely to be minor and you are no more 
likely to experience a side-effect with the new medicine than the old one. If you experience 
any problems tell your doctor who can review your symptoms and if expected to be a side 
effect to losartan they can change your prescription back to the one you were using 
previously. 
 
Will I be asked to change this medicine again? We expect this medicine to be the most cost-
effective for a few years so it is unlikely that you would be asked to change again, certainly 
not for at least a few years.  
 
How much money will this save the NHS? A substantial amount (many millions of pounds). 
Money that is saved will be used to improve other local NHS services. 
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10.3.5 Hypertension Patient Information Leaflet (PIL) 
 
Patient Information: Changes to your blood pressure medication  
 
This leaflet aims to explain the reasons why one of the medications to lower your blood 
pressure has been changed. The UCLH Use of Medicines Committee is a group of specialist 
consultants, pharmacists and nurses that has a special interest in medicines. They regularly 
review the medicines we prescribe to check that we’re using the most effective ones. For 
conditions for which there are a number of similar medicines we also check that we are using 
the most cost-effective medicine (see below for more information). This group has recently 
reviewed the potential benefits of each of the medicines used to lower blood pressure and it 
was agreed that losartan should be used in preference to candesartan, eprosartan, irbesartan, 
olmesartan, telmisartan or valsartan. 
 
We have changed your prescription to losartan 50mg or 100mg to be taken once a day to 
lower your blood pressure. If you have any questions about this change please contact our 
Medicines Information department on 0845 1555 000 extension 73500. This line is open 
between 10am to 5pm from Monday to Friday.  If you have any candesartan, eprosartan, 
irbesartan, olmesartan, telmisartan or valsartan at home please return them to your local 
chemist so that they can be disposed of. Do not take candesartan, eprosartan, irbesartan, 
olmesartan, telmisartan or valsartan AND losartan at the same time. 
 
Some reasons for the change: 
 
For many illnesses there are a number of similar medicines. The more expensive one is not 
necessarily better than less expensive ones. When there is more than one choice it is sensible 
for the doctor to prescribe the one that is the best value (or most cost-effective).  
 
We do not believe there is anything medically wrong with the medicine you have been using 
previously. But we do believe that losartan can give you the same results while also giving the 
NHS better value for money. 
 
If the new medicine does not suit you, your GP can change your prescription back to the 
medicine you have been taking. 
 
Frequently asked questions: 
Why change my medicine if my current one works fine? Your previous medicine was one of a 
number of very similar medicines. The newer medicine you have been given is currently the 
most cost-effective of this class and allows us to use these savings to help improve other NHS 
services. 
 
Is there any risk of side effects with the change? As with all medicines the risk is not zero but 
it is a small risk. If you do experience a side effect it is likely to be minor and you are no more 
likely to experience a side-effect with the new medicine than the old one. If you experience 
any problems tell your doctor who can review your symptoms and if expected to be a side 
effect to losartan they can change your prescription back to the one you were using 
previously. 
 
Will I be asked to change this medicine again? We expect this medicine to be the most cost-
effective for a few years so it is unlikely that you would be asked to change again, certainly 
not for at least a few years.  
  
How much money will this save the NHS? A substantial amount (many millions of pounds). 
Money that is saved will be used to improve other local NHS services. 
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10.4 Appendix IV: NOAC systematic review: data extraction guide 
 
Using the Access Database 
DATA EXTRACTION GUIDE 
Getting started:  
 Double-click on the Access database file “Pritesh_NOACs_AF.mdb” or 
right click and select open to open. The first page displays many tabs: - 
‘Documentation’, ‘Dataset Information’, ‘Data Entry’, ‘Codes & 
Recoding’, ‘Utilities’, and ‘Data Administrator’.  
 Click once on ‘Data Entry’ tab ignoring others. Three options display 
under Data Entry.  
 Double-click on ‘NOACs Data Entry’. Two options display under 
NOACs Data Entry.  
 Double-click on ‘Start NOACs Data Entry’ to open the database. When 
the database is open, four tabs will be displayed: Paper Retrieval 
Admin, Screen Titles and Abstracts, Screen Full Papers, and Data 
Extraction.  
 Click once on ‘Data Extraction’ tab to start data extraction. The first 
level of data extraction is for the trial-level data. The form to extract 
information with is the first form that displays when you click on ‘Data 
Extraction’ tab. Displayed horizontally at the middle of the form are five 
tabs for different sections of trial-level data. Clicking on each tab will 
open a sub-form with which to extract data for that section.  
 Start with the first tab on the far right i.e. Trial data extraction 
administration tab and work towards the left until complete ‘Trial-level 
risk of bias assessment’.  
 The ‘trial references’ tab displays all of the papers that are related to a 
specific trial. The ‘trial population characteristics’ tab displays 
population level characteristics and will only need to be completed if 
arm level characteristics are not reported. 
Arm-level information and outcomes/results 
1. After completing trial-level data extraction, open arm-level data form by 
clicking on the ‘Arm-level data’ tab at the top left of the trial level 
information form. When open, there are two ‘computer repair’ symbols 
– a large symbol at the top left of the form, and a smaller symbol at the 
middle aspect of the form towards the right. First, add study 
intervention arms for them to be displayed in the vertical box on the 
right. To add an intervention arm, click on the smaller ‘computer repair’ 
symbol and then click on ‘add a new event’. A new form will open up. 
Trial ID, Trial name and Trial registration number are already 
populated. Add the intervention arm number (as in the study), and 
select an intervention code and the date of the extraction (i.e. the date 
that you are doing the extraction). To add other intervention arms, click 
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on ‘Add Event’. When you finish adding all the intervention arms, click 
on ‘Add Event’ again to return to the Arm-level information page. The 
added arms now appear in the vertical box to the right. Click on an 
intervention arm and then click on ‘Study Details’ tab to add 
intervention arm specific information for each of the arms. When 
complete for all intervention arms, close the arm-level form by clicking 
on the tab marked ‘X’ on the top mid-left corner of the form beside the 
big ‘computer repair’ symbol.  
2. To enter outcomes/results, click on ‘Enter Outcomes and Results’ tab 
at the top left of the trial level information form (below the ‘Enter Arm-
level data’). A similar form to the arm-level form (already completed 
above) will open. To add outcomes, follow the same process for 
adding the different intervention arms as described above. When all 
outcomes have been added, the outcomes will now appear on the 
vertical box to the right (just like the intervention arms are displayed). 
Click on an outcome and then click on ‘Outcome details and RoB’ tab 
to add outcome details and complete risk of bias assessment for that 
outcome. To add results for an outcome, first select the intervention 
arms in a study. To do this, select the outcome, click on ‘Results’ tab at 
the top, then click on add at the top of the vertical box on the right side 
of the result page that opened up. All intervention arms already stored 
at ‘1’ above will appear in a drop down. Now select the arm number as 
in the study. Click ‘Add Result’ at the top of the page to repeat the 
process and add another intervention arm. When all intervention arms 
have been added they will all be displayed on the vertical box to the 
right. Select each intervention arm to add the result for each arm. To 
exit outcomes and results page after completing the fields, click on the 
‘X’ tab at the top left of the main form.  
Note: When the data field in a form is clicked once, the description of the field 
will normally appear at the bottom of the screen as it does in Access version 
2003. However, this display may depend on the MS Access version that is in 
use; so this display may not appear in some versions. Below are important 
data fields and descriptions. 
Data field description 
1. Trial Identification: This is a unique id automatically assigned to each 
trial by the computer. 
2. Trial registration no.: This is a unique registration number that 
published trials have. The field is a text field so for any trial with 
missing registration number, make up a registration number for it but 
keep a record of such trials. 
3. Trial name: This is a name (usually, but not exclusively an 
abbreviation) that a trial is known with – for example RE-LY. This is a 
text field so type in the name as it is on publication. 
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4. Trial country: This is a list of all countries where a trial was conducted. 
It is a memo field so add all countries.  
5. Trial description: This is a description of a trial. This is a text field.  
6. Trial dates: This is the commencement & end dates for a trial; example 
"1970 to 1973". 
7. Data extracted by: This is the identification code for a reviewer who is 
extracting data (id codes are selected from the drop down menu).  
8. Extraction date: This is the date that data was extracted for this 
research project.  
9. Data checked by: This is identification code for the reviewer who 
checked extracted data. 
10. Check date: This is the date on which data extraction was 
independently checked. 
11. Data agreed and final: This is whether data extraction discrepancies 
have been resolved.  
12. Was this paper used: This informs whether data was extracted from a 
paper or not. 
13. Number of trial centres: This is the number of centres where a trial was 
conducted. 
14. Trial setting: This is the setting where a trial was conducted. For 
example, hospital etc.  
15. Number screened: This is the number of all screened individuals for 
consideration in a trial.  
16. Number eligible: This is the number of eligible individuals after 
screening. 
17. Number randomised: This is the total number of participants 
randomised in a trial. 
18. List all composite outcomes reported in this trial: This is a list of all 
composite outcomes reported in a study, if any. 
19. Inclusion criteria: This is the specified criteria used to include study 
participants. This is a text field. 
20. Exclusion criteria: This is the specified criteria for exclusion of 
individuals from a study. This is a text field. 
21. Mean age of population, SD mean age, Measure bleed risk, Mean 
bleed risk, SD mean bleed risk, Mean BMI for population, SD mean 
BMI, Mean weight for population, SD mean weight, Male %, % 
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Previous stroke/TIA, % Previous thromboembolic event, % Previous 
MI, % Hypertension, % Diabetes Mellitus, % Liver disease, % Renal 
disease, % Pregnancy, % CHF. 
  (The above are self-descriptive and should be extracted as documented in a 
trial) 
22. Ethnicity information: This is the percentage of different ethnic groups 
among participants as reported in a trial. For example, %White, 
%Black, %Hispanic, etc. This is a text field. 
23. AF type: This is the type of atrial fibrillation (by %) among the trial 
population. For example, Paroxysmal, Persistent, Permanent, New 
onset, Mixed. This is a text field. 
24. Index event: This is the index event in the study population. For 
example, DVT, PE, etc. Complete this for secondary prevention of VTE 
only.  
25. Arm Number: This is the number given to an intervention arm in a trial.  
(Please ensure that the correct arm results are documented for an intervention 
arm) 
26. Outcome Type: This is whether an outcome is single outcome or 
composite.  
27. Outcome Definition: This is the definition of an outcome in a trial. You 
could copy from a trial paper and paste in the field. 
28. Treatment duration: This is the duration of intervention administered. It 
is a text field. (Please specify whether the duration is in days, weeks or 
months) 
29. Time to outcome measure: This is the time from baseline (start of 
intervention) to when an outcome was measured; in weeks, months, 
years (please specify). This is a text field.  
30. Location of results: This is the location of extracted result in a paper. 
This is a text field. 
Risk of bias assessment 
1. Statement: This is the supporting statements for a reviewer’s judgment 
on a specific risk of bias. This is a text field.  
2. Quote: This is the supporting quote from a paper for judgment on a 
specific risk of bias. The quote should be copied from a paper and 
pasted into the field. This is a text field.  
3. Quote location: This is the location in a paper from which a quote is 
copied. For example, “third paragraph on page 23”. This is a text field.  
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10.5 Appendix V: NOAC systematic review: database screenshots 
 
 
Figure 79: Screening for inclusion at abstract level 
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Figure 80: Screening for inclusion at full text stage 
 
Figure 81: Trial level information (reviewer extraction build page) 
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Figure 82: Trial level information (reference page)  
[where more than one publication related to a single trial set of data, a TRIAL ID was created for the 
principal publication and all sequential ones included within this section]  
Figure 83: Trial level information (trial subject demographics and outcome information 
page) 
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Figure 84: Trial level information (trial subject detailed characteristics page) 
Figure 85: Trial level information (trial data risk of bias assessment page) 
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Figure 86: Trial level information (arms build page) 
 
Figure 87: Trial level information (detailed arm level data page) 
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Figure 88: Trial data extraction (outcomes build page) 
 
 
Figure 89: Trial data extraction (outcomes type and risk of bias page) 
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Figure 90: Trial data extraction (arm level data) 
 
  
Appendices 
     - 420 - 
10.6 Appendix VI: Forest Plots (stroke prevention in AF)  
 
  
Figure 91: Forest plot of stroke or SE [1/4] 
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Figure 92: Forest plot of stroke or SE [2/4]  
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Figure 93: Forest plot of stroke or SE [3/4] 
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Figure 94: Forest plot of stroke or SE [4/4] 
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Figure 95: Forest plot of ischaemic stroke 
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Figure 96: Forest plot of myocardial infarction   
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Figure 97: Forest plot of major bleeding [1/4]   
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Figure 98: Forest plot of major bleeding [2/4]  
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Figure 99: Forest plot of major bleeding [3/4]  
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Figure 100: Forest plot of major bleeding [4/4]  
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Figure 101: Forest plot of clinically relevant bleeding [1/3]  
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Figure 102: Forest plot of clinically relevant bleeding [2/3]  
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Figure 103: Forest plot of clinically relevant bleeding [3/3]  
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Figure 104: Forest plot of clinically intracranial bleeding 
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Figure 105: Forest plot of all cause mortality  
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10.7 Appendix VII: Antiepileptic drugs for refractory epilepsy 
(publication abstract) 
 
Br J Clin Pharmacol. 2013 Nov; 76[5]: 649-667.  
Bodalia PN, Grosso AM, Sofat R, MacAllister RJ, Smeeth L, Dhillon S, Casas 
JP, Wonderling D, Hingorani AD.  
Department of Pharmacy, University College London Hospitals NHS 
Foundation Trust, London, UK. pritesh.bodalia@uclh.nhs.uk  
 
AIMS: To evaluate the comparative efficacy (50% reduction in seizure frequency) and 
tolerability (premature withdrawal due to adverse events) of anti-epileptic drugs 
(AEDs) for refractory epilepsy. 
METHODS: We searched Cochrane Central Register of Controlled Trials (Cochrane 
Library 2009, issue 2) including Epilepsy Group's specialized register, MEDLINE 
(1950 to March 2009), EMBASE (1980 to March 2009), and Current Contents Connect 
(1998 to March 2009) to conduct a systematic review of published studies, developed 
a treatment network and undertook a network meta-analysis. 
RESULTS: Forty-three eligible trials with 6346 patients and 12 interventions, including 
placebo, contributed to the analysis. Only three direct drug comparator trials were 
identified, the remaining 40 trials being placebo-controlled. Conventional random-
effects meta-analysis indicated all drugs were superior in efficacy to placebo (overall 
odds ratio (OR] 3.78, 95% CI 3.14, 4.55) but did not permit firm distinction between 
drugs on the basis of the efficacy or tolerability. A Bayesian network meta-analysis 
prioritized oxcarbazepine, topiramate and pregabalin on the basis of short term 
efficacy. However, sodium valproate, levetiracetam, gabapentin and vigabatrin were 
prioritized on the basis of short-term efficacy and tolerability, with the caveat that 
vigabatrin is recognized as being associated with serious visual disturbance with 
chronic use. 
CONCLUSION: Of the wide range of AEDs licensed for the treatment of refractory 
epilepsy, sodium valproate, levetiracetam and gabapentin demonstrated the best 
balance of efficacy and tolerability. Until regulators mandate greater use of active 
comparator trials with longer term follow-up, network meta-analysis provides the only 
available means to quantify these clinically important parameters. 
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10.8 Appendix VIII: Angiotensin Receptor Blockers for the 
management of hypertension and heart failure (publication abstract) 
 
Int J Clin Practice 2011 March; 65[3]: 253-263.  
Grosso AM, Bodalia PN, MacAllister RJ, Hingorani AD, Moon JC, Scott MA.  
Department of Pharmacy, University College London Hospitals NHS 
Foundation Trust, London, UK. pritesh.bodalia@uclh.nhs.uk  
 
BACKGROUND: The UK National Health Service (NHS) currently spends in excess of 
£250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of 
hypertension and heart failure; with candesartan currently dominating the market. With 
the recent introduction of generic losartan, we set out to directly compare the branded 
market leader to its now cheaper alternative. 
AIMS: The primary objectives were to compare the blood pressure (BP) lowering 
efficacy and cardiovascular outcomes of candesartan and losartan in the treatment of 
essential hypertension and chronic heart failure, respectively. The secondary objective 
was to model their comparative incremental cost-effectiveness in a UK NHS setting. 
METHODS: The Cochrane Central Register of Controlled Trials (Cochrane Library 
2009, issue 2), which contains the Hypertension and Heart Group’s specialist register, 
Medline (1950–February 2010), and Embase (1980–February 2010) were included in 
the search strategy. Selection criteria were randomised studies of candesartan versus 
losartan in adults (> 18 years). The main outcome measures were as follows: 
Hypertension: mean change from baseline in trough (24 h postdose) systolic and 
diastolic BP. Heart failure: composite of cardiovascular death and hospital admission 
for management of heart failure. 
RESULTS: Two reviewers applied inclusion criteria, assessed trial quality, and 
extracted data. Eight (three of which met inclusion criteria) and zero trials compared 
candesartan directly with losartan in the treatment of hypertension and heart failure, 
respectively. A between-treatment difference of −1.96 mmHg [95% confidence interval 
(CI) −2.40 to −1.51] for trough diastolic BP and −3.00 mmHg (95% CI −3.79 to −2.22) 
for trough systolic BP in favour of candesartan was observed. Based on this 
differential, a 10-year Markov model estimates the cost per quality-adjusted life-year 
gained to exceed £40,000 for using candesartan in place of generic losartan. 
CONCLUSION: Candesartan reduces BP to a slightly greater extent when compared 
with losartan; however, such difference is unlikely to be cost-effective based on 
current acquisition costs, perceived NHS affordability thresholds and use of 
combination regimens. We could find no robust evidence supporting the superiority of 
candesartan over losartan in the treatment of heart failure. We therefore recommend 
using generic losartan as the ARB of choice which could save the UK NHS 
approximately £200 million per annum in drug costs. 
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10.9 Appendix IX: Antimuscarinics for the management of overactive 
bladder syndrome (abstract) 
 
DRAFT abstract [unpublished] 
Bodalia PN, Wood DN, Welton NJ.  
Department of Pharmacy, University College London Hospitals NHS 
Foundation Trust, London, UK. pritesh.bodalia@uclh.nhs.uk  
 
BACKGROUND: Guidelines for the treatment of Overactive Bladder (OAB) currently 
recommend antimuscarinics as first-line pharmacological therapy. Mirabegron is then 
considered for subjects in whom an antimuscarinic is contraindicated, clinically 
ineffective or intolerable.  However, the optimal choice for frontline antimuscarinic 
therapy remains unclear with a variety of licensed agents available. 
AIM: The aim of this study was to perform a mixed-treatment comparison (MTC) to 
define a prescribing hierarchy for antimuscarinics in OAB.  
METHODS: We searched Cochrane Central Register of Controlled Trials (Cochrane 
Library 2009, issue 2), MEDLINE (1950 to June 2014) and EMBASE (1980 to June 
2014) to conduct a systematic review of published studies, developed a treatment 
network and undertake a network meta-analysis. Selection criteria were randomised 
studies of pharmacological treatments in the management of OAB in adults 
(> 18 years) that were published after year 2000 to supplement new studies following 
a previous systematic review. The main outcome measures were as follows: 
micturition frequency per 24 hours; urgency urinary incontinence (UUI) episodes per 
24 hours; incidence of dry mouth; and incidence of constipation. 
RESULTS: The MTC analysis on micturition frequency was based on 21 studies 
involving 18,863 patients.
 
The median placebo-corrected difference from baseline to 
week 12 was statistically significantly different from placebo for all treatments except 
darifenacin. Solifenacin 10mg was deemed the most effective agent for the ranking 
analysis. The MTC analysis on urge urinary incontinence (UUI) episodes was based 
on 17 studies involving 15,502 patients).
 
The median placebo-corrected difference 
from baseline to week 12 was statistically significantly different for all treatments 
except immediate-release 4mg tolterodine, 4mg fesoterodine, 40mg immediate-
release trospium and darifenacin. 10mg Solifenacin demonstrated the greatest 
reduction in number of UUI episodes with 5mg solifenacin and 10mg modified-release 
oxybutynin demonstrating joint second greatest reduction. 
CONCLUSION: All antimuscarinics were associated with recognised anticholinergic 
adverse events such as dry mouth and constipation. In general, treatment efficacy 
appears to be inversely proportional to incidence of adverse events with the possible 
exception of darifenacin, which appeared to perform sub-optimally in terms of both 
efficacy and safety. 
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10.10 Appendix X: Novel Oral Anticoagulants for the prevention of 
stroke in AF (abstract) 
 
DRAFT submission to BMJ 
Sterne JAC, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, 
Thom HZ, Caldwell DM, Dias S, Eaton D, Higgins JPT, Hollingworth W, 
Salisbury C, Savovic J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD. 
School of Social and Community Medicine, University of Bristol, Bristol, UK. 
jonathan.sterne@bristol.ac.uk  
Department of Pharmacy, University College London Hospitals NHS 
Foundation Trust, London, UK. pritesh.bodalia@uclh.nhs.uk  
 
OBJECTIVE: Compare the effectiveness and cost-effectiveness of all available 
directly acting oral anticoagulants (DOACs) for patients with atrial fibrillation (AF). 
DESIGN: Systematic review, network meta-analysis (NMA), and cost-effectiveness 
analysis. We ranked the effects of warfarin, antiplatelet drugs and licensed doses of 
NOACs for seven efficacy and safety outcomes studied in patients with AF. 
DATA SOURCES: MEDLINE, Pre-MEDLINE, EMBASE, and the Cochrane Library. 
ELIGIBILITY CRITERIA: Published randomised trials evaluating the use of a NOAC, 
vitamin K antagonist, or antiplatelet agent in individuals with AF for stroke prevention. 
RESULTS: We analysed 23 randomised trials involving 94,656 individuals: 13 
compared a NOAC with warfarin dosed to achieve a target INR of 2-3. Apixaban 5mg 
bd (OR 0.79; 95% CI 0.66-0.94), dabigatran 150mg bd (OR 0.65; 0.52-0.81), 
edoxaban 60mg od (OR 0.86; 0.74-1.01) and rivaroxaban 20mg od (0.88; 0.74-1.03) 
reduced risk of stroke or systemic embolism compared with warfarin. Risk of stroke or 
systemic embolism was higher with edoxaban 60mg od (1.33; 1.02-1.75) and 
rivaroxaban 20mg od (1.35; 1.03-1.78) than dabigatran 150mg bd. Risk of all-cause 
mortality was lower with all DOACs than warfarin. Apixaban 5mg bd (0.71; 0.61-0.81), 
dabigatran 110mg bd (0.80; 0.69-0.93), edoxaban 30mg od (0.46; 0.40-0.54) and 
edoxaban 60mg od (0.78; 0.69-0.90) reduced risk of major bleeding compared with 
warfarin. Risk of major bleeding was higher with dabigatran 150mg bd than apixaban 
5mg bd (1.33; 1.09-1.62), and with rivaroxaban 20mg bd than apixaban 5mg bd (1.45; 
1.19-1.78) and edoxaban 60mg od (1.31; 1.07-1.59). Risk of intracranial bleeding was 
substantially lower for most DOACS compared with warfarin. Apixaban 5mg bd was 
ranked as the best intervention for most outcomes, and was cost-effective compared 
with warfarin.   
CONCLUSION: Our NMA informs choice of DOAC for stroke prevention in AF. At 
licensed doses, a number of DOACs are of net benefit compared with warfarin, with 
apixaban ranked as the best intervention across a range of outcomes. A trial directly 
comparing DOACs would overcome the need for indirect comparisons to be made 
through NMA. 
